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Background: Following primary breast cancer treatment, the early detection of ipsilateral 
breast tumour recurrence (IBTR) or ipsilateral secondary cancer in the treated breast and 
detection of new primary cancers in the contralateral breast is beneficial for survival. 
Surveillance mammography is used to detect these cancers, but the optimal frequency of 
surveillance and the length of follow-up are unclear.
Objectives: To identify feasible management strategies for surveillance and follow-up of 
women after treatment for primary breast cancer in a UK setting, and to determine the 
effectiveness and cost-effectiveness of differing regimens.
Methods: A survey of UK breast surgeons and radiologists to identify current surveillance 
mammography regimens and inform feasible alternatives; two discrete systematic reviews 
of evidence published from 1990 to mid 2009 to determine (i) the clinical effectiveness and 
cost-effectiveness of differing surveillance mammography regimens for patient health 
outcomes and (ii) the test performance of surveillance mammography in the detection of 
IBTR and metachronous contralateral breast cancer (MCBC); statistical analysis of 
individual patient data (West Midlands Cancer Intelligence Unit Breast Cancer Registry and vi Abstract
Edinburgh data sets); and economic modelling using the systematic reviews results, 
existing data sets, and focused searches for specific data analysis to determine the 
effectiveness and cost–utility of differing surveillance regimens.
Results: The majority of survey respondents initiate surveillance mammography 12 months 
after breast-conserving surgery (BCS) (87%) or mastectomy (79%). Annual surveillance 
mammography was most commonly reported for women after BCS or after mastectomy 
(72% and 53%, respectively). Most (74%) discharge women from surveillance 
mammography, most frequently 10 years after surgery. The majority (82%) discharge from 
clinical follow-up, most frequently at 5 years. Combining initiation, frequency and duration 
of surveillance mammography resulted in 54 differing surveillance regimens for women 
after BCS and 56 for women following mastectomy. The eight studies included in the 
clinical effectiveness systematic review suggest surveillance mammography offers a 
survival benefit compared with a surveillance regimen that does not include surveillance 
mammography. Nine studies were included in the test performance systematic review. For 
routine IBTR detection, surveillance mammography sensitivity ranged from 64% to 67% 
and specificity ranged from 85% to 97%. For magnetic resonance imaging (MRI), 
sensitivity ranged from 86% to 100% and specificity was 93%. For non-routine IBTR 
detection, sensitivity and specificity for surveillance mammography ranged from 50% to 
83% and from 57% to 75%, respectively, and for MRI from 93% to 100% and from 88% to 
96%, respectively. For routine MCBC detection, one study reported sensitivity of 67% and 
specificity of 50% for both surveillance mammography and MRI, although this was a highly 
select population. Data set analysis showed that IBTR has an adverse effect on survival. 
Furthermore, women experiencing a second tumour measuring > 20 mm in diameter were 
at a significantly greater risk of death than those with no recurrence or those whose tumour 
was < 10 mm in diameter. In the base-case analysis, the strategy with the highest net 
benefit, and most likely to be considered cost-effective, was surveillance mammography 
alone, provided every 12 months at a societal willingness to pay for a quality-adjusted life-
year of either £20,000 or £30,000. The incremental cost-effectiveness ratio for surveillance 
mammography alone every 12 months compared with no surveillance was £4727. 
Limitations: Few studies met the review inclusion criteria and none of the studies was a 
randomised controlled trial. The limited and variable nature of the data available precluded 
any quantitative analysis. There was no useable evidence contained in the Breast Cancer 
Registry database to assess the effectiveness of surveillance mammography directly. The 
results of the economic model should be considered exploratory and interpreted with 
caution given the paucity of data available to inform the economic model.
Conclusions: Surveillance is likely to improve survival and patients should gain maximum 
benefit through optimal use of resources, with those women with a greater likelihood of 
developing IBTR or MCBC being offered more comprehensive and more frequent 
surveillance. Further evidence is required to make a robust and informed judgement on the 
effectiveness of surveillance mammography and follow-up. The utility of national data sets 
could be improved and there is a need for high-quality, direct head-to-head studies 
comparing the diagnostic accuracy of tests used in the surveillance population. 
Funding: The National Institute for Health Research Health Technology 
Assessment programme.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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Executive summary
Background
Survival following breast cancer treatment is increasing. A key question is, therefore, how best to 
follow up patients after completion of primary treatments. There is considerable debate about the 
role and optimal organisation of the follow-up of patients following treatment for primary breast 
cancer. Data indicate that the early detection of ipsilateral breast tumour recurrence or ipsilateral 
second primary cancer [ipsilateral breast tumour recurrence (IBTR)] in the treated breast and 
detection of new primary cancers in the contralateral breast [metachronous contralateral breast 
cancer (MCBC)] is beneficial in terms of survival. This raises the question as to how best to 
identify ipsilateral local recurrence of disease and new contralateral primary breast cancer at the 
earliest possible stage. Surveillance mammography is directed towards the detection of IBTR 
and MCBC. However, the optimal frequency of mammographic surveillance and the length of 
follow-up are unclear.
Objectives
1.  Identify feasible management strategies for surveillance and follow-up of women after 
treatment for breast cancer in a UK setting.
2.  Determine the effectiveness of differing surveillance and follow-up regimens after treatment 
for breast cancer.
3.  Estimate the costs of differing surveillance and follow-up regimens after treatment for 
breast cancer.
4.  Estimate the cost-effectiveness of differing surveillance and follow-up regimens after 
treatment for breast cancer.
5.  Identify future research needs.
Methods
The work comprised a survey of UK breast surgeons and radiologists to identify current UK 
surveillance mammography regimens and inform feasible alternative regimens. In addition, we 
undertook two discrete systematic reviews to determine the clinical effectiveness of differing 
surveillance mammography regimens carried out after treatment for primary breast cancer on 
patient health outcomes and the test accuracy of surveillance mammography in the detection 
of IBTR and MCBC. Sensitive search strategies of several major bibliographic databases were 
conducted from 1990 to mid 2009. We undertook statistical analysis of individual patient data 
[West Midlands Cancer Intelligence Unit (WMCIU) Breast Cancer Registry and Edinburgh data 
sets] and economic modelling using the systematic reviews results, existing data sets, and focused 
searches for specific data analysis to determine the effectiveness and cost–utility of differing 
surveillance regimens. We developed an economic model in the form of a Markov model to 
represent the alternative surveillance regimens modelled at varying surveillance intervals. 
Parameter estimates for the Markov model were determined from a survey of existing data sets, a 
series of systematic reviews, and focused searches for specific data.xiv Executive summary
Results
Survey
We received responses from 17% (183/1048) of those surveyed, 64% were surgeons and 35% 
radiologists and were based in 105 NHS trusts across the UK. The majority initiate surveillance 
mammography 12 months post surgery for women who have had breast-conserving surgery 
(BCS) (87%) and for women who have had a mastectomy (79%). Annual surveillance 
mammography was the most commonly reported surveillance mammography frequency for 
women after breast-conserving surgery (BCS) or after mastectomy (72% and 53%, respectively), 
with biennial mammography the next most frequently reported (12% and 30%, respectively). 
Most (74%, 136/182) discharge women from surveillance mammography and they do this 
most frequently 10 years after surgery. The majority (82%, 148/180) do discharge from clinical 
follow-up and most frequently at 5 years. Just over half (55%, 98/179) responded that they 
discharge women to the NHSBSP if eligible. Combining initiation, frequency and duration 
of surveillance mammography resulted in 54 differing surveillance regimens for women after 
BCS and 56 for women following mastectomy. The most commonly followed four regimens for 
women after BCS or after mastectomy are to initiate surveillance mammography 12 months after 
surgery, conduct annual surveillance mammography with indefinite duration (12%, 19/154, 7%, 
10/136 respectively); or discharge from both clinical and mammographic surveillance at 5 years 
(14%, 22/154, 10%, 13/136 respectively); or 10 years (12%, 18/154, 11%, 15/136 respectively) 
after surgery or discharge from clinical follow-up at 5 years with continued mammographic 
surveillance until 10 years (13%, 20/154, 8%, 11/136 respectively). Our findings suggest that, 
although common patterns in surveillance mammography practice exist, there is considerable 
variation in the combinations of start, frequency, duration and discharge from surveillance 
mammography. Our findings reflect the different guidance given by the various professional 
organisations with an interest in surveillance after breast cancer, in combination with the local 
protocols of the respondents.
Systematic reviews
Eight studies, involving 3775 women, were included in the systematic review of clinical 
effectiveness. Although none of the tests of interest was used for the same purpose (i.e. 
routine or non-routine surveillance) in all studies, results suggest that the use of surveillance 
mammography offers a survival benefit compared with a surveillance regimen that does not 
include surveillance mammography. 
Nine studies, involving 3724 women, were included in the systematic review of test performance. 
For the detection of IBTR in routine surveillance where there was no prior suspicion of 
recurrence, the highest sensitivity was shown for magnetic resonance imaging (MRI) and 
combined MRI/clinical examination at 100%, whereas the highest specificity was shown for 
surveillance mammography alone (97%) although this was obtained in a highly select population. 
Clinical examination alone had the lowest sensitivity (50%) and surveillance mammography 
with clinical examination had the lowest specificity (67%). For the detection of IBTR in patients 
for whom there was a suspicion of recurrence, sensitivity of tests varied from 50% (surveillance 
mammography) to 100% (MRI) and specificity ranged from 31% (ultrasound) to 96% (MRI). In 
the detection of MCBC in routine surveillance, sensitivity ranged from 0% (clinical examination) 
to 100% for the combination of surveillance mammography, clinical examination, ultrasound and 
MRI. Specificity ranged from 50% for surveillance mammography, MRI or clinical examination 
to 99% for the combination of surveillance mammography and ultrasound. Again, the highly 
selected nature of the population should be borne in mind in the context of these results.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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Analyses of the WMCIU and Edinburgh data sets
The analyses showed that IBTR has an adverse effect on survival that is independent of known 
risk factors. Furthermore, in those women experiencing a second tumour (either IBTR or 
MCBC) the size of this second tumour is important, with those women with tumours of > 20 mm 
in diameter being at a significantly greater risk of death than those with no recurrence or those 
whose tumour was < 10 mm in diameter.
Economic evaluation
The results of the economic model should be considered exploratory and interpreted with caution 
given the paucity of data available to inform the economic model. In the base-case analysis, the 
strategy with the highest net benefit, and therefore the most likely to be considered cost-effective, 
was surveillance mammography alone, provided every 12 months at a societal willingness 
to pay for a quality-adjusted life-year (QALY) of either £20,000 or £30,000. The incremental 
cost-effectiveness ratio for surveillance mammography alone every 12 months compared to 
no surveillance was £4727. This result holds for women previously treated for their primary 
cancer with either breast-conserving surgery or mastectomy or for women who suffer IBTR. 
The results of the model are sensitive to changes in the incidence of recurrent cancer. When the 
expected incidence is increased towards the maximum that could be expected (approximately 
0.008 per annum) clinical surveillance plus mammography has an incremental cost per QALY 
of approximately £30,000. As the surveillance interval and incidence increase regimens that are 
more costly but more effective (proxied by the MRI plus clinical surveillance) may also have 
incremental costs per QALY < £30,000. This suggests that there may be some scope for research 
into alternative technologies that could be used for surveillance.
We did not conduct probabilistic sensitivity analysis due to statistically imprecise and limited 
data. We did conduct both one-way and multiway sensitivity analyses, however. Sensitivity 
analysis included varying the probability of cancer, inflating the risk of death from cancer, 
inflating the risk of cancer progression in undiagnosed or untreated cancers, varying diagnostic 
accuracy of the surveillance tests and varying costs and age.
The results of the model were sensitive to incidence and other factors, for example age, tumour 
characteristics, etc., which might define women with greater or lesser likelihoods of developing 
an IBTR or MCBC. These results suggest that a more intensive follow-up of women with greater 
likelihood of IBTR or MCBC may be worthwhile. Conversely, for women with less likelihood of 
IBTR or MCBC it may be more cost-effective for surveillance to be performed less often (every 
2 or 3 years) with mammography alone. As the surveillance interval and incidence increase, 
strategies that are more costly, but more effective, may also have incremental costs per QALY 
below typical threshold values.
Limitations
Despite considerable and rigorous methods adopted for both systematic reviews, we found 
few studies meeting our inclusion criteria, none of which were a randomised controlled trial 
(RCT). The limited and variable nature of the data available precluded any quantitative analysis. 
There was no useable evidence contained in the Breast Cancer Registry database to assess the 
effectiveness of surveillance mammography directly. As few data were available, the economic 
results need to be treated cautiously. In particular, a series of simplifying assumptions were made 
about disease progression and prognosis of recurrent cancers. We took care to err on the side 
of caution when making these assumptions, however, in order to minimise the possibility of 
overestimating the value of surveillance. Furthermore, few data relevant to the UK were available 
on health-state utilities. We assumed that the data used were applicable to the UK and the health 
states modelled. xvi Executive summary
Conclusions
Implications for service provision
Surveillance is likely to improve survival, with a strategy of mammography alone, every 
12–24 months, appearing to have the highest net benefits. The evidence base on which to 
recommend any change in current practice is relatively weak, however. Careful consideration 
should be given to stratification of patients to ensure maximum benefit to ensure optimal use 
of resources, with those women with a greater likelihood of developing IBTR or MCBC being 
offered more comprehensive (e.g. mammography and clinical follow-up) and more frequent 
surveillance (every 12 months). The greatest net benefit for women with the lowest likelihood 
of IBTR or MCBC is mammography only every 3 years. Although there may be arguments for 
delivering a varying surveillance regimen this would present challenges and, without provision of 
information and reassurance, might be a source of unnecessary anxiety for patients.
Suggested research priorities
  ■ The utility of the national data sets could be improved. In addition to the nationally agreed 
collection, it would be extremely valuable to record details of mode of detection for IBTR or 
MCBC; the frequency of the clinical and mammographic surveillance regimens, and how 
this varies over time; and whether a woman’s IBTR or MCBC was detected during routine 
surveillance or as a result of it causing symptoms for the patient.
  ■ There is a need for high-quality, direct head-to-head studies comparing the diagnostic 
accuracy of tests used in the surveillance population. Further primary work should also 
consider whether the use of existing technologies, such as MRI, which may have better 
performance, could be worthwhile for patients at high risk of IBTR or MCBC. An economic 
analysis should form part of such work.
  ■ Further economic evaluation modelling should compare differing mixed regimens of clinical 
follow up, delivered in lower cost settings, combined with surveillance mammography in the 
long term. This would be important to inform further primary research (e.g. an RCT) which 
could then focus on regimens that appeared most promising.
  ■ A definitive RCT would be ideal and, although costly, could focus on those women at higher 
risk of IBTR or MCBC. The interventions considered might include mammography and 
MRI, for those at the highest risk, or surveillance mammography of 1 year versus a longer 
time interval, for example 3 years. Such a trial might also compare more sophisticated 
surveillance regimens, which vary not only in terms of the frequency of mammography but 
also in terms of the frequency and setting of clinical follow-up. An economic evaluation 
should form part of any RCT.
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Chapter 1  
Background
Description of health problem
Breast cancer affects one in nine women in the UK. At present, the 5-year survival rate in the 
UK is 82%. It is estimated that there are > 550,000 women who are alive and have been treated 
for breast cancer in the UK, which represents 2% of the total female population.1 Survival 
following breast cancer treatment is increasing and a key question is how these patients should be 
followed up after completion of treatment for primary breast cancer. Surveillance mammography 
is directed towards the detection of ipsilateral breast tumour recurrence or ipsilateral second 
primary cancer (IBTR) in the treated breast and detection of new primary cancers in the 
contralateral breast [metachronous contralateral breast cancer (MCBC)]. In addition, follow-up 
of patients after treatment for primary breast cancer is aimed at detection of regional recurrence 
in the chest wall (following mastectomy) and axillae, detection of metastatic disease, and 
monitoring for side effects of adjuvant treatments and making changes in treatment where 
appropriate, together with psychological support and treatment as required.
The Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis of data from 
randomised controlled trials (RCTs) demonstrated that IBTR is associated with an adverse effect 
on survival in patients undergoing a variety of standard treatments for breast cancer. This may 
take up to 15 years to become evident, however.2–4 Lu5 recently conducted a systematic review to 
determine the impact of early detection of isolated locoregional and contralateral recurrence on 
survival. The author reported better overall survival for recurrences detected by mammography 
or in asymptomatic patients, with an absolute reduction in mortality of 17–28% if all breast 
cancer recurrences are detected early. Similarly, an analysis of the Surveillance, Epidemiology, 
and End Results (SEER) database reporting on 174,453 women who had previously been treated 
for a primary breast cancer demonstrated that, for women with MCBC with stage 0–I disease, 
there was an 81% reduction in breast cancer mortality compared with that of women who were 
identified with more advanced contralateral disease.6 Therefore, the data suggest that the early 
detection of IBTR and of MCBC is beneficial in terms of survival. This raises the question as to 
how best to identify IBTR and MCBC.
Aetiology, pathology and prognosis
It is now generally accepted that IBTR has an adverse influence on patient survival. There is, 
however, no general agreement on the best treatment regimen for those who have experienced 
an IBTR.7 Furthermore, it is not clear whether IBTR itself increases the risk of the development 
of distant metastases, or whether IBTR and risk of distant disease is merely a reflection of the 
original aggressiveness of the tumour with its resultant effect on survival.
Younger women (defined as those < 35 years of age), extensive ductal carcinoma in situ, excision 
margins involved with tumour and lymphovascular invasion by tumour are well recognised 
risk factors for IBTR.8 Tumour size, grade and nodal involvement are risk factors for both local 
and distant recurrence.9 Of patients experiencing IBTR, 40–50% will have further recurrence or 2 Background
develop distant disease subsequently, particularly if the local recurrence occurs within 2 years of 
the initial presentation and treatment.10
Epidemiology
Breast cancer is an age-related disease, with 81% of cases occurring in those over 50 years of 
age. It is more prevalent in affluent societies, with the highest incidence being in North America 
and Western/Northern Europe. In those areas and countries, the most deprived socioeconomic 
groups have a lower incidence compared with the most affluent groups. Women who migrate 
from countries with a low incidence to those with a high incidence (e.g. Japan to the USA) often 
increase their risk, suggesting a strong effect for lifestyle and/or environmental factors. Early 
menarche, late menopause, oral contraceptive use, later age at first pregnancy, lower parity, lack 
of breastfeeding and use of hormone replacement therapy (HRT) after the age of 50 years are all 
recognised risk factors for breast cancer development. Following the publication of the Women’s 
Health Initiative trial in 200211 there was a marked reduction in the use of HRT, which has 
resulted in a reduction of breast cancer incidence in the over-50-years age group.12 In the UK, 
approximately 25% of women in the 45- to 69-year age group were using HRT by 2001 but this 
had fallen by half by 2006. This is estimated to have resulted in a reduction of around 1400 cases 
of breast cancer in the 50- to 59-year age group.13
Incidence and prevalence
There are 45,822 new cases of breast cancer in the UK each year.14 Figure 1 details Cancer 
Research UK incidence rates for women by age for 2006 in the UK. Approximately 20% of 
patients will develop a systemic recurrence and die within 5 years. In patients who undergo 
breast-conserving therapy (BCT), IBTR occurs in 1–2% of patients each year15 and MCBC occurs 
at a rate of up to 0.8% each year.16,17
Around 550,000 women were living in the UK with a diagnosis of breast cancer in 2008.18
FIGURE 1  Number of new cases and age-specific incidence rates for female breast cancer, UK 2006. Reproduced with 
permission from Cancer Research UK.14
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Impact of health problem
Significance for patients in terms of ill health
Ipsilateral breast tumour recurrence and MCBC have significant adverse effects on the patient. 
Further treatment is required and this often necessitates mastectomy for the patient who has a 
previously conserved breast together with the consideration of the use of systemic treatments 
(chemotherapy, hormone therapy, biological therapy). Disease recurrence has a significant 
adverse impact psychologically with major implications for the patient, their health and quality of 
life. There are data to indicate that patients who experience local disease recurrence have a poorer 
survival than those who do not have local recurrence.2,7
Significance for the NHS
The significance to the NHS in terms of the provision of clinical and mammographic 
surveillance, and treatment of IBTR and MCBC, is great. Following the treatment of primary 
breast cancer, patients are followed up with regular clinical examinations and surveillance 
mammography carried out at intervals as described below. Subsequent investigations are carried 
out to confirm disease recurrence or to exclude disease in those incorrectly identified as positive 
by a prior test or examination (‘false-positive’).
For each annual cohort of approximately 45,000 new cases of breast cancer, 20% (9000) will have 
developed metastatic disease and die within 5 years, requiring complex, demanding and costly 
treatment regimens. Taking a mean age of 70 years for primary breast cancer diagnosis, if 1% 
develop IBTR each year, and accounting for death from other causes, then over a 20-year period 
approximately 6358 patients will require treatment for this with 20% requiring further treatment 
for systemic disease.
Current service provision
Ipsilateral breast tumour recurrence and MCBC are detected by mammography, clinical breast 
examination and/or by the presence of symptoms noted by the patient. There are various 
recommendations in the UK for surveillance of patients with breast cancer ranging from ‘no 
follow-up’ to 6-monthly clinical examination (sometimes more frequently) and surveillance 
mammography (carried out at intervals ranging from 1- to 3-yearly). Follow-up is sometimes 
stratified by the likelihood of disease recurrence (defined as local and/or distant metastatic 
disease), based on prognostic factors taken from the patient’s initial primary breast cancer. The 
majority of surveillance is carried out in secondary care (e.g. surgeons, oncologists, breast-care 
nurses), with patients being discharged to primary care after an interval which varies from 
3 years to continued follow-up in secondary care. The uncertainty about best practice and current 
knowledge about variation in practice is further described below (see Variation in services and/or 
uncertainty about best practice).
Management of disease
Women with primary disease are usually treated using a combination of treatment modalities, 
including surgery, radiotherapy, chemotherapy, hormone therapy and biological therapy 
(trastuzumab), either alone or in a variety of combinations tailored to the patient and the 
type and stage of disease. However, most patients undergo surgery initially, which is either 
mastectomy or BCT, together with axillary surgery (sentinel lymph node biopsy, axillary sample 
or axillary clearance) and tailored adjuvant therapy afterwards. Patients with large or locally 
advanced breast cancer may receive either primary (neoadjuvant) chemotherapy or hormone 4 Background
therapy prior to undergoing surgery. A small number of patients who are unfit for surgery but 
are hormone receptor positive may receive endocrine treatment and/or palliative radiotherapy as 
their sole treatment.
The management of locoregional recurrence following the treatment of primary breast 
cancer is variable in the UK, as there is an absence of RCTs to guide management decisions. 
Following breast conservation surgery it has been reported that, in those patients who 
experience locoregional recurrence, up to 20% may have distant metastases at the same 
time.19,20 Furthermore, other studies have indicated that patients who experience a locoregional 
relapse have a reduced 5-year survival.2,3 Where there is a recurrence in the chest wall after 
mastectomy, patients will frequently have systemic recurrence and therefore all patients 
presenting with recurrent breast cancer should be restaged [investigations may include 
combinations of haematological investigations, chest radiography, abdominal ultrasound, 
computerised tomography (CT) scan of chest and abdomen, isotope bone scan] prior to 
definitive management.21
A multidisciplinary approach is required for the management of patients with locoregional 
recurrence following treatment for primary breast cancer. For patients who have undergone 
breast conservation surgery, treatment is usually mastectomy (with axillary clearance if not 
already performed), together with consideration of further systemic therapy (chemotherapy, 
hormone therapy) to reduce the risk of subsequent metastatic relapse. In patients who have 
a local chest wall recurrence following mastectomy, local therapy (surgery if possible with 
radiotherapy afterwards or if surgery is not possible due to the extensive nature of the disease 
then radiotherapy alone) may be undertaken together with systemic therapy (chemotherapy, 
hormone therapy) given the high risk of subsequent metastatic relapse in this group of patients.
There are no RCTs on which to base the decision to offer systemic adjuvant therapies. In those 
patients without detectable systemic metastases, factors taken into account are as for the use of 
adjuvant therapy, for example tumour size, tumour grade, lymph node status, lymphovascular 
invasion, hormone receptor and human epidermal growth factor receptor 2 (HER2) status and 
the time interval from the treatment of the patient’s original primary breast cancer.
Variation in services and/or uncertainty about best practice
There is considerable debate about the optimal organisation of a surveillance service following 
treatment for primary breast cancer. The number of different guidelines produced by various 
professional groups and policy-makers reflects this.21–25 Previous surveys of breast surgeons, 
oncologists26 and NHS breast-screening units27 indicate that there is wide variation in follow-up 
practice but, in general terms, surveillance includes regular clinical examination, up to 
3–5 years, with annual mammography for up to 10 years, or in some units this is carried out 
indefinitely. The most recent National Institute for Health and Clinical Excellence (NICE) 
guidance recommends mammography annually for 5 years and then follow-up through the 
NHS Breast Screening Programme (NHSBSP).24 There is concern over whether the 3-yearly 
interval is sufficient for the group under surveillance, and some believe a stratified approach 
based on risk of recurrence or contralateral disease is more appropriate. The American Society 
of Clinical Oncology28 recommended that surveillance should include annual mammography 
but acknowledges that there is a lack of high-level evidence to support decisions about the 
frequency and timing of mammographic surveillance. These guidelines have usually been based 
on consensus approaches and literature reviews, and their key recommendations are shown 
in Table 1.
For women who have had treatment for breast cancer there is, however, general agreement that 
there is no survival advantage conferred by an intensive surveillance regimen (comprising chest © Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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radiography, liver ultrasound, haematological investigations and isotope bone scans) compared 
with a simpler follow-up schedule of clinical examination and mammographic surveillance.29
Given the variation in recommendations, it would be surprising if there were no variation in 
practice. The results of a survey of practice conducted for this study are described in more detail 
in Chapter 3.
Current and anticipated costs
As reported above, there are follow-up regimens for women following treatment of primary 
breast cancer. Illustrative annual costs of alternative surveillance regimens are presented in 
Table 2. The calculation of these costs is reported in detail in Chapter 7.
Description of technology
Surveillance mammography
Mammography has been in use for > 30 years and is the standard imaging technique for 
detection of breast cancer.30 In women previously treated for breast cancer, surveillance 
mammography is useful for early detection of tumour recurrence or for confirming the absence 
of recurrent cancer. While tumour recurrence may display similar mammographic features 
to the previous primary breast cancer,31 interpretation of the surveillance mammogram is 
hindered by changes in the breast caused by postoperative scarring and changes to breast density 
caused by primary treatment modalities. For example, following surgery and/or radiotherapy, 
detectable abnormalities on mammography include haematoma, scar formation, fat necrosis, 
skin thickening, increased soft tissue density in the ipsilateral breast and microcalcifications, 
all of which can be misinterpreted as malignancy. Therefore, surveillance mammography after 
the treatment for breast cancer is associated with the possibility of false-positive results causing 
further unnecessary investigations (invasive and non-invasive) and reduction in sensitivity 
for the detection of IBTR. There may also be an effect on MCBC detection with a lack of a 
comparator side.
Although published figures vary, it has been estimated that approximately 50% of IBTRs will 
be detected by mammography, with the remainder being detected by clinical examination.31–33 
TABLE 1  Comparison of guidelines for the surveillance of women who have received treatment for primary 
breast cancer
Organisation publishing 
guidelines Clinical follow-up Mammography Additional comments
ABS at BASO21 Continue follow-up while on 
active treatments; at least 5 years 
recommended
1–2 yearly for up to 10 years after 
the primary diagnosis
High-risk or active treatment then 
more frequent and with agreed 
local protocols
SIGN22 Pragmatic – indefinite 1–2 yearly
NICE (Cancer Service)25 Up to 3 years’ follow-up No recommendation
NICE (Early and Locally Advanced 
Breast Cancer)24
Follow-up to completion of 
adjuvant treatment then choose 
setting in which follow-up occurs
Yearly for 5 years then move 
to NHSBSP screening – more 
frequently than 3-yearly stratified 
by risk
RCR23 1–2 yearly
ABS, Association of Breast Surgery; BASO, British Association of Surgical Oncology; RCR, Royal College of Radiologists; SIGN, Scottish 
Intercollegiate Guidelines Network.6 Background
Patients who have had a mastectomy or those who have undergone breast reconstruction 
following mastectomy do not have mammographic surveillance of that side. Clinical examination 
alone is the standard method of follow-up to detect IBTR, although mammography is undertaken 
of the remaining breast. Patients who have undergone mastectomy may find it easier to detect 
IBTR clinically than those who have undergone breast conservation surgery or reconstruction. 
Approximately 10% of breast cancers that can be palpated on clinical examination are not clearly 
visible on mammography and require the use of additional imaging techniques. Recurrent breast 
cancers detected by mammography are generally smaller and less aggressive than those found on 
clinical examination.31,32 It is presumed, therefore, that mammography, combined with clinical 
examination, allows the earliest possible diagnosis of IBTR and also allows surveillance of the 
contralateral breast for the detection of MCBC. Whether such surveillance regimens reduce 
mortality remains unclear at present.
Mammography involves low-dose X-ray imaging of the breast to create detailed soft tissue, 
high-contrast, high-resolution images, which are recorded on photographic film. Mammograms 
are usually produced by a radiographer and interpreted by a radiologist who is trained in breast 
imaging. Recent developments have led to an increasing use of solid-state detectors rather 
than X-ray film, termed digital mammography or full-field digital mammography (FFDM). 
These convert X-rays into electrical signals. The images produced are displayed on a computer 
screen but can be printed onto radiographic film that is similar to conventional mammograms. 
It is possible to manipulate digital images on-screen to enhance visibility of certain areas. 
Digital mammography is quicker to produce than film mammography, uses lower doses of 
radiation and digital images require less physical storage space than traditional films. Digital 
mammography systems are, however, one to four times more costly than film mammography 
systems.34 In the screening population, digital mammography has improved performance over 
film mammography in younger women and in women with dense breasts. Overall, however, 
the diagnostic accuracy of digital mammography is not significantly greater than that of 
film mammography.35
Other relevant new interventions
Imaging tests
Ultrasound
Breast ultrasound is an imaging technique for diagnosing breast cancer. A hand-held transducer 
produces high-frequency sound waves, which pass through the breast and reflect back or echo 
from various tissue surfaces to form an image of the internal structures. It is not an invasive 
technique and does not involve radiation. The transducer is linked to a computer so that images 
TABLE 2  Illustrative costs of alternative surveillance regimens
Mammographic 
surveillance yearly for 
10 years
Mammographic and 
clinical follow-up yearly 
for 10 years
Mammographic 
surveillance every 2 
years for 10 years
Mammographic and 
clinical follow-up every 
2 years for 10 years
Cost per woman per screen 
(£)
55.45 141.45 55.45 141.45
Cost for first episode of 
surveillance for an initial 
cohort of 10,000 women (£)
552,204 1,408,643 544,259 1,388,376
Cost over 10 yearsa (£) 5,147,650 13,131,382 2,552,363 6,510,943
a  Assuming that mean age of cohort is 57 years, women face the same risk of death as the general population and that they leave this follow-
up regimen once cancer is detected.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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can be viewed on a monitor screen. A radiologist or radiographer is responsible for interpreting 
the ultrasound images generated.
Breast ultrasound has been reported as having a lower sensitivity for detecting breast cancer 
than mammography.36 When biopsies were indicated on the basis of the results of either 
mammography or ultrasound the positive predictive value was lower for ultrasonography than 
for mammography.34 The use of ultrasound in routine practice is therefore mainly as an adjunct 
to mammography as a problem-solving tool to investigate an area in the breast which has been 
designated as ‘suspicious’ by mammography. Here, ultrasound acts as an additional diagnostic 
tool in determining whether a lesion identified on mammography or clinical examination 
requires further invasive investigation, for example in distinguishing between a fluid-filled 
cyst and a solid mass. Breast ultrasound is also particularly useful in evaluating women whose 
mammograms are difficult to interpret due to the density of their breasts.37–39 Ultrasound is not 
used as a surveillance technique due to the low sensitivity of detection of breast cancer but can be 
helpful after mammography in order to differentiate scar tissue from IBTR or MCBC. It can also 
be used to undertake an ultrasound-guided biopsy of a suspicious area found on mammography. 
Ultrasound is a low-cost technique and, unlike mammography, does not involve any harm 
or discomfort to the patient. Test performance is operator dependent and time-consuming, 
however (approximately 30 minutes per ultrasound), and the results are less consistent 
than mammography.
Magnetic resonance imaging
Magnetic resonance imaging (MRI) uses a powerful magnetic field and radio frequencies to 
produce detailed images of the breast. Breast imaging is undertaken using dedicated breast coils 
and with the patient lying prone on the examination table. The body coil around the base of the 
magnet sends radio waves into the breast tissues. The breast coils receive radio waves recording 
signals from the breast tissue. A computer then processes the signals and generates a series of 
images, each of which shows a thin slice of the breast, which can be viewed in different planes. 
An intravenous contrast agent is required to highlight breast cancers within the glandular tissue. 
The examination is carried out in the second week of the menstrual cycle to reduce background 
tissue enhancement.
Magnetic resonance imaging is used in women who are at high risk of developing breast cancer 
as a result of their family history; in distinguishing between scar tissue and recurrent tumour; in 
women for whom ultrasound and mammography findings are discordant; and in patients with 
lobular cancer and/or where there is suspected multifocal disease and a higher risk of MCBC. 
MRI has greater sensitivity than mammography or ultrasound, which makes it a particularly 
useful imaging modality for detecting small tumours and in women with dense breast tissue. 
Specificity, however, has been reported as being as low as 37%, as MRI is poor at distinguishing 
between cancer and benign breast disease.34 MRI is not used as a primary surveillance tool 
at present.
The magnetic field used in MRI is not harmful, although internal medical devices that contain 
metal may malfunction or cause problems during an MRI examination. Some women may 
find the procedure uncomfortable and claustrophobic. There is also a small risk of mild allergic 
reaction if contrast material is injected. MRI investigations carry a greater financial cost (the NHS 
Reference Costs40 report a mean cost of £232) than mammography (a mean cost of £45 for the 
mammogram alone has been estimated from Breast Screening Programme data) or ultrasound 
(the NHS Reference Costs40 report a mean cost of £56). MRI is also more time consuming 
to perform (30–40 minutes) than mammography and is not as readily available, making it 
impractical to perform as part of the outpatient breast clinic.8 Background
Physical examination tests
Specialist-led clinical examination
Up to 10% of breast cancers are not detected by mammography but can be felt during a clinical 
breast examination. The clinical examination involves taking a history together with performing 
a physical examination (visual and palpation) of the breast(s) and lymph-draining areas (axillae, 
supraclavicular regions) and sometimes abdominal examination. It also provides an opportunity 
for monitoring treatment side effects (with appropriate therapy given as required) and its 
outcomes, changing adjuvant therapies, and providing psychological reassurance and treatment, 
if necessary, for the patient. This is conducted by a trained clinician and/or a nurse practitioner, 
and may be performed by other appropriately trained health-care professionals. If there are 
causes for concern then additional investigations can be undertaken, for example mammography, 
ultrasound or MRI. There is broad agreement for frequent clinical examination, usually at 
6-monthly intervals initially and then annually for up to 3–5 years.21,22,25
Unstructured primary care follow-up (including primary care follow-
up and self-examination)
Primary care follow-up  Clinical follow-up of breast cancer patients is routinely coordinated and 
conducted in the secondary care outpatient hospital setting. Patients, however, may detect IBTR 
or MCBC themselves during the interval between clinic visits. There have been suggestions that 
follow-up could be transferred to the primary care setting with the general practitioner (GP) 
performing a similar role to the specialist clinician during the clinical examination.29,41 If a GP 
detects a possible IBTR or MCBC, they should refer the patient back to the secondary care breast 
unit for further investigation.21,24 Primary care follow-up also encompasses the role of the GP 
in assessment and referral of patients presenting in primary care with self-reported symptoms. 
These patients may be under secondary care supervision and/or may not have been taking part 
in any follow-up regimen for a variety of reasons. This latter group of women is classified as 
undergoing unstructured primary care follow-up, as they commonly self present with symptoms 
in the primary care setting.41
Self-examination  The breast self-examination is a physical examination performed by the patient 
to detect any changes in the breast. Special training is given to the patient in palpation techniques 
and to promote breast self-awareness. Training teaches women how to identify new lumps in the 
breast or the axilla that may be potentially malignant, and to identify any changes, such as skin 
rash or nipple discharge, on examining the breast surface. Patients are also taught to recognise 
additional symptoms, such as bone, chest or abdominal pain, difficulty breathing and persistent 
coughs or headaches, that may be indicative of recurrent breast cancer. It is recommended that 
patients should perform a self-examination every month in addition to scheduled imaging and 
clinical examinations.42
Reference standard test
Histopathological examination is the commonly agreed reference standard for diagnosing IBTR 
or MCBC, based on tissue obtained from either a biopsy or cytological examination of a fine-
needle aspirate. Histopathological examination of tissue is usually undertaken where there is a 
suspicion of malignancy on a prior surveillance test. In contrast, there is no reference standard 
for ascertaining the true-negative and false-negative measures of a surveillance test for IBTR 
or MCBC, although this is usually ascertained by a negative result or a positive test result at 
subsequent testing after a period of follow-up has elapsed (e.g. 1 year – mammography interval, 
2–3 years – MRI interval, etc.). A pragmatic reference standard is therefore the diagnosis of IBTR 
or MCBC up to 3 years after a surveillance test has been carried out.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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Identification of important subgroups of patients
It is known that certain groups of patients are at increased risk of IBTR. Those patients tend 
to be under 50 years of age at the time of diagnosis of their first breast cancer, have tumours 
classified histologically as being grade 3 cancers, have larger tumours, lymph node involvement 
and lymphovascular invasion (Table 3 gives an estimate of importance of these factors in IBTR). 
Pathologists in the UK report this information routinely and much of these data are held by the 
cancer registries. We focused on these risk factors as it is possible to stratify patients according 
to these variables and also give some indication on the hazard ratio (HR) of developing IBTR 
or MCBC when taking these factors into account. These variables have been used to estimate 
prognosis, as with the Nottingham Prognostic Index, for example, which is based on tumour size, 
grade and lymph node status. Adjuvant! Online also uses similar criteria to calculate the benefits 
of different types of treatment for each particular patient.
TABLE 3  Factors associated with ipsilateral breast tumour recurrence8
Characteristics associated with primary tumour 10-year LR rate (%) 95% CI
Age at diagnosis (years)
≤ 35 35 17 to 53
36–40 9 2 to 17
41–50 9 7 to 13
51–60 11 7 to 16
> 60 7 4 to 11
Tumour size (pathological) (cm)
< 1.0 4 0 to 8
1.2–2.0 13 9 to 16
≥ 2.1 11 7 to 15
Nodal status (pathological)
Negative 10 7 to 13
Positive 11 7 to 15
Histological type
Infiltrating ductal 9 7 to 12
Infiltrating ductal with EIC 21 11 to 32
Infiltrating lobular 10 2 to 18
Histological grade
Low/intermediate 7 5 to 10
High 15 10 to 19
Vascular invasion
No 8 6 to 11
Yes 15 10 to 20
CI, confidence interval; EIC, extensive intraductal component; LR, local recurrence.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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Chapter 2  
Definition of the decision problem
Decision problem
There is considerable debate about the role and optimal organisation of follow-up of patients after 
treatment for primary breast cancer. The number of differing guidelines that have been produced 
by various professional groups and policy-makers reflects this.21–23,25 There is broad agreement 
that surveillance should include frequent clinical examination, initially up to 3–5 years, with 
mammography starting 6 months after treatment, and then 1- to 2-yearly, for up to 10 years or 
indefinitely. The American Society of Clinical Oncology28 recommended in 2006 that surveillance 
should include annual mammography, although acknowledging that there is a lack of high level 
evidence to support decisions about the frequency and timing of mammographic surveillance.
Seven reviews,4,29,41,43–48 of varying methodological quality, have summarised the evidence of the 
effectiveness of differing surveillance regimens after treatment for breast cancer.
Summary of existing systematic reviews
Lu5 recently conducted a systematic review to determine the impact of early detection of isolated 
locoregional and contralateral recurrence on survival. Thirteen studies considered routine 
follow-up (regular mammography and physical examination) or intensive follow-up (with 
the inclusion of routine additional tests) aimed at early detection of recurrence. The authors 
defined early detection as detection by mammography instead of physical examination or in 
asymptomatic patients, as opposed to those presenting with symptoms or detected via physical 
examination either by clinician or by the patient. The authors reported better overall survival for 
recurrences detected by mammography or in asymptomatic patients, with an absolute reduction 
in mortality of 17–28% if all breast cancer recurrences are detected early. The authors had 
insufficient data to study the contribution of differing frequency of mammography (e.g. yearly 
mammography compared with 6-monthly mammography) or to analyse the effect of prognostic 
factors such as age, tumour stage and surgical treatment. Rojas and colleagues29 focused on the 
effectiveness of different surveillance policies for the detection of distant metastatic disease and 
concluded that follow-up programmes of regular physical examination and yearly mammography 
alone are as effective as more intensive approaches involving laboratory and radiological tests 
in terms of timeliness of detection of tumour recurrences, overall survival and quality of life. 
In addition, follow-up of patients performed by a trained general primary care practitioner 
is comparable to that of hospital-based secondary care specialists in terms of detection of 
tumour recurrence and quality of life. Collins and colleagues44 reported that patient survival 
and quality of life were not affected by intensity of follow-up or location of care, although the 
authors note that data were not sufficiently homogeneous to integrate statistically. Montgomery 
and colleagues46 systematically reviewed RCT evidence for alternative follow-up methods and 
concluded that the trials reviewed were not adequately powered to establish the safety of reducing 
or replacing hospital clinic visits.
Only Grunfeld and colleagues,47 Montgomery and colleagues46 and Barnsley and colleagues43 
specifically considered the role of mammography in surveillance, and Barnsley and colleagues43 
focused solely on surveillance mammography of the reconstructed breast, concluding that 12 Definition of the decision problem
certain local recurrences are detectable by surveillance mammography but that there is a paucity 
of evidence.
De Bock and colleagues45 conducted a review of 18 uncontrolled, prospective and retrospective 
non-randomised studies of the effectiveness of routine follow-up visits and tests. The proportion 
of isolated locoregional recurrences diagnosed during routine visits or routine tests in 
asymptomatic patients was compared with the proportion of isolated locoregional recurrences in 
symptomatic patients. The authors were unable to assess whether recurrences, as defined by the 
study authors, were detected by physical examination or other tests, including mammography, or 
whether the detection of asymptomatic isolated recurrences had any influence on the potential 
for cure or quality of life of the patients.
Montgomery and colleagues,4 in a meta-analysis of 12 studies (11 non-randomised cohorts and 
one randomised trial), aimed to determine the relevant contributions of clinical examination, 
patient self-examination and mammography to the detection of potentially treatable locoregional 
recurrence and contralateral primary cancers. It was reported that 30–40% of treatable 
recurrences, as defined by the study authors, were detected by the patients self-examining. Prior 
to 2000, 15% of relapses were mammographically detected compared with 46% detected by 
routine clinical examination. Post 2000, 40% were mammographically detected and 15% were 
detected through routine clinical examination. Patients with ipsilateral recurrence detected by 
clinical examination appeared to do less well in terms of survival than those detected by self-
examination or mammography. The authors concluded that there was no evidence that clinical 
examination confers a survival advantage compared with other methods of detection and thus 
the need for clinical follow-up in detection of relapse is uncertain. The authors suggest that the 
temporal trend for increased detection by mammography is due to technical improvements in 
mammography and better quality assurance. Houssami and colleagues48 recently reported a 
similar trend for mammographic detection, although they propose that this effect is largely due 
to increased uptake of surveillance mammography by women rather than increased sensitivity 
of mammography.
Grunfeld and colleagues47 systematic review to define the effect of routine surveillance 
mammograms in detecting ipsilateral and contralateral cancer included 15 observational studies 
(published 1980–99). The 10 studies of ipsilateral recurrence showed that mammography 
detected the recurrence in between one-quarter and one-half of the women (range 8–50%), 
with the remainder being found by the women themselves between follow-up or by a hospital 
practitioner during clinical examination. The majority of studies did not report outcomes. Where 
this was reported, the method of detection of ipsilateral tumour did not appear to influence 
survival, except in the study conducted by Voogd.49 Here it was reported that patients had a better 
5-year survival if their tumour recurrence was detected mammographically. The nine studies 
of MCBC showed similar variation of detection methods. However, only one study reported 
outcome and this showed there was no difference in survival when comparing mammographic 
detection of the tumour with other methods.33 The authors did not conduct a meta-analysis 
and concluded that further research is needed to better define the optimum surveillance 
mammography regimen following breast cancer treatment.
Overall, from these reviews the optimal frequency and duration of surveillance mammography 
is not clear. Furthermore, more recent information is required on whether there is new evidence 
concerning the effectiveness of surveillance mammography. This is now extremely important 
because of the development and use of new and increasingly effective treatments for patients 
with breast cancer since 1990. These may offer women an improvement in survival if there is an 
early detection of either IBTR and/or MCBC. A further limitation of all these reviews is that they 
did not consider the costs and cost-effectiveness of surveillance mammography compared with © Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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other follow-up regimens despite there being methods for incorporating economic evidence into 
systematic reviews.50 This is important because the evidence to date has not been systematically 
reviewed to assess whether or not surveillance mammography is cost-effective in the follow-up of 
patients with breast cancer. As health-care resources are limited, they have to be used effectively 
for the benefit of society. Using limited resources to provide surveillance mammography will 
mean that we cannot use those resources to provide some other form of potentially beneficial 
care. For surveillance mammography to be considered efficient the benefits that it provides must 
be greater than the benefits we could have obtained from providing other care.
Relevance of existing data to the decision problem
The introduction of the NHSBSP in the UK in 1988, coupled with advances in the treatment of 
primary breast cancer around 1990, has led to improvements in overall survival, with the 5-year 
relative survival rate now 82% in England and Wales.1 Although long-term follow-up would be 
the most useful to inform the decision problem, technological developments in all aspects of 
diagnosis, treatment and follow-up of women make those women with the longest follow-up 
data the less relevant and their outcomes less generalisable to current practice. Therefore, in 
consultation with expert members of our Advisory Group (see Appendix 1 for details of Advisory 
Group members) we decided to narrow our population of interest to consider data only for 
women treated for breast cancer from 1990 onwards. In addition, we decided not to include 
information from 1990 onwards relating to the Breast Screening Programme. This is because 
the screening population differs greatly to women who have been diagnosed and treated for 
breast cancer due to changes in breast density following treatment for primary breast cancer. 
We therefore felt that it would be inappropriate to use data from breast-screening studies of test 
performance in the systematic reviews (Chapters 4 and 5) to make assumptions regarding test 
performance for surveillance of the contralateral breast. We used parameter estimates for MRI 
test performance in the screening population in the economic evaluation in Chapter 7 of this 
report; however, it was felt that these would provide an indication of the relative value of a more 
costly but more effective test.
Key issues
The key issues to be addressed are:
  ■ Can surveillance mammography improve overall survival for women treated for primary 
breast cancer?
  ■ Does surveillance mammography improve detection of IBTR and MCBC?
  ■ What is the incremental cost-effectiveness of surveillance mammography?
Current care pathway
There are a number of different surveillance mammography regimens in place in the UK for 
women following the treatment of primary breast cancer. In this section, we describe current 
pathways of care for women who are diagnosed, treated and followed up for breast cancer. In 
Chapter 3 we describe the potential alternative care pathways that we will attempt to consider and 
how we derived them.
However, when evaluating different surveillance regimens it is important to understand the 
sequence of care that a woman might receive after treatment for a primary breast cancer. 
Consideration can then turn to how different surveillance regimens may alter the care that a 
woman may receive over time.
Care pathways for current practice
We developed a care pathway for Aberdeen via discussions with experts in Aberdeen 
(Figures 2–4). This care pathway starts with initial presentation and describes the sequence of 14 Definition of the decision problem
events from diagnosis, through treatment and eventual longer-term follow-up. It is useful to 
consider the whole sequence of events, but of central importance to this project is how different 
surveillance regimens will potentially alter this care pathway.
Development of alternative surveillance regimens
Taking the care pathways above as a basis, we used the data reported in Chapter 3 to identify 
potentially relevant pathways for alternative surveillance regimens. We also considered whether 
or not there are any clinically attractive follow-up regimens that might not be used in practice but 
that we might consider useful to estimate their effectiveness, cost-effectiveness and feasibility in 
our subsequent modelling exercise. This consideration was partly informed by our discussions 
at the last Advisory Group Meeting, the literature and the results of our survey reported 
in Chapter 3.
When considering what surveillance regimens might be relevant, answers to the following 
questions were sought.
For mammographic surveillance:
  ■ For which women is the issue of mammographic surveillance relevant?
  ■ What mammography surveillance should be used?
  ■ Does it vary between women and if so why would it vary?
  ■ How often is it performed?
  ■ Where does it take place?
FIGURE 2  Current care pathway: Aberdeen: diagnosis of breast cancer – symptomatic presentation. I-guided core 
biopsy, image-guided core biopsy; MDT, multidisciplinary team; U/S, ultrasound. 
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For clinical follow-up:
  ■ What clinical follow-up is used?
  ■ Does it vary between women and if so why?
  ■ Where does it take place?
  ■ How often?
For unstructured primary care follow-up:
  ■ How might a diagnosis be made?
  ■ At what point would these women enter the care pathway described in Figures 2–4?
More specifically, what factors might influence the choices made about mammographic 
surveillance and clinical follow-up?
Other factors to consider:
  ■ age
  ■ risk factors
  ■ type of primary disease
  ■ type of treatment.
We describe the care pathways developed from this process in Chapter 3. We then used the 
care pathways to structure data collection in the remainder of the project and to help to define 
the comparators for the economic evaluation. The structure of the model, which is detailed 
in Chapter 7, was based upon the current care pathway described above. The structure of the 
economic model was defined to directly address the aim of the review set out below.
Aim of the review
To examine the clinical effectiveness and cost-effectiveness of different surveillance 
mammography regimens after the treatment for primary breast cancer in the UK in primary and 
secondary care settings.
The aim is addressed through:
1.  A survey of UK breast surgeons and radiologists to identify current practice and estimate 
resource consequences of the varying regimens.
2.  Two discrete systematic reviews to determine the clinical effectiveness of differing 
surveillance mammography regimens after treatment for breast cancer on patient health 
outcomes and the diagnostic accuracy of surveillance mammography in the detection of 
IBTR and MCBC.
3.  Statistical analysis of individual patient data and and economic modelling using the 
systematic review results, existing data sets and focused searches for specific data analysis to 
determine the effectiveness and cost–utility of differing surveillance regimens.
The specific objectives are to:
1.  identify feasible management strategies for surveillance and follow-up of women after 
treatment for breast cancer in a UK context18 Definition of the decision problem
2.  determine the effectiveness of differing surveillance and follow-up regimens after treatment 
for breast cancer
3.  estimate the costs of differing regimens for surveillance and follow-up regimens after 
treatment for breast cancer
4.  estimate the cost-effectiveness of differing regimens for surveillance and follow-up regimens 
after treatment for breast cancer
5.  identify future research needs.
Structure of the remainder of the report
The remainder of the report is structured as follows: Chapter 3 describes a survey of current 
practice and feasible management strategies for surveillance in the UK; Chapter 4 assesses 
the clinical effectiveness of surveillance mammography, Chapter 5 assesses test performance 
of surveillance mammography compared with alternative diagnostic tests and combinations 
of diagnostic tests. Chapter 6 describes the analysis of individual patient data (Breast Cancer 
Registry database) and Chapter 7 assesses the cost-effectiveness of surveillance mammography. 
Chapter 8 is a discussion of the findings and Chapter 9 presents the review’s conclusions, 
including implications for NHS service provision and for future research priorities.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Chapter 3  
Identifying feasible UK management 
strategies for surveillance mammography 
and follow-up of women after treatment for 
primary breast cancer
Overview
In the UK, there is considerable debate about the role and optimal organisation of a surveillance 
service following breast cancer treatment. The number of different guidelines produced by 
various professional groups and policy-makers reflects this. The guidelines include those of the 
British Association of Surgical Oncology (BASO) 2009,21 the NICE Guidance on Cancer Services 
2002,25 the NICE Early and Locally Advanced Breast Cancer: Full Guideline (CG80) 2009,24 
the Royal College of Radiologists (RCR) Breast Group 2003,23 and the Scottish Intercollegiate 
Guidelines Network (SIGN) 2005.22 Typically, consensus approaches and literature reviews are 
the basis for these guidelines. We show the variations in key recommendations in Table 1 (see 
Chapter 1).
Donnelly and colleagues’ survey in 200726 of 256 specialists registered to Cancer Trials Units 
suggested that the majority (84%) adhered to locally developed protocols for surveillance, 
and annual mammography was the most common surveillance interval for both invasive 
and non-invasive disease. Maxwell and colleagues’ survey of breast-screening units taking 
part in the Sloane project27 concluded that there was wide variation in follow-up practice 
after surgery (breast conservation or mastectomy) for non-invasive breast cancer. The most 
common frequency of clinical follow-up was annual for up to 5 years and, for surveillance 
mammography, annual up to 10 years after breast conservation, and annual or biennial to 
10 years after mastectomy.
The optimal frequency and duration for conducting surveillance mammography is unclear, thus 
leading to variation in follow-up protocols for breast cancer throughout the UK.
Aim
To describe the variations in current mammographic surveillance and follow-up practice in the 
UK, in order to inform the development of the care pathways for the economic evaluation.
We addressed this aim via a survey of breast surgeons and radiologists (see Methods for the survey 
and Results of the survey) and consultation with our expert project Advisory Group.20 Identifying feasible UK management strategies
Methods for the survey
Objectives
  ■ To identify current UK surveillance mammography regimens.
  ■ To inform the feasible alternative surveillance regimens (care pathways) for:
  – populating the economic model
  – informing the systematic reviews
  – providing context for the individual patient data analysis.
  ■ To inform the choice of comparator surveillance regimens (inclusive or not of 
mammography) for the systematic review components of the wider project.
Population and sample
Our population was all health-care professionals providing surveillance of women following 
treatment for primary breast cancer. We chose our sample from this population to reflect 
those most likely to be currently involved with organising and/or undertaking surveillance 
mammography and to try to ensure UK-wide information. We sampled from the Association 
of Breast Surgery (ABS) at the BASO and the RCR Breast Group. Both the ABS and RCR Breast 
Group (to the best of their knowledge) held current and complete e-mail contacts for their 
members and these lists formed our sample. We sampled all full members (496) and associate 
members (73) of the ABS, and ordinary members (447 radiologists) and associate members (32 
breast physicians) of the RCR Breast Group. We excluded the retired and overseas members of 
both organisations.
Data collection, management and analysis
Questionnaire development
We developed a questionnaire for use in a web-based survey (Appendix 2). The development 
of the data items and questions were informed by recently published similar surveys26,27 and 
with the expert advice of the project Advisory Group. We tested the questionnaire items with 
members of the project Advisory Group and subsequently piloted the questionnaire with the first 
100 members on the ABS and RCR e-mail distribution lists.
Survey invitation and distribution
We invited the ABS and RCR Breast Group members to participate in the survey via an e-mail-
based web link to the online questionnaire sent to them by the ABS and RCR Breast Group 
membership administrators. All responses to the survey were anonymous. The Health Services 
Research Unit (HSRU) (University of Aberdeen) Programming Team created a web-based 
version of the survey questionnaire (see Appendix 2 for content details).
The ABS and RCR Breast Group membership administrators e-mailed the link to the 
questionnaire through a secure website using the e-mail distribution lists for each college. The 
website used for sending the questionnaire URL was password protected to prevent unauthorised 
access. Only persons with authorised login were able to access this website. Once logged on to 
this site, the administrators added the individual e-mail addresses into a text box for submission. 
An automated e-mail (see Appendix 3 for content details) was then sent to all submitted e-mail 
addresses, containing text inviting potential participants to consider participating in the survey 
and the URL link to the survey questionnaire itself. The administrators were able to view only 
the e-mail addresses they submitted and were not able to view e-mail addresses entered by any 
other administrator.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Once potential participants received the e-mail they could then access the survey questionnaire 
by clicking the URL hyperlink contained in the e-mail. Participants could then complete and 
submit the questionnaire. Participants could view their own data only.
We could not target reminders to individuals who had not responded, as participants’ responses 
were anonymous. One general reminder e-mail was sent via the ABS and the RCR Breast 
Group membership administrators to all potential participants after the initial mailing, asking 
those members who had not yet completed the survey to consider doing so (see Appendix 4 for 
content details).
We tested the survey invitation and distribution with members of the project Advisory 
Group and subsequently piloted with the first 100 members on the ABS and RCR e-mail 
distribution lists.
Ethics and consent
We consulted members of the North of Scotland Research Ethics Service to consider whether 
the survey required review by a Research Ethics Committee (REC). They had access to the aims, 
objectives and the content of the questionnaire and concluded that as they viewed it as service 
evaluation it did not require REC review.
The text of the accompanying e-mail and the survey form itself informed potential participants 
that their responses were anonymous and the information would be held in strictest confidence.
The project team did not have access to the e-mail addresses of individual ABS or RCR Breast 
Group members, nor did the questionnaire contain individual personal details. Submitted survey 
data were stored within a secure database on a secure server within HSRU. All researchers who 
could have access to the data had signed and were required to adhere to a ‘Protecting Information 
Policy’ and were expected to adhere to the principles of Good Clinical Practice (GCP).
Data management
The website used for sending the survey invitation e-mails automatically generated unique, study 
identifiers (study ID) for each completion of the survey without identifying individual e-mail 
addresses. Submitted survey data were stored within a secure database on a secure server within 
HSRU. We cleaned survey data and recoded text fields as required.
Data analysis
We defined the response rate to the survey as the number of participants who responded divided 
by the numbers of potential participants on the ABS and RCR Breast Group e-mail distribution 
lists. We summarised the responses to the survey by type and frequency (%).
Results of the survey
We received responses from 17% (183/1048) of those surveyed (see Appendix 5 for the number 
and percentage of respondents who completed each question). The majority of respondents 
(64%) named their specialty as surgery and 35% as radiology (Table 4). Fifty per cent of 
individuals practise in units that annually manage > 300 women with newly diagnosed breast 
cancer, with 26% practising in units managing between 200 and 300 women with breast cancer 
(Table 4). Respondents were based in 105 NHS trusts across the UK (see Appendix 6 for the list 22 Identifying feasible UK management strategies
of NHS trusts) and one in full-time private practice. The number of respondents per trust was 
just one for 60 trusts (57%); in 26 trusts (25%) there were two respondents and in 12 trusts (11%) 
there were three respondents; the maximum number of respondents per trust was six, with only 
seven trusts with four or more respondents per trust.
Initiation, frequency and duration of surveillance mammography
The large majority of respondents initiate surveillance mammography at 12 months post surgery 
for women who have had breast-conserving surgery (BCS) (87%) and for women who have had a 
mastectomy (79%) (Table 5).
Responses ranged from six to 24 months post surgery, with the next most frequent being 
24 months (13%) post mastectomy.
Table 6 shows the respondents standard practice frequencies or intervals of surveillance 
mammography for women after BCS and after mastectomy. Annual surveillance mammography 
was the most commonly reported standard frequency of surveillance mammography for women 
after BCS or after mastectomy (72% and 53%, respectively), with biennial mammography the 
next most frequently reported (12% and 30%, respectively). The ‘other’ responses varied but can 
generally be described as showing a pattern of increasing mammography surveillance intervals 
with increasing time since surgery, for example surveillance mammography at 1, 2, 3, 5, 7 and 
10 years.
Fourteen per cent (26/180) of respondents said that they varied their standard surveillance 
mammography practice (initiation of surveillance mammography post surgery or frequency of 
mammography) for women who had BCS. They varied their practice according to the survey-
prompted criteria of in situ tumours (n = 14); size of tumour (n = 5); grade of tumour (n = 1); 
lymphovascular invasion (n = 4); age (n = 9); absence of radiotherapy (n = 3); combinations of 
these (n = 2); or other criteria (n = 10). Other criteria included ‘close margins’, comorbidities, 
family history and genes predisposing to breast cancer.
Similarly, 13% (23/180) varied their standard surveillance mammography practice (initiation of 
or frequency) for women who had a mastectomy, by factors such as age, cancer grade and size, 
comorbidities, family history, genes predisposing to breast cancer or ‘high-risk’ groups.
In addition, a further 16/183 (9%) commented in text within the questionnaire that they vary 
their standard initiation and frequency surveillance practices, trying to take into account factors 
TABLE 4  Respondent specialty and unit size
Specialty
No. (%) of respondents
n = 183 Percentage of n
Surgery 117 63.9
Radiology 64 35.0
Other 2 1.1
No. of women with newly diagnosed breast cancer unit manages annually
< 100 5 2.7
100–199 33 18.0
200–300 48 26.2
> 300 92 50.3© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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such as age, density of breast tissue, comorbidities, family history, genes predisposing to breast 
cancer or ‘high-risk’ groups.
When asked about through which service they arrange their surveillance mammography, the 
majority responded [175/182 (96%)] that it is through their symptomatic breast service, although 
seven (4%) said through the NHSBSP.
The majority (75%, 136/182) indicated they discharge women from surveillance mammography 
and they do this most frequently 10 years after surgery (Table 7). The majority (82%, 148/180) do 
discharge from clinical follow-up and most frequently at 5 years (Table 7). Just over half (55%, 
98/179) responded that they discharge women to the NHSBSP (Table 8) if eligible.
However, around 28% (47/167) of those who discharge from follow-up (clinical and/
or mammographic follow-up) commented that they vary the duration of surveillance 
mammography and this is influenced by the age of the women (24%), or by other factors 
including family history, genes predisposing to breast cancer, and tumour characteristics.
Combining our respondents’ standard initiation, frequency and duration of surveillance 
mammography resulted in 54 differing surveillance regimens for women after BCS and 56 for 
women following mastectomy (Appendices 7 and 8, respectively). Fifty-one per cent (79/154) of 
respondents follow one of four surveillance regimens for women after BCS. The most commonly 
followed regimens are to initiate surveillance mammography at 12 months after surgery and 
conduct annual surveillance mammography with indefinite duration (12%, 19/154); discharge 
TABLE 5  Initiation of surveillance mammography
No. of months post surgery
After BCS After mastectomy
Number and percentage of respondents
n = 181 Percentage of n n = 159 Percentage of n
6 7 4 2 1
8 1 1 0 0
9 2 1 1 1
11 3 2 1 1
12 157 87 125 79
18 7 4 9 6
24 4 2 21 13
TABLE 6  Frequency of surveillance mammography
Frequency of surveillance 
mammography
After BCS After mastectomy
Number and percentage of respondents
n = 182 Percentage of n n = 181 Percentage of n
Annually 131 72 96 53
Every 18 months 11 6 16 9
Every 2 years 22 12 54 30
Every 3 years 0 0 5 3
Annually to 5 years then every 2 years 9 5 6 3
Other  9 5 4 224 Identifying feasible UK management strategies
from both clinical and mammographic surveillance at 5 years (14%, 22/154) or 10 years 
(12%, 18/154) after surgery; or discharge from mammographic surveillance at 10 years and 
clinical follow-up at 5 years (13%, 20/154). Similarly, after mastectomy the most commonly 
followed regimens are to initiate surveillance mammography at 12 months after surgery and 
conduct annual surveillance mammography, with indefinite duration (7%, 10/136); or discharge 
from both clinical and mammographic surveillance at 5 years (10%, 13/136); or 10 years 
TABLE 7  Duration of surveillance mammography: discharge from surveillance mammography and from clinical 
follow-up
Discharge from:
Surveillance mammography Clinical follow-up
Number and percentage of respondents
Discharge
n = 182 Percentage of n n = 180 Percentage of n
No 46 25 32 18
Yes 136 75 148 82
How many years post surgery
n = 121 Percentage of n n = 130 Percentage of n
1 0 0 3 2
2 0 0 2 1
3 1 1 9 7
5 42 35 85 65
6 3 2 1 1
8 1 1 1 1
9 6 5 0 0
10 67 55 29 22
11 1 1 0 0
TABLE 8  Duration of surveillance mammography: discharge to NHSBSP
Discharge to NHSBSP Number and percentage of respondents
n = 179 Percentage of n
No 81 45
Yes 98 55
At age (years)
n = 39 Percentage of n
50 26 67
70 3 8
75 1 2
Or years of follow-up 
n = 39 Percentage of n
5 2 5
6 1 2
9 1 2
10 5 13© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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(11%, 15/136) after surgery; or discharge from clinical follow-up at 5 years with continued 
mammographic surveillance until 10 years (8%, 11/136).
Ideal practice
Twenty-nine per cent (53/180) of respondents suggested that their ideal surveillance 
mammographic practice differs from their current practice and that this is influenced by the 
factors listed in Box 1.
The most common ideal frequency of surveillance mammography given was annually for 
women who had undergone BCS (80%, 85/106) or mastectomy (57%, 61/106) (Table 9). These 
ideal frequencies of surveillance did not differ from their current practice for the majority of 
respondents, for women after BCS (80%, 84/106) or for women after mastectomy (69%, 73/106). 
However, three respondents suggested that their ideal practice would be to arrange surveillance 
mammography through the screening units, as they are set up to manage the appointment and 
recall system.
Care pathway development
We used the results of our survey, other relevant surveys26,27 and advice from the clinical experts 
involved in this study to identify alternative follow-up regimens. This work formed the basis for 
the care pathways, which, in turn, provided the basis of the economic model that is described in 
Chapter 7. The economic model aims to determine the effectiveness and cost–utility of differing 
surveillance regimens.
Administration
Capacity
Cost or funding
Evidence to guide decisions
Infrastructure
Organisation and resources
Local and national policies and guidance
Patient and staff preconceptions
BOX 1  Factors that influence why ideal practice differs from current practice
TABLE 9  Ideal frequency of surveillance mammography
Ideal frequency of surveillance mammography
After BCS After mastectomy
Number and percentage of respondents
n = 106 Percentage of n n = 106 Percentage of n
Annually 85 80 61 57
Every 18 months 5 5 18 17
Every 2 years 9 8 21 20
Every 3 years 0 0 0 0
Annually to 5 years, then every 2 years 0 0 0 0
Other 7 7 6 626 Identifying feasible UK management strategies
Development of alternative surveillance regimens
Taking the care pathways described in Table 1 (see Chapter 1) and Figures 1–3 (see Chapter 2) as a 
basis, we used the results of the surveys to identify if there were any clinically attractive follow-up 
regimens that might be used in practice or are currently not used in practice. This consideration 
was partly informed by our discussions during project Advisory Group Meetings (which were 
informed by the literature and the results of the survey described above).
When considering what surveillance regimens might be relevant, answers to the following 
questions were sought, which can be briefly summarised as: who would be under surveillance/
follow-up; what technology would be used (e.g. mammography, clinical examination, etc.); where 
would the surveillance be performed; who would perform the surveillance; and what would 
be the frequency of surveillance/follow-up (the questions used are described in more detail in 
Appendix 9).
Surveillance regimens
Figure 5 describes the potential alternative care pathways developed from this process. For 
example, individuals can be followed up using surveillance mammography at different intervals, 
for example once yearly, every 18 months, every 24 months or every 36 months. Alternatively, 
individuals could present to a GP with a problem, i.e. discover a lump. Individuals who present 
to their GP with a lump would be given a clinical examination by the GP. Current practice in the 
economic model is assumed to be once-yearly mammograms.
The alternative surveillance regimens in the economic model vary by screening interval and/
or screening technology. For example, alternative mammographic surveillance regimens to the 
standard regimen would be for mammography to take place at less or more frequent intervals, 
for example every 18 months or every 24 months. Although not explicitly noted, one important 
option to consider as an alternative would be surveillance mammography organised through 
the NHSBSP.
Alternative primary care regimens would be for an individual to attend a GP surgery and 
receive a clinical examination followed by a mammogram if there was a suspicious finding on 
the clinical examination. Other potential surveillance regimens include the use of alternative 
technologies, i.e. MRI or ultrasound in replacement of mammography. For all regimens other 
than GP opportunistic finding, individuals are invited to attend screening at different intervals, 
for example once yearly. An individual can either choose to attend or not attend the screening 
programme. Given that this is a higher-risk group (women who have previously had breast 
cancer), and, also for simplicity of modelling, we are assuming that all individuals who are invited 
for screening do attend. In the intervals in which screening does not occur, we assumed that 
individuals could still be diagnosed with breast cancer through their GP.
Following further discussion within the project Advisory Group, these options were further 
reduced to three regimens that we felt broadly represented the most relevant comparators. This 
decision was also informed by knowledge of the preliminary findings of the research reported 
in Chapters 4–6. These regimens were: mammographic surveillance with and without clinical 
follow-up organised either through secondary care or through the screening service (this option 
embraces regimens 1, 3 and 6 in Figure 5) and the identification of cancer following referral from 
primary care following the identification of a suspicious lump on self-examination (regimen 7).© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
27   Health Technology Assessment 2011; Vol. 15: No. 34 DOI: 10.3310/hta15340
Discussion
The findings of our survey suggest that although common patterns in surveillance 
mammography practice exist there is considerable variation in the way surveillance is organised.
The most commonly followed regimens for surveillance of women after BCS are to initiate 
surveillance mammography at 12 months after surgery and conduct annual surveillance 
mammography with indefinite duration, discharge from both clinical and mammographic 
surveillance at 5 or 10 years after surgery, or discharge from mammographic surveillance at 
10 years and clinical follow-up at 5 years. Similarly, after mastectomy the most commonly 
followed regimens are to initiate surveillance mammography at 12 months after surgery and 
conduct annual surveillance mammography, with indefinite duration or discharge from both 
clinical and mammographic surveillance at 5 or 10 years after surgery or discharge from clinical 
follow-up at 5 years with continued mammographic surveillance until 10 years. However, 
respondents varied greatly in the combinations of start, frequency, duration and discharge from 
surveillance mammography.
Our findings reflect the varying guidance given by the various professional organisations with 
an interest in surveillance after breast cancer (see Table 1, Chapter 1) in combination with ‘local 
circumstances’ of the respondents, and are generally consistent with those of recent surveys 
addressing similar questions.26,27
FIGURE 5  Potential alternative care pathways. F/U, follow-up.
Setting Technology
Secondary care
Secondary care 1
2
4
5
6
7
8
9
3
Mammography
Secondary care
Secondary care
Clinical exam
Clinical exam Mammography
Primary care
Screening service
Primary care
Primary/secondary care
Primary/secondary care
Other technology
Clinical exam
Mammography
Unstructured
Questionnaire F/U
Telephone F/U28 Identifying feasible UK management strategies
Our response rate was not high in comparison with what might be expected for a postal 
questionnaire in medicine or in comparison with the recent surveys.26,27 We discuss further the 
implications of this in Chapter 8.
The plethora of different ways of conducting surveillance mammography in practice mean that 
there are potentially a large number of care pathways that are worthy of further consideration. It 
would not be possible to consider the merits of each of these options especially when there are 
additional methods of follow-up that do not include mammography. Therefore, using the results 
of the survey and expert opinion provided by the project group, a relatively small number of 
follow-up methods were defined, which differed by the diagnostic technology used. It is possible, 
however, that this list excludes potentially important pathways.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Chapter 4  
Systematic review of clinical effectiveness of 
surveillance mammography after treatment 
for primary breast cancer
Overview
As Chapter 3 illustrated, although there is some similarity between surveillance regimens 
used in practice there is also considerable variation. It is unclear which of these alternative 
methods of organising a service represent the most effective and efficient regimen. Previous 
systematic reviews 4,29,43–47 have been unable to clarify the optimal frequency and duration of 
surveillance mammography.
We conducted a systematic review to determine the clinical effectiveness of differing surveillance 
mammography regimens after treatment for primary breast cancer in detecting IBTR and MCBC. 
The results of this review were used to inform the economic evaluation described later in this 
report (Chapter 7).
Methods
Inclusion and exclusion criteria
Types of study
Evaluations of any screening or follow-up regimens are prone to lead and length time bias, i.e. 
detecting tumours early in the course of disease without influencing survival (lead time bias) or 
detecting slower growing tumours that would not reduce length of life or underdetecting rapidly 
progressive tumours that have a poorer survival prognosis (length time bias). As RCTs are the 
optimal method of ameliorating for these biases, we included RCTs of differing surveillance 
mammography regimens and alternative breast cancer follow-up regimens in this evaluation, i.e. 
where women are randomly allocated to one surveillance regimen or another. In addition, we 
included non-randomised comparative studies of differing surveillance mammography regimens 
and alternative breast cancer follow-up regimens. We also included prospective and retrospective 
cohort studies of differing surveillance mammography regimens or alternative breast cancer 
follow-up regimens containing 100 or more participants and where participants were followed up 
for at least a median time of 5 years.
All studies were required to include participants with a diagnosis of primary breast cancer from 
1990 or later. In consultation with expert members of our Advisory Group, we chose 1990 as the 
start date for our inclusion criteria to avoid the introduction of bias for overall survival outcomes. 
Improvements in overall survival around 1990 are attributable to the introduction of the NHSBSP 
in the UK, coupled with advances in the treatment of primary breast cancer and changes to the 
ways in which patients with breast cancer are managed. The 5-year relative survival rate is now 
80% in England and Wales.130 Systematic review of clinical effectiveness 
Types of participants
Women previously treated for primary breast cancer without detectable metastatic disease at 
their initial presentation for treatment.
Types of interventions
Routine surveillance mammography for detecting IBTR and/or MCBC.
Comparator(s)
  ■ No surveillance mammography.
  ■ Differences in frequency of surveillance mammography regimens.
  ■ Alternative follow-up regimens, for example, including, but not limited to, breast-care 
physician-led clinical examination.
Types of outcome measures
We included studies that reported any of the following outcomes:
  ■ Primary outcome – overall survival. We defined overall survival as the amount of time 
that a woman remains free from all-cause mortality following primary treatment. We also 
considered mortality rates to optimise data collection of outcome measures relating to the 
effectiveness of a surveillance regimen.
  ■ Secondary outcomes – IBTR and/or MCBC event rate. We considered event rates and time 
to detection of IBTR and/or MCBC. We did not include tumour recurrences outside of the 
breast, for example regional (axillary) recurrence, or distant metastatic disease, as we would 
not expect surveillance mammography to detect these types of disease recurrence.
  ■ Quality of life – We considered any measure of health-related quality of life attributable to 
surveillance mammography or other follow-up regimen.
  ■ Harms of mammography (adverse events) – Undergoing mammography entails exposure to 
radiation, which carries a small risk of developing cancer. Mammography can also be an 
uncomfortable procedure that can cause pain in some women. Following mammography, 
further investigations may be required, which subsequently turn out to be normal.
  ■ Uptake of mammography – We considered data relating to numbers of women attending for 
planned surveillance mammography.
  ■ Economic data – Reporting of any data on costs to the NHS and patients including resource 
use for the actual interventions and resource use consequent to implementation of that 
intervention, which may occur up to the end of the woman’s life, were planned. This would 
have included the costs arising as a consequence of both true-positives and false-negatives 
and the costs of investigating incidental findings. Estimates of cost-effectiveness would have 
been taken as they were defined in the study and incremental cost per life-year or quality-
adjusted life-year (QALY) were calculated if they could be estimated from the data reported.
In addition to our study eligibility criteria, economic evaluations had to meet the following 
inclusion criteria:
  ■ compare a surveillance mammography regimen with an alternative follow-up regimen
  ■ relate information on costs to effectiveness or have reported both cost and effectiveness data 
(in the same or separate study reports) for the reviewer to relate data on costs to effectiveness
  ■ include detailed methods for estimating costs and effects data in the methods section of the 
study report and report the results in a results section.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Search methods for identification of studies
We conducted an extensive electronic search to identify reports of relevant published and 
ongoing studies, as well as any grey literature. The search strategies were designed to be highly 
sensitive, including both appropriate subject heading and text word terms to capture the concepts 
of surveillance mammography or other follow-up strategies and the study designs meeting the 
inclusion criteria for this review. The searches were restricted to full text papers published from 
1990 onwards without language restriction. We searched the following databases for primary 
studies: MEDLINE, MEDLINE In-Process, EMBASE, BIOSIS, Science Citation Index (SCI), 
CANCERLIT and Cochrane Central Register of Controlled Trials (CENTRAL). We also searched 
the Cochrane Database of Systematic Reviews (CDSR), Database of Abstracts of Reviews of 
Effects (DARE) and the HTA Database for reports of evidence syntheses. Reports of ongoing and 
recently completed trials were sought from the Current Controlled Trials (CCT), Clinical Trials, 
WHO International Clinical Trials Registry Platform (ICTRP), NCI Clinical Trials Database, 
National Research Register (NRR) Archive, and NIHR Portfolio Database. Appendix 10 gives full 
details of the search strategies used.
In addition, we searched relevant websites, namely those of the National Cancer Institute, 
National Comprehensive Cancer Network, CancerWEB, Breast Cancer Surveillance Consortium, 
and the National Library for Health, as well as relevant professional organisations including the 
American Society of Clinical Oncology, the American Society of Breast Disease, the American 
College of Radiology, and the European Society for Medical Oncology. We scanned reference lists 
of all included studies for additional reports.
Data extraction strategy
One reviewer (from GM, CR, RT and SZ) screened the titles and available abstracts of all 
reports identified by the search strategy for relevance to the inclusion criteria. One reviewer 
independently assessed full text copies of all potentially relevant studies to assess them for 
inclusion (from CB, CR and SZ). An economist reviewer examined reports relating to an 
economic evaluation or cost analysis.
We conducted a 10% check of inclusion assessment for all potentially relevant studies (RT). We 
resolved any disagreements by consensus or arbitration by a third party. A list of the included and 
excluded studies is given in Appendices 11 and 12, respectively.
One reviewer (from CR and SZ) independently extracted details of study design, participant 
characteristics, description of the intervention and outcome data (see Appendix 13 for data 
extraction form). A second reviewer independently validated the data extraction (from CR 
and SZ). In the event of any uncertainty, a third reviewer advised on and validated the data 
extraction (CB).
Quality assessment strategy
We assessed the methodological quality of non-randomised studies using a quality assessment 
tool (Appendix 14) adapted from the Review Body for Interventional Procedures (ReBIP) 
checklist for quality assessment of non-randomised studies (comparative studies and case 
series). We included additional items (questions 18 and 19) to assess whether study authors 
attempt to correct for lead and length time bias in their analyses. Each of the items was checked 
as ‘yes’, ‘no’ or ‘unclear’. Each item was worded so that a rating of ‘yes’ was the optimal rating 
of methodological quality, except item 14 regarding differential dropout rate/participants lost 32 Systematic review of clinical effectiveness 
to follow-up. We planned to use an adapted version of the Cochrane Collaboration’s tool for 
assessing risk of bias51 for assessing the methodological quality of individual RCTs. For the 
quality assessment of any economic evaluations, we planned to use the NHS Economic Evaluation 
Database Handbook.52
Data analysis
We planned statistical synthesis of results (using meta-analysis) of included studies directly 
comparing different surveillance mammography regimens or comparing surveillance 
mammography with an alternative follow-up regimen, for RCTs and non-randomised 
comparative studies, favouring intention to treat over per-protocol results for our analysis. We 
planned to derive a pooled HR for time-to-event outcomes (e.g. recurrence and survival). 
For data on harms of mammography, adverse events and quality of life we planned to use 
standardised mean difference to combine quality-of-life scores depending on the suitability of 
study data. We did not plan quantitative synthesis of economic outcomes data.
Results
Number and type of studies included and excluded
Figure 6 shows the number of potentially relevant studies identified by the search strategy with 
details of the number meeting the inclusion criteria and the number that were ineligible by 
exclusion criteria. 
From the literature searches 2849 titles and abstracts were identified, 422 of which were selected 
for full text assessment. We excluded 414 reports, which did not meet the inclusion criteria for 
this review, of which we retained 114 reports to assess eligibility for inclusion in the systematic 
review of test performance (see Chapter 5 of this report). Seven reports were unavailable. We list 
the bibliographic details of the eight studies that met the inclusion criteria in Appendix 11. We list 
the bibliographic details of the excluded studies, plus the reasons for exclusion in Appendix 12.
Characteristics of the included studies
Eight studies met our inclusion criteria.53–60 Appendix 15 provides full details of the characteristics 
of the included studies. Six studies53–58 were retrospective cohort studies. Two studies59,60 were 
prospective cohort studies. We did not identify any RCTs or economic evaluation studies 
meeting our inclusion criteria. Three studies53–55 were conducted in the UK, whereas three58–60 
were conducted in the USA. The study by Paszat and colleagues56 was conducted in Canada, and 
the study by Yau and colleagues57 was conducted in China (Hong Kong). Table 10 provides a 
summary of overall characteristics for the included studies. Table 11 provides further details of 
the characteristics of individual studies.
As we lacked RCT studies directly comparing different surveillance mammography regimens 
we could not conduct a formal meta-analysis of these studies. In addition, none of the included 
studies compared surveillance regimens; therefore, it was not possible to undertake meta-analysis 
assessing surveillance regimens, including investigation of subgroup factors. Consequently, we 
decided to present a narrative synthesis of results for this review.
Four studies reported data for surveillance mammography only56,58–60 and did not report 
details of any additional follow-up given to participants. Three studies considered surveillance 
mammography combined with clinical examination.53–55 The study conducted by Yau and 
colleagues57 considered surveillance mammography, combined with clinical and ultrasound 
examination of the breasts, conducted at the clinician’s discretion. Six studies did not include © Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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a comparator regimen53–55,57,58,60 Lash and colleagues59 comparatively analysed the number 
of consecutive years of guideline surveillance (defined as annual history, annual clinical 
examination and annual surveillance mammography) received by women in their cohort with 
women who had not received consecutive years of guideline surveillance (i.e. women who 
FIGURE 6  Flow chart of the number of potentially relevant reports of identified studies and the number subsequently 
included and excluded from the effectiveness review.
2849 titles/abstracts screened
2427 excluded
422 reports selected for full
text assessment
414 reports excluded:
Surveillance regimen not included: n = 76
Required study design not met: n = 156
Required outcomes not reported: n = 12
Retained for background information: n = 49
Retained for diagnostic accuracy review: n = 114
Not available: n = 7
8 reports included
TABLE 10  Summary of the total number of patients and number of studies by study type, primary surgical treatment 
and type of surveillance test for the included effectiveness studies
Characteristic No. of patients  No. of studies 
Patients
Enrolled 7337 8
Analysed 3775
Type of study
Prospective cohort 637 2
Retrospective cohort 3138 6
Type of primary surgical treatment
Mastectomy 1190 5
Breast conserving 2571 8
No surgery 3 1
Information missing 9 2
Reported as ‘other’ 2 1
Type of surveillance test
XRM 2350 4
Combined XRM, CE 918 3
Combined XRM, CE, US 507 1
CE, clinical examination; US, ultrasound; XRM, X-ray mammography.34 Systematic review of clinical effectiveness 
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had missed one or more annual surveillance appointment for unspecified reasons). Paszat and 
colleagues56 compared women in receipt of more than one episode of surveillance mammography 
within their cohort with women who did not receive surveillance mammography.
Overall, the eight studies enrolled 7337 patients. After exclusions, due to eligibility or participant 
dropout, the studies included 3775 patients in their analyses. The studies included 1626 
mastectomy patients and 4864 breast conservation surgery patients all treated for primary 
breast cancer and without detectable metastatic disease. Five studies53,56,58–60 reported participant 
age details, with 444 participants aged < 50 years and 4168 participants aged 50 years or older. 
Two studies54,55 reported mean ages, 56 and 58 years, and age ranges, 24–91 and 28–91 years, 
respectively. Yau and colleagues57 reported a median age of 46 years and range 25–90 years. 
The earliest report was published in 200153 and the latest in 2009.55 The earliest date of primary 
treatment reported was 199058 and the latest was 2003.57 Follow-up ranged from 2.4 months to 
15 years.
Quality of the included studies
The results of the quality assessment for the individual studies are shown in Appendix 16. Figure 7 
summarises the quality assessment of the included studies.
Four studies56,58–60 were considered to include samples that were unrepresentative of those women 
who we considered eligible for surveillance mammography (i.e. all women treated for primary 
breast cancer). Three of these studies, conducted by the same lead author,58–60 included only 
women aged over 65 years. It is unclear whether the cohorts of women included in the studies 
conducted in 200559 and by Lash and colleagues58 included the same women and hence whether 
or not the studies had an overlap of patients. This older age group represents only a proportion of 
what we consider the eligible population. A pragmatic surveillance mammography regimen could 
include women of all ages, with those over the age of 50 years possibly benefiting from eligibility 
for inclusion in the national NHSBSP. In addition, we also considered that the sample included 
in the study conducted by Paszat and colleagues56 was unrepresentative. In this study, the authors 
randomly selected two samples from their previously identified population of women treated for 
FIGURE 7  Summary of quality assessment of the included effectiveness studies.
Representative sample
Inclusion/exclusion criteria clearly defined
Participants at similar point in disease progression
Selection of patients consecutive
Data collection undertaken prospectively
Groups comparable
Intervention clearly defined
Comparison clearly defined
Overall survival, disease-free survival and relative survival
Objective outcome measures used for ascending disease
Assessment of disease-free outcomes blind
Follow-up long enough
Information on non-respondents, dropouts
Participants lost to follow-up likely to introduce bias
Length of follow-up similar between comparison groups
Important prognostic factors identified
Analyses adjusted for confounding factors
Analyses adjusted for lead time bias
Analyses adjusted for length time bias
0% 20% 40% 60% 80% 100%
Yes
No
Unclear
N/A36 Systematic review of clinical effectiveness 
primary breast cancer. The authors drew one random sample from women without any further 
breast surgery after their initial primary treatment. A larger second sample was drawn from 
the same group who had undergone further breast surgery 6 or more months after their initial 
treatment. The second sampling fraction was larger (0.237 compared with 0.055) to increase the 
probability of including women with an episode of IBTR and/or MCBC. We therefore considered 
that this second group of women with subsequent breast surgery were over-represented in 
comparison to our study population.
It was unclear for five reports53,55–58 whether participants were a consecutively treated series 
of patients, whereas in three studies54,59,60 patient selection was consecutive. All studies clearly 
described their inclusion/exclusion criteria and the intervention, and avoided disease progression 
bias by enrolling participants who were all at a similar point in their condition, as opposed to 
including patients at mixed levels of advancement in their cancer. All studies used objective 
outcome measures for ascertaining overall and disease-free survival, and mortality and IBTR/
MCBC event rates. All studies included a median follow-up time of at least 5 years, which we 
considered adequate for detecting important outcome effects. We did not consider lead and 
length time bias to be applicable to the studies by Montgomery and colleagues55 and Yau and 
colleagues57 as neither study reported mortality data. The remaining studies did not adjust for 
lead or length time bias in their analyses.
Four studies54,55,59,60 provided information on non-respondents and dropouts (e.g. incomplete case 
note data, losses to follow-up, etc.) and all were judged to have avoided attrition bias, defined as 
bias introduced by high or differential dropout of patients. This information was judged as being 
unclear in the remaining studies.53,56–58 All but one study54 identified important prognostic factors 
for patients’ overall survival or mortality.
Two studies59,60 undertook prospective data collection, whereas the remainder undertook 
retrospective data review.53–58
Assessment of effectiveness
Two studies provided data on overall survival, cause-specific survival and the annual hazard 
rate of ipsilateral locoregional and new contralateral relapse in graph form.54,55 Those remaining 
reports eligible for inclusion in this review reported numbers of overall deaths,53,56,58–60 deaths due 
to breast cancer53,56,58–60 and IBTR and/or MCBC events only.53,56–58
Overall survival and mortality
Table 12 summarises the data for mortality as reported by the individual studies. For breast 
cancer-specific mortality, four studies53,56,59,60 did not report whether deaths were due to primary 
breast cancer, breast cancer recurrence or a second primary cancer. Two studies54,58 reported 
deaths due to recurrent cancer or a second primary cancer.
Churn and colleagues53 reported 112 deaths from all causes from an analysis of 612 women.
Lash and colleagues59 reported 63 deaths from all causes from an analysis of 303 women. Of 
these deaths, 27 were due to breast cancer. For all-cause mortality the authors reported a crude 
conditional odds ratio (OR) of 0.62 [95% confidence interval (CI) 0.48 to 0.80] for the effect of a 
consecutive year of mammographic surveillance with clinical examination compared with lack 
of consecutive years of surveillance (i.e. women did not receive surveillance at each consecutive 
year). The age-adjusted OR was reported as 0.66 (95% CI 0.51 to 0.86). For breast cancer-specific 
mortality an OR of 0.7 (95% CI 0.52 to 1.1) was reported. For all but breast cancer mortality, the 
OR was 0.69 (95% CI 0.48 to 0.99).© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Lash and colleagues60 reported 32 deaths from all causes from an analysis of 334 women. Of 
these deaths, 13 were due to breast cancer. The authors reported a decline in mortality rate with 
increasing number of surveillance mammograms received (p for trend = 0.007). The crude OR 
for an additional surveillance mammogram compared with no surveillance mammography was 
0.79 (95% CI 0.56 to 1.1). After adjusting for age, primary tumour stage and receipt of adjuvant 
tamoxifen treatment, this figure was reported as 0.77 (95% CI 0.53 to 1.1). The authors stated that 
they had insufficient data to analyse the effect of surveillance mammography on breast cancer-
specific mortality rates.
Lash and colleagues58 reported 391 deaths from all causes and 178 deaths due to breast cancer 
within the first 5 years of follow-up. Of those women dying from breast cancer, 130 had 
experienced breast cancer recurrence. Thirteen of these recurrences were local and five of the 
women received a surveillance mammogram in the preceding year (38%). In addition, 101 
women had a recurrence and did not die from breast cancer. Of these women 24 had a local 
recurrence, of whom 19 received a surveillance mammogram in the preceding year (79%).
Montgomery and colleagues54 reported a series of 1312 patients who were treated by breast 
conservation surgery. There were 116 patients with an isolated local recurrence and from this 
group 110 were available for analysis (attrition due to either incomplete case notes or patients lost 
to follow-up). In this group of 110 patients, two patients had ipsilateral breast relapse diagnosed 
incidentally during breast reshaping procedures, both of whom subsequently died. Thirty-five of 
the remaining 108 women died. Of these 35 deaths, 12 had IBTR recurrence, 11 had ipsilateral 
axillary recurrence, three had recurrence in both the breast and axilla, eight had MCBC and one 
patient had bilateral breast (IBTR and MCBC) recurrence.
Paszat and colleagues56 reported 512 deaths, of which 374 were breast cancer specific, from 
an analysed study population of 901 patients. The authors analysed the association between 
exposure to one or more episodes of surveillance mammography and the risk of death. Adjusting 
for age, tumour stage, surgery, and adjuvant chemotherapy and adjuvant tamoxifen treatment, 
the authors reported a HR of 0.28 (95% CI 0.22 to 0.37) for breast cancer-specific death. Of those 
TABLE 12  Numbers of deaths due to all causes, breast cancer and IBTR/MCBC, as reported by the included 
effectiveness studies
Study ID
No. of patients 
studied
No. of deaths due to:
Follow-up time for whole cohort
All-cause 
mortality 
Breast cancer-
specific mortality
IBTR/MCBC 
specific
n/N % n/N % n/N %
Churn 200153 612 112/612 18 NR NR 5 years
Lash 200559 303 63/303 21 27/303 9 NR Median 7.4 years (range 10 months to 
9.5 years)
Lash 200660 334 32/334 10 13/334 4 NR 5–8 years
Lash 200758 812 391/812 48 178/812 22 130 5 years
Montgomery 
200754
110 NR NR 24/110 22 Median 10 years (range 1.5–15 years)
Montgomery 
200955
196 NR NR NR Median 5.9 years (range 4 months to 
10.5 years)
Paszat 200856 901 512/901 57 374/901 42 NR 15 years
Yau 200857 507 NR NR NR Median 5.9 years (range 0.2–13 
years)38 Systematic review of clinical effectiveness 
women with IBTR the authors reported an unadjusted HR of 0.36 (95% CI 0.13 to 1.00). The 
authors reported an unadjusted figure of 0.86 (95% CI 0.20 to 3.77) for women with MCBC.
The remaining studies55,57 did not report survival data.
IBTR and/or MCBC event rate
Table 13 summarises the data for IBTR and/or MCBC event rates as reported by the individual 
studies. Two studies did not report details of IBTR and/or MCBC recurrence and are therefore 
excluded from this table.59,60 The remaining six studies53–58 did not report raw data time points 
for when IBTR and/or MCBC events occurred but reported numbers of individual IBTR and/or 
MCBC events experienced within the individual cohort. We have not included any recurrences 
occurring outside the breast in Table 13, for example regional (axillary) recurrences or distant 
metastatic recurrences. Details of these recurrence events are available in Appendix 15 if reported 
by individual study authors.
Lash and colleagues58 reported details for locoregional recurrence. We were able to identify 37 
cases of IBTR recurrence in this study but were unable to identify numbers with MCBC only. 
Montgomery and colleagues55 reported one case of MCBC in the first year following treatment 
of the primary breast cancer, with a case of IBTR and one case of MCBC within the first 3 years; 
with a further three IBTR and four MCBC cases occuring 3 years after treatment.
Method of detection
Five studies53–57 reported details of the mode of IBTR/MCBC detection where this was known. 
The study conducted by Montgomery and colleagues55 reports subsequent deaths where known. 
Table 14 summarises this data. The remaining studies58–60 did not report data regarding the 
method of detection.
We did not find any studies meeting our inclusion criteria that reported data on quality of life, 
harms of mammography, uptake of mammography or economic data.
TABLE 13  Number of patients diagnosed with IBTR/MCBC as reported by the included effectiveness studies
Study ID
No. of patients 
studied
Nos. of patients diagnosed with:
Follow-up time for whole cohort
IBTR MCBC
Bilateral IBTR 
and MCBC
n/N % n/N % n/N %
Churn 200153 612 25/505 5 9/104 9 0 0 5 years
Lash 200758 812 37/851 4a NR NR 5 years
Montgomery 
200754
110 48/110 44 35/110 32 2/110 2 Median 10 years (range 1.5–15 years)
Montgomery 
200955
196 4/196 2 6/196 3 0 0 Median 5.9 years (range 4 months to 
10.5 years)
Paszat 200856 901 84/584 14 49/317 16 0 0 15 years
Yau 200857 507 23/507 5 13/507 3 0 0 Median 5.9 years (range 0.2–13 
years)
a  Overall, 851 BCS patients and 973 mastectomy patients were enrolled in this cohort and 812 patients were analysed. Breakdown of surgery 
type included in the analysis is not given.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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Summary
We conducted a systematic review to determine the clinical effectiveness of differing surveillance 
mammography regimens in detecting IBTR and MCBC in women who were previously 
diagnosed and treated for primary breast cancer without metastatic disease from 1990 onwards. 
We aimed to include RCT and non-randomised comparative studies of differing surveillance 
mammography and alternative breast cancer follow-up regimens. We also included prospective 
and retrospective cohort studies of differing surveillance mammography regimens or alternative 
breast cancer follow-up regimens containing 100 or more participants, where participants were 
followed up for at least a median time of 5 years. The methods used for conducting this review 
are systematic, explicit and comprehensive, and our inclusion criteria are both clinically relevant 
and scientifically rigorous.
Despite extensive searching, we identified only eight studies that met our inclusion criteria, all 
of which were cohort studies. Furthermore, none of the regimens described in these studies 
was identical. For this review, we sought data from the included studies on eight outcomes but 
for six of these outcomes no data were available. Only two studies54,55 provided time-to-event 
data for overall and disease-free survival in graph form. In terms of numbers of patients alive 
and dead, only five studies contributed data towards this outcome.53,54,56,59,60 Only six studies 
reported data on numbers of patients experiencing IBTR and/or MCBC events.53–58 The paucity 
of the underlying evidence base mirrors the findings of previous reviews4,29,43–47 described earlier. 
Nevertheless, a number of conclusions may be drawn.
Firstly, there is a suggestion from two studies that surveillance mammography offers a protective 
effect against death from all causes.59,60 The data reported by Paszat and colleagues56 also suggest 
a protective effect of surveillance mammography for breast cancer-specific death. Furthermore, 
the data reported by Montgomery and colleagues54 suggest a protective effect against death for 
surveillance mammography-detected IBTR when compared with clinical examination, although 
numbers of patients and events are small. In addition, the Montgomery data suggest that a high 
proportion of patients (20%) were recalled in between routine appointments, in most cases to 
report a recurrence detected by the patients themselves. As the remaining studies did not include 
a comparator for surveillance mammography, neither in frequency, nor with an alternative 
regimen, it is not possible to make recommendations for the effectiveness of any surveillance 
regimen beyond these three studies.
Few studies met our eligibility criteria and those included in this review are prone to lead and 
length time bias. The limited and variable nature of the data provided by the included studies 
precluded formal quantitative synthesis, thus only a narrative synthesis of evidence was possible. 
The predefined inclusion criteria for this review did not include measures of psychological effects, 
which are known to be important to the patient experience of surveillance. We further discuss 
key findings and limitations of this review in Chapter 8.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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Chapter 5  
Systematic review of test performance of 
surveillance mammography and comparator 
tests in detecting IBTR/MCBC
Overview
Introduction
The aim of this review was to determine the diagnostic accuracy of surveillance mammography 
for detecting IBTR and MCBC in women who were previously treated for primary breast cancer.
  ■ Primary objective  To determine the performance of surveillance mammography, alone or 
in combination with other tests, in detecting IBTR and/or MCBC in women undergoing 
routine surveillance.
  ■ Secondary objective  To determine the performance of surveillance mammography, alone or 
in combination with other tests, compared with alternative tests, alone or in combination, 
in detecting IBTR and/or MCBC in women with a prior diagnostic test result indicating 
suspicion of IBTR and/or MCBC (referred to subsequently as non-routine surveillance).
Methods
Inclusion and exclusion criteria
Types of study
The following types of study were considered for inclusion:
  ■ RCTs in which women are randomised to receive either the index or comparator test(s) and 
all receive the reference standard test.
  ■ Diagnostic consecutive cohort studies in which both index and comparator tests are 
evaluated against the reference standard test in the same women within the study (head-
to-head design).
  ■ Indirect (between-study) comparisons by comparing cohort studies where women received 
either the index test, or the comparator test, or a combination of tests with the reference 
standard test, and where at least 100 participants were included in the analysis of test 
performance. This type of study design is less reliable than direct studies, as differences in 
diagnostic accuracy are susceptible to confounding factors between studies.61
We did not consider case reports and studies investigating technical aspects of a test.
Types of participants
The types of participants considered were women previously treated for primary breast cancer 
without detectable metastatic disease at initial presentation.42 Systematic review of test performance of surveillance mammography and comparator tests in detecting IBTR/MCBC
Index test
The index test was surveillance mammography.
Comparator test(s)
The following comparator tests were considered:
  ■ ultrasound
  ■ magnetic resonance imaging
  ■ specialist-led clinical examination:
  – hospital clinician led
  – hospital nurse led
  ■ unstructured primary care follow-up (here defined as absence of formal routine secondary 
care follow-up, which may, or may not, involve mammography)
  ■ GP-led follow-up:
  – self-presentation
  – self-examination.
We planned to consider comparisons of both individual and combinations of tests. We 
considered test performance in all settings.
Target condition
The target condition was IBTR and MCBC following treatment for primary breast cancer. For 
the purposes of diagnostic test accuracy, we made no distinction between detection of ipsilateral 
recurrent breast tumours and ipsilateral second primary tumours.
Reference standard
Histopathological examination is the commonly agreed reference standard for diagnosing 
recurrent breast cancer based on tissue obtained by biopsy, usually as a needle biopsy under local 
anaesthesia or in some patients following a surgical biopsy. In addition, in some breast clinics, 
fine-needle aspiration cytology (with or without immediate reporting) is available to allow a 
diagnosis of recurrence. This is usually confirmed by biopsy. Cytological and/or histopathological 
examination is undertaken if suspicion of malignancy is raised on a surveillance test. In contrast, 
there is no reference standard for ascertaining the true-negative and false-negative measures of 
a surveillance test for recurrent breast cancer, although this is usually ascertained by a negative 
result or a positive test result at subsequent testing after a period of follow-up has elapsed (e.g. 
1-year mammography interval, 2- to 3-year MRI interval, etc.). A pragmatic reference standard 
is therefore diagnosis of IBTR or MCBC that occurs within a 3-year period of conducting a 
surveillance test.
The reference standard for this review was histopathological assessment for test positives, along 
with a follow-up period of up to 3 years for test negatives (in order to differentiate between true-
negatives and false-negatives).
Outcomes
The following types of outcome were considered.
Test performance in diagnosing:
  ■ IBTR in women undergoing routine surveillance
  ■ IBTR in women undergoing non-routine surveillance
  ■ MCBC in women undergoing routine surveillance
  ■ MCBC in women undergoing non-routine surveillance.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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To be considered for inclusion, the studies had to report the absolute numbers of true-positives, 
false-positives, false-negatives and true-negatives, or provide information allowing their 
calculation, and report a per-patient analysis.
In studies reporting the above outcomes, we planned to record the following additional 
outcomes, if reported:
  ■ adverse effects (defined as physical harms) of mammography and other tests
  ■ acceptability of the tests
  ■ reliability of the tests
  ■ radiological/operator expertise (who conducts the test and previous experience)
  ■ interpretability/readability of the tests.
Search strategy
Electronic searches were conducted to identify reports of published, unpublished and ongoing 
studies. The search strategies were designed to be highly sensitive, including both appropriate 
subject heading and text word terms to identify diagnostic accuracy studies of mammography 
and comparative tests when used in surveillance. To ensure data consistency with other areas 
of this project, searches were restricted to English-language reports published from 1990 
onwards. Conference abstracts were not included. The following databases were searched for 
primary studies: MEDLINE, MEDLINE In-Process, EMBASE, BIOSIS, SCI and CANCERLIT, 
whereas Medion, the CDSR, DARE and the HTA database were searched for reports of evidence 
syntheses. Reports of ongoing and recently completed trials were sought from the CCT, Clinical 
Trials, WHO ICTRP, NCI Clinical Trials Database, NRR Archive and NIHR Portfolio Database. 
Appendix 17 gives full details of the search strategies used.
In addition, relevant websites were searched and included the National Cancer Institute, National 
Comprehensive Cancer Network, CancerWEB, Breast Cancer Surveillance Consortium, and 
National Library for Health, as well as relevant professional organisations including the RCR, 
ABS at the BASO, American Society of Clinical Oncology, American Society of Breast Disease, 
American College of Radiology, and European Society for Clinical Oncology. The reference lists 
of all included studies were also scanned for additional reports.
Data extraction strategy
One reviewer (from FG, GM, CR, SKA, RT or SZ) screened the titles and abstracts (if available) 
of all reports identified by the search strategy. One reviewer (from FG, JH, GM, CR, SKA, RT 
or SZ) assessed potentially relevant full text studies for inclusion. One reviewer (RT) conducted 
a 10% check of the inclusion assessment for all potentially relevant studies. Any disagreements 
were resolved by consensus or arbitration by a third party.
One reviewer (from JH, CR, SKA or SZ) independently extracted details of study design, 
participants, index, comparator and reference standard tests, and participant flow and outcome 
data (see Appendix 18 for details of the data extraction form). A second reviewer independently 
validated the data extraction. In the event of any uncertainty regarding the data extraction, a 
third reviewer gave advice and validated the data extraction (CB).
Quality assessment strategy
Two reviewers (from JH, CR, SKA or SZ) independently assessed the methodological quality of 
all included studies, using a modified version of the Quality Assessment of Diagnostic Accuracy 
Studies (QUADAS) tool (Appendix 19).62 QUADAS is a quality assessment tool for assessing the 
methodological quality of individual studies in systematic reviews of diagnostic accuracy. It is 
designed to be adapted to make it applicable to a specific review topic. QUADAS was developed 44 Systematic review of test performance of surveillance mammography and comparator tests in detecting IBTR/MCBC
through a formal consensus method and was based on empirical evidence. The original QUADAS 
checklist contained 14 questions. We adapted the QUADAS tool to make it more applicable for 
assessing reports of tests for IBTR/MCBC. We omitted three questions in the original QUADAS 
tool that related to the quality of reporting rather than methodological quality (questions 2, 8 and 
9). These questions related to the description of (1) the selection criteria; (2) the execution of the 
index test; and (3) the execution of the reference standard test.
In question 1 we defined the spectrum of patients representative of those receiving the test in 
practice as women of all ages previously treated for primary breast cancer, without detectable 
metastatic disease. We defined the reference standard (question 2) of the modified tool as 
histopathological assessment for correctly identifying the target condition. We did not include 
follow-up time in this question, as follow-up alone will only identify a possible false-negative 
result but will not identify the target condition as a stand-alone test. We split question 3 (disease 
progression bias) into two parts for (1) test positives and (2) test negatives to assess whether 
the target condition was likely to have changed between the test and the two types of reference 
standard test. We split question 5 (differential verification bias) to assess whether (1) all test 
positives were verified by histopathological assessment and (2) whether all test negatives received 
appropriate follow-up. We added an additional item (question 9) to assess whether the index and 
comparator tests were independently interpreted.
We did not change the remaining questions. These concerned partial verification bias (question 
4), incorporation bias (question 6), test review bias and diagnostic review bias (questions 7 and 
8), clinical review bias (question 10), reporting of uninterpretable/intermediate results (question 
11) and attrition bias (question 12).
Any disagreements were resolved by consensus or arbitration by a third party. Each of the 
items was checked as ‘yes’, ‘no’ or ‘unclear’. Each item was worded so that a rating of ‘yes’ was 
the optimal rating of methodological quality. A study was considered to be of higher quality if 
it was checked as ‘yes’ to items assessing patient spectrum, partial verification and differential 
verification bias and test review bias. We planned to use a separate quality assessment tool using a 
checklist adapted from Verhagen and colleagues63 for any RCTs.
Data analysis
The results of the individual studies were tabulated into a 2 × 2 table, and sensitivity, specificity, 
positive and negative likelihood ratios and diagnostic odds ratio (DOR) were calculated along 
with 95% CIs. The intention was to combine the results of the included studies in a meta-analysis 
using the hierarchical summary receiver operating characteristic (HSROC) framework, where 
three or more studies reported sufficient data. However, due to limited data and variability 
across studies, we felt it unwise to perform a meta-analysis and therefore a narrative synthesis 
of the results is presented (see Table 16 and Appendix 22 for summary characteristics of the 
included studies).
Results
Number and type of studies included and excluded
Nine studies met our inclusion criteria. Figure 8 shows the number of potentially relevant reports 
of the studies identified, the number included and excluded and a summary of the exclusion 
criteria. Appendix 20 lists the bibliographic details of the nine studies that were included in 
the review.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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The bibliographic details of the potentially relevant studies identified by the search strategy, for 
which full text papers were obtained, but which subsequently failed to meet the inclusion criteria, 
are given in Appendix 21. These studies were excluded because they failed to meet one or more 
of the inclusion criteria in terms of types of studies, participants, test, reference standard or 
outcomes (see also Figure 8).
Characteristics of the included studies
Appendix 22 provides details of the characteristics of the included studies. Table 15 provides a 
summary of the overall characteristics of the included studies. Table 16 provides further details of 
the characteristics of study design, patient type, considered index/comparator test and follow-up 
periods for verifying test-negative results for the individual studies arranged alphabetically 
by author.
Overall, the nine studies enrolled 4002 participants. After exclusions, due to eligibility or 
participant dropout, the studies included 3724 participants in their analyses. The earliest study 
took place in 199564 and the latest in 2009.65 The earliest participant enrolment date given was 
199264 and the latest was 2003.65 Four studies did not give any indication of the enrolment time 
period.66–69 One study took place in Sweden,64 two in the UK,67,68 two in Germany,69,70 two in 
South Korea,65,71 one in Italy66 and one in France.72 The ages of the participants ranged from 
22 to 82 years.65 Most participants were aged in their fifties. Details of mean, with standard 
deviations (SDs), and median ages for individual studies are shown, where these were reported, 
in Appendix 22. Reported follow-up of test negatives ranged from 5 to 32 months.
The studies by Rieber and colleagues69 and Shin and colleagues71 were cohort studies, in 
which participants received a comparator test (MRI in the study by Rieber and colleagues69 
and ultrasound in the study by Shin and colleagues71) and the reference standard. The seven 
remaining studies64–68,70,72 were direct head-to-head studies, in which participants all received the 
index test, comparator test and reference standard.
FIGURE 8  Flow chart of the number of potentially relevant reports of identified studies and the number subsequently 
included and excluded from the diagnostic accuracy review.
1815 excluded
246 reports selected for full
text assessment
9 reports included
237 reports excluded:
Required participant eligibility not met: n = 77
Index/comparator test(s) not assessed for
IBTR/MCBC detection: n = 49
Required reference standard not met: n = 6
Required study design not met: n = 67
Required outcomes not reported: n = 8
Required comparator test not met: n = 19
Retained for background information: n = 8
Not available: n = 3
2061 titles/abstracts screened
(after exclusion of reports
already identified by
effectiveness review search)46 Systematic review of test performance of surveillance mammography and comparator tests in detecting IBTR/MCBC
In breast cancer surveillance, the considered diagnostic tests can be used at different stages in the 
assessment pathway prior to a positive test result receiving verification via the reference standard 
test. As described earlier, test administration may be as a first routine surveillance test in a patient 
with no prior suspicion of IBTR/MCBC, or it may be used to evaluate a suspicious test finding 
on a prior diagnostic test (non-routine surveillance patients). Six studies assessed performance 
of the diagnostic test used as a routine first surveillance test.64–67,70,71 The three remaining studies, 
by Mumtaz and colleagues,68 Rieber and colleagues69 and Ternier and colleagues,72 assessed the 
performance of the diagnostic test as part of non-routine surveillance to evaluate a suspicious 
result from a prior diagnostic test.
Three studies reported data on ultrasound.66,71,72 Six studies reported data on MRI.64,66–70 Four 
reported data on specialist-led clinical examination.64,66,67,72 The studies did not explicitly state 
whether a hospital-based consultant or an alternative health-care professional conducted 
the clinical examination. We assumed in all cases that the examination was conducted at a 
consultant-supervised clinic. Drew and colleagues67 reported test performance for surveillance 
mammography, combined with clinical examination. Viehweg and colleagues70 reported test 
performance for combined surveillance mammography, clinical examination and ultrasound 
(known as conventional methods). This study also reported performance for combined MRI and 
TABLE 15  Summary of the total number of patients and number of studies by type of study, numbers analysed, type of 
surveillance and focus of surveillance for the included diagnostic accuracy studies
Characteristic No. of patients (%) No. of studies (%)
Type of study
Cohort 2108 2 (22)
Head to head 1616 7 (78)
Patients
Enrolled 4002 9
Analysed 3724
Type of surveillance
Routine surveillance 3451 (93) 6 (77)
Non-routine surveillance 273 (7) 3 (33)
Focus of surveillance
Local recurrence (IBTR) 298 (8) 5 (56)
Contralateral recurrence (MCBC) 1375 (37) 2 (22)
Both 2051 (55) 2 (22)
Type of testa
XRM 344 5
US 2094 3
MRI 500 6
CE 314 4
Combined XRM, CE 105 1
Combined XRM, US 1256 1
Combined XRM, CE, US 119 1
Combined XRM, CE, US, MRI 119 1
CE, clinical examination; US, ultrasound; XRM, X-ray mammography.
a  Multiple tests used within studies.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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conventional methods. Kim and colleagues65 reported performance for combined surveillance 
mammography and ultrasound. None of the studies meeting our inclusion criteria reported data 
on unstructured primary care follow-up.
The study by Boné and colleagues64 involved mastectomy patients who had all received breast 
reconstruction with implants. Currently, these patients are offered clinical follow-up for the 
ipsilateral breast and surveillance mammography for the contralateral breast annually or once 
every 2 years. Surveillance mammography of the ipsilateral reconstructed breast is performed if 
there is a clinical concern. A previous systematic review of surveillance mammography following 
breast reconstruction was published in 2007 by Barnsley and colleagues.43 This review considered 
case reports and case series literature published between January 1980 and August 2004. The 
included studies involved implants and immediate or delayed transverse rectus abdominis muscle 
(TRAM) flap reconstructions. The authors did not conduct a meta-analysis due to heterogeneity 
in study design, follow-up and surveillance mammography regimen. Review findings suggested 
TABLE 16  Summary of characteristics for individual diagnostic accuracy studies
Study ID Study design
Type of primary 
surgery Index tests  Comparator test
Follow-up time for verifying test-
negative results
Belli  
200266
Direct head-to-
head cohort
Non-routine 
surveillance BCS 
patients
MRI for local 
recurrence
XRM, CE, US for 
local recurrence
MRI and CE follow-up performed at 
3 months
All MRI test negatives underwent cytological 
examination
Boné  
199564
Routine surveillance 
mastectomy 
patients, all with 
breast reconstruction 
and implants
XRM for local 
and contralateral 
recurrence
MRI, CE for local 
and contralateral 
recurrence
Median 10 months (range 5–18 months)
Drew  
199867
Routine surveillance 
BCS patients
MRI for local 
recurrence
XRM, CE, XRM + CE 
for local recurrence
Median 341 days (range 168–451 days)
Kim  
200965
Routine surveillance 
breast-conserving 
and mastectomy 
patients
Adjunct US 
(XRM + US) for 
contralateral 
recurrence
None 1–2 years
Mumtaz 
199768
Non-routine 
surveillance BCS 
patients 
XRM for local 
recurrence
MRI for local 
recurrence
Median 12 months (range 6–15 months)
Rieber 
199769
Cohort MRI for local 
recurrence 
None CE, US performed at 6-month follow-up. 
XRM performed at 12-month follow-up. In 
22 patients a control MRI was performed 
at intervals of 2–16 months (mean 
7.2 months)
Shin  
200571
Routine surveillance 
patients (primary 
surgery type not 
reported)
US for local and 
contralateral 
recurrence
None 6 months
Ternier 
200672
Direct head-to-
head cohort
Non-routine 
surveillance BCS 
patients
XRM for local 
recurrencea
CE, US for local 
recurrence
6 months
Viehweg 
200470
Routine surveillance 
BCS patients
MRI for 
contralateral 
recurrence
CM 
(XRM + CE + US); 
MRI + CM for 
contralateral 
recurrence
12 months
CE, clinical examination; CM, conventional methods; NS, not stated; US, ultrasound; XRM, X-ray mammography.
a  Study authors considered computerised tomography as the index test in this study, but this test was not considered as an included comparator 
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that surveillance mammography is able to detect certain local recurrences, although the authors 
concluded that, due to the paucity of evidence, further research in this area is required. We 
therefore believe that this study merits inclusion in our review, as, although these women 
represent a subset of our considered population, they are an increasingly relevant subgroup who 
might receive surveillance mammography in the future.
Quality of the included diagnostic accuracy studies
The results of the quality assessment for the individual studies are shown in Appendix 23. 
Figures 9 and 10 summarise the quality assessment of the included studies.
None of the studies met all of our quality criteria specified for higher-quality studies, although in 
five studies65,66,68,69,72 this was due to lack of clarity as to whether reference standard results were 
interpreted without knowledge of index test results only.
The study conducted by Boné and colleagues64 was considered to be unrepresentative of our 
considered patient population as a whole; as previously discussed, the participants had all 
received mastectomy for primary breast cancer with breast reconstruction and implants. As 
discussed earlier, it is not standard practice to offer routine surveillance of the treated breast 
to patients receiving either mastectomy alone, or mastectomy with breast reconstruction and 
implants. We therefore felt that, although this patient group represents a subset of our considered 
population, they differ from the wider spectrum of women who would receive surveillance 
in practice.
Only the Shin and colleagues71 study was judged as free of disease progression bias for positive 
index test results. Disease progression bias occurs when the time delay between the index and 
reference standard test is such that improvement or progression of the condition may occur 
in the intervening period. It was unclear whether the remaining eight (89%) studies64–70,72 had 
FIGURE 9  Summary of quality assessment of included diagnostic accuracy studies for routine surveillance.
Spectrum representative
Reference standard confirmed target condition
Disease progression bias avoided for positive
index test results
Disease progression bias avoided for negative
index test results
Partial verification bias avoided
Differential verification bias avoided for positive
index test results
Differential verification bias avoided for negative
index test results
Incorporation bias avoided
Index test results interpreted without knowledge of reference
standard results/diagnostics review bias avoided
Reference standard results interpreted without knowledge
of index test results/diagnostic review bias avoided
Index and comparator tests interpreted independently
Clinical review bias avoided
Uninterpretable/intermediate results reported
Withdrawals explained
0% 20% 40% 60% 80% 100%
Yes
No
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avoided disease progression bias for positive index test results, whereas all studies successfully 
avoided disease progression bias for negative index test results.
Seven (78%) studies64–66,68–70,72 (three routine surveillance and four non-routine surveillance) were 
free from partial verification bias. It was unclear in the study conducted by Shin and colleagues,71 
however, whether test negatives received follow-up. The study by Drew and colleagues67 was 
considered to be vulnerable to partial verification bias, as only those participants testing 
positively on MRI received reference standard verification.
In all studies, positive index/comparator test results were verified by the same reference standard 
(histopathological assessment). In eight (89%) studies (four routine surveillance and four 
non-routine surveillance), participants with negative index/comparator test results all received 
follow-up.64–70,72 In the study conducted by Shin and colleagues71 it was unclear whether all 
patients with negative test results received follow-up.
While it was unclear for all studies whether reference standard results had been interpreted 
without knowledge of the index/comparator test result, it was unclear in the study by Viehweg 
and colleagues70 whether index test results had been interpreted without knowledge of the 
reference standard. Five (56%) studies (three routine surveillance and two non-routine 
surveillance) interpreted index and comparator test results independently. It was unclear 
in the study by Boné and colleagues64 whether index and comparator tests were interpreted 
independently. In the remaining studies,65,69–72 index and comparator test results were not 
analysed separately. Clinical examination and mammography were usually performed before 
MRI or ultrasound. Knowledge of a prior test result could influence the subjective assessment, 
and hence the diagnostic accuracy performance, of the subsequent test(s).
In the study conducted by Rieber and colleagues69 it was unclear whether the same clinical 
data were available as would be the case when the test is used in practice. It was also unclear 
FIGURE 10  Summary of quality assessment of included diagnostic accuracy studies for non-routine surveillance.
Spectrum representative
Reference standard confirmed target condition
Disease progression bias avoided for positive
index test results
Disease progression bias avoided for negative
index test results
Partial verification bias avoided
Differential verification bias avoided for positive
index test results
Differential verification bias avoided for negative
index test results
Incorporation bias avoided
Index test results interpreted without knowledge of reference
standard results/diagnostics review bias avoided
Reference standard results interpreted without knowledge
of index test results/diagnostic review bias avoided
Index and comparator tests interpreted independently
Clinical review bias avoided
Uninterpretable/intermediate results reported
Withdrawals explained
0% 20% 40% 60% 80% 100%
Yes
No
Unclear50 Systematic review of test performance of surveillance mammography and comparator tests in detecting IBTR/MCBC
in the studies by Belli and colleagues66 and Kim and colleagues65 whether uninterpretable or 
intermediate results had been reported, and in the study conducted by Belli and colleagues66 
whether the number of or reason for withdrawals had been explained.
Assessment of test performance
Test performance in diagnosing IBTR
Table 17 shows test performance in detecting IBTR in routine surveillance patients. The studies 
by Boné and colleagues64 and Drew and colleagues67 involving a total of 188 patients reported 
the performance of surveillance mammography, MRI and clinical examination in routine 
surveillance patients. These studies reported sensitivities of 64% and 67%, and specificities of 97% 
and 85%, for surveillance mammography. For MRI the studies reported sensitivities of 86% and 
100%, and 50% and 89% for clinical examination. Boné and colleagues64 did not report specificity 
for MRI or clinical examination. The highest reported sensitivity was for MRI, and surveillance 
mammography combined with clinical examination (both 100%), whereas the highest specificity 
was for surveillance mammography (97%). Similarly, a high specificity of 93% was reported for 
MRI. The lowest reported sensitivity was for clinical examination (50%) and the lowest specificity 
was for surveillance mammography combined with clinical examination (67%).
Table 18 shows test performance in detecting IBTR in non-routine surveillance patients, as 
reported by Belli and colleagues,66 Mumtaz and colleagues,68 Rieber and colleagues69 and Ternier 
and colleagues.72 The studies by Boné and colleagues64 and Drew and colleagues67 involved a total 
of 156 patients and reported median (and range) sensitivity of 71% (50–83%) and specificity of 
63% (57–75%) for surveillance mammography. For MRI, the studies by Belli and colleagues,66 
Mumtaz and colleagues68 and Rieber and colleagues,69 involving a total of 193 patients, reported 
sensitivity of 93% and 100% and a median (and range) specificity of 94% (88–96%). Belli and 
colleagues66 and Ternier and colleagues72 reported the test performance of ultrasound sensitivities 
of 43% and 87%, and specificities of 31% and 73%, and clinical examination, sensitivities of 
43% and 62%, and specificities of 56% and 49%. The highest reported sensitivity (100%) and 
specificity (96%) were for MRI. The lowest reported sensitivities were for both ultrasound and 
clinical examination (43%). The lowest specificity was for ultrasound (31%).
TABLE 17  Test performance as measured by sensitivity, specificity, likelihood ratio and DOR for detecting IBTR in 
routine surveillance patients
Test Study ID
Primary 
surgical 
treatment
Reported 
sensitivity 
(%)
Reported 
specificity 
(%) LR+ LR– DOR (95% CI)
XRM Boné 199564 Mastectomy 64 97 22.2 0.4 60.3 (10.2 to 358.1)
Drew 199867 Breast 
conserving
67 85 4.6 0.4 11.7 (2.6 to 52.4)
1.9 0.5 4.2 (0.6 to 28.6)
MRI Boné 199564 Mastectomy 86 NR
Drew 199867 Breast 
conserving
100 93 14.3 IC IC
CE Boné 199564 Mastectomy 50 NR
Drew 199867 Breast 
conserving
89 76 3.7 0.2 25.4 (3.0 to 213.9)
Combined 
XRM and CE
Drew 199867 Breast 
conserving
100 67 3.0 IC IC
CE, clinical examination; IC, incalculable; LR+, likelihood ratio of a positive test result; LR–, likelihood ratio of a negative test result; XRM, X-ray 
mammography.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Test performance in diagnosing MCBC
Table 19 shows test performance in detecting MCBC in routine surveillance patients. The studies 
by Boné and colleagues64 and Viehweg and colleagues,70 involving a total of 202 patients, reported 
67% and 91% sensitivity and 50% and 90% specificity, respectively, for MRI. Only individual 
studies reported the test performance of surveillance mammography, clinical examination, and 
combinations of tests involving surveillance mammography. The highest reported sensitivity 
(100%) was for combined surveillance mammography, clinical examination, ultrasound 
and MRI,70 whereas the highest reported specificity (99%) was for combined surveillance 
mammography and ultrasound.65 The lowest reported sensitivity (0%) was for clinical 
examination and the lowest specificity was for surveillance mammography, MRI and clinical 
examination (all 50%).64
None of the studies reported diagnostic accuracy of the included tests for diagnosing MCBC in 
non-routine surveillance patients with a prior suspicious test result.
Test performance in diagnosing IBTR and MCBC
The study conducted by Shin and colleagues71 was the sole study reporting overall test 
performance for diagnosing IBTR and MCBC. Shin and colleagues71 evaluated ultrasound in 
routine surveillance patients, reporting a sensitivity of 71% and a specificity of 98% [LR+ 41.4, 
LR– 0.3, OR 138.25 (95% CI 61.26 to 312.04)].
Adverse effects, acceptability of the tests, reliability, radiological/operator 
expertise and interpretability/readability of the tests
None of the included studies reported data concerning these outcomes.
Histology of cancers detected and not detected (true-positives and 
false-negatives)
The histology of cancers detected and those that were not detected (true-positives and 
false-negatives), by each diagnostic test, where reported, are detailed in Appendix 24 (see 
Tables 60–63). We found no discernible pattern for cancers detected and not detected both within 
and between diagnostic tests.
TABLE 18  Test performance as measured by sensitivity, specificity, likelihood ratio and DOR for detecting IBTR in non-
routine surveillance patients
Test Study ID
Primary 
surgical 
treatment
Reported 
sensitivity 
(%)
Reported 
specificity 
(%) LR+ LR– DOR (95% CI)
XRM Belli 200266 Breast 
conserving
71 63 1.9 0.5 4.2 (2.6 to 52.4)
Mumtaz 199768 50 75 2.0 0. 7 3 (0.6 to 14.0)
Ternier 200672 83 57 1.9 0.3 6.3 (2.5 to 15.6)
US Belli 200266 43 31 0.6 1.8 0.3 (0.1 to 2.1)
Ternier 200672 87 73 3.2 0.2 17 (6.2 to 46.5)
MRI Belli 200266 100 94 16.0 IC IC
Mumtaz 199768 93 88 7.4 0.1 91 (7.4 to 1126. 9)
Rieber 199769 100 96 24.2 IC IC
CE Belli 200266 43 56 1.0 1.0 1.0 (0.2 to 5.8)
Ternier 200672 62 49 1.2 0.8 1.5 (0.7 to 3.4)
CE, clinical examination; IC, incalculable; US, ultrasound; XRM, X-ray mammography.52 Systematic review of test performance of surveillance mammography and comparator tests in detecting IBTR/MCBC
Summary
Systematic reviews of diagnostic accuracy are highly complex and methodology in this area 
continues to evolve. We undertook a systematic review to determine the diagnostic accuracy 
of surveillance mammography for detecting IBTR and MCBC in women previously treated 
for primary breast cancer. We aimed to include RCT, head-to-head cohort and single cohort 
studies of women treated for primary breast cancer without detectable metastatic disease. 
The index test for our review was surveillance mammography and our comparator tests were 
ultrasound, MRI, specialist-led clinical examination and unstructured primary care follow-up. 
Our primary outcome was test performance in diagnosing IBTR and/or MCBC in routine and 
non-routine surveillance patients. The methods we adopted for this review are scientifically 
rigorous and compatible with current guidance in this area. Only nine studies, involving 3724 
patients, evaluating the performance of tests for detecting IBTR and/or MCBC in women 
previously treated for primary breast cancer met our inclusion criteria. None of our considered 
tests was used for the same purpose (i.e. routine or non-routine surveillance) in all nine studies. 
Two studies evaluated the performance of surveillance mammography, and MRI, for detecting 
IBTR in routine surveillance patients. Three studies evaluated the performance of surveillance 
mammography, and MRI, for detecting IBTR in non-routine surveillance patients. None of the 
studies evaluated test performance for detecting MCBC in non-routine surveillance patients. 
Table 20 summarises the sensitivities and specificities of the included studies. Results for the Boné 
and colleagues64 study are excluded from this table due to the highly selected patient population 
of this study (mastectomy patients with breast reconstruction and implants).
For the detection of IBTR in routine surveillance patients with no prior suspicion of recurrence, 
the highest reported sensitivity was for MRI and surveillance mammography combined with 
clinical examination (both 100%), whereas the highest reported specificity was for surveillance 
mammography (97%) although it should be noted that this was reported for a highly select 
patient group (mastectomy patients with breast reconstruction and implants). The lowest 
reported sensitivity was for clinical examination (50%), whereas the lowest specificity (67%) 
was also for surveillance mammography combined with clinical examination. For the detection 
of IBTR in non-routine patients, with a suspicious result on a prior test, the highest reported 
sensitivity (100%) and specificity (96%) were for MRI. The lowest reported sensitivities were 
(43%) for both ultrasound and clinical examination each, whereas the lowest specificity was for 
ultrasound (31%).
TABLE 19  Test performance as measured by sensitivity, specificity, likelihood ratio and DOR for detecting MCBC in 
routine surveillance patients
Test Study ID
Primary surgical 
treatment
Reported 
sensitivity (%)
Reported 
specificity (%) LR+ LR– DOR (95% CI)
XRM Boné 199564 Mastectomy 67 50 1.3 0.7 2.0 (0.1 to 78.2)
MRI Boné 199564 Mastectomy 67 50 1.3 0.7 2.0 (0.1 to 78.2)
Viehweg 200470 Breast conserving 91 90 9.4 0.1 93.1 (11.0 to 786.2)
CE Boné 199564 Mastectomy 0 50
Combined XRM 
and US
Kim 200965 Mastectomy 95 99 61.5 0.05 1149.2 (148.0 to 
8937.8)
Combined XRM, CE 
and US
Viehweg 200470 Breast conserving 64 84 3.9 0.4 8.9 (2.4 to 33.0)
Combined XRM, CE, 
US and MRI
Viehweg 200470 Breast conserving 100 89 8.9 IC IC
CE, clinical examination; IC, incalculable; US, ultrasound; XRM, X-ray mammography.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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For the detection of MCBC in routine surveillance patients, with no prior suspicion of 
contralateral cancer, the highest reported sensitivity (100%) was for a combination of surveillance 
mammography, clinical examination, ultrasound and MRI, whereas the highest reported 
specificity (99%) was for a combination of surveillance mammography and ultrasound. The 
lowest reported sensitivity (0%) was for clinical examination, with the lowest specificity for 
surveillance mammography, MRI and clinical examination (all 50%), although these results 
were reported for the highly selected patient group mentioned above. No study reported test 
performance for detecting MCBC in suspicious patients.
From the available data, MRI can be considered as a highly sensitive test for diagnosing IBTR 
in both routine surveillance and non-routine surveillance patients. In both routine and non-
routine surveillance aimed at detecting IBTR, MRI67–69 achieved higher reported specificities 
than surveillance mammography.67,68,72 For the purposes of detecting routine surveillance MCBC, 
MRI70 had the highest reported sensitivity and specificity of any other individual test. From the 
data presented, combining tests increases both sensitivity and specificity for detecting MCBC. 
Combining surveillance mammography, clinical examination, ultrasound and MRI70 produced 
the highest reported sensitivity of 100%. This test combination produced a lower reported 
specificity of 89% compared with combining surveillance mammography and ultrasound,65 which 
produced the highest reported specificity of 99% and the second highest reported sensitivity 
of 95%. Of those test combinations reported here, surveillance mammography combined with 
ultrasound could be considered as the most accurate test combination for detecting MCBC via 
routine surveillance. No data were available to assess test performance for the detection of non-
routine surveillance MCBC.
These results should be interpreted with caution as they are based on a small evidence base of 
nine studies in total, with no one test evaluated by more than three studies, and most reported 
on by single studies only. Of the included studies, few have evaluated the performance of the 
considered tests for similar purposes. Due to differences between a ‘treated’ and ‘untreated’ breast 
(i.e. a breast that has undergone surgery and/or received radiotherapy) it is not appropriate to 
TABLE 20  Summary of test performance in detecting IBTR and MCBC in routine surveillance and non-routine 
surveillance patients
Test
IBTR (routine surveillance) IBTR (non-routine surveillance) MCBC (routine surveillance)
No. of 
studies
Sensitivity 
(%)
Specificity 
(%)
No. of 
studies
Sensitivity 
(%)
Specificity 
(%)
No. of 
studies
Sensitivity 
(%)
Specificity 
(%)
XRM 2 64–67 85–97 3 (50–83) (57–75) 1 67 50
US 2 (43–87) (31–73)
MRI 2 86–100  93 3 (93–100) (88–96) 2 67–91 50–90
CE 2 50–89 76 2 (43–62) (49–56) 1 0 50
Combined 
XRM, CE 
1 100 67
Combined 
XRM, US
1 95 99
Combined 
XRM, CE, 
US
1 64 84
Combined 
XRM, CE, 
US, MRI
1 100 89
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compare test accuracy in detecting IBTR and MCBC. Similarly, it is inappropriate to compare test 
accuracy between routine and non-routine surveillance patients, as the test operator is primed to 
evaluate a suspicious finding in the non-routine surveillance patient. It is unclear what effect this 
has on test accuracy but it is likely to focus attention on a particular area of the breast and may 
arguably increase sensitivity. Given differences in breast density following treatment for primary 
breast cancer, we felt it would also be inappropriate to include studies of test performance in the 
screening population to make inferences for surveillance of the contralateral breast, although 
parameter estimates for MRI in the screening population have been used in the economic 
evaluation in Chapter 7 of this report as it was felt that these would provide an indication of the 
relative value of a more costly but more effective test. Furthermore, no data were reported by the 
included studies on other test performance factors such as adverse effects or acceptability of the 
tests. We further discuss key findings and limitations of this review in Chapter 8.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
55   Health Technology Assessment 2011; Vol. 15: No. 34 DOI: 10.3310/hta15340
Chapter 6  
Analysis of Breast Cancer Registry database
Statement of overall aim and methods
The purpose of surveillance mammography is to try to allow the earliest possible diagnosis of 
breast cancer and hence assume the tumour size at diagnosis is reduced. In order to ascertain 
the effectiveness of surveillance mammography we tried to identify a database with information 
on mammographic detection of IBTR and MCBC. Despite contacting a number of clinical and 
research groups and searching several databases, we were unable to locate a suitable data set with 
the required information. Furthermore, there was no information on how the IBTR or MCBC 
had been detected or on the follow-up mammography regimen of women diagnosed with breast 
cancer in any of the databases to which we had access. We required a representative UK cohort 
on which to base assumptions for our economic model (reported in Chapter 7). We also required 
a data set with a large number of IBTR and MCBC in a contemporary cohort with detailed 
information about the primary tumour to determine whether IBTR or MCBC constituted 
an independent risk of death. In the absence of mammography information, we wanted to 
determine whether size of the IBTR or MCBC was an independent risk factor for death, because 
if this is not the case then surveillance mammography is irrelevant.
We undertook an analysis of the West Midlands Cancer Intelligence Unit (WMCIU) breast 
cancer database to assess the generalisability of this database to UK breast cancer patients, to 
confirm risk factors for IBTR and MCBC, to determine if IBTR and MCBC were risk factors for 
all-cause death and breast cancer death, and to determine whether the size of the subsequent 
breast cancer tumour was a risk factor for death, given the risk factors of the primary tumour. If it 
was demonstrated that women who had an IBTR or MCBC were at an increased risk of death and 
that the size of the second tumour was associated with an elevated risk of death then it could be 
inferred that surveillance mammography may be an effective way to detect these second tumours 
and improve prognosis in breast cancer survivors.
The WMCIU breast cancer primary tumour cohorts
The WMCIU database contained information on 68,677 tumours in women diagnosed with 
breast cancer from 1 January 1990 to 31 December 2007. Follow-up data were available up 
until 31 January 2009. Tumours were excluded from analysis if the primary cancer was non-
invasive or the treatment did not include surgical management in order to be able to distinguish 
future occurrences of ipsilateral local recurrence from progressive disease (Figure 11). Further 
exclusions were made if there was no information on risk factors recorded or if date of death 
was the same as the date of diagnosis. In the event of multiple primary tumours in the same 
breast or bilateral tumours, the worst tumour, as defined by the Nottingham Prognostic Index, 
was used.73 Prior to 1997 the WMCIU did not routinely collect information on all of the risk 
factors included in the analyses. For example, since 1997 the number of involved lymph nodes 
has been collected in addition to nodal status (positive or negative), which had not been 
collected prior to this date. Because of this, we took the pragmatic decision to include tumours 
diagnosed only after 1 January 1997 in the analyses. After exclusions, there were 32,877 women 56 Analysis of Breast Cancer Registry database
with tumour data available for analysis. This total was split into two primary tumour cohorts to 
be analysed separately based on the type of surgery received: the BCS cohort of 17,706 women 
and the mastectomy cohort of 15,171 women. Descriptive information on both of the cohorts is 
contained in Table 21.
Methods
In both cohorts of primary tumours, Cox proportional hazards regression models74,75 were used 
to model four outcomes: time to IBTR, time to MCBC, time to death from all causes, and time to 
death from breast cancer. All risk factors were explored univariately in a simple Cox regression 
model and then simultaneously in a multiple Cox regression model. Risk factors modelled were 
age at diagnosis (≤ 34, 35–49, 50–64, 65–74, 75–79, ≥ 80 years); grade of primary tumour (grade 
1, grade 2, grade 3, grade unknown); size of primary tumour (≤ 10 mm, > 10 mm to < 20 mm, 
≥ 20 mm, size unknown); nodal status (no nodes involved, one to three nodes involved, four or 
more nodes involved, nodal status unknown); and vascular invasion (no, yes, unknown). For all 
risk factors the level of the factor with the best prognosis was used as the reference category, with 
the exception of age at diagnosis where the screening age group (50–64 years of age) was used 
as the reference category. If a woman was indicated as having both an IBTR and MCBC then 
whichever event was detected earliest defined the event for that particular woman. Any IBTR or 
MCBC that occurred within 6 months of diagnosis was excluded, as this might be identified as 
FIGURE 11  Flow chart of exclusion of primary tumours. Mx, mastectomy cohort.
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62,888 primary tumours
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33,715 primary tumours
33,136 primary tumours
33,122 primary tumours
32,877 primary tumours
BCS cohort
17,706 primary
tumours
Mx cohort
15,171 primary
tumours
5789 non-invasive
tumours
17,475 tumours treated
without surgery
11,698 were diagnosed
before 1997
579 were bilateral or
multiple primaries
14 had date of death
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part of the management of the primary tumour and therefore would not be identifiable as part of 
a surveillance regimen.
Ipsilateral breast tumour recurrence (no, yes) and MCBC (no, yes) were entered into the multiple 
Cox regression for modelling death from all causes and death from breast cancer. HRs and 95% 
CIs are presented. Complete tables of the univariate Cox regression models are reported in 
TABLE 21  Description of the primary tumour cohorts
BCS (n = 17,706) Mastectomy (n = 15,171) Total (n = 32,877)
Outcomes
Death all cause 2528 4345 6873
Death breast cancer 1378 2713 4091
Ipsilateral event 455 310 765
Contralateral event  260 262 522
Age at diagnosis (years)
Mean (SD) 59 (12) 61 (14) 60 (13)
Median (25th, 75th centile) 58 (50, 67) 61 (50, 72) 59 (50, 69)
Minimum, maximum 20, 99 20, 97 20, 99
 n   %  n   %  n   %
Age categories (years)
≤ 34 350 2.0 360 2.4 710 2.2
35–49 3513 19.8 3188 21.0 6701 20.4
50–64 8511 48.1 5229 34.5 13,740 41.8
65–74 3491 19.7 3422 22.6 6913 21.0
75–79 1034 5.8 1547 10.2 2581 7.9
80+ 807 4.6 1425 9.4 2232 6.8
Grade
1 4193 23.7 1827 12.0 6020 18.3
2 7697 43.5 6918 45.6 14,615 44.5
3 5388 30.4 5852 38.6 11,240 34.2
Unknown 428 2.4 574 3.8 1002 3.0
Size (mm)
≤ 10 3473 19.6 1103 7.3 4576 13.9
> 10 to < 20 8663 48.9 4224 27.8 12,887 39.2
≥ 20 4885 27.6 8627 56.9 13,512 41.1
Size cat. unknown 685 3.9 1217 8.0 1902 5.8
Nodes
0 11,630 65.7 6938 45.7 18,568 56.5
1–3 3367 19.0 4147 27.3 7514 22.9
4+ 1232 7.0 3402 22.4 4634 14.1
Unknown 1477 8.3 684 4.5 2161 6.6
Vascular invasion
No 12,887 72.8 8608 56.7 21,495 65.4
Yes 3559 20.1 5341 35.2 8900 27.1
Unknown 1260 7.1 1222 8.1 2482 7.558 Analysis of Breast Cancer Registry database
Appendix 25, summary tables of the multiple regression models are below. Kaplan–Meier76 failure 
curves are presented for selected risk factors and outcomes. Incidence rates were plotted against 
time for both IBTR and MCBC in both primary tumour cohorts.
Results
There were 32,877 women with primary breast cancer who met the inclusion criteria for analysis 
(see Table 21). These cohorts were younger on average than the total population of women 
diagnosed with breast cancer. This is because we excluded all women who were not treated with 
a surgical option and these tended to be older women. The BCS cohort consisted of 90,171 years 
of follow-up and the women had a median follow-up of 5 years. There were 73,500 years of 
follow-up in the mastectomy cohort and median follow-up was 4 years.
Incidence of recurrences
Incidence rates per 1000 persons are plotted against year of follow-up in Figures 12 and 13.
FIGURE 12  Incidence per 1000 per year of IBTR and MCBC occurrence for BCS cohort.
FIGURE 13  Incidence per 1000 per year of IBTR and MCBC occurrence for mastectomy cohort.
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Breast-conserving surgery cohort
Estimates from Cox proportional hazards regression models for time to outcome (IBTR, MCBC, 
death from all causes and death from breast cancer) in the BCS cohort are shown in Table 22. 
Tables with details of the univariate regression models are included in Appendix 25.
All risk factors were univariately associated with an increased hazard of IBTR. In particular, age 
≤ 34 years, grade 3 tumour, large tumour (≥ 20 mm), nodal involvement (four or more nodes) 
and vascular invasion (yes) all had HRs of approximately two or above (Appendix 25, Table 64). 
In the multiple Cox regression model (Table 22) the estimates were broadly consistent with the 
univariate models. Grade 3 tumour, age ≤ 34 and nodal involvement (four or more nodes) in 
particular were associated with elevated risk of IBTR.
Univariately there was little that was associated with an increased risk of MCBC in the BCS group 
of women (Appendix 25, Table 65). Older women were at a reduced risk of MCBC. Women with a 
primary tumour ≥ 20 mm were at an increased risk of MCBC, HR 1.60 (95% CI 1.08 to 2.38).
The Kaplan–Meier failure curves in Figure 14 show that women who experienced IBTR were at 
an increased risk of death from all causes. All risk factors were associated univariately with an 
increased risk of all-cause death although there was no evidence that the group aged 35–49 years 
was different in terms of all-cause mortality to the reference group (Appendix 25, Table 66). 
In the multiple Cox regression model (Table 22) all of the risk factors were associated with an 
increased risk of death, but the youngest age group (age ≤ 34 years) was no longer different from 
the reference group. IBTR was a risk factor, which was associated with an increased risk of death 
univariately, HR 2.29 (95% CI 1.97 to 2.67). In the multiple Cox regression model, adding IBTR 
was still associated with an increased risk of death, HR 1.76 (95% CI 1.51 to 2.05). There was no 
evidence that MCBC was related to an elevated risk of death in the BCS cohort, HR 1.05 (95% CI 
0.80 to 1.39) (see Figure 14).
All risk factors were associated univariately with an increased risk of death from breast cancer 
(Appendix 25, Table 67). In particular, the worst prognostic categories of each risk factor were 
associated with an increased risk of death from breast cancer. IBTR was also associated with an 
increased risk of death from breast cancer (Figure 15). MCBC was excluded from the models as a 
risk factor as there were only three cases out of 260 MCBC cases that were coded as having died 
from breast cancer. In the multiple Cox regression model (Table 22) there was no evidence that 
the age groups younger than the reference group were different in terms of risk of death from 
breast cancer. The remaining risk factors were associated with an increased risk of death from 
breast cancer and after adjusting for the other risk factors IBTR was an independent predictor, 
HR 2.13 (95% CI 1.78 to 2.56).
Mastectomy cohort
Estimates from Cox proportional hazards regression models for time to outcome (IBTR, MCBC, 
death from all causes and death from breast cancer) in the mastectomy cohort are shown in 
Table 23. Tables with details of the univariate regression models are included in Appendix 25.
Univariately the worst prognosis levels of the risk factors were associated with an increased risk of 
IBTR in women treated with mastectomy (Appendix 25, Table 68). In the multiple Cox regression 
model the increased risk was associated with grade 3 primary tumour, nodal involvement (four 
or more nodes) and vascular invasion (yes).
Univariately the worst levels of risk factors were associated with an increased risk of MCBC in 
cases treated with mastectomy (Appendix 25, Table 69). In the multiple Cox regression model, 
older women were at reduced risk of contralateral tumour, adjusting for other risk factors 60 Analysis of Breast Cancer Registry database
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(compared to the reference screening age group). Tumour size (≥ 20 mm) and nodal involvement 
(four or more nodes) were associated with an increased risk of MCBC.
All risk factors were associated univariately with increased risk of all-cause death, although 
there was evidence that risk of death from all causes in the 35- to 49-year age group of women 
was slightly reduced (Appendix 25, Table 70). In the multiple Cox regression model all the risk 
factors were associated with an increased risk of death, but the youngest age group (≤ 34 years) 
had a similar risk of all-cause death as that of the reference age group. IBTR was a risk factor 
for death from all causes in a univariate analysis, HR 2.14 (95% CI 1.86 to 2.47), but MCBC 
was not, HR 1.01 (95% CI 0.83 to 1.24) (Figure 16). The estimates of the HRs for all risk factors 
from the univariate model were attenuated slightly in the multiple Cox model and IBTR was still 
associated with increased risk of death. However, a contralateral recurrence was not associated 
with an elevated risk of all-cause death in the mastectomy cohort.
FIGURE 14  Kaplan–Meier failure curves for BCS cohort for time to death from all causes by disease status. BC, breast 
cancer.
FIGURE 15  Kaplan–Meier failure curves for BCS cohort for time to death from breast cancer by disease status. BC, 
breast cancer.
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All risk factors were associated univariately with an increased risk of breast cancer death 
although there was no evidence that the group aged 35–49 years were different in terms of risk of 
death from breast cancer compared with the reference group (Appendix 25, Table 71). IBTR was a 
risk factor which was associated with an increased risk of death from breast cancer, HR 2.78 (95% 
CI 2.37 to 3.27) (Figure 17). In the multiple Cox regression model (Table 23) all of the risk factors 
were associated with an increased risk of death, but in the youngest age group (age ≤ 34 years) 
the risk of death from breast cancer was reduced. There was no evidence that, after correcting 
for other risk factors, this age group is at a different risk of death from breast cancer compared 
with the reference group. In the multiple Cox regression model IBTR was still associated with an 
increased risk of death from breast cancer, HR 2.12 (95% CI 1.80 to 2.50). This indicates that an 
IBTR was related to an increased risk of death from breast cancer even after adjusting for all the 
other risk factors. MCBC was excluded from the models as a risk factor, as there were only six out 
of 262 MCBC cases that were coded as having died from breast cancer.
FIGURE 16  Kaplan–Meier failure curves for mastectomy cohort for time to death from all causes by disease status. BC, 
breast cancer.
FIGURE 17  Kaplan–Meier failure curves for mastectomy cohort for time to death from breast cancer by disease status. 
BC, breast cancer.
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WMCIU second tumour cohorts
The WMCIU database contained information on 2045 ipsilateral tumours and 1355 contralateral 
tumours, defined as ‘second’ tumours, in women diagnosed with breast cancer from 1 January 
1990 to 31 January 2007. Second tumours were excluded from our analysis if the primary 
tumour could not be identified or management of the primary tumour did not include a surgical 
treatment (Figures 18 and 19). A further exclusion category was a non-invasive primary tumour. 
However, after exclusion on the previous criteria there were no women remaining who had 
experienced a non-invasive primary tumour. Further exclusions were made if there was no 
information on risk factors recorded or if date of death was the same as the date of diagnosis. 
In the event of multiple second tumours in the same breast, or in the contralateral breast, the 
tumour with the worst prognosis as defined by the Nottingham Prognostic Index was used.73 
Descriptive information on both these cohorts of women is contained in Tables 24 and 25.
Methods
We modelled the following risk factors relating to characteristics of the primary tumour: age at 
diagnosis (≤ 34, 35 to 49, 50–64, 65–74, 75 to 79, ≥ 80 years), grade of primary tumour (grade 
1, grade 2, grade 3, grade unknown), size of primary tumour (≤ 10 mm, > 10 mm to < 20mm, 
≥ 20mm, size unknown), nodal status (no nodes involved, one to three nodes involved, four or 
more nodes involved, nodal status unknown), vascular invasion (no, yes, unknown), and type 
of surgery (BCS or mastectomy). Modelled risk factors associated with the second tumour were 
time to second tumour (< 60 months or ≥ 60 months) and size of second tumour (≤ 10 mm, 
> 10 mm to < 20 mm, ≥ 20 mm, size unknown). For all categorical risk factors the level of the 
factor with best prognosis was used as the reference category, with the exception of age at 
diagnosis where the screening age group (50–64 years of age) was used as the reference category. 
FIGURE 18  Flow chart of ipsilateral recurrence tumours (IBTR).
2045 ipsilateral recurrence
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1830 ipsilateral recurrence
tumours
1776 ipsilateral recurrence
tumours
1671 ipsilateral recurrence
tumours
1182 ipsilateral recurrence
tumours
1174 ipsilateral recurrence
tumours
215 unable to match to
primary tumours
54 had errors in date of
recurrence
105 had recurrence within
6 months of primary tumour
489 did not receive surgical
treatment for the primary
tumour
8 had no valid risk
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FIGURE 19  Flow chart of contralateral tumours.
1355 contralateral tumours
1226 contralateral tumours
1223 contralateral tumours
1194 contralateral tumours
983 contralateral tumours
975 contralateral tumours
129 unable to match to
primary tumours
3 had errors in date of
occurrence
29 had occurrence within
6 months of primary tumour
211 did not receive surgical
treatment for the primary
tumours
8 had no valid risk
factor data
TABLE 24  Description of the IBTR cohort
 
Received BCS: 739 
(62.9%)
Received mastectomy: 435 
(37.1%) Total: 1174
Death all cause 322 291 613
Death breast cancer 219 223 442
Age at diagnosis of primary tumour (years)
Mean (SD) 55 (13) 59 (13) 57 (14)
Median (25th, 75th centile) 53 (45, 63) 58 (49, 70) 55 (47, 67)
Minimum, maximum 20, 88 24, 93 20, 93
 n   %  n   %  n   %
Age categories (years)
≤ 34 41 5.5 13 3.0 54 4.6
35–49 227 30.7 97 22.3 324 27.6
50–64 295 39.9 158 36.3 453 38.6
65–74 100 13.5 99 22.8 199 17.0
75–79 42 5.7 42 9.7 84 7.2
80+ 34 4.6 26 6.0 60 5.1
Grade
1 108 14.6 30 6.9 138 11.8
2 270 36.5 178 40.9 448 38.2
3 282 38.2 188 43.2 470 40.0
Unknown 79 10.7 39 9.0 118 10.1
continued68 Analysis of Breast Cancer Registry database
We undertook a multiple Cox regression model that included the risk factors associated with the 
primary tumour, time to the second tumour event and the size of second tumour. Outcomes for 
these models were time to death from all causes and time to death from breast cancer.
Results
There were 1174 women with 3870 years of follow-up in the IBTR cohort, of whom there were 
613 deaths from all causes and 442 deaths from breast cancer. Median time from diagnosis of 
primary tumour to diagnosis of second tumour was 21 months.
Estimates from Cox regression models for time to death from all causes in the IBTR cohort are 
shown in Table 26. Women with a second tumour of ≥ 20 mm in maximum diameter were at an 
elevated risk of death compared with the reference group of ≤ 10 mm, HR 1.75 (95% CI 1.29 to 
2.37). This was also evident from the Kaplan–Meier failure curves in Figure 20.
Estimates from Cox regression models for time to death from breast cancer in the IBTR cohort 
are shown in Table 26. Women with a second tumour of ≥ 20 mm were at an elevated risk of death 
compared with the reference group of ≤ 10 mm, HR 1.99 (95% CI 1.37 to 2.89). This was also 
evident from the Kaplan–Meier failure curves in Figure 21.
 
Received BCS: 739 
(62.9%)
Received mastectomy: 435 
(37.1%) Total: 1174
Size (mm)
≤ 10 111 15.0 13 3.0 124 10.6
> 10 to < 20 287 38.8 91 20.9 378 32.2
≥ 20 247 33.4 244 56.1 491 41.8
Size unknown 94 12.7 87 20.0 181 15.4
Nodes
0 333 45.1 150 34.5 483 41.1
1–3 139 18.8 96 22.1 235 20.0
4+ 72 9.7 126 29.0 198 16.9
Unknown 195 26.4 63 14.5 258 22.0
Vascular invasion
No 376 50.9 152 34.9 528 45.0
Yes 194 26.3 193 44.4 387 33.0
Unknown 169 22.9 90 20.7 259 22.1
Time to second tumour (months)
Median (25th, 75th centile) 45 22, 83 34 18, 64 21 40.76
 < 60 447 60.5 309 71.0 756 64.4
Size of recurrence
≤ 10 140 18.9 51 11.7 191 16.3
> 10 to < 20 199 26.9 61 14.0 260 22.1
≥ 20 190 25.7 62 14.3 252 21.5
Size unknown 210 28.4 261 60.0 471 40.1
TABLE 24  Description of the IBTR cohort (continued)© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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TABLE 25  Description of the MCBC occurrence cohort
Received BCS: 534 (54.8%)
Received mastectomy: 441 
(45.2%) Total: 975
Death all cause 158 200 358
Death breast cancer 11 12 23
Age at diagnosis of primary tumour (years)
Mean (SD) 55 (11) 56 (12) 55 (12)
Median (25th, 75th centile) 55 (47, 62) 55 (47, 65) 55 (47, 63)
Minimum, maximum 25, 86 26, 86 25, 86
 n   %  n   %  n   %
Age categories (years)
≤ 34 27 5.1 18 41 45 4.6
35–49 141 26.4 122 27.7 263 27.0
50–64 278 52.1 188 42.6 466 47.8
65–74 65 12.2 80 18.1 145 14.9
75–79 17 3.2 24 5.4 41 4.2
80+ 6 1.1 9 2.0 15 1.5
Grade
1 113 21.2 47 10.7 160 16.4
2 199 37.3 165 37.4 364 37.3
3 150 28.1 167 37.9 317 32.5
Unknown 72 13.5 62 14.1 134 13.7
Size (mm)
≤ 10 84 15.7 22 5.0 106 10.9
> 10 to < 20 249 46.6 106 24.0 355 36.4
≥ 20 133 24.9 241 54.6 374 38.4
Size unknown 68 12.7 72 16.3 140 14.4
Nodes
0 298 55.8 187 42.4 485 49.7
1–3 74 13.9 103 23.4 177 18.2
4+ 24 4.5 106 24.0 130 13.3
Unknown 138 25.8 45 10.2 183 18.8
Vascular invasion
No 288 53.9 187 42.4 475 48.7
Yes 80 15.0 144 32.7 224 23.0
Unknown 166 31.1 110 24.9 276 28.3
Time to second tumour (months)
Median (25th, 75th centile) 60 33, 95 44 26, 79 52 29, 88
< 60 261 49.0 281 63.4 542 55.6
Size of recurrence (mm)
≤ 10 119 22.3 86 19.5 205 21.0
> 10 to < 20 185 36.6 124 28.1 309 31.7
≥ 20 135 25.3 119 27.0 254 26.1
Size unknown 95 17.8 112 25.4 207 21.270 Analysis of Breast Cancer Registry database
There were 975 women with 4268 years of follow-up in the MCBC tumour cohort, with 358 
deaths from all causes and 23 deaths from breast cancer. Median time from diagnosis of primary 
tumour to diagnosis of second tumour was 52 months.
Estimates from Cox regression models for time to death from all causes in the MCBC cohort are 
shown in Table 26. Women with a second tumour of ≥ 20 mm in maximum diameter were at an 
elevated risk of death compared with the reference group of ≤ 10 mm, HR 2.14 (95% CI 1.49 to 
3.06). This was also evident from the Kaplan–Meier failure curves shown in Figure 22.
Estimates from Cox proportional hazards regression models for time to death from breast cancer 
in the MCBC cohort are not included. This was because of the relatively few deaths recorded 
from breast cancer (see Table 25 and Figure 23). A univariate analysis of the size of second 
tumour showed that women with a second tumour of ≥ 20 mm in maximum diameter were at an 
FIGURE 20  Kaplan–Meier failure curves for IBTR cohort for time to death from all causes by size of second tumour.
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FIGURE 21  Kaplan–Meier failure curves for IBTR cohort for time to death from breast cancer by size of second tumour.
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elevated risk of death compared with the reference group of ≤ 10 mm, HR 1.99 (95% CI 1.38 to 
2.83) (see also Figure 23).
Edinburgh breast cancer data set
We also analysed a smaller but cleaner data set from Edinburgh to confirm risk factors for IBTR 
and MCBC, and also risk factors for all-cause death and breast cancer death. This analysis is 
included in Appendix 26. In summary, this analysis confirmed the findings from the WMCIU 
analysis. Women who experienced IBTR were at an increased risk of death from all causes (HR 
1.87, 95% CI 1.41 to 2.49) and of death from breast cancer (HR 2.69, 95% CI 1.94 to 3.72). This 
was not true for women who experienced MCBC; there was no evidence that these women were 
at increased risk.
FIGURE 22  Kaplan–Meier failure curves for MCBC occurrence cohort for time to death from all causes by size of 
second tumour.
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FIGURE 23  Kaplan–Meier failure curves for MCBC occurrence cohort for time to death from breast cancer by size of 
second tumour.
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Summary
The WMCIU data set confirms the known risk factors for death from breast cancer, which 
are tumour size, grade, lymph node involvement, lymphovascular invasion and age, and 
demonstrates that IBTR is an independent variable affecting survival. This was also confirmed in 
a second data set. However, the occurrence of MCBC did not adversely affect survival. In those 
women experiencing a second tumour, the size of the second tumour is important, with tumours 
of > 20 mm in maximum diameter being at a significantly greater risk of death than those with 
either no second tumour or those with a second tumour < 10 mm in maximum diameter.
We have shown that IBTR has an adverse effect on survival. This is independent of the primary 
tumour and in our analysis of BCS the HR was 2.13 (95% CI 1.78 to 2.56). This has been found 
in several previously published series.20,77–80 Furthermore, the time to the event is important, 
with those events that happen later having a survival advantage compared with those that occur 
earlier. This was also found in a combined analysis of five National Surgical Adjuvant Breast and 
Bowel Project trials of women treated by BCS who had node-negative disease77 and the Tuscan 
second breast cancer case series.81© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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Chapter 7  
Economic evaluation
Introduction
This chapter has four main sections: a brief outline of the principles of economic evaluation, 
followed by sections reporting the methods, results and summary of the findings of the 
economic evaluation.
The objectives of this chapter are to determine whether or not (1) any method of surveillance 
could potentially be cost-effective for the whole population of women eligible for the service and 
(2) the method of surveillance should be varied between subgroups of women who are eligible 
for surveillance following surgery for breast cancer.
Principles of economic evaluation
A brief introduction to economic evaluation
The decision to use resources to provide one method of breast cancer surveillance means that 
the opportunity to use these resources in other desirable ways (either to provide another method 
of surveillance or to meet an entirely different health need) is given up. The cost of this decision 
is the benefits (health gains, etc.) that could have been obtained had the resources been used in 
another desirable way. This is the economic notion of ‘opportunity cost’. Strictly speaking, the 
opportunity cost of a decision to use resources in one way is equivalent to the benefits that could 
have been obtained had the resources been used to provide the next best alternative. Economic 
evaluation is a method of providing decision-makers with information about the opportunity 
cost of the decisions that could be made. It does this by comparing alternative courses of action 
in terms of both their costs and consequences.82
An economic evaluation in this context would involve assessing the relative costs and benefits 
associated with alternative surveillance regimens for breast cancer. The objective of such an 
economic evaluation would be to provide information to assist decision-makers in the allocation 
of available resources so that benefits could be maximised. A cost-effectiveness plane (Figure 24) 
illustrates how an economic evaluation brings together information on costs and benefits. The 
vertical axis represents the difference in costs between surveillance regimens (e.g. mammography 
vs MRI). The horizontal axis represents differences in effectiveness between the two regimens.
In the north-west and south-east quadrants of Figure 24 a clear decision about which surveillance 
regimen should be preferred is provided because one or other regimen is less costly but more 
effective (i.e. it dominates the other treatment). In the north-west quadrant the experimental 
regimen is more costly and provides less benefit, therefore the control regimen is more efficient 
(is dominant). In the south-east quadrant the opposite situation occurs and the experimental 
regimen is more efficient (is dominant), as it is less costly and provides more benefit. The 
circle in the centre of the figure represents the possibility that no meaningful differences in 
costs or benefits exist between the regimens and for practical purposes the two regimens are 
equally efficient.76 Economic evaluation
In the two remaining areas of the figure, the north-east and south-west quadrants, a judgement 
is required as to whether the more effective regimen is worth the extra cost. To aid these 
judgements, information can be provided in terms of an incremental cost-effectiveness ratio 
(ICER). The higher the ICER of one intervention compared with another, the less likely it is that 
this intervention will be considered efficient.
Methods
Economic modelling of alternative surveillance regimens
A surveillance programme needs to be not only effective, but also cost-effective. Using Markov 
modelling methods, the cost-effectiveness of various surveillance programmes is compared. The 
economic model describes the pathway of care of individuals from the point where they received 
treatment for breast cancer and will receive some form of ongoing surveillance. This includes 
their longer-term (ideally their lifetime) costs and consequences, including those that might arise 
from any subsequent cancers. Surveillance can be considered as an event undertaken at discrete 
intervals and repeated over time and hence a Markov model was developed. This can be used to 
describe the logical and temporal sequence of events following the implementation of alternative 
surveillance regimens. We used the model to provide the estimated costs and outcomes for a 
selected period for a cohort of women for different surveillance regimens.
The model
Markov models comprise a set of states and at any point in time an individual will be in one of 
these states and will stay in that state for a defined period of time (the cycle length) before they 
FIGURE 24  Relationship between the difference in costs and effects between a new (experimental) method of 
surveillance and an alternative (control) method. NE, north-east; NW, north-west; SE, south-east; SW, south-west.
Experimental intervention
more costly
Experimental intervention
more effective
Control intervention
more effective
Control intervention
more costly
NW NE
SW SE© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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are allowed to move to another state. The cycle length must be a period relevant to the condition 
considered (e.g. 6 months, 1 year, 18 months, etc.) At the end of each cycle, individuals can 
remain in the state in which they started the cycle or move to a different state. The probabilities 
of moving from one state to another are called transition probabilities. In each state, the model 
will assign costs and benefits for each individual according to different interventions and/or time 
spent in each state. In a Markov model, there must be at least one absorbing state, typically death, 
from which the person will not be able to leave.
Figure 25 shows a simplified version of the model presented for illustrative purposes (Appendix 27 
contains a copy of a section of the full model structure). In this figure, the states are presented 
as ovals, whereas the arrows show the possible directions in which individuals could move at 
the end of each cycle. The rate at which an individual moves (makes a transition) between states 
is governed by the transition probabilities. The states considered in the model are thought to 
reflect possible paths of individuals. The top line in Figure 25 represents the possible path for 
individuals who start off after ‘successful’ (the belief being that the woman has been successfully 
treated for cancer but is at risk of developing subsequent disease) treatment free from cancer but 
who develop breast cancer over time but remain undiagnosed. The bottom section of Figure 25 
represents those individuals who start in the model after ‘successful’ treatment free of cancer, but 
go on to develop IBTR or MCBC over time but are identified and treated for the disease.
If a woman initially has no evidence of IBTR or MCBC then over time she will have the chance 
of IBTR or MCBC occurring. The natural history of disease and the effectiveness of initial 
treatment determine the chance of this occurrence. Surveillance will not alter the chance of IBTR 
or MCBC occurring but may alter the chance of that cancer being detected, the stage at which it 
is found and hence the treatment and possible final outcome. Within the simplified version of the 
model shown in Figure 25 only three treatment states are depicted. These treatment states vary 
according to the risk profile of the breast cancer being treated. Once IBTR or MCBC is identified 
it is assumed that the cancer is treated and that subsequently individuals may have an altered life 
expectancy as a result of the recurrence. We also assumed that women who have had a further 
cancer will be judged as being at ‘moderate’ risk of developing further disease and so will have 
a more intensive follow-up. The absorbing state in the model is death. Any individual can move 
into this state from any other state within the model. The chance of moving into this state will be 
determined by the age of the woman through all-cause mortality and cancer-specific mortality. 
If a cancer is missed during surveillance then it is assumed that it will remain untreated until it 
is identified.
FIGURE 25  Depiction of a simplified version of the Markov model. Risk profile refers to the mortality risk for a given 
cancer. In this simplified figure, it is assumed that cancers differ in terms of the risk of death.
No cancer
Untreated cancer
High-risk profile
Untreated cancer
Medium-risk profile
Untreated cancer
Low-risk profile
Treated cancer
High-risk profile
Treated cancer
Medium-risk profile
Treated cancer
Low-risk profile78 Economic evaluation
The model will compare different regimens but, for each regimen, a cohort of women will pass 
through the different health states. The costs per woman and speed at which they progress 
through the states will vary between regimens. The intuitive idea behind the model is to identify 
the regimen that leads to the most effective and cost-effective surveillance regimen.
Description of a woman’s movement through a model regimen
The model includes women who may develop IBTR and or MCBC. The model itself does 
not differentiate between these situations. The model starts with a surveillance year; based 
on information from the survey of current practice this frequency could be once every 6, 12, 
18, 24 or 36 months. In regimen 1, individuals can either be followed up using surveillance 
mammography or present to their GP with a symptom, i.e. discover a lump. Women who have 
a mammogram can either be identified as free of disease or have a positive mammogram. The 
model structure allows this to be either a true- or false-positive or a true- or false-negative. If the 
mammogram is a true-negative, individuals will then go back to the surveillance programme. If 
the mammogram is a false-negative, individuals also return to the surveillance programme, but 
these individuals would not receive any treatment or care for that cancer although it remains 
undetected. Furthermore, it is possible that if a cancer is undiagnosed or untreated the severity 
of the cancer will increase and the prognosis worsen, for example over time the tumour may 
increase in size. We handle this within the model by increasing the severity of untreated disease 
over time. It is also possible for individuals who have had a true-negative, over the duration of the 
cycle, to go on to develop breast cancer in a subsequent cycle. The likelihood of this happening 
will be dictated by the expected incidence of IBTR and MCBC over the cycle length (for example, 
if the cycle length were 1 year then it would be based upon an estimate of the annual incidence of 
IBTR and MCBC).
If the mammogram is a true-positive, individuals will be diagnosed with invasive or non-invasive 
cancer and managed appropriately. If the mammogram is a false-positive it will be assumed that 
the individual will undergo further invasive tests and on a negative finding of these tests they will 
return to the surveillance programme at the end of the cycle.
The regimens considered
We outlined the alternative surveillance regimens in Chapter 3 (see Methods for the survey). The 
intention was to compare each of these within the economic model. We planned to combine 
surveillance regimens for hypothetical cohorts of the population defined in terms of the nature of 
primary disease, treatment and demographic characteristics, etc. These cohorts reflect the prior 
hypothesised risk of IBTR and MCBC in the population of women previously treated surgically 
for a primary breast cancer.
As described in Methods for the survey, we identified nine different surveillance regimens. 
We reduced these to three regimens, which we felt broadly represented the most relevant 
comparators. Furthermore, as reported in Chapter 5, few data on the diagnostic performance 
of the alternative methods of identifying a breast cancer were available. Consequently, it was 
not possible to model all of these options. However, some data were available to facilitate the 
modelling of mammographic surveillance with and without clinical follow-up organised either 
through secondary care or through the screening service. The presentation of the woman 
following referral from primary care following the identification of a suspicious lump on self-
examination was also modelled. We used this form of diagnosis in two specific ways within the 
model. First, we used it to define a situation where no formal surveillance is used. It is also used 
to model the possibility that a woman presents between surveillance points with symptoms 
suggestive to a GP of breast cancer, for example if surveillance is performed every 36 months 
then within this 36-month interval the model will allow a woman to present with clinical 
symptoms that are suggestive of breast cancer and for this cancer to be identified.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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Populating the model with parameter estimates
To provide estimates of relative cost-effectiveness, the model requires estimated values for a range 
of different types of parameters. Such parameter estimates should be derived in a systematic 
and reproducible manner to avoid bias caused by the distorted and selective use of data.50 The 
assembly of such data need not necessarily be comprehensive; rather, effort should focus on 
identifying the most relevant data to the decision problem, which in this case was the comparison 
of alternative surveillance regimens for women after treatment for primary breast cancer.
We assembled the different types of data required for the economic model from analyses of 
existing data sets, a series of systematic reviews, and focused searches for specific pieces of data. 
We report the methods and results of the reviews and analyses of existing data sets in detail in 
Chapters 4–6. In brief, the broad types of data required to populate the economic model relate to:
  ■ the uptake of surveillance and follow-up
  ■ the prevalence, incidence and risk of progression of the disease, i.e. its epidemiology and 
natural history
  ■ the performance of different regimens (e.g. clinical examinations, mammograms, etc.) in 
terms of the accuracy of the diagnostic tests
  ■ resource use and unit costs required to estimate the costs of alternative surveillance 
regimens; the specific parameters and methods used to provide estimates that are relevant to 
the UK context
  ■ health-state utilities.
Within the model, we based estimates of uptake upon simplifying assumptions and advice 
from the members of the project Advisory Group. We derived the data on the natural history of 
women from the analysis of the large data set reported in Chapter 6. Further data relating to the 
management and outcomes came from the source data used to inform recent NICE guidelines.24
We derived information on the diagnostic performance of different types of clinical tests, for 
example the accuracy of mammography, from data reported in Chapter 5.
We derived data on the costs incurred for the different surveillance regimens and their 
consequences from structured reviews of the published literature, as well as routine data sources 
such as the NHS Reference Costs.40 The perspective for costs is the NHS.
Data on the utilities associated with differing severities of cancer and the possible differences in 
quality of life associated with various surveillance regimens were obtained from the published 
literature, including the review of economic evaluations, as described above, as well as a search of 
the Cost-Effectiveness Analysis Registry (CEA Registry: www.cearegistry.org/).
We report how we derived each of these sets of data and the values used in the model in more 
detail in the sections below.
Uptake of surveillance and follow-up
Within the model, we assumed that, if individuals are invited to attend surveillance, they do in 
fact attend. This may be too high, as approximately 75–80% of the normal population attend for 
breast screening. The other variable required for the model is the probability that a woman will 
present to the GP with symptoms that she thinks are suspicious. Based upon advice from the 
clinical members of the Advisory Group we assumed that 30% of women with prior treatment 
for breast cancer might present to the GP per annum. We then converted this percentage into a 
probability of presenting per 6-month cycle by fitting an exponential curve. The probability used 
within the model was 0.1393, i.e. in the no surveillance arm of the model, and for during the 80 Economic evaluation
surveillance interval in the surveillance arms of the model, just under 14% of surviving women 
who have not been diagnosed with a recurrent cancer will present to a GP every 6 months. 
The following formula assumes that events occur at a constant rate over time: p = 1–e–rt, where 
p = probability, e = base of natural logarithm, r = rate and t = time period.
Epidemiology and natural history of breast cancer
Data relating to the natural history of breast cancer required for the model can be split into four 
components. These are:
1.  recurrence/occurrence rates for women initially treated for breast cancer
2.  estimated survival of women without and with IBTR or MCBC
3.  estimated proportions of the different types of IBTR or MCBC occurring
4.  estimated change in the severity of untreated cancer over time.
IBTR and/or MCBC rates for women initially treated for breast 
cancer
Part of the analysis reported in Chapter 6 related to the time to event for IBTR and MCBC 
cancers. Using the estimated 10-year survival and the same methods as described above, an 
exponential curve was fitted so that the probability of experiencing an event for IBTR or MCBC 
per cycle (a 6-month period) was estimated. We report the estimated 10-year incidence rate for 
women initially treated by BCS or mastectomy, as well as the incidence per cycle (per 6-month 
period) in Table 27. Within the model, we assumed IBTR and MCBC events were independent 
and that the rates summed within the model to provide a net rate of cancer incidence. As 
described below this assumption was relaxed in sensitivity analyses, where we modelled the 
impact on costs and benefits of the incidence of the more serious IBTR events separately.
The data reported in Table 27 are taken to be representative of the rates expected for the whole 
population of women who received either BCS or mastectomy as part of the treatment of their 
primary cancer. It should be noted that the rates of MCBC in women who were originally treated 
by mastectomy are higher than the rates in those who were originally treated using BCS. These 
estimates are based upon observed estimates and the difference may simply be a reflection of 
imprecision in estimates, i.e. in reality no difference exists. Whether this is true or not is a matter 
for debate. A finding from Chapter 6 was that the incidence of subsequent cancer events was 
predicted in part by the characteristics of the primary cancer. Using the same methods described 
we have estimated the incidence per cycle for the reference case used in Cox proportional hazard 
models reported in Chapter 6 (Table 28).
We calculated upper and lower estimates of incidence by combining estimates of the hazard 
rates obtained from the Cox proportional hazard models with the event rates and probabilities 
reported in Table 29. It was assumed that hazard rates were additive but upper and lower 
estimates were based only on proportional hazard rates for factors, for example tumour size, age, 
grade, etc., which were found to be statistically significant at the 5% level in the analyses reported 
in Chapter 6.
TABLE 27  Estimated incidence of IBTR and MCBC disease for women following surgery for primary disease
Initial form of surgery Type of event 10-year failure probability
6-month cycle failure 
probability
BCS IBTR 0.045 0.0023
MCBC 0.030 0.0015
Mastectomy IBTR 0.035 0.0018
MCBC 0.035 0.0018© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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Estimated survival of women with and without IBTR and/or MCBC
The economic model does not stop with the diagnosis of cancer. It seeks to model the impact on 
survival caused by delayed identification. To do this estimates of survival of women who develop 
a further case of cancer are required. Also required are estimates of survival for those women 
who do not develop further cancer. Estimates of the former depend upon whether or not the 
cancer was diagnosed and treated and the effectiveness of any treatment.
We conducted a structured review of relevant management guidelines to estimate data on the 
survival of women who go on to develop further cancer (reported in more detail in Appendix 28). 
The recent NICE guideline was identified as providing the best available evidence of treatments 
for early breast cancer relevant to the UK.24 The data used to support the NICE guideline 
recommendations came from the EBCTCG83 and Adjuvant! Online computer program.84 We 
prepared estimates of survival following various treatment options using the Adjuvant! Online 
computer program due to its flexibility. Adjuvant! Online draws on information from mortality 
statistics in the USA, the SEER database, and meta-analyses and individual clinical trials. Based 
on well-validated factors, such as age, menopausal status, oestrogen receptor (ER) status, tumour 
size and grade, nodes status, etc., predictions can be made about survival for alternative adjuvant 
treatment regimens, such as chemotherapy and hormone therapy. The programme derives 
survival estimates from the US population, however.
As survival estimates are linked to the effectiveness of treatments it was necessary to also 
define the therapy given for a cancer. The choice about what therapies would be adopted for 
which categories of cancer were based upon the recommendations in the NICE guideline24 and 
clinical advice from members of the study team about typical treatments within the UK. Based 
upon these data we derived specific therapies for cancers with specific characteristics. Using 
Adjuvant! Online, we estimated predictions of 10-year cancer-related mortality. Table 30 shows 
the simplified classification of prognostic factors used by Adjuvant! Online. We grouped these 
TABLE 28  Alternative values for the subgroup of women taken as the reference case in Cox proportional hazard modela
Initial form of surgery Type of event 10-year failure probability
6-month cycle failure 
probability
BCS IBTR 0.040 0.0020
MCBC 0.020 0.0010
Mastectomy IBTR 0.038 0.0019
MCBC 0.028 0.0014
a  The reference group in the Cox proportional hazard model was: age 50–64 years, grade 1, size < 1 cm, no lymph node involvement, no 
vascular invasion.
TABLE 29  Hazard rates for high and low estimates and the incidence per cycle estimated from these rates
Initial form of surgery Type of event
Cumulative hazard rate
6-month cycle failure 
probability
Low High Low High
BCS IBTR 0.72 6.64 0.0015 0.0135
MCBC 0.34 1.60 0.0003 0.0016
Mastectomy IBTR 0.85a 5.36 0.0016 0.0104
MCBC 0.27 1.53 < 0.0014 0.0022
a  There was no evidence of a statistically significant difference. The smallest point estimate of a difference was for age 35–49 years.82 Economic evaluation
estimates, as described below, for cancers that had similar management costs and survival. This 
simplification was performed because Adjuvant! Online can provide more data than were readily 
manageable in the economic model, and the economic model itself was focused on surveillance 
regimens rather than treatments of women with breast cancer.
We grouped the different cancers into five different risk profiles, which had an increasingly worse 
prognosis. The cancers included in each risk profile had a predicted 10-year mortality that fell 
into the range defined for the risk profile. We derived the range for each risk profile following 
consideration of the mortality data derived from Adjuvant! Online and discussions within the 
Advisory Group.
As each risk profile contained several different cancers (defined in terms of size, ER status, etc.) 
an average mortality had to be calculated. To calculate this average mortality we required data 
on the estimated proportion of each type of cancer in each risk profile. These data were derived 
from the further analysis of the WMCIU Breast Cancer Registry data set used in Chapter 6. 
Cases were included if they were invasive tumours and diagnosed from 1997 (due to the extent 
of missing data prior to that date). We considered only tumours that were surgically treated. For 
the selected cases, descriptive information about the proportions of women with cancers with the 
following combination of characteristics were derived: ER positive or negative, grade of cancer 
(grades 1, 2 or 3), tumour size (0.1–2.0 cm, 2.1–5.0 cm, > 5.0 cm) and number of positive lymph 
nodes (zero, one to three, four or more). Unfortunately, ER status was mostly missing within the 
data set so could not be provided. Therefore, using published information85 we considered that 
70% of cancers would be ER positive with the remainder being ER negative. We report these data 
in detail in Appendix 28. We assumed that the proportions of the different types of IBTR and 
MCBC would be the same as those for primary cancer. We made this assumption because there 
were more cases of primary cancer and hence less likelihood of there being no data to provide 
estimates for the combination of tumour characteristics described below.
From the WMCIU Breast Cancer Registry data, the proportion of each type of cancer (in terms 
of the proportion with a particular tumour grade, size, nodal involvement, etc.) was defined in 
each risk profile. We then multiplied the proportions by the 10-year mortality estimates for the 
corresponding cancer. We then summed the product of these calculations to give an average 
10-year mortality rate for each risk profile.
Using the estimated 10-year mortality derived for each risk profile we fitted an exponential curve 
so that the probability of dying from cancer per cycle (a 6-month period) for each risk profile 
(Table 31) could be estimated using a formula similar to the one described above. For example, 
Table 31 shows that the average mortality rate from cancer at 10 years for risk profile state 1 was 
4.86%, and, using the formula reported above, the risk of dying from cancer in any 6-month 
cycle was estimated to be 0.002%. Further detail of the data underpinning Table 31 is shown in 
Appendix 30.
TABLE 30  The simplified classification of prognostic factors
Comorbidity Average for age
ER status Positive Negative
Tumour size (cm) 0.1–2 2.1–5 > 5
Positive nodes 0 1–3 4–9 > 9
Tumour gradea 1 2 3
a  Excluded factors in current subgroups.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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This formula used to estimate the probability of dying from cancer per cycle (a 6-month period) 
assumes that deaths occur at a constant rate over time. If mortality is positively skewed then for 
a shorter time horizon of the model this may represent an underestimate of mortality, and it may 
overestimate mortality for longer time horizons. The cancer mortality data also assume that risk 
of death from cancer is independent of the women’s age; this may underestimate the risks from 
cancer in younger women (i.e. those under 50 years of age).
These mortality rates are based on data for women who have received treatment for breast 
cancer. Therefore, they may not be applicable to women whose cancer is untreated because it is 
undetected. We hypothesised that at each time point a woman with an untreated cancer would 
face a higher risk of death in the next cycle (6-month period) than an identical woman whose 
cancer had been treated. This increased risk of death was proxied by comparing the estimated 
risk of dying at 5 years following a diagnosis of cancer for a woman diagnosed with cancer in the 
period 1980–4 with the risk for an identical woman from 2000 to 2004. The data used to derive 
the parameter value used in the model came from information produced by the Information 
and Statistics Division of NHS Scotland.86 The base-case value was based upon all women aged 
15–74 years. In this group of women, expected 5-year mortality for women diagnosed between 
1980 and 1984 was 34.9%. In the period 2000–4 the expected 5-year mortality was 14.9%. The 
ratio of these two numbers gives a value of 2.34. This value was used to inflate the 6-month breast 
cancer mortality rates reported in Table 31. Table 32 summarises the base-case and high and 
low values used within the model. Low and high values are based upon the lowest and highest 
values obtained for any age grouping reported by the Information and Statistics Division of 
NHS Scotland.
Within the base-case analysis we assumed that an IBTR that fits within a given risk profile will 
have the same probability of death per 6-month cycle period as an otherwise identical MCBC. 
The data reported in Chapter 6 suggests that mortality following IBTR may be substantially 
higher than the mortality for an otherwise identical MCBC, however. As noted above, we 
conducted sensitivity analyses to explore the impact of the increased risk of death from IBTR. We 
derived the increased risk of death per 6-month period by multiplying the HR for mortality from 
IBTR reported in Chapter 6 with the mortality rates for treated and untreated cancers. The point 
estimate for the hazard rate for death for IBTR was 1.76 (with an upper value from the 95% CI 
of 2.13). We used the extremes of the CIs for this hazard rate to define low and high rates within 
the model.
Data were also required on all-cause mortality. These data were required because women who do 
not develop cancer still have a chance of dying from other causes. In addition, women who do 
develop cancer also have the risk of dying from other causes. For both sets of women as they age 
within the model, mortality will increase. Estimates of all-cause mortality were obtained from the 
published UK life tables for the years.87 From these data a mortality rate for each 6-monthly cycle 
was calculated using the previously defined formula. This is reported in detail in Appendix 31.
TABLE 31  Mortality rates (%) from breast cancer at 10 years and per 6-month cycle for each risk profile (data used 
within the model)
Risk profile 10-year mortality rate 6-month cycle mortality rate
1 4.86 0.002425
2 12.47 0.006217
3 21.19 0.010539
4 36.81 0.018236
5 57.20 0.02819784 Economic evaluation
Estimated proportions of the different types of IBTR and/or MCBC 
cancers occurring
For the model, information was needed not just on whether a cancer occurs or not, but 
also on the severity of that cancer. We assumed that at the point where a cancer technically 
becomes detectable the size of the cancer is below 1 cm in diameter. In terms of the risk profile 
classification defined above we further assumed that all these people are initially in risk profile 
category 1 at the point when the cancer becomes detectable. Over time, an undetected cancer will 
increase in severity and the estimates used to model this are described below.
Estimated change in the risk profile of untreated cancer over time
One variable required for the economic evaluation is the rate at which an undiagnosed cancer 
may move to a worse risk profile (with a consequent reduction in life expectancy and quality 
of life and an increase in treatment costs). We sought data on which to base estimates for this 
variable from a structured review of the literature relating to doubling time of a breast cancer 
and the factors, for example grade of cancer, which might affect the doubling time of tumours. 
We sought these data as the individual patient analysis reported in Chapter 6 found that a 
significant predictor of mortality was tumour size, with larger-sized tumours having a shorter life 
expectancy than smaller tumours.
It is recognised that there is a considerable degree of uncertainty about the rates of growth of 
breast cancers.88 However, data were sought about plausible rates of growth and about potential 
range in the rates of growth that can be explored in a subsequent sensitivity analysis. A summary 
of the findings of this structured review is reported in Appendix 32. Given the information 
found in this review of the literature, it is clear that there is little consensus on the doubling 
times of breast cancer tumours. The data we have used in the economic model are based on the 
information provided by Peer and colleagues,89 taking the mean doubling time in tumour volume 
to be 157 days. We tested the consequences of this in a high/low sensitivity analysis where we will 
vary this rate between the plausible extremes of the data presented in Table 33.
To use information on the mean doubling time within the model we had to estimate how long it 
would take a tumour of the minimum technically identifiable size to increase in size, where an 
untreated tumour would move from one risk profile to a risk profile with a worse prognosis. We 
took the minimum diameter of a detectable cancer to be 0.75 cm. This value was taken because 
the volume of a cancer with this diameter is close to the minimum volume size considered by 
Adjuvant! Online. The data on time to reach the threshold tumour size were converted into 
risks of increasing the risk profile by one level for each cycle that a cancer remains untreated. 
We performed this using the same methods described above to estimate incidence and 
mortality rates.
TABLE 32  Summary of breast cancer mortality inflators used within the model to derive breast cancer mortality for 
those with undiagnosed breast cancer
5-year mortality
Inflator Notes
Cancer detected 
1980–4 (%)
Cancer detected 
2000–4 (%)
Base case 34.9 14.9 2.340 Based on the cohorts of women aged 15–74 
years at time of diagnosis
Low estimate 36.4 12.5 1.508 Based on the cohorts of women aged 75–84 
years at time of diagnosis
High estimate 39.1 25.9 2.916 Based on the cohorts of women aged 55–64 
years at time of diagnosis© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Diagnostic performance of tests
As reported in Chapter 5, relatively few data were available on the diagnostic performance of any 
of the tests. Within the model, we assumed that at the time a woman receives a diagnostic test as 
part of surveillance she is asymptomatic.
For IBTR, we based data on data reported in Chapter 5, and summarised in Table 20 (Chapter 5), 
and on discussions with the clinical experts involved in the study. Where relevant published 
data were available in the absence of pooled data the study judged to be closest to the median of 
reported results was used to inform the values chosen for the base-case analysis. We used data 
from other studies to define plausible extremes. Where it was feasible for these tests to be used 
then they were also used for MCBC, as few additional data were available (Table 34).
For surveillance mammography the values used in the base-case analysis were based upon those 
derived from Drew and colleagues.67 We based low and high estimates of sensitivity upon the 
ranges for these parameters reported in Table 20 (Chapter 5). These data represent extreme values 
that will be used in the sensitivity analysis.
As reported in Chapter 5, only one study provided data on the sensitivity and specificity of 
mammography and clinical follow-up. These data did not seem plausible (e.g. the reported 
sensitivity was 100%). The values reported in Table 34 are assumptions derived following 
discussions with clinical experts. The consensus of opinion was that the combination of follow-up 
and mammography would slightly improve the sensitivity and specificity. In a sensitivity analysis 
we will explore the impact of changing these values between high and low estimates. We will also 
seek to identify whether there is a threshold in terms of diagnostic performance, which would 
make the additional cost of clinical follow-up worthwhile.
TABLE 33  Mean breast cancer doubling times by age
Age at diagnosis (years) Mean doubling time (days)
Time for a 0.75-cm diameter 
tumour to move up one risk 
profile (days)
6-month rate for increase in 
risk profile
< 50 80 300 0.2623
50–70 157 540 0.1555a
a  Value taken in the base-case analysis.
Source: Peer and colleagues.89
TABLE 34  Diagnostic performance of the different tests
Test  Parameter
Base-case 
value (%) Low (%) High (%)
Surveillance mammography Sensitivity 67 65 70
Specificity 85 65 90
Surveillance mammography and clinical follow-up Sensitivity 75 70 80
Specificity 90 70 95
Clinical examination Sensitivity 35 25 50
Specificity 35 25 50
Rates available for other tests explored in a sensitivity analysis
MRI Sensitivity 67 65 70
Specificity 85 65 9086 Economic evaluation
Within the model, data are also required for the diagnostic performance of a clinical examination 
when performed by a GP. Again, few data were available and following discussions we assumed 
that the rates used within the model would be slightly lower than those reported in the systematic 
review of diagnostic performance (Chapter 5).
We considered the impact of using a higher cost but more effective diagnostic test. As a proxy 
for such a test data were based upon the performance of MRI. It should be noted that the 
values identified, especially at the upper level, are where MRI has been used in a higher risk 
group of women. Hence, the values are not necessarily illustrative of MRI itself but rather of a 
hypothetical test. The values for the base-case analysis were based upon those reported by Drew 
and colleagues67 but it was assumed that the sensitivity was slightly less than perfect (i.e. 95% vs 
the 100% reported by Drew and colleagues).65 Low values of sensitivity were based upon data 
from Warner and colleagues90 who conducted a systematic review of prospective studies in which 
women at very high risk for breast cancer were screened with both MRI and mammography.90 
Hence even these data may not be fully representative of women eligible for surveillance 
mammography. The specificity values were informed by the estimates of one study91 included 
in the Warner and colleagues review.90 This study had the lowest specificity of any of the studies 
included in Warner and colleagues’ 2008 study.90
Costing data
The costs of surveillance were broken down into the following cost categories:
  ■ Cost of:
  – inviting women for screening
  – the surveillance test (e.g. mammogram, MRI, clinical examination)
  – health-care professional time (e.g. GP consultation, clinical examination)
  – further invasive tests (e.g. core biopsy)
  – treatment (e.g. mastectomy, radiotherapy, drug treatment).
Tables 35–37 show the cost estimates used in the economic model. All costs are reported in 2008 
pounds sterling. Table 35 shows the current cost of the alternative screening strategies. The cost 
of inviting women to attend screening was obtained from a recent HTA report.92 The cost of the 
alternative surveillance tests were all derived from routine sources. The cost of a mammogram 
was based on information from the NHSBSP 2009.93 The NHSBSP estimates the cost of a 
mammogram in England to be £37.50 per woman invited and £45.50 per woman screened. An 
alternative costing source was obtained from the Scottish Breast Screening Programme, which 
estimates the cost of a mammogram to be £77.80.94 The implications of the variation in costs 
between Scotland and England were explored in a sensitivity analysis. The cost of an MRI was 
estimated as being twice the cost of that reported in the NHS Reference Costs40 for an outpatient 
MRI. This is because an MRI on a breast takes twice as long as a normal MRI and involves the 
use of a contrast. The lower quartile and upper quartile of the NHS Reference Costs40 for this 
category are used to inform sensitivity analysis. We derived the costs of a clinical examination 
from routine data sources. The cost of a GP clinical examination was obtained from the Personal 
Social Services Research Unit (PSSRU)95 and was based on the average cost of a GP consultation. 
In addition, we also included the cost of a clinical examination conducted in a secondary care 
setting by either a consultant or non-consultant. These costs were obtained from NHS Reference 
Costs.40 Information on the range of costs (lower and upper quartile) was also available and these 
were used as upper and lower estimates in sensitivity analysis.
The costs of further invasive tests were obtained from a NICE evidence review group (ERG) 
report96 and inflated to current prices using the PSSRU inflation index. The cost of a mastectomy © Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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was based on the same source, and inflated to 2008 prices. The cost of radiotherapy was based 
on the cost of complex treatment on a mega-voltage machine,40 assuming that women get on 
average 20 sessions of radiotherapy. This assumption was based on information from the PRIME 
trial, which reported that, on average, women receive 20 sessions of radiotherapy.97 Again, lower 
quartile and upper quartile estimates of the cost of a single session of radiotherapy will be used in 
a sensitivity analysis.
The costs of drug treatment, for example the cost of hormone treatment, chemotherapy 
and combined treatment, were obtained from recent NICE guidance. The cost of hormone 
treatment was based on information reported in the costing template for technology appraisal 
TABLE 35  Cost of screening regimens
Type of test
Cost (lower quartile/upper quartile), 
[alternative] (£) Source
Clinical examination – GP 36 PSSRU95
Clinical examination – consultant 86 (63 to 100) NHS Reference Costs40 (ref. 103)
Clinical examination – non-consultant 65 (55 to 75) NHS Reference Costs40 (ref. 103)
Mammogram 45.50 [77.8] NHSBS93 (Scottish Breast Screening 
Programme)94
MRI – outpatient 232 (165 to 269) NHS Reference Costs40 (ref. TDIAGIM_APC; 
RA03Z)
TABLE 36  Cost of invasive tests and treatments98
Type of treatment Cost (low/high) (£) Source
Core biopsy 126.6 ERG report96
Mastectomy 3429 ERG report96
Radiotherapy 2395.58 (1649.20 to 2784.80) NHS Reference Costs40 (based on 20 sessions)
Hormone therapy (per year): tamoxifen 29.92a TA11298
Hormone therapy (per year): aromatase 
inhibitor
919.6 to 1115.4 TA11298
Chemotherapy (per six treatment) 
administrations
4137a to 9850 TA10999
a  Value taken in breast cancer analysis.
TABLE 37  Surveillance regimen: clinical examination plus mammography for women receiving hormone therapy
Surveillance regimen Cost (£)
Screening invitation 10.45
Mammography + clinical examination (consultant) 45.50 + 86
On positive finding
Core biopsy 126.6
Mastectomy 3429
Radiotherapy 2395.58 (20 sessionsa) 
Drug treatment (tamoxifen) 29.92 (per year)
a  Based on information from the PRIME trial.9788 Economic evaluation
guidance 112.98 This included the costs of tamoxifen for 5 years and the cost of aromatase 
inhibitors (anastrozole or letrozole) for 5 years. The cost of chemotherapy was based on the costs 
reported in NICE technology appraisal guidance 109.99 The cost of chemotherapy is based on 
the cost of two different regimens (TAC – taxotere, adriamycin and cyclophosphamide; FEC – 
fluorouracil, epirubicin and cyclophosphamide). This is based on six cycles of treatment.
Each risk profile consists of a series of different types of cancers (defined in terms of ER status, 
grade, size and number of lymph nodes involved). As described above, an average mortality for 
each risk profile was estimated by combining information on the expected mortality for each 
specific cancer within a risk profile with information on the proportion of women in that risk 
profile that had that specific type of cancer. Adjuvant! Online reports mortality by the type of 
adjuvant therapy used. The clinical members of the research team determined, based on UK 
practice, which specific cancer in a profile would receive hormone therapy and/or chemotherapy. 
Using information on the proportion of cancers in a given risk profile that would be treated with 
a given adjuvant therapy a proportion of a cost of a course of hormone treatment or radiotherapy 
was incorporated into the cost assigned to each risk profile.
Table 37 shows the costs of one surveillance regimen for a woman invited to screening and who 
received a clinical examination and a mammogram. The costs include the costs of screening, the 
mammogram and clinical examination, conducted by a consultant. On a positive mammogram, 
the woman would then go on to have further invasive tests to confirm the result (core biopsy). 
On a true-positive finding, the woman would have a mastectomy followed by radiotherapy, 
followed by drug treatment (depending on the severity of the IBTR or MCBC). We based the 
costs of treatment on a number of assumptions:
  ■ It is assumed that all ER+ women will receive hormone treatment. It is assumed that those 
women who have an excellent prognosis (survival rate at 10 years of 96% or greater) and are 
postmenopausal will receive tamoxifen for 5 years. Women who are postmenopausal, with a 
poorer prognosis, will receive an aromatase inhibitor for 5 years.
  ■ All women who are premenopausal and are ER+ will receive tamoxifen.
  ■ All women who have grade 3 tumours will receive chemotherapy.
  ■ Women who are ER+ and have positive lymph nodes will receive combined treatment 
(hormone + chemotherapy).
  ■ Women who are ER– and have 0 nodes will receive no treatment (exception to this is that 
15% might get hormone therapy).
  ■ Women who are ER– and have positive lymph nodes will receive chemotherapy (exception to 
this is that 15% might receive combined therapy).
Health-state utility values
The primary purpose of the economic model was to inform decision-making in a UK setting, 
given that treatment for breast cancer affects not only survival, but also quality of life, for example 
different types and stages of cancer are likely to be associated with differences in quality of life, as 
would different treatment options. Therefore, we have also sought to assess the impact on quality 
of life, through the incorporation of health-state utility weights, which have been combined with 
estimates of survival to estimate QALYs.
Recent guidance suggests that estimates of QALYs should ideally be based on generic health-state 
valuation methods using UK population tariffs.100 Therefore, we conducted a focused search of 
the literature and other relevant sources such as the Harvard cost–utility database. We identified 
a number of studies reporting health-state utilities. In particular, we found a recent systematic 
review of breast cancer utility weights.101 In their systematic review, 59 studies were identified © Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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for review and nine studies included. Of the nine studies included, three were based on UK 
data.102–104 In addition, the utility values used in the paper by Sorensen and colleagues105 were 
based on a combination of UK and US data.105
It is difficult to determine how comprehensive this review is as, being available as a conference 
poster, the details provided on the literature searching are brief. The authors searched an 
appropriate selection of databases but the sensitivity of the search strategies used is unclear due 
to a lack of information. Missing information included whether MeSH terms were ‘exploded’ 
to include more specific terms, which Emtree terms were used in EMBASE, and how the terms 
were combined in the final search. From the information reported, one error was noted: ‘breast 
neoplasms’ was incorrectly described as a non-MeSH term.
Overall, the authors of the systematic review found considerable variability and inconsistency in 
the reported utility values. A selection of other studies eliciting health-state utilities was further 
identified. Overall, there was considerable variation in values and in definitions of health states; 
however, there is a general trend in the values reported in the literature. As would be expected, 
utilities decrease with increasing breast cancer severity and utilities are also found to be sensitive 
to treatment. For example, there is a general trend for those receiving chemotherapy to have 
lower utility values than those receiving hormone therapy, most likely due to the severity of the 
side effects of the respective treatments.
For the economic model, we have used the results reported in the systematic review of breast 
cancer utility weights.101 Using this information, we defined utilities for each of the five risk 
profiles in the model. For example, risk profile state 1 assumes a utility state with a low value of 
0.75 and a high value of 0.85 (based on the distribution of values from the systematic review). 
We adjusted these utility states to include a decrement for those women who will receive 
chemotherapy. This decrement is based on the percentage of women in each of the five severity 
states who would receive chemotherapy. For example, 24% of women in risk profile state 1 would 
receive chemotherapy. The chemotherapy decrement is based on information on patients’ utilities 
for cancer treatments.106 In their study, using the time trade-off method utilities for chemotherapy 
were estimated to be 0.74 from an actual health state estimated to be 0.94. All health-state utilities 
after treatment are assumed to be the same as the utilities defined before treatment without the 
chemotherapy decrement.
Utility values for risk profile states 3 and 4 are based on the health-state values in Tosteson and 
colleagues.107 This is based on the value for regional cancer in the age group 50–59 years. The 
utility value for risk profile state 5 is based on the value provided for distant rather than regional 
cancer in the age group 50–59 years. Each of these values has also been reduced by the decrement 
factor for chemotherapy. To achieve the high values reported in Table 38 for risk profile states 4 
and 5 an additional 0.05 was added to the low value.
The values used in the base-case analysis are the low values reported in Table 38. Individuals in a 
‘no-cancer’ state are assumed to have a health-state utility value of 0.80 in the base-case analysis.
Key assumptions of the economic model
This section provides a brief summary of the key assumptions made when developing the 
economic model.
Structural assumptions
The cycle length is assumed to be 6 months.90 Economic evaluation
It is assumed that, if individuals are invited to attend mammographic screening, they do in fact 
attend. This assumption may be too high, as approximately 75–80% of the normal population 
attend for breast screening.
Strategies compared are assumed to be homogeneous in that they do not change over time. More 
sophisticated strategies where the surveillance intervals and method of follow-up change over 
time have not been modelled.
Estimates of survival were based upon predictions derived from Adjuvant! Online and were 
grouped into five broad groupings based upon survival. This is a simplification of the different 
types of tumour that might occur, as well as how prognosis of untreated disease might change 
over time.
Parameter value assumptions – natural history assumptions
The incidence of IBTR and MCBC are assumed to be independent.
Incidence is assumed to have occurred at the point when a cancer could technically be identified.
The grade of IBTR does not have to be the same as that of the primary tumour but the grade 
of IBTR or MCBC does not have to change over time. There is some evidence to suggest that 
grade does not change. Should it occur as other evidence suggests, then, given the model 
structure, this would reduce the life expectancy of a woman. However, the impact on cost-
effectiveness is unclear as it depends upon the likelihood of a tumour progressing to a higher 
grade, the speed of progression, the diagnostic performance of the surveillance regimen and the 
surveillance interval.
Estimates of survival are assumed to be independent of age (age-adjusted all-cause mortality is 
included as a separate model parameter). This may underestimate risks to younger women whose 
cancers might be more aggressive.
Treatments for IBTR and MCBC were based upon NICE guidelines and expert opinion.
If a cancer is not detected in a given cycle (6 months) then it is assumed that it can only advance 
one risk profile level. The likelihood of this occurring was estimated from the literature on 
doubling times.
Many of the estimates used to model natural history of disease are assumed to be constant 
over time. Some of these assumptions are not consistent with the observed data. However, the 
consensus of opinion for other parameters, for example probability of progressing to a risk profile 
TABLE 38  Health-state utilities
Severity 
Percentage on 
chemotherapy
Managed
Unmanaged On treatment After treatment
Low High Low High Low High
1 0.240 0.71165 0.80654 0.8 0.95 0.8 0.95
2 0.759 0.59673 0.67629 0.8 0.95 0.8 0.95
3 0.769 0.52693 0.60376 0.63 0.68 0.8 0.95
4 0.991 0.49716 0.60807 0.63 0.68 0.8 0.95
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with a worse prognosis, is that they may decline over time. Allowing such probabilities to change 
over time would not greatly change costs but might be expected to increase QALYs over time for 
those strategies which have a better diagnostic performance.
Parameter value assumptions – diagnostic performance
Sensitivity and specificity for surveillance mammography and clinical follow-up were 
based upon expert opinion and assumed that it performed slightly better than surveillance 
mammography alone.
Sensitivity and specificity for clinical examination was based on clinical opinion. It was assumed 
that clinical examination has a lower sensitivity and specificity than reported in Chapter 5.
Parameter value assumptions – cost assumptions
Management packages previously prepared for UK guidance and HTAs have been used to 
estimate care, and hence costs. If treatment patterns have greatly altered in the last few years these 
data may not be applicable.
It is assumed that all women who have a breast cancer will incur the cost of a mastectomy. 
Obviously a woman who has had a previous mastectomy cannot have a further mastectomy on 
the same breast but the cost of a mastectomy has been used as a proxy for the cost of care such a 
woman would receive.
Parameter value assumptions – utilities assumptions
Data from different populations and elicited using different methods have been assumed to be 
sufficiently similar to the relevant UK population of women to be useful.
Utilities are assumed to reduce with increasing severity of disease and also on the use of 
chemotherapy. Other decrements to utility, for example complications of disease or treatment, are 
not modelled.
Presentation of results
The base-case analysis was run for a cohort of women (starting age in the model 57 years) with 
surveillance occurring once yearly. The starting age was chosen as this was the mean age of the 
women contributing to the analysis of data from the WMCIU Breast Cancer Registry, which was 
reported in Chapter 6. The model was run for different starting ages in further sensitivity analysis. 
The cycle length of the model is 6 months and cumulative costs and benefits are estimated over 
a maximum of 100 cycles, which is equivalent to a time horizon of 50 years. This time horizon 
was taken as a proxy for life expectancy of women treated for primary breast cancer. All costs are 
reported in 2008 pounds sterling and effectiveness in QALYS. A discount rate of 3.5% for costs 
and benefits was used following guidelines for NICE.100 Results are presented as incremental 
cost per QALY gained. The modelling exercise will use a net benefit framework to combine cost 
and benefit estimates. The results of the analyses will be presented as point estimates of mean 
incremental costs, effects, incremental cost per QALY. This measure is a ratio of the difference 
in costs divided by the difference in effectiveness between two alternative strategies. These data 
can be interpreted as how much society would have to pay for an extra unit of effectiveness. 
Whether or not a more costly but more effective regimen is considered worthwhile depends upon 
society’s willingness to pay for a QALY and, within England, the threshold adopted by NICE lies 
somewhere between £20,000 and £30,000.
Incremental cost per QALYs is a common way for presenting the results of an economic 
evaluation. They are, however, difficult to interpret when the choice is between several mutually 
exclusive options. In this circumstance the judgement can be informed by considering the net 92 Economic evaluation
benefit statistic. The regimen with the greatest net benefit at a given value for society’s willingness 
to pay for a QALY is considered to be most cost-effective. The net benefit statistic itself is 
defined as:
NBj = (QALYj × λ) – costj  [Equation 1]
where NB = net benefit, QALYi = QALYs for intervention i, costi = cost for intervention i, and 
λ = society’s willingness to pay per QALY.
Intervention i would be chosen over intervention j when NBi > NBj.
Sensitivity analysis
We did not conduct probabilistic sensitivity analysis. The reason for this is that parameter values 
used are statistically imprecise and, as data are so limited, the model estimates may be unreliable. 
Therefore, the results of the economic evaluation should be interpreted cautiously and, at most, 
indicate situations where a particular method(s) of surveillance may be worthy of further 
consideration. Nevertheless, we conducted both one-way and multiway sensitivity analysis to 
assess how results may change as a consequence of plausible changes in parameter values. We 
also used deterministic sensitivity analysis to identify threshold values for key parameters. The 
methods used in the sensitivity analysis are described below.
Probability of developing IBTR or MCBC
We varied the probability of developing IBTR or MCBC in the sensitivity analysis from a low 
of 0.0030 [the lowest estimated 6-month cycle failure probability was for women who had a 
mastectomy and cumulatively had a risk of IBTR or MCBC of 0.0036 (Table 27)] to 0.0125 [the 
highest 6-month probability recurrence rate for IBTR and MCBC combined from the predicted 
HRs was 0.0125 (Table 29)].
Inflating the risk of death from cancer for people who are 
unmanaged
We also explored the effect of an increase in the risk of death for unmanaged individuals in 
sensitivity analyses. This was varied in the sensitivity analysis from the base-case assumption of 
2.34 to a high of 2.916 (Table 32 in the base-case model).
We repeated the same analysis in the IBTR model, varying the increase in the risk of death in 
unmanaged states from 2.33 to 2.916.
Changes to the risk of progressing to a higher risk profile
The consequences of changing the risk of unmanaged women progressing to higher-risk profiles 
was explored in both the base-case model and the IBTR model. The risk of progressing was 
altered from the base-case estimate of 0.1555 to 0.2623 in sensitivity analysis; 0.26 relates to a 
mean doubling time of 80 days and an estimated time of 300 days for a tumour to reach 2 cm3 
(Table 33). In addition, in a further sensitivity analysis the risk of progressing was further lowered 
form the base-case assumption, to a mean doubling time of 942 days. This equates to a risk of 
0.0923 per 6-month cycle.
Sensitivity and specificity of the surveillance tests
The diagnostic performance of the surveillance tests (sensitivity and specificity) was varied in the 
base-case model for both high and low sensitivity and specificity values (reported in Table 34). 
This was undertaken in multiway sensitivity analysis, varying all the tests simultaneously.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Sensitivity analysis on costs
A range of sensitivity analyses on costs were performed. This included high treatment costs 
and surveillance costs. For example, the base-case model assumes that all women who receive 
hormone therapy receive tamoxifen. The consequences of this assumption were tested in 
sensitivity analyses. This involved re-estimating the model when all treatment costs were set to 
their highest estimates (highest cost for hormone and chemotherapy). In addition to treatment 
costs, higher surveillance costs were also incorporated into this sensitivity analysis. This included 
using the higher mammography cost (£77.80 as opposed to base-case assumption of £45.50) and 
also doubling the cost of an MRI. These cost estimates can be seen in Tables 35 and 36. The same 
analyses were conducted for the IBTR model.
The cost of all clinical examinations conducted either at the point of surveillance or in follow-up 
visits were varied from the base-case assumption that these clinical examinations would be 
carried out by a consultant grade, to the alternative assumption that these examinations were 
carried out by a non-consultant (Table 35). This analysis was conducted for both the base-case 
model and the IBTR model.
Sensitivity analysis on health-state utilities
Health-state utility values were also tested in a range of sensitivity analyses. This included 
replacing the base-case values for quality of life (assumed to be the low values reported in 
Table 38) with high estimates of quality of life (Table 38).
In addition, quality of life was further tested in both the base-case model and the IBTR model 
by varying the quality of life in unmanaged states. The base-case model assumes that women 
in unmanaged states have the same quality of life as women free of disease. This assumption is 
tested in sensitivity analysis by giving women in unmanaged states the same quality of life as 
women after treatment.
Age
The effect of age was tested in the sensitivity analysis with the base-case model and IBTR model, 
which we ran for a starting age of 40 years and a starting age of 70 years. This analysis was 
conducted as multiway sensitivity analysis with a range of values varied in the analysis. For the 
younger age group (starting age 40 years) this included high chemotherapy and high hormone 
therapy costs (Table 36), high cancer incidence (0.0152, Table 29) and a short doubling time 
(0.2623, Table 33). In addition, for this age group, a further multiway analysis was conducted, 
repeating the analysis above, with the addition of the high inflation factor for unmanaged states 
(2.916, Table 32).
For a starting age of 70 years, sensitivity analysis was conducted for the base-case model and 
IBTR model using the new starting age of 70 years and the low hazard rate (0.0018, Table 29). All 
of the other variables were assumed to be as the base-case assumptions.
Results
Base-case results
Results for women who received BCS or mastectomy for their 
primary cancer
Tables 39 and 40 report the results of the base-case analyses for the average women treated for 
their primary breast cancer with BCS or with a mastectomy. These data can be used to inform 94 Economic evaluation
judgements about what would be the single best regimen for the NHS to adopt for all women 
who had previously been treated with BCS or all women who had previously been treated with 
mastectomy. For both populations the results are shown for a range of surveillance intervals 
ranging from 12 months to 36 months. The costs and outcomes for the ‘no surveillance’ option 
are the same regardless of the surveillance interval. For the other surveillance regimens, both 
costs and QALYs fall as the surveillance interval increases. However, for each surveillance 
regimen the reduction in QALYs is more than compensated for by a reduction in cost. This is 
illustrated by the reduction in the incremental cost per QALY reported for each regimen as the 
surveillance interval increases. For example, for women who had received BCS the incremental 
cost per QALY for mammography alone compared with ‘no surveillance’ is £4727 for a 
12-month surveillance regimen and £3811 for an 18-month regimen. Similarly, for a 12-month 
surveillance regimen the incremental cost per QALY for mammography and clinical follow-up 
alone compared with mammography is £236,826. For an 18-month surveillance interval the 
incremental cost per QALY falls to £118,455.
The results of the two sets of analyses reported in Tables 39 and 40 are very similar. As would 
be expected, the no surveillance regimen is least costly but also least effective. Whether 
or not a more costly but more effective regimen is considered worthwhile depends upon 
society’s willingness to pay for a QALY. Within England, the threshold adopted by NICE lies 
somewhere between £20,000 and £30,000, and, as shown in Tables 39 and 40, only one regimen, 
mammography alone, is associated with an incremental cost per QALY below £20,000.
TABLE 39  Results of the base-case analysis for women treated for their primary cancer with BCS
Regimen Cost (£) QALY ICER (£)
Net benefits (£)
λ = £20,000 Rank λ = £30,000 Rank
12-month interval
No surveillance 1033 12.925 257,459 12 386,705 13
Mammography alone 1970 13.123 4727 260,484 1 391,711 1
Mammography + clinical 3396 13.129 236,826 259,178 8 390,465 7
MRI + clinical 6499 13.139 297,848 256,283 13 387,675 12
18-month interval
No surveillance 1033 12.925 257,459 12 386,705 13
Mammography alone 1722 13.105 3811 260,385 2 391,438 2
Mammography + clinical 2743 13.114 118,455 259,536 6 390,675 5
MRI + clinical 4969 13.130 142,331 257,623 11 388,919 11
24-month interval
No surveillance 1033 12.925 257,459 12 386,705 13
Mammography alone 1587 13.089 3366 260,197 3 391,089 3
Mammography + clinical 2408 13.100 78,167 259,586 5 390,583 6
MRI + clinical 4200 13.120 90,382 258,191 10 389,387 10
36-month interval
No surveillance 1033 12.925 257,459 12 386,705 14
Mammography alone 1498 13.075 3099 259,994 4 390,740 4
Mammography + clinical 2201 13.086 59,607 259,528 7 390,392 8
MRI + clinical 3734 13.109 66,789 258,453 9 389,547 9© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Incremental cost per QALYs, as reported in Tables 39 and 40, can be difficult to interpret when 
the choice is between several different options (e.g. in Table 39 there are 13 different regimens 
and it is not immediately obvious which option might be considered most cost-effective). 
Therefore, we used the net benefit statistic to compare regimens. When society’s willingness 
to pay for a QALY is £20,000, the regimen that is associated with the highest net benefit is 
mammography alone every year (Tables 39 and 40). When the threshold was increased to 
£30,000 mammography only had the greatest net benefit. Regardless of the surveillance interval, 
mammography alone had the highest net benefits and the regimen with the lowest net benefit 
was always no surveillance.
In Table 39 the impact of substituting a more effective but more costly surveillance technology 
(MRI) for mammography was considered. Regardless of the surveillance interval, this regimen 
was associated with a net benefit greater than that of the no surveillance regimen but less than 
that of all of the other regimens.
Modelling IBTR alone
The analyses reported in Tables 39 and 40 made the assumption that the consequences of an IBTR 
are the same as those of an otherwise identical contralateral recurrence. However, the analyses 
reported in Chapter 6 suggest that the mortality associated with IBTR is substantially higher than 
that associated with an otherwise identical recurrence in the contralateral breast. In this analysis 
this increased risk of death from IBTR is modelled (Table 41).
In these analyses the regimen mammography alone has an incremental cost per QALY compared 
with ‘no surveillance’ of < £4000 and the highest net benefit regardless of the surveillance interval. 
Mammography alone at 12 months has a marginally higher net benefit than mammography 
alone at 24 months for both a £20,000 and a £30,000 threshold for society’s willingness to pay for 
a QALY.
TABLE 40  Results of the base-case analysis for women treated for their primary cancer with mastectomy
Regimen Cost (£) QALY ICER (£)
Net benefits (£)
λ = 20,000 Rank λ = 30,000 Rank
12-month interval
No surveillance 1012 12.938 257,753 8 387,136 10
Mammography alone 1927 13.127 4861 260,603 1 391,868 1
Mammography + clinical 3360 13.132 250,230 259,285 8 390,608 7
18-month interval
No surveillance 1012 12.938 257,753 8 387,136 9
Mammography alone 1680 13.110 3885 260,521 2 391,621 2
Mammography + clinical 2705 13.118 125,115 259,660 7 390,842 5
24-month interval
No surveillance 1012 12.938 257,753 8 387,136 10
Mammography alone 1545 13.095 3407 260,349 3 391,296 3
Mammography + clinical 2369 13.105 82,525 259,725 5 390,772 6
36-month interval
No surveillance 1012 12.938 257,753 8 387,136 10
Mammography alone 1457 13.081 3117 260,160 4 390,969 4
Mammography + clinical 2161 13.092 62,899 259,680 6 390,600 896 Economic evaluation
Sensitivity analyses
We conducted a range of different sensitivity analyses, as described above in Presentation of 
results. As the results for the analyses for women who received BCS for their primary cancer are 
similar to those obtained when we consider women who received a mastectomy for their primary 
cancer we present sensitivity analyses solely for the scenario where women received BCS for their 
primary cancer. However, we also report selected analyses for a model that considers IBTR alone.
Sensitivity analysis around the breast-conserving model
Probability of developing cancer
Figures 26–29 illustrate the impact on incremental cost per QALYs as the incidence of cancer 
increases. In each figure, three lines are shown:
1.  The incremental cost per QALY of mammography alone compared with no surveillance. 
This line can be used to inform the question: is it worth adopting the more effective but 
more costly mammography alone follow-up in place of the less costly and less effective no 
surveillance regimen?
2.  The incremental cost per QALY of mammography plus clinical follow-up compared with 
mammography alone. This line can be used to inform the question: is it worth adopting the 
more effective but more costly mammography plus clinical follow-up in place of the less 
costly and less effective mammography alone regimen?
3.  The incremental cost per QALY of MRI plus clinical follow-up compared with 
mammography plus clinical follow-up. This line can be used to inform the question: is it 
TABLE 41  Ipsilateral breast tumour recurrence has a substantial higher risk of death than MCBC
Regimen Cost (£) QALY ICER (£)
Net benefits (£)
λ = £20,000 Rank λ = £30,000 Rank
12-month interval
No surveillance  978 12.830 255,620 12 383,920 13
Mammography alone 1956 13.076 3973 259,565 1 390,326 1
Mammography + clinical 3384 13.084 177,150 258,298 8 389,139 5
MRI + clinical 6491 13.098 216,537 255,478 13 386,463 12
18-month interval
GP only 978 12.830 255,620 12 383,920 13
Mammography alone 1703 13.053 3247 259,359 2 389,890 2
Mammography + clinical 2727 13.064 92,265 258,557 5 389,198 4
MRI + clinical 4958 13.085 108,007 256,739 11 387,587 11
24-month interval
GP only 978 12.830 255,620 12 383,920 13
Mammography alone 1563 13.032 2887 259,084 3 389,407 3
Mammography + clinical 2387 13.046 62,482 258,523 6 388,978 6
MRI + clinical 4185 13.071 70,315 257,237 10 387,947 10
36-month interval
GP only 978 12.830 255,620 12 383,920 13
Mammography alone 1468 13.014 2664 258,808 4 388,946 7
Mammography + clinical 2175 13.028 48,551 258,393 7 388,676 8
MRI + clinical 3716 13.058 52,811 257,435 9 388,010 9© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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worth adopting the more effective but more costly MRI plus clinical follow-up in place of the 
less costly and less effective mammography plus clinical follow-up regimen?
The results of the analysis shown in these figures suggest that:
  ■ At all screening intervals considered some form of active surveillance might be considered 
cost-effective.
  ■ Should the incidence of IBTR and MCBC increase towards the upper values of incidence 
considered, which are typical of those we might expect for higher risk women (e.g. those 
whose primary cancers were of higher grade, who were younger than 50 years and who had 
lymph node involvement), a regimen of clinical follow-up and mammography is more likely 
to be worthwhile. Furthermore, when the surveillance interval is 24 months the incremental 
FIGURE 26  Incremental cost per QALYs for the different surveillance regimens at a 12-month surveillance interval.
FIGURE 27  Incremental cost per QALYs for the different surveillance regimens at an 18-month surveillance interval.
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cost per QALY compared with mammography alone approaches £30,000. At a surveillance 
interval of 36 months, it is approximately £25,000.
  ■ As the screening interval and risk of IBTR and MCBC increases towards 36 months, it 
becomes more likely that a more costly but more effective surveillance intervention (in this 
analysis typified by MRI plus clinical follow-up) might be worthwhile.
Inflating the risk of death from untreated cancer
Sensitivity analysis was conducted to test the effect of inflating the risk of death for women who 
are unmanaged for cancer. In the sensitivity analysis the increased risk of death from cancer in 
unmanaged states was inflated from the base-case risk of 2.34 to a high of 2.196 (Table 42). The 
results of this analysis were broadly similar to the base-case analysis presented in Table 39. We 
conducted this sensitivity analysis for both the base-case model and the IBTR model.
FIGURE 28  Incremental cost per QALYs for the different surveillance regimens at a 24-month surveillance interval.
FIGURE 29  Incremental cost per QALYs for the different surveillance regimens at a 36-month surveillance interval.
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Changes to the probability of progressing to a more serious risk 
profile
Table 43 reports the impact of increasing the speed that an untreated cancer progresses to a risk 
profile with a worse prognosis. As would be expected the higher the probability of progression 
(which would be analogous to a shorter doubling time of a tumour) the more likely earlier and 
more intensive follow-up becomes. Nevertheless, in this one-way sensitivity analysis none of 
the options, other than mammography alone, is associated with incremental costs per QALY 
approaching a value that society typically might be willing to pay.
Changes to the sensitivity and specificity of the tests
Tables 44 and 45 show multiway sensitivity analysis on the diagnostic performance of the 
surveillance tests. Again, changes in the sensitivities and specificities alone do not greatly alter the 
estimated cost-effectiveness of the different regimens.
Changes to costs of tests and treatments
Sensitivity analysis was also performed on costs. This included a high treatment cost and high 
surveillance cost sensitivity analysis. This involved re-estimating the model when all treatment 
costs were set to their highest estimates (highest cost for hormone and chemotherapy). In 
addition to treatment costs, higher surveillance costs were also incorporated into this sensitivity 
analysis. This included using the higher mammography cost (£78 as opposed to base-case 
assumption of £45.50) and also doubling the cost of an MRI. These cost estimates can be seen 
in Table 46. The same analyses were conducted for the IBTR model (and are reported in the 
next subsection).
TABLE 42  Increasing the risk of death for unmanaged disease
Regimen Cost (£) QALY ICER (£)
Net benefits (£)
λ = £20,000 Rank λ = £30,000 Rank
12-month interval
GP only 1014 12.898 256,939 13 385,915 13
Mammography alone 1967 13.120 4278 260,440 1 391,644 1
Mammography + clinical 3394 13.127 217,826 259,145 8 390,414 7
MRI + clinical 6498 13.138 274,030 256,267 14 387,649 12
18-month interval
GP only 1014 12.898 256,939 12 385,915 13
Mammography alone 1718 13.101 3451 260,312 2 391,326 2
Mammography + clinical 2740 13.111 108,767 259,477 6 390,586 4
MRI + clinical 4967 13.128 130,986 257,590 11 388,869 11
24-month interval
GP only 1014 12.898 256,939 13 385,915 13
Mammography alone 1581 13.084 3045 260,096 3 390,935 3
Mammography + clinical 2403 13.095 71,562 259,504 5 390,457 6
MRI + clinical 4197 13.117 83,055 258,142 10 389,312 10
36-month interval
GP only 1014 12.898 256,939 13 385,915 13
Mammography alone 1490 13.068 2796 259,867 4 390,546 5
Mammography + clinical 2194 13.081 54,384 259,422 7 390,231 8
MRI + clinical 3730 13.106 61,238 258,388 9 389,447 9100 Economic evaluation
TABLE 43  The impact of changing the probability of progressing to a higher risk profile
Surveillance interval Regimen
ICER at low and high probability of increasing to next risk 
profile per cycle:
0.0923 0.1555 0.2623
12 months No surveillance
Mammography alone 6580 4727 3679
Mammography + clinical 389,207 236,826 137,745
MRI + clinical 487,420 297,848 170,226
18 months No surveillance
Mammography alone 5168 3811 3093
Mammography + clinical 193,537 118,455 71,767
MRI + clinical 235,502 142,331 83,040
24 months No surveillance
Mammography alone 4456 3366 2833
Mammography + clinical 125,343 78,167 49,644
MRI + clinical 148,299 90,382 54,714
36 months No surveillance
Mammography alone 4014 3099 2690
Mammography + clinical 93,489 59,607 39,604
MRI + clinical 107,873 66,789 42,079
TABLE 44  High sensitivity and specificity values
Regimen Cost (£) QALY ICER (£)
Net benefits (£)
λ = £20,000 Rank λ = £30,000 Rank
12-month interval
No surveillance 1058 12.958 258,097 11 387,674 13
Mammography alone 1944 13.126 5280 260,568 1 391,823 1
Mammography + clinical 3343 13.132 211,875 259,300 8 390,622 8
MRI + clinical 6390 13.141 338,553 256,433 13 387,845 12
18-month interval
No surveillance 1058 12.958 258,097 11 387,674 13
Mammography alone 1690 13.110 4150 260,511 2 391,612 2
Mammography + clinical 2676 13.120 104,218 259,715 7 390,910 5
MRI + clinical 4826 13.133 159,306 257,835 12 389,165 11
24-month interval
No surveillance 1058 12.958 258,097 11 387,674 13
Mammography alone 1554 13.096 3597 260,360 3 391,317 3
Mammography + clinical 2335 13.107 67,680 259,810 5 390,882 6
MRI + clinical 4040 13.124 99,707 258,447 10 389,691 10
36-month interval
No surveillance 1058 12.958 258,097 11 387,674 13
Mammography alone 1466 13.083 3263 260,189 4 391,017 4
Mammography + clinical 2126 13.096 50,836 259,789 6 390,746 7
MRI + clinical 3566 13.116 72,694 258,745 9 389,900 9© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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In addition, Table 47 shows sensitivity analysis in which the cost of a clinical examination is 
priced at the consultant and non-consultant rate and the effect on the incremental cost per 
QALYs. Although the changes are minor, adopting a lower cost for a clinical examination makes 
the mammography alone regimen marginally less cost-effective compared with ‘no surveillance’. 
This is because the lower cost is also incurred for all clinical examinations, including those during 
follow-up for those with IBTR or MCBC.
Changes to utility estimates used
The analysis presented in Table 48 is based on the high estimates of quality of life reported in 
Table 38. The results suggest that at a willingness-to-pay threshold of £20,000 the regimen with 
the highest net benefit is likely to be mammography alone at 12-month surveillance intervals, 
followed by mammography alone at 18-, then 24- and then 36-month intervals. At a willingness-
to-pay threshold of £30,000 the ordering is very similar with the exception that mammography 
plus clinical examination has the fourth highest net benefit at a willingness-to-pay threshold 
of £30,000.
In addition to sensitivity analysis on higher quality-of-life values, we conducted further 
sensitivity analyses to test the base-case assumption that women in unmanaged states have 
the same quality of life as women who are disease free. We tested this assumption by giving 
all women in unmanaged states the same utility as women who had been treated for IBTR 
or MCBC. These results are presented in Table 49. Decreasing the quality of life of women in 
unmanaged states has no appreciable effect on the analysis presented above for a threshold value 
of £20,000 or £30,000.
TABLE 45  Low sensitivity and specificity values
Regimen Cost (£) QALY ICER (£)
Net benefits (£)
λ = £20,000 Rank λ = £30,000 Rank
12-month interval
No surveillance 1061 12.900 256,942 12 385,944 13
Mammography alone 2023 13.121 4365 260,388 1 391,594 1
Mammography + clinical 3467 13.125 342,589 259,029 8 390,277 6
MRI + clinical 6600 13.128 859,244 255,969 13 387,253 12
18-month interval
No surveillance 1061 12.900 256,942 12 385,944 13
Mammography alone 1792 13.102 3622 260,246 2 391,264 2
Mammography + clinical 2835 13.108 173,779 259,323 6 390,401 5
MRI + clinical 5094 13.113 425,796 257,170 11 388,301 11
24-month interval
No surveillance 1061 12.900 256,942 12 385,944 13
Mammography alone 1664 13.084 3270 260,026 3 390,870 3
Mammography + clinical 2508 13.092 116,098 259,327 5 390,244 7
MRI + clinical 4331 13.098 278,691 257,634 10 388,617 10
36-month interval
No surveillance 1061 12.900 256,942 12 385,944 13
Mammography alone 1577 13.069 3063 259,796 4 390,483 4
Mammography + clinical 2303 13.077 89,497 259,232 7 390,000 8
MRI + clinical 3866 13.084 211,068 257,818 9 388,660 9102 Economic evaluation
TABLE 46  High-cost sensitivity analysis
Regimen Cost (£) QALY ICER (£)
Net benefits (£)
λ = £20,000 Rank λ = £30,000 Rank
12-month interval
No surveillance 1704 12.925 256,787 9 386,033 10
Mammography alone 3940 13.123 11,284 258,514 3 389,741 1
Mammography + clinical 5384 13.129 239,765 257,191 8 388,478 8
MRI + clinical 11826 13.139 618,286 250,957 13 382,348 13
18-month interval
No surveillance 1704 12.925 256,787 9 386,033 10
Mammography alone 3483 13.105 9842 258,623 1 389,676 2
Mammography + clinical 4532 13.114 121,600 257,747 7 388,887 6
MRI + clinical 9173 13.130 296,783 253,419 12 384,715 12
24-month interval
No surveillance 1704 12.925 256,787 9 386,033 10
Mammography alone 3219 13.089 9199 258,565 2 389,458 3
Mammography + clinical 4075 13.100 81,481 257,920 6 388,917 5
MRI + clinical 7826 13.120 189,286 254,565 11 385,760 11
36-month interval
No surveillance 1704 12.925 256,787 9 386,033 10
Mammography alone 3034 13.075 8861 258,459 4 389,205 4
Mammography + clinical 3777 13.086 63,077 257,951 5 388,815 7
MRI + clinical 7,001 13.109 140,417 255,186 10 386,280 9
TABLE 47  Consultant and non-consultant cost of clinical examinations
Surveillance interval Regimen
ICER at low and high clinical examination cost (£):
 65  86
12 months No surveillance
Mammography alone 4945 4727
Mammography + clinical 178,716 236,826
MRI + clinical 297,829 297,848
18 months No surveillance
Mammography alone 4057 3811
Mammography + clinical 89,362 118,455
MRI + clinical 142,296 142,331
24 months No surveillance
Mammography alone 3644 3366
Mammography + clinical 59,002 78,167
MRI + clinical 90,339 90,382
36 months No surveillance
Mammography alone 3410 3099
Mammography + clinical 45,043 59,607
MRI + clinical 66,741 66,789© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Exploration of the impact of age at the time surveillance starts
Table 50 reports the results of sensitivity analysis based on a starting age in the model of 40 years 
old. This table not only reports multiway sensitivity analysis for a starting age of 40 years, 
but also includes high chemotherapy costs and high hormone therapy costs (Table 36). In 
addition, a higher incidence rate for cancer is used in this model (0.0152, Table 29) and high 
probability of moving to the next risk profile. This analysis was conducted for surveillance 
intervals ranging from 12 to 36 months. In this analysis, the option with the highest net benefit 
is mammography alone at a surveillance interval of 12 months for a willingness-to-pay threshold 
of £20,000 per QALY. At a higher willingness-to-pay threshold of £30,000 per QALY, MRI plus 
clinical examination at a surveillance interval of 12 months has the highest net benefit. The 
second highest net benefit at a threshold of £20,000 and £30,000 is mammography and clinical 
examination at 12-month surveillance intervals.
In addition to a starting age of 40 years old, sensitivity analysis was also conducted on a higher 
starting age. In this model all parameters are assumed to be as the base-case assumptions with 
two differences: (1) starting age is 70 years old and (2) the incidence of cancer is based on the 
lowest hazard estimates (Table 29). The results of this analysis are presented in Table 51. At 
a willingness-to-pay threshold of £20,000 per QALY, the test with the highest net benefit is 
mammography alone at a 36-month interval. At a willingness-to-pay threshold of £30,000, the 
regimen with the highest net benefit is mammography alone at intervals of 24 months.
TABLE 48  Sensitivity analysis using high estimates of quality of life
Regimen Cost (£) QALY ICER (£)
Net benefits (£)
λ = £20,000 Rank λ = £30,000 Rank
12-month interval
No surveillance 1033 13.080 260,573 12 391,376 13
Mammography alone 1970 13.320 3902 264,436 1 397,638 1
Mammography + clinical 3396 13.328 183,571 263,165 8 396,445 5
MRI + clinical 6499 13.341 231,932 260,329 9 393,743 12
18-month interval
No surveillance 1033 13.080 260,573 391,376 13
Mammography alone 1722 13.298 3164 264,237 2 397,216 2
Mammography + clinical 2743 13.309 91,801 263,438 5 396,529 4
MRI + clinical 4969 13.329 109,808 261,618 11 394,911 11
24-month interval
No surveillance 1033 13.080 260,573 12 391,376 13
Mammography alone 1587 13.277 2813 263,958 3 396,731 3
Mammography + clinical 2408 13.291 61,015 263,407 6 396,314 6
MRI + clinical 4200 13.316 69,854 262,128 10 395,292 10
36-month interval
No surveillance 1033 13.080 260,573 12 391,376 13
Mammography alone 1498 13.259 2606 263,676 4 396,263 7
Mammography + clinical 2201 13.274 46,960 263,272 7 396,009 8
MRI + clinical 3734 13.303 51,938 262,329 13 395,361 9104 Economic evaluation
TABLE 49  Sensitivity analysis on quality of life in unmanaged states: breast-conserving model
Regimen Cost (£) QALY ICER (£)
Net benefits (£)
λ = £20,000 Rank λ = £30,000 Rank
12-month interval
No surveillance 1033 12.880 256,573 12 385,377 13
Mammography alone 1970 13.122 3868 260,478 1 391,702 1
Mammography + clinical 3396 13.129 230,558 259,175 8 390,461 6
MRI + clinical 6499 13.139 293,795 256,283 13 387,674 12
18-month interval
No surveillance 1033 12.880 256,573 12 385,377 13
Mammography alone 1722 13.087 3075 260,021 3 390,892 3
Mammography + clinical 2743 13.098 112,416 259,227 7 390,211 8
MRI + clinical 4969 13.119 137,827 257,418 11 388,612 11
24-month interval
No surveillance 1033 12.880 256,573 12 385,377 13
Mammography alone 1587 13.087 2679 260,155 2 391,027 2
Mammography + clinical 2408 13.098 72,359 259,561 5 390,546 5
MRI + clinical 4200 13.119 85,807 258,188 10 389,381 10
36-month interval
No surveillance 1033 12.880 0 256,573 12 385,377 13
Mammography alone 1498 13.071 2435 259,927 4 390,640 4
Mammography + clinical 2201 13.084 53,905 259,485 6 390,328 7
MRI + clinical 3734 13.109 62,168 258,445 9 389,535 9
TABLE 50  Sensitivity analysis for a starting age of 40 years: breast-conserving model
Regimen Cost (£) QALY ICER (£)
Net benefits (£)
λ = £20,000 Rank λ = £30,000 Rank
12-month interval
No surveillance 5097 14.592 286,742 13 432,661 13
Mammography alone 11,885 16.364 3831 315,392 1 479,031 3
Mammography + clinical 13,332 16.428 22,596 315,226 2 479,505 2
MRI + clinical 16,389 16.540 27,173 314,419 3 479,823 1
18-month interval
No surveillance 5097 14.592 286,742 13 432,661 13
Mammography alone 11,308 16.183 3904 312,348 7 474,175 7
Mammography + clinical 12,457 16.272 12,929 312,976 5 475,692 6
MRI + clinical 14,850 16.437 14,459 313,893 4 478,265 4
24-month interval
No surveillance 5097 14.592 286,742 13 432,661 13
Mammography alone 10,829 16.019 4016 309,558 10 469,751 10
Mammography + clinical 11,853 16.124 9769 310,630 9 471,871 9
MRI + clinical 13,966 16.328 10,350 312,600 6 475,883 5© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Sensitivity analysis around model considering IBTR only
Probability of developing cancer
Figures 30–33 report the impact of increasing the incidence of IBTR only. In these analyses, the 
impact on costs and QALYs or MCBC is not considered. As described earlier, IBTR has a much 
worse prognosis than MCBC. As would be expected, as incidence increases the incremental cost 
per QALYs fall when we compare a more effective but more costly surveillance regimen with the 
next most costly and effective. For mammographic and clinical follow-up the incremental cost 
per QALY compared with mammography alone begins to fall below £30,000 once the incidence 
TABLE 51  Sensitivity analysis for a starting age of 70 years: breast-conserving model
Regimen Cost (£) QALY ICER (£)
Net benefits (£)
λ = £20,000 Rank λ = £30,000 Rank
12-month interval
No surveillance 541 9.068 180,828 271,512 6
Mammography alone 1047 9.100 16,182 180,947 4 271,944 4
Mammography + clinical 2082 9.101 880,839 179,935 9 270,944 9
MRI + clinical 4340 9.103 1,093,357 177,719 12 268,749 13
18-month interval
No surveillance 541 9.068 180,828 5 271,512 6
Mammography alone 867 9.096 11,701 181,060 3 272,023 2
Mammography + clinical 1603 9.098 451,156 180,357 8 271,337 8
MRI + clinical 3211 9.101 529,198 178,810 11 269,820 12
24-month interval
No surveillance 541 9.068 180,828 5 271,512 6
Mammography alone 773 9.093 9331 181,093 2 272,026 1
Mammography + clinical 1359 9.095 305,494 180,546 7 271,498 7
MRI + clinical 2644 9.099 342,629 179,336 10 270,326 11
36-month interval
No surveillance 541 9.068 180,828 5 271,512 6
Mammography alone 713 9.091 7751 181,100 1 272,006 3
Mammography + clinical 1210 9.093 238,858 180,644 6 271,571 5
MRI + clinical 2302 9.097 258,696 179,636 10 270,606 10
Regimen Cost (£) QALY ICER (£)
Net benefits (£)
λ = £20,000 Rank λ = £30,000 Rank
36-month interval
No surveillance 5097 14.592 286,742 13 432,661 13
Mammography alone 10,404 15.875 4135 307,100 12 465,852 12
Mammography + clinical 11,363 15.989 8414 308,422 11 468,314 11
MRI + clinical 13,337 16.219 8573 311,053 8 473,248 8
TABLE 50  Sensitivity analysis for a starting age of 40 years: breast-conserving model (continued)106 Economic evaluation
of disease exceeds 0.00775 every 6 months and the surveillance interval is 24 months or longer. 
When the surveillance interval reaches 36 months, the adoption of a more effective but more 
costly regimen (again typified by MRI plus clinical follow-up) may be cost-effective once the 
incidence per cycle exceeds 0.0068.
Inflating the risk of death from untreated cancer
In this sensitivity analysis, the increased risk of death from cancer in unmanaged states was 
inflated from the base-case risk of 2.34 to a high of 2.196 (Table 52). The results of this analysis 
were broadly similar to the base-case analysis presented in Table 41.
FIGURE 30  Incremental cost per QALYs for the different surveillance regimens at a 12-month surveillance interval.
FIGURE 31  Incremental cost per QALYs for the different surveillance regimens at an 18-month surveillance interval.
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Changes to the probability of progressing to a more serious risk 
profile
Table 53 reports the impact of increasing the speed that an untreated cancer progresses to a 
risk profile with a worse prognosis. The results of this analysis are similar to those reported 
above and it is unlikely that changes in this variable alone will result in any regimen other than 
mammography alone having an incremental cost per QALY that society might be willing to pay.
Changes to costs of tests and treatments
Table 54 shows a high treatment cost and high surveillance cost sensitivity analysis for the 
IBTR model. Again, the results of this sensitivity analysis are broadly similar to those reported 
in Table 41.
FIGURE 32  Incremental cost per QALYs for the different surveillance regimens at a 24-month surveillance interval.
FIGURE 33  Incremental cost per QALYs for the different surveillance regimens at a 36-month surveillance interval.
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TABLE 52  Increasing the risk of death for unmanaged disease
Regimen Cost (£) QALY ICER (£)
Net benefits (£)
λ = £20,000 Rank λ = £30,000 Rank
12-month interval
GP only 956 12.798 255,010 13 382,994 12
Mammography alone 1952 13.072 3634 259,494 1 390,217 1
Mammography + clinical 3381 13.081 160,846 258,243 7 389,054 4
MRI + clinical 6490 13.097 196,526 255,450 12 386,420 11
18-month interval
GP only 956 12.798 255,010 13 382,994 12
Mammography alone 1696 13.047 2973 259,243 2 389,713 2
Mammography + clinical 2721 13.059 83,817 258,462 5 389,054 4
MRI + clinical 4955 13.082 97,976 256,685 11 387,504 10
24-month interval
GP only 956 12.798 255,010 13 382,994 12
Mammography alone 1553 13.024 2642 258,928 3 389,168 3
Mammography + clinical 2379 13.039 56,792 258,392 6 388,778 5
MRI + clinical 4180 13.067 63,721 257,156 10 387,825 9
36-month interval
GP only 956 12.798 255,010 13 382,994 12
Mammography alone 1456 13.004 2433 258,615 4 388,651 6
Mammography + clinical 2164 13.020 44,151 258,228 8 388,424 7
MRI + clinical 3710 13.052 47,805 257,329 9 387,848 8
TABLE 53  The impact of changing the probability of progressing to a higher risk profile
Surveillance interval Regimen
ICER at low and high probability of increasing to next risk profile 
per cycle:
 0.1555  0.2623
12 months No surveillance
Mammography alone 3973 3231
Mammography + clinical 177,150 110,112
MRI + clinical 216,537 131,811
18 months No surveillance
Mammography alone 3247 2523
Mammography + clinical 92,265 42,743
MRI + clinical 108,007 44973.0307
24 months No surveillance
Mammography alone 2887 2523
Mammography + clinical 62,482 42,743
MRI + clinical 70,315 44,973
36 months No surveillance
Mammography alone 2664 2391
Mammography + clinical 48,551 34,901
MRI + clinical 52,811 34,980© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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In addition, Table 55 shows sensitivity analysis in which the cost of a clinical examination is 
priced at the consultant and non-consultant rate. Although the incremental cost per QALYs 
changes, none is of sufficient magnitude to change conclusions.
Changes to utility estimates used
We tested the base-case assumption that women in unmanaged states have the same quality of life 
as women who are disease free (Table 56). In this analysis, all women in unmanaged states had 
the same utility as women who had been treated for IBTR or MCBC. A similar pattern of results 
is observed in the IBTR model sensitivity analysis as was observed in the breast-conserving 
model sensitivity analysis.
Exploration of the impact of age at the time surveillance starts
Table 57 reports the results of sensitivity analysis based on a starting age of 40 years old in 
the IBTR model. This table reports multiway sensitivity analysis for starting age 40 years, and 
includes the high chemotherapy costs and high hormone therapy costs (Table 36). In addition, 
the higher incidence rate for cancer is used in this model (0.0152, Table 29) and a short doubling 
time. This analysis was conducted for surveillance intervals ranging from 12 to 36 months.
TABLE 54  Ipsilateral breast tumour recurrence model: high costs
Regimen Cost (£) QALY ICER (£)
Net benefits (£)
λ = £20,000 Rank λ = £30,000 Rank
12-month interval
No surveillance 1578 12.830 255,021 9 383,320 11
Mammography alone 3869 13.076 9309 257,652 2 388,413 1
Mammography + clinical 5317 13.084 179,674 256,365 8 387,206 6
MRI + clinical 11,768 13.098 449,596 250,202 13 381,186 12
18-month interval
No surveillance 1578 12.830 255,021 9 383,320 11
Mammography alone 3400 13.053 8164 257,662 1 388,193 2
Mammography + clinical 4454 13.064 95,002 256,830 7 387,471 4
MRI + clinical 9107 13.085 225,253 252,590 12 383,438 10
24-month interval
No surveillance 1578 12.830 255,021 9 383,320 11
Mammography alone 3124 13.032 7638 257,523 3 387,846 3
Mammography + clinical 3987 13.046 65,386 256,924 5 387,379 5
MRI + clinical 7752 13.071 147,255 253,670 11 384,381 9
36-month interval
No surveillance 1578 12.830 255,021 9 383,320 11
Mammography alone 2929 13.014 7345 257,348 4 387,486 3
Mammography + clinical 3679 13.028 51,600 256,888 6 387,172 7
MRI + clinical 6919 13.058 110,989 254,232 10 384,808 8110 Economic evaluation
TABLE 55  Consultant and non-consultant cost of clinical examinations
Surveillance interval Regimen
ICER at low and high clinical examination cost (£):
 65  86
12 months No surveillance
Mammography alone 4148 3973
Mammography + clinical 133,736 177,150
MRI + clinical 216,515 216,537
18 months No surveillance
Mammography alone 3446 3247
Mammography + clinical 69,664 92,265
MRI + clinical 107,973 108,007
24 months No surveillance
Mammography alone 3113 2887
Mammography + clinical 47,228 62,482
MRI + clinical 70,274 70,315
36 months No surveillance
Mammography alone 2919 2664
Mammography + clinical 36,756 48,551
MRI + clinical 52,766 52,811
TABLE 56  Sensitivity analysis on quality of life in unmanaged states: IBTR model
Regimen Cost QALY ICER
Net benefits
λ = £20,000 Rank λ = £30,000 Rank
12-month interval
No surveillance 978 12.797 254,969 13 382,943 13
Mammography alone 1956 13.076 3513 259,559 1 390,317 1
Mammography + clinical 3384 13.084 173,840 258,295 7 389,135 5
MRI + clinical 6491 13.098 214,485 255,478 12 386,463 12
18-month interval
No surveillance 978 12.797 254,969 13 382,943 13
Mammography alone 1703 13.052 2844 259,340 2 389,861 2
Mammography + clinical 2727 13.064 88,891 258,546 5 389,183 4
MRI + clinical 4958 13.085 105,565 256,738 10 387,586 6
24-month interval
No surveillance 978 12.797 254,969 13 382,943 13
Mammography alone 1703 13.030 2295 258,906 3 389,210 3
Mammography + clinical 2727 13.044 45,211 258,161 8 388,604 8
MRI + clinical 4958 13.071 50,179 256,460 11 387,170 11
36-month interval
No surveillance 978 12.797 254,969 13 382,943 13
Mammography alone 1468 13.011 2295 258,748 4 388,856 10
Mammography + clinical 2175 13.026 45,211 258,354 6 388,619 7
MRI + clinical 3716 13.057 50,179 257,427 9 387,999 9© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Summary
In the base-case analysis the regimen with the highest net benefit and, therefore, most likely to 
be considered cost-effective was mammographic surveillance alone provided yearly. This result 
holds for women who had previously been treated for their primary cancer with either BCS or 
mastectomy or women who suffer IBTR.
As might be expected in a comparison of surveillance regimens, the results of the model are 
very sensitive to changes in the incidence of recurrent cancer. When the expected incidence 
is increased toward the maximum that could possibly be expected for any group of women 
mammography and clinical surveillance potentially becomes cost-effective when the surveillance 
interval is 24 months or longer. As the surveillance interval and incidence increase regimens 
that are more costly but more effective may also have incremental costs per QALY below typical 
threshold values. This suggests that there may be some scope for research into alternative 
technologies that could be used for surveillance.
The results of the analysis did not substantially alter for any of the other sensitivity analyses 
reported. The exception to this is when we changed several parameter values simultaneously. 
This was undertaken in an attempt to compare surveillance regimens for a hypothetical 
40-year-old woman (who can be thought of as having a greater likelihood of developing 
TABLE 57  Sensitivity analysis for starting age of 40 years: IBTR
Regimen Cost (£) QALY ICER (£)
Net benefits (£)
λ = £20,000 Rank λ = £30,000 Rank
12-month interval
No surveillance 4332 14.023 276,121 13 416,347 13
Mammography alone 11,383 16.013 3542 308,885 2 469,019 3
Mammography + clinical 12,859 16.093 18,630 308,994 1 469,920 2
MRI + clinical 15,970 16.237 21,569 308,767 3 471,136 1
18-month interval
No surveillance 4332 14.023 276,121 13 416,347 13
Mammography alone 10,724 15.792 3613 305,109 7 463,026 7
Mammography + clinical 11,909 15.896 11,347 306,013 5 464,974 6
MRI + clinical 14,376 16.099 12,171 307,600 4 468,588 4
24-month interval
No surveillance 4332 14.023 276,121 13 416,347 13
Mammography alone 10,176 15.598 3709 301,784 10 457,765 10
Mammography + clinical 11,239 15.717 8945 303,098 9 460,266 9
MRI + clinical 13,441 15.961 9033 305,772 6 465,378 5
36-month interval
No surveillance 4332 14.023 276,121 13 416,347 13
Mammography alone 9693 15.431 3807 298,921 12 453,228 12
Mammography + clinical 10,692 15.556 7943 300,438 11 456,002 11
MRI + clinical 12,764 15.827 7663 303,775 8 462,045 8112 Economic evaluation
IBTR or MCBC) and a hypothetical 70-year-old woman (representing a lower likelihood of 
developing IBTR or MCBC). In the sensitivity analysis conducted for a 40-year-old woman, 
the following changes were made: the incidence of recurrent cancer was increased and the 
time it took for an undetected cancer to progress to risk profiles with a worse prognosis was 
reduced. Furthermore, it was assumed that should IBTR or MCBC be detected then it would 
be treated more aggressively (and at higher cost). For 40-year-old women facing these risks 
and costs, mammographic surveillance every 12 months had the highest net benefit, although 
it was only slightly greater than mammography and clinical follow-up every 12 months. These 
results suggest that a more intensive follow-up of women judged to be at high risk may be cost-
effective. Conversely, for women at lower risk it may be more cost-effective for surveillance to 
be performed less often (every 2 or 3 years) with mammography alone or another similarly less 
intensive and costly test or tests.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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Chapter 8  
Discussion
Statement of overall aim and methods
Our aim was to examine the clinical effectiveness and cost-effectiveness of different surveillance 
mammography regimens after the treatment for primary breast cancer in the UK in both primary 
and secondary care settings.
We addressed this by undertaking a survey of UK breast surgeons and radiologists to identify 
current practice and estimate resource consequences of the varying regimens. In addition, we 
undertook two discrete systematic reviews to determine the clinical effectiveness of differing 
surveillance mammography regimens carried out after treatment for primary breast cancer 
on patient health outcomes and the diagnostic accuracy of surveillance mammography in the 
detection of IBTR and MCBC. We undertook statistical analysis of individual patient data 
and economic modelling using the results of the systematic reviews and existing data sets, and 
focused searches for specific data analysis to determine the effectiveness and cost–utility of 
differing surveillance regimens.
We identified feasible management strategies for surveillance of women after treatment for breast 
cancer in a UK context, and have modelled the effectiveness and costs of these strategies. As is 
described later, we used these data to assess implications for clinical practice and to inform needs 
for future research.
Summary of main findings
The first two elements of research reported focused on describing and summarising current 
practice and current evidence with respect to mammographic surveillance after the treatment for 
primary breast cancer. Our survey of UK breast surgeons and radiologists described in Chapter 3 
suggests that although common patterns in surveillance mammography practice exist there 
is considerable variation in the combinations of start, frequency, duration and discharge from 
surveillance mammography.
The most common approach was to start surveillance mammography 12 months after initial 
surgery for the treatment of the primary breast cancer (87%), offer mammography annually 
(72%), organised through a symptomatic breast service (96%), discharging women (74%) after 
either 5 years (35%) or 10 years (55%). Over 55% stated that they discharged women to the 
NHSBSP for surveillance mammography to be carried out. Overall, 18% stated that they did not 
discharge patients from clinical follow-up but, of those who did, 65% discharged after 5 years 
with 22% discharging at 10 years after initial treatment.
Although our response rate was low (17%), which we discuss further below (see Strengths and 
limitations), we received responses from surgeons or radiologists working at 105 trusts across the 
UK. Our findings were concordant with previous surveys on this topic.26,27 Therefore, we feel that 
our results are valid and informative, as they represent the views of the surgeons and radiologists 
involved in delivering breast cancer care and treatment from throughout the UK.114 Discussion
The plethora of different ways of conducting surveillance mammography in clinical practice 
means that there are potentially a large number of care pathways that are worthy of further 
consideration. It would not be possible to consider the merits of each of these options, especially 
when there are additional methods of follow-up that do not include mammography. Therefore, 
using the results of the survey and expert opinion from the project group a relatively small 
number of follow-up regimens was selected and defined. These differed in terms of the diagnostic 
technology used and the surveillance interval considered. It is possible, however, that potentially 
important pathways have been excluded from this list.
At the outset of this project, we felt that it would be important to evaluate the existing evidence 
regarding the effectiveness and cost-effectiveness of surveillance mammography, although we 
were unsure if the evidence base would be sufficient to guide any policy recommendations.
The systematic review we conducted to determine the effectiveness of differing surveillance 
mammography regimens after treatment for primary breast cancer in detecting IBTR and 
MCBC is described in Chapter 4. Our systematic review suggests that receipt of surveillance 
mammography offers a survival benefit compared with a surveillance regimen that does not 
include surveillance mammography. The surveillance regimens were complex and varied 
between studies (and only in broad terms could they be considered to fit within the different 
regimens of surveillance developed from the results of the survey). Furthermore, the influence of 
combinations of alternative surveillance regimens (e.g. clinical examination, ad hoc referral to the 
symptomatic service, etc.) remains unclear.
We adopted considerable and rigorous methods in an attempt to identify relevant studies. Despite 
this, only eight studies met our inclusion criteria, none of which was an RCT. We sought data 
from the included studies on eight outcomes, but few data on effectiveness, and none on cost-
effectiveness, were identified. The limited and variable data that were available precluded any 
quantitative analysis, and the paucity of the underlying evidence base mirrors the findings of 
previous reviews.4,29,43–47
As we anticipated that the existing evidence base would not be sufficiently informative, we 
planned a formal systematic review of diagnostic performance and analyses of existing individual 
patient data held in potentially appropriate data sets and registries. We conducted this work 
not only because we felt the data sets to be important in their own right, but also to inform an 
economic evaluation.
We conducted a systematic review to determine the performance (diagnostic accuracy) of 
surveillance mammography, alone or in combination with other tests, in detecting IBTR and/or 
MCBC. The primary purpose of this review was to evaluate the test performance of surveillance 
mammography. Two studies reported sensitivity and specificity for surveillance mammography 
in detecting IBTR in patients undergoing routine surveillance; although we chose to describe 
results from the study by Boné and colleagues,64 they should be treated individually owing to 
their highly selected patient population. The remaining study66,67 reported a sensitivity of 67% 
and a specificity of 85% for surveillance mammography. The study authors included MRI as a 
comparator and reported 100% sensitivity and 93% specificity for MRI in this group of patients. 
Three studies66,68,72 reported the median (and range) sensitivity and specificity of surveillance 
mammography for detecting IBTR in non-routine surveillance patients as 71% (50–83%) and 
63% (57–75%), respectively. Two of these studies68,72 included MRI and reported sensitivities of 
93% and 100% and specificities of 88% and 96%, respectively. In detecting MCBC in patients 
undergoing routine surveillance, only one study70 reported data for a single diagnostic test, MRI, 
with 91% sensitivity and 90% specificity.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Again, few data were available regarding MRI. Nevertheless, our findings suggest that MRI is the 
most accurate test for detecting IBTR and MCBC. Of the test combinations reported, surveillance 
mammography combined with breast ultrasound could be considered as the most accurate 
combination of tests for detecting MCBC. 
We decided that it was inappropriate to use studies of population-screening mammography to 
calculate diagnostic test performance, as patients with breast cancer will have had treatment that 
may affect their breast density and the operation site can show marked changes due to scar tissue, 
with the adjacent parenchymal tissue changed as a result of postoperative radiotherapy. The 
sensitivity of mammography is reduced when a more sensitive test (MRI) is also used and this 
accounts for the difference in the literature with respect to screening mammography. Parameter 
estimates for MRI in the screening population were used in the economic evaluation in Chapter 7 
of this report, however, as it was felt that these would provide an indication of the relative value 
of a more costly but more effective test. Similarly, it was not possible to explore the effects of 
adjuvant treatments or any other subgroup effects that may have reduced breast density, and 
which theoretically would increase the sensitivity of surveillance mammography.
We have shown that IBTR has an adverse effect on survival. This is independent of the primary 
tumour and its characteristics, and in our analysis of BCS the HR was 2.13 (95% CI 1.78 to 
2.56). This has been found in several previously published series.20,77–80 Furthermore, the time 
from the treatment of the primary cancer to the event occurring is important, with those 
events that happen later having a survival advantage compared with those that occur earlier. 
This was also found in a combined analysis of five trials of women treated by BCS who had 
node-negative disease.77
We did not find that MCBC has an independent adverse effect on survival in either the BCS 
or mastectomy group. This is contrary to a large series of women with bilateral disease, who 
developed MCBC within 5 years of the primary tumour occurring and were under the age of 
50 years. They were 3.9 times more likely to die than those who did not develop MCBC.108 Our 
result may be due to there being too few deaths in our cohort with MCBC. We did find that older 
women are at reduced risk of MCBC and that women with larger tumours are at an increased 
risk of MCBC. It is known that women who have more advanced disease are at increased risk 
of developing contralateral disease. This needs to occur relatively early, as women with more 
advanced disease have poor survival. Therefore, it is likely that those women who develop MCBC 
later actually have a survival advantage from their primary disease. With respect to survival there 
was no evidence that women who develop MCBC have a different risk to those women who do 
not develop either IBTR or MCBC.
We have shown that there is a survival advantage if the IBTR or MCBC is detected at a smaller 
size compared with a larger size. The reference category was taken as < 10 mm in maximum 
diameter. Women with tumours of > 20 mm had an independent relative risk of death of 2.26 
(95% CI 1.58 to 3.24). In those women for whom the data about size were missing (i.e. those 
women who did not have surgery) the risk of death is even greater at 3.19 (95% CI 2.24 to 4.53). 
While we have no information as to how these events were detected in clinical practice, the 
implication is that surveillance mammography may be of value. We know from the NHSBSP 
that 80% of cancers detected by 3-yearly mammography are < 20 mm in maximum diameter. 
This suggests that surveillance mammography could be used to reduce the size at which IBTR or 
MCBC cancers are detected. In our primary tumour cohorts the incidences of IBTR and MCBC 
are fairly constant over the first 10 years, although we did not follow this for a longer time period. 
This supports the fact that surveillance mammography should be continued for at least 10 years.116 Discussion
We used information derived from the prior analyses to inform the economic evaluation. The 
methods and results of this are reported in Chapter 7. The structure for the economic evaluation 
was informed by our survey, together with detailed discussions with clinical members of the 
research team. Rigorous and systematic attempts were then made to identify data relevant to 
the UK. These included the reviews and individual patient data analyses from existing data sets, 
and also included a series of focused reviews to identify other necessary data (e.g. on aspects 
of epidemiology/natural history of disease, health-state utilities, etc.). Despite these efforts, few 
data were available to inform many of the estimates used by the model and consequently the 
economic analysis should be considered as exploratory, and hence interpreted cautiously. Despite 
this, the results of the economic analysis suggest that the regimen with the highest net benefit, 
and therefore most likely to be considered cost-effective, was mammographic surveillance alone 
provided yearly. This result holds for women who were previously treated for their primary 
cancer with either BCS or mastectomy or for women who suffer an IBTR.
The results of the model were very sensitive to changes in the incidence of IBTR and MCBC. The 
maximum expected incidence modelled was 1.25% every 6 months. This exceeds the maximum 
that might be expected based on an interpretation of the Kaplan–Meier survival curves and 
the HRs reported in Chapter 6 where there was moderate evidence of a statistically significant 
difference (i.e. the reported p-value was ≤ 5%). As the incidence of recurrent cancer increased 
to 0.9% every 6 months, a surveillance regimen of mammography and clinical surveillance 
potentially becomes cost-effective when the surveillance interval is 24 months or longer. This is 
because as incidence increases there is more scope for more costly regimens that have a better 
diagnostic performance to prove their worth. When the surveillance interval was increased to 
36 months and the modelled incidence of IBTR and MCBC every 6 months was approaching 1%, 
a regimen of MRI and clinical follow-up also had an incremental cost per QALY below £30,000 
(a typical threshold adopted by, for example, NICE). This suggests that there may be some scope 
for research into alternative technologies that could be used for surveillance for women at the 
highest risk of recurrence.
To test how robust the results were we explored the impact of changes in many of the other model 
parameters in a number of sensitivity analyses. The results of these analyses were not substantially 
different to the base-case results.
The exception to this was when we changed several parameter values simultaneously. This 
was carried out in an attempt to compare surveillance regimens for a hypothetical 40-year-old 
woman (where the model was changed so that a woman has a greater likelihood of developing 
IBTR and MCBC and has a worse prognosis) and a hypothetical 70-year-old woman (potentially 
representing a patient with less likelihood of developing IBTR and MCBC). In the sensitivity 
analysis conducted for a 40-year-old woman the following changes were made: the incidence of 
IBTR and MCBC cancer was increased and the time it took for an undetected cancer to progress 
to risk profiles with a worse prognosis was reduced. Furthermore, we assumed that should IBTR 
or MCBC be detected then it would be treated more aggressively (and at a higher cost).
For the scenario considering the cost-effectiveness of surveillance for a 40-year-old woman (a 
high-risk scenario) mammographic surveillance every 12 months had the highest net benefit, 
although it was only slightly greater than mammography combined with clinical follow-up 
every 12 months. These results suggest that a more intensive follow-up of women judged to be 
at high risk may be cost-effective. Conversely, for women at lower risk of IBTR or MCBC (the 
scenario modelled was for a 70-year-old woman) it may be more cost-effective for surveillance to 
be performed less often (every 2 or 3 years) with mammography alone or another similarly less 
intensive and less costly test or combination of tests.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Taken together, the results of the economic analysis would suggest that were the NHS to adopt 
a single policy covering all women after treatment for a primary breast cancer then a policy 
of mammographic surveillance alone at 12, 18 or 24 months might be the best policy. If the 
base-case analysis underestimated the risk of IBTR or MCBC then a more intensive regimen, for 
example mammography and clinical follow-up, might be more efficient, although because of the 
trade-off between cost and diagnostic performance the surveillance interval might increase to 
24–36 months. Were the NHS to consider targeting intensive surveillance for those deemed at 
higher risk of recurrence then it is possible that more intensive methods of surveillance would 
be considered worthwhile given the conventional threshold for society’s willingness to pay for 
a QALY. For women deemed at lower risk of recurrence a less intensive regimen may be the 
most cost-effective. This raises questions about the feasibility of providing different patterns of 
surveillance according to perceived risk of recurrence. It also raises questions about the ethics 
of treating women who have been treated for a primary breast cancer differently, based not just 
upon characteristics of their primary cancer, but also other demographic characteristics such 
as age.
Strengths and limitations
Our work focused on the question posed by the HTA programme: what is the clinical 
effectiveness and cost-effectiveness of different surveillance mammography regimens after the 
treatment for primary breast cancer? Mammography is the primary follow-up examination 
conducted in the UK at the present time in clinical practice. For this reason, our survey and 
systematic reviews concentrated on surveillance mammography, although other tests were 
considered when reported with mammography results in this particular patient population. 
Overall, we believe the main strengths of this project are the rigorous, systematic, explicit and 
comprehensive methods used. We have identified that there is limited evidence available to 
answer our research question and, as such, this is the main limitation of our findings.
Identifying feasible management strategies for surveillance and follow-up 
of women after treatment for breast cancer (Chapter 3)
Our survey findings reflect the different guidance given by the various professional organisations 
with an interest and expertise in surveillance following treatment for breast cancer in 
combination with ‘local circumstances’ and protocols of the respondents (see Table 10). Our 
findings are generally consistent with those of recent surveys addressing similar questions. 
Donnelly and colleagues’ survey26 of 256 specialists registered to Cancer Trials Units suggested 
that the majority (84%) adhered to locally developed protocols and that mammography at 
annual intervals was the most common surveillance interval for both invasive and non-invasive 
primary breast cancer. Respondents favoured a risk-adjusted protocol and their preferred median 
clinical follow-up time overall was 5 years. Maxwell and colleagues’ survey27 of breast-screening 
units taking part in the Sloane project concluded that there was wide variation in follow-up 
practice after surgery (breast conservation or mastectomy) for non-invasive breast cancer, the 
most common frequency and duration of clinical follow-up being annually for the first 5 years 
after treatment, and surveillance mammography being annually for the first 10 years in patients 
undergoing breast conservation, and annually or 2-yearly in patients who had undergone a 
mastectomy, also for 10 years.
The final response rate to our survey was low compared with other recent similar surveys.26,27 
Cook and colleagues109 recently reported in a review of response rates of surveys of health-care 
professionals that response rates are low and probably declining [average response rate in doctors 
was 57.5% (95% CI 55.2% to 59.8%), but this is significantly lower than the estimate for the 118 Discussion
prior 10-year period]. Rates are lower without a reminder and with larger surveys. Our survey 
was a ‘cold-calling’ mass e-mailing with no personal reminders to complete the survey, whereas 
the sample taking part in these previous surveys was a selected population with an interest in 
clinical trials or taking part in national audit. Our response rate also highlights the disadvantages 
of undertaking an anonymous survey, as it is probable that our low response rate would have 
been improved if we could have used personal reminders to non-responders. Our low response 
rate may mean our results are not representative of the population of health-care professionals 
organising, providing and overseeing the follow-up care of women after surgery for primary 
breast cancer. However, taken together with data from Donnelly and colleagues26 and Maxwell 
and colleagues,27 it has provided an insight into the more common patterns of surveillance 
mammography practice and the feasible strategies for follow-up.
Systematic review of effectiveness of surveillance mammography after 
treatment for primary cancer (Chapter 4)
The methods used for conducting the review of the clinical effectiveness and cost-effectiveness 
of surveillance mammography were systematic, explicit and comprehensive. We believe that our 
inclusion criteria were both clinically relevant and scientifically rigorous. The main limitation 
of the review relates to the limitations of the underlying evidence base. Few published studies 
met the inclusion criteria, none of which was an RCT. Few data were available and what data 
were available were potentially biased. Owing to limited data and variability across studies we 
felt it unwise to perform a meta-analysis, thus a narrative synthesis of evidence was presented. 
The included studies are likely to be prone to both lead and length time bias. There was no 
comparison of varying surveillance mammography regimens. An RCT study design with survival 
as the end point would take these biases into account as the random allocation of participants 
to intervention groups minimises the impact of bias due to confounding variables. Such a study 
would be possible, as equipoise exists as to the ideal interval between surveillance mammograms.
It is possible that there are unpublished reports that may have otherwise met our inclusion 
criteria. The clinical members of the research team did not suggest any potentially relevant 
work that we could have included and, at the time of writing this report, we are unaware of any 
unpublished studies meeting our inclusion criteria.
Health-related quality of life was included as a review outcome and we were not restrictive in the 
measures that we considered. Some of the potential methods could have captured the effects on 
the psychological health of the woman. Nevertheless, we did not explicitly consider psychological 
factors as outcomes. This may be of greater concern in the NHSBSP, in which women who 
are ‘well’ are invited for mammography, because psychological harm or anxiety due to the 
examination or a suspicious test result or a false reassurance could have greater adverse impact. It 
is, however, worth noting that none of the included studies reported quality-of-life data and it is 
unclear if any would have provided data regarding psychological outcomes.
Systematic review of the test performance of mammography and 
comparator tests in detecting IBTR/MCBC (Chapter 5)
We believe that the methods adopted for this review are scientifically rigorous and compatible 
with current guidance in this area. Very few studies met our review inclusion criteria. The 
included studies were restricted to those published in the English language. This potentially limits 
the evidence base available, although non-English-language studies were less likely to be relevant 
to UK practice. As with the review of clinical effectiveness and cost-effectiveness we deliberately 
chose broad participant inclusion criteria. We based our rationale for this decision on our 
preliminary knowledge of the limited evidence base available. Narrowing our inclusion criteria 
would further limit the amount of available data. Although broadening our inclusion criteria 
carried the risk of finding variation between studies we believe that the limited data presented © Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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have greater generalisability to the whole spectrum of women who would be offered surveillance 
in practice. Of the studies included here, few evaluated the performance of the considered 
tests for similar purposes. Furthermore, even where data were available it was not clinically 
appropriate to combine them. For example, because of anatomical differences between a ‘treated’ 
and an ‘untreated’ breast (due to the effects of treatments) it was not appropriate to combine 
data on test performance for the detection of IBTR and MCBC. Similarly, it was inappropriate to 
combine data from routine and non-routine surveillance patients, as the test operator is primed 
to evaluate a suspicious finding in the non-routine surveillance patient. It is unclear what effect 
this has on test accuracy but it is likely to focus their attention on a particular area of the breast 
and may conceivably increase the sensitivity of the diagnostic test. Furthermore, no data were 
reported by the studies included on other test performance factors, such as adverse effects or 
acceptability of the tests.
Systematic reviews of diagnostic accuracy are highly complex and methodology in this area 
continues to evolve. One of the problems with a diagnostic review in this area is that there is 
not an established reference standard for ascertaining the true- and false-negative results of 
a surveillance test for IBTR or MCBC breast cancer. One potential solution is that true- and 
false-negatives are ascertained by a negative result or a positive test result at subsequent testing 
after a period of follow-up has elapsed. While this represents a pragmatic reference standard for 
verifying negative test results it introduces the possibility of an interval cancer occurring during 
the time period between tests.
Disease progression bias refers to instances where there is a time delay between an index test 
result and administration of the reference standard test, thus allowing the possibility of a 
misclassified reference standard test result. In breast cancer, uncertainty might exist as to whether 
a false-negative index test truly represents a cancer missed at the time of administering the 
index test, or whether a positive test result on subsequent testing represents a cancer that has 
occurred in the time interval after administration of the index test and before verification via the 
subsequent surveillance test. The possibility of this bias can be minimised through short time 
intervals between test administrations, although it cannot be completely eliminated. All studies 
in this review were considered to have adequate time intervals for verifying negative results for 
all tests. Similarly, we defined a time interval of no longer than 3 months between a positive test 
result and confirmation by reference standard assessment by fine-needle aspiration cytology or 
tissue biopsy, and no longer than 6 months for histopathological assessment by biopsy. The time 
period between a positive test result and reference standard confirmation was unclear in all but 
one study.71
Results for the index and comparator tests evaluated in this review were ascertained by subjective 
operator interpretation, either by visual inspection of an image of the breast (surveillance 
mammography, ultrasound and MRI) or by clinical examination of the breast. We do not have 
available data on the level of operator expertise or intra/inter-rater reliability for the included 
studies. It is therefore unclear whether these factors had any influence on reported test accuracy 
within, and between, studies and therefore whether any potential test operator bias exists.
Analysis of breast cancer data set (Chapter 6)
The strength of this analysis is that it is based on a large consecutive cohort of women diagnosed 
with breast cancer in the UK and treated within the NHS. The data have been collected 
prospectively and without selection bias. There were a large number of IBTR and MCBC events. 
The results of this analysis are generalisable to the UK as the WMCIU collects information from 
a large geographical area with a population of over 5.3 million. We used the time period from 
1997 onwards to ensure consistency in data coding. As discussed earlier, this time period reflects 
the current management and follow-up of breast cancer patients and was after the introduction 120 Discussion
of the screening programme. Some previous analyses, although having the advantage of longer 
follow-up, cover time periods where cancer diagnosis and treatment were different.108 Our large 
data set allowed us to model the effects of IBTR and MCBC, and the time when they occurred, on 
survival and to examine whether these were independent risk factors.
The limitations of this analysis are that the data set did not contain information on surveillance 
mammography required to assess the effectiveness of such a regimen on survival after breast 
cancer treatment (i.e. frequency and duration of surveillance regimen). We used an NHS 
cancer data set, which was reflective of routine data collection within the NHS, although 
not as intensively populated or meticulously recorded as a trial data set. It was only possible 
to have a maximum of 10 years of follow-up because we wanted to ensure that our results 
were relevant to current practice. The shorter median follow-up time will possibly have the 
effect of underestimating the long-term adverse effect of second cancers. The data set did not 
contain information on whether the IBTR/MCBC were detected by mammography or clinical 
examination or from the patient’s symptoms but we could not expect this as this is not routinely 
recorded by cancer registries. Women who did not have surgery for their primary breast tumour 
were not included in our analysis. This was because curative intent was unlikely when they were 
treated. Logically, it would be inappropriate to offer them surveillance mammography in the 
same way as women following curative treatments. A small number of older women are treated 
with endocrine therapy and possible radiotherapy if the tumour progresses while on hormone 
therapy. In addition, those who are ER negative and unfit for surgery may have radiotherapy and 
are monitored by mammography but this was not felt to equate with surveillance mammography.
There were perhaps fewer IBTR and MCBC events than expected compared with many published 
studies. For example, the recent Guy’s data set reported a cumulative 10-year combined IBTR/
MCBC risk of 0.11 (95% CI 0.09 to 0.14) in patients undergoing BCS, whereas this was 0.071 
(95% CI 0.065 to 0.077) in the WMCIU data set.110 This is most probably due to the relatively 
short follow-up time compared with the Guy’s data set (median 9 years compared with median 
5 years). The WMCIU data set also only includes those patients who have had pathological 
confirmation of IBTR or MCBC, and this partly accounts for the apparent underascertainment 
of events in the WMCIU data set. The Guy’s data set was meticulously collected and the IBTR or 
MCBC events continued to be collected even after distant metastases were found. In some clinical 
practices, once distant metastases are found, breast cancer follow-up, with respect to detection of 
IBTR and MCBC, is not consistently undertaken, thus such events may not be recorded. We did 
not incorporate information about distant metastases and so could not censor at this time point. 
It is possible that this accounts for the apparent lack of worse prognosis for those women who 
develop an MCBC compared with women who do not develop further breast cancer.
It is important to recognise that the second tumour cohort data set that we used to inform the 
risk of death from IBTR or MCBC was created by taking all events from 1990 onwards from 
women who had been treated surgically for primary breast cancer. This was performed in order 
to have a sufficiently long follow-up period to calculate long-term survival in a large sample. 
Although they contain related information, the data sets should be treated independently and 
therefore information not extrapolated from one to another.
Economic evaluation (Chapter 7)
The main strength of the economic evaluation is that it has attempted to use rigorous and 
systematic methods to obtain parameter inputs into the economic evaluation. These were then 
assembled in the economic model whose structure was informed by both detailed discussions 
with the clinical members of our research team and the results of the survey of current and 
desired practice, commissioned as part of this study. One of the most important challenges 
faced when conducting the economic evaluation was the limited evidence base available. This © Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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constrained the model in a number of key ways. First, there were insufficient data available to 
model all the potential strategies that we considered relevant, and, second, few data were available 
on many model parameters. Furthermore, what data were available were not ideally suited to 
the question being addressed. For example, for health-state utilities few data relevant to a UK 
decision-making context were identified. In response to this, we adapted our plans to focus on 
three basic patterns of surveillance, the cost-effectiveness of which was explored in extensive 
sensitivity analyses. The object of these sensitivity analyses was not necessarily to provide 
definitive conclusions about the best regimen for the UK to adopt but rather to identify ‘best bets’ 
that would be worthy of further consideration. Our economic evaluation did not model all the 
commonly used surveillance regimens in the UK. This, in part, was due to limitations in existing 
evidence, but also because there were so many variants.
A further limitation relates to the way the available data were structured in the economic analysis. 
The model structure contains a number of simplifying assumptions. First, IBTR and MCBC are 
treated identically and it is assumed that they are of the lowest level of severity at the point where 
it is technically possible to detect them. Severity of disease has also been defined in an arbitrary 
manner (by grouping cancers according to the expected 10-year survival). This was driven, 
in part, by a desire to keep this element of the model manageable. However, it may mean that 
relatively subtle differences between strategies might be missed.
The economic evaluation took the UK NHS as its perspective. This meant that only costs 
incurred by the NHS were included, and benefits were measured in terms of the effects on health 
(measured in QALYs) that were consequent on increased survival caused by earlier detection. 
This perspective is the one recommended by NICE,100 for instance, but it means that other 
potentially important costs and benefits are excluded. With respect to costs it might be expected 
that the women’s costs of accessing surveillance services would increase as the frequency of 
surveillance increases. However, earlier detection and successful treatment would reduce time 
away from usual activities following treatment and those caused by ill health attributed to more 
advanced disease. The net effect of these aspects is uncertain.
Similarly, this project did not consider psychological implications for women and their families. 
Quality-of-life measures used as the basis of QALYs can capture some aspects of the effects 
on anxiety and mental health. However, the model only considered those effects relating to 
health effects from treatment/non-treatment of the cancer. It did not consider the whole patient 
experience of undergoing surveillance. We sought opinion from the patient representative 
member of our Advisory Group regarding our results. Variation in the manner in which 
surveillance is organised can be a source of anxiety to women due to concerns that differences 
in frequency and duration of follow-up have implications for risk of recurrence and survival. A 
woman could, for example, assume that 10 compared with 5 years of follow-up implies that she 
is at a heightened personal risk of developing IBTR or MCBC, rather than being an association 
with eligible screening age or local practice. Similarly, a patient undergoing mammography every 
3 years compared with one having annual mammography may either feel reassured that she has 
less risk of developing further cancer or feel anxiety that any further cancer will go undetected 
for a greater length of time. With respect to the model, these aspects could be further explored 
using preference elicitation techniques that go beyond the QALY framework. In more practical 
terms, this concern highlights the potential need to ensure that patients with breast cancer have a 
greater understanding of how and why their follow-up regimen has been ‘personalised’ to match 
their personal breast cancer type and its risk factors. Greater standardisation of practice in timing 
of implementing and discharging surveillance regimens would also provide reassurance that 
patients throughout the UK are all receiving the same standard of care.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Chapter 9  
Conclusions
Summary of findings
The most common mammographic surveillance regimen identified by our survey was annual 
mammography commencing 12 months after surgical treatment of the primary breast cancer. 
There was considerable variation in the combinations of start, frequency, duration and discharge 
from different surveillance regimens, however. Prior to our work, there was little existing 
evidence on the effectiveness of surveillance mammography and follow-up after treatment for 
primary breast cancer. Our systematic review of clinical effectiveness suggests that surveillance 
mammography offers a survival benefit compared with a surveillance regimen that does 
not include surveillance mammography. However, the effects of combinations of alternative 
surveillance regimens (e.g. clinical examination, referral to secondary care between planned 
surveillance if the patient has symptoms, etc.) remain unclear. Few data were identified regarding 
the diagnostic performance. The few data we found suggest that mammography is associated 
with a high sensitivity and specificity but MRI is the most accurate test for detecting IBTR 
and MCBC. The results from the systematic reviews should be interpreted with caution due to 
the limited evidence base from which they are derived (effectiveness review, eight studies; test 
performance review, nine studies).
No existing data set was identified that was ideally suited to answering our research questions. 
Our analysis of the WMCIU data set confirmed the previously known risk factors for mortality 
from breast cancer. It also demonstrated that IBTR is an independent predictor of survival. 
For women experiencing IBTR size is important, with those women with tumours > 20 mm in 
size being at a significantly greater risk of death than those with IBTR of < 10 mm. There was 
no evidence that MCBC is an independent predictor of survival; however, in women who do 
experience MCBC the size of the tumour is important. Women with tumours > 20 mm in size 
are at a significantly greater risk of death than those with MCBC tumours of < 10mm. Given the 
limited evidence base the results of the economic evaluation should be considered as exploratory. 
If it were decided that the NHS should adopt a single surveillance regimen for all women then 
the economic evaluation suggests that the regimen most likely to be considered cost-effective 
when the cost per QALY threshold was either £20,000 or £30,000 would be mammographic 
surveillance alone, provided every 12–24 months. The results of the economic model were 
sensitive to incidence and other factors, for example age, tumour characteristics, etc., that might 
define groups of women with greater or lesser likelihoods of developing a IBTR or MCBC. These 
results suggest that a more intensive follow-up of women judged to be at greater likelihood might 
be worthwhile. Conversely, for women with less likelihood it may be more cost-effective for 
surveillance to be performed less often (every 2 or 3 years) with mammography alone.
Implications for the NHS and patients
  ■ Results suggest that surveillance, when combined with effective treatment of the cancers 
detected, is likely to improve survival.
  ■ The evidence base on which to recommend any change in current practice is relatively weak.124 Conclusions
  ■ The current evidence base suggests that should the NHS choose to standardise surveillance 
for all women then a regimen of mammography alone every 12–24 months appears to have 
the highest net benefits when society’s willingness to pay for a QALY is £20,000 or £30,000.
  ■ Rather than offering the same regimen to all patients, careful consideration should be given 
to stratification of patients to ensure maximum benefit to ensure optimal use of resources. 
How best to deliver a varying surveillance regimen would be challenging, and consideration 
is also needed about how such a service could be best organised.
  ■ The current evidence base suggests that should the NHS choose to tailor surveillance 
for those women with a greater likelihood of developing IBTR or MCBC then more 
comprehensive (e.g. mammography and clinical follow-up) and more frequent surveillance 
(every 12 months) would be associated with the greatest net benefit.
  ■ The current evidence base suggests that should the NHS choose to tailor surveillance for 
those women least likely to develop IBTR or MCBC then only less frequent mammographic 
surveillance (e.g. every 36 months) would be associated with the greatest net benefit.
  ■ Variation in surveillance practice (e.g. frequency and duration of follow-up regimen) can be 
a source of anxiety to women. This implies that efforts to improve the patient’s understanding 
of how they will be followed up are important. Should the NHS choose to tailor surveillance 
then there would need to be the provision of information and reassurance about how the 
follow-up regimen has been tailored to match the type of breast cancer they have had and 
their risk factors for developing IBTR or MCBC.
  ■ Although evidence is limited about how best to standardise practice greater standardisation 
of an agreed surveillance regimen would provide reassurance that patients throughout the 
UK are receiving the same standard of care.
Suggested research priorities
Further evidence is required to make a robust and informed judgement on the effectiveness of 
mammographic surveillance and follow-up. From a scoping search conducted on 25 August 
2010, 14 months after conducting the search for the main effectiveness systematic review, 
we identified 192 potential titles and abstracts. Of these, we found no RCT studies directly 
addressing our research question. We found one RCT for which primary outcomes considered 
psychological morbidity for point of need compared with 6-monthly clinic surveillance. Only 
the secondary outcomes of this RCT, recurrences and method of detection, are relevant for 
this report. We found six non-RCT studies, two of which are referenced in the introductory 
section of this report,5,48 providing indirectly relevant evidence. We found no new HTA report 
or ongoing RCTs. The evidence trajectory for the clinical and cost-effectiveness of surveillance 
mammography therefore appears to be slow moving. Research is suggested in the following areas:
  ■ The data sets that exist at the moment are an excellent resource for researchers and 
considerable further analysis, addressing both clinically and economically important 
questions, could be undertaken using the data they contain. For example, further work 
could focus on extending our analyses by incorporating the influence of distant metastases 
on survival. Where appropriate such analyses should be incorporated into an economic 
evaluation model.
  ■ With respect to the research question posed within this report the utility of the data sets 
could be improved. The optimal data set would record details of mode of detection for 
IBTR or MCBC; the frequency of the clinical and mammographic surveillance regimen, 
and how this varies over time; and whether a woman’s IBTR or MCBC was detected during 
routine surveillance or as a result of it causing symptoms for the patient. Some of this 
information is well collected currently and additional information might reasonably be 
captured in a thorough audit. It is important to record accurate and timely information on © Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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grade, size, tumour type, ER status and lymph node status of both the primary tumour and 
subsequent IBTR or MCBC tumour; details of the primary treatment given (i.e. type and 
extent of surgery, excision margins, radiotherapy, hormone therapy, chemotherapy and 
other treatments); details of IBTR or MCBC treatment; when and where distant metastases 
occurred; and cause of death. Once available such data should be incorporated into refined 
statistical and economic analyses addressing the research question posed within this report.
  ■ The paucity of data on the diagnostic performance of tests in the group of women of 
interest needs to be addressed. There is a need for high-quality, direct head-to-head studies 
comparing the diagnostic accuracy of tests used in the surveillance population. Such studies 
are likely to be lower cost than a definitive RCT and provide data sooner. Such data should 
then be incorporated into an economic evaluation model.
  ■ The economic evaluation suggested that there were circumstances where the use of tests with 
a better diagnostic performance but higher cost might be potentially cost-effective. Further 
primary work should also consider whether the use of existing technologies, such as MRI, 
which may have better performance, could be worthwhile for patients at high risk of IBTR or 
MCBC. An economic analysis should form part of such work.
  ■ It would be useful to compare within an economic evaluation mixed clinical follow-up in 
lower cost settings combined with surveillance mammography in the long term. It would 
also be important to consider psychological factors associated with differing types, settings 
and frequency of surveillance regimens using a major health psychology theory so that 
the economic modelling could focus down on regimens that, based on the psychological 
analyses, look most promising.
  ■ A definitive RCT would be ideal and, although costly, could focus on those women at higher 
risk of IBTR or MCBC. The interventions considered might include mammography and 
MRI, for those at the highest risk, or surveillance mammography of 1 year versus a longer 
time interval, for example 3 years. Such a trial might also compare more sophisticated 
surveillance regimens that vary not only in terms of the frequency of mammography, but 
also in terms of the frequency and setting of clinical follow-up.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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Appendix 2  
Questionnaire content: a survey of UK 
surveillance mammography practice after 
treatment for primary breast cancer140 Appendix 2
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Appendix 3  
E-mail invitation to participate in a survey 
of UK surveillance mammography practice 
after treatment for primary breast cancer
From: hsru.notification.service@abdn.ac.uk
Sent:
To:
Subject: Survey of UK Surveillance Mammography practice after treatment for primary 
breast cancer
Survey of UK Surveillance Mammography practice after treatment for primary breast cancer
We are inviting you to complete an online questionnaire about your current surveillance 
mammography practice (please see web link below). We are surveying members of the 
Association of Breast Surgery at BASO and the Royal College of Radiologists Breast Group. 
The survey is part of a National Institute for Health Research, Health Technology Assessment 
programme commissioned study (HTA Project 07/47/01 – to determine the clinical effectiveness 
and cost-effectiveness of different surveillance mammography regimens after the treatment of 
primary breast cancer in the UK). The study is being conducted by a multidisciplinary research 
team led by Professor Fiona Gilbert (Roland Sutton Chair of Radiology) at the University 
of Aberdeen.
The questionnaire should take no longer than 5–10 mins to complete. Your valuable participation 
will contribute towards identifying the clinical and cost-effectiveness of differing surveillance 
mammography regimens, and help to identify future research priorities in this area. We would be 
very grateful if you would consider helping us with our important research.
The questionnaire is strictly confidential and anonymous. In order to ensure anonymity, please 
note that you will not be able to save your responses and return to the survey at a later stage. 
Please review your responses before clicking ‘submit’ to send your completed survey. You will not 
be able to return to your responses after submitting the survey.
Please click on the web link below to begin the questionnaire. Thank you very much for giving 
your time to help us with our research.
https://viis.abdn.ac.uk/HSRU/htamammography/default.aspx?uid=52b54a34-12d1-41f8-86d8- 
b60786762426148 Appendix 3
If you have any queries or comments about the questionnaire or the research study, 
please contact:
Clare Robertson
Research Fellow
Health Services Research Unit
University of Aberdeen
3rd Floor, Health Sciences Building
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Appendix 4  
Reminder e-mail invitation to participate in 
a survey of UK surveillance mammography 
practice after treatment for primary 
breast cancer
From: hsru.notification.service@abdn.ac.uk
Sent:
To:
Subject: REMINDER: Survey of UK Surveillance Mammography practice after treatment for 
primary breast cancer
REMINDER: Survey of UK Surveillance Mammography practice after treatment for primary 
breast cancer
You may have already received an e-mail inviting you to participate in this survey. If you have 
already completed and returned the questionnaire, please accept our thanks and delete this 
e-mail as no further involvement is required. If you have not completed the questionnaire please 
take the time to consider helping us with this important research.
We are inviting you to complete an online questionnaire about your current surveillance 
mammography practice (please see web link below). We are surveying members of the 
Association of Breast Surgery at BASO and the Royal College of Radiologists Breast Group. 
The survey is part of a National Institute for Health Research, Health Technology Assessment 
programme commissioned study (HTA Project 07/47/01 – to determine the clinical effectiveness 
and cost-effectiveness of different surveillance mammography regimens after the treatment of 
primary breast cancer in the UK). The study is being conducted by a multidisciplinary research 
team led by Professor Fiona Gilbert (Roland Sutton Chair of Radiology) at the University 
of Aberdeen.
The questionnaire should take no longer than 5–10 mins to complete. Your valuable participation 
will contribute towards identifying the clinical and cost-effectiveness of differing surveillance 
mammography regimens, and help to identify future research priorities in this area. We would be 
very grateful if you would consider helping us with our important research.
The questionnaire is strictly confidential and anonymous. In order to ensure anonymity, please 
note that you will not be able to save your responses and return to the survey at a later stage. 
Please review your responses before clicking ‘submit’ to send your completed survey. You will not 
be able to return to your responses after submitting the survey.150 Appendix 4
Please click on the web link below to begin the questionnaire. Thank you very much for giving 
your time to help us with our research.
https://viis.abdn.ac.uk/HSRU/htamammography/default.aspx?uid=52b54a34-12d1-41f8-86d8- 
b60786762426&Reminder=true
If you have any queries or comments about the questionnaire or the research study, 
please contact:
Clare Robertson
Research Fellow
Health Services Research Unit
University of Aberdeen
3rd Floor, Health Sciences Building
Aberdeen AB25 2ZD© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Appendix 5  
Number and percentage of respondents 
completing questions in the survey of UK 
surveillance mammography practice after 
treatment for primary breast cancer
Question n = 183
Percentage 
of n
1 What is your specialty? 183 100
2 Please name your NHS trust 182 99
3 How many women with newly diagnosed breast cancer does your unit manage annually (include both 
symptomatically and screen detected)?
183 100
4 How soon after completing surgery for primary breast cancer do you initiate surveillance mammography? 
(answer in months)
181 99
5 Please describe your standard surveillance mammography for women who have had BCS:
I arrange surveillance mammography (give frequency) 182 99
6 Do you ever vary your standard surveillance mammography practice for women who have had BCS? 
(filter question)
180 98
7 If yes please tick all below that apply:
7a In situ cancers (DCIS, LCIS): 14 8
For which in situ tumours do you vary your standard surveillance mammography practice? 11 6
How soon after completing BCS for primary breast cancer do you initiate surveillance mammography? 14 8
How often do you arrange surveillance mammography? 13 7
7b Primary tumour size: 5 3
For tumours above what size do you vary your standard follow up (in cm) 4 2
How soon after completing BCS for primary breast cancer do you initiate surveillance mammography? 4 2
How often do you arrange surveillance mammography? 4 2
7c Primary tumour grade: 4 2
For which grades(s) do you vary your standard surveillance mammography practice? 4 2
How soon after completing BCS for primary breast cancer do you initiate surveillance mammography? 4 2
How often do you arrange surveillance mammography? 4 2
7d Lymphovascular invasion: 4 2
How soon after completing BCS for primary breast cancer do you initiate surveillance mammography? 4 2
How often do you arrange surveillance mammography? 3 2
7e Age: 9 5
For which ages do you vary your standard surveillance mammography practice? 9 5
How soon after completing BCS for primary breast cancer do you initiate surveillance mammography? 9 5
How often do you arrange surveillance mammography? 9 5
7f Absence of radiotherapy: 3 2
How soon after completing BCS for primary breast cancer do you initiate surveillance mammography? 3 2
How often do you arrange surveillance mammography? 2 1152 Appendix 5
Question n = 183
Percentage 
of n
7g Combination of criteria above: 2 1
Please describe which criteria you combine 1 1
How soon after completing BCS for primary breast cancer do you initiate surveillance mammography? 1 1
How often do you arrange surveillance mammography? 1 1
7h Other: 10 5
Other criteria not listed above 8 4
How soon after completing BCS for primary breast cancer do you initiate surveillance mammography? 6 3
How often do you arrange surveillance mammography? 7 4
8 Please describe your surveillance mammography practice for the contralateral breast for women who 
have had mastectomy
8a I initiate surveillance mammography x months after mastectomy for primary breast cancer 159 87
8b I arrange surveillance mammography (give frequency) 181 99
9 Do you ever vary your standard surveillance mammography practice for the contralateral breast for 
women who have had mastectomy? (filter question)
180 98
10 Please describe the criteria you use for varying your standard surveillance mammography for the 
contralateral breast for women who have had mastectomy
20 11
How soon after completing mastectomy surgery for primary breast cancer do you initiate surveillance 
mammography?
23 13
How often do you arrange surveillance mammography? 24 13
11 Through which service is your surveillance mammography scheduled? 182 99
12 If eligible do you discharge women into the screening programme for surveillance mammography? 179 98
If yes, at what age? 39 21
13 Do you discharge women from clinical follow up? 180 98
If yes, please indicate when 130 88
13b Do you discharge women from surveillance mammography follow-up? 182 99
If yes, please indicate when 121 89
14 Are there any exceptions to your normal surveillance mammography practice (e.g. patient participating in 
a clinical trial)?
178 97
If yes, can you specify what this would involve? 38 21
15 Does your current surveillance mammography practice differ from how you would ideally like to arrange 
surveillance mammography?
180 98
16 Can you please indicate how often you would ideally like to arrange surveillance mammography?
16a How often would you ideally arrange surveillance mammography for women who have had BCS? 106 58
16b How often would you ideally arrange surveillance mammography for women who have had mastectomy? 106 58
17 If your current surveillance mammography practice differs from your ideal surveillance mammography 
practice what factors influence this difference?
53 29
18 Please use this space to provide any comments 63 34
DCIS, ductal carcinoma in situ; LCIS, lobular carcinoma in situ.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Appendix 6  
List of NHS trusts of respondents to the 
survey of UK surveillance mammography 
practice after the treatment for primary 
breast cancer
Abertawe Bro Morgannwg University NHS Trust
Barking, Havering & Redbridge NHS Trust
Barts and the London NHS Trust
Basingstoke and North Hampshire NHS Foundation Trust
Royal United Hospital Bath NHS Trust
Bedford Hospital NHS Trust
Belfast Health & Social Care Trust
Blackpool Fylde and Wyre NHS Foundation Trust
Bradford Teaching Hospitals NHS Foundation Trust
Brighton and Sussex University Hospitals NHS Trust
Buckinghamshire Hospitals NHS Trust
Cambridge University Hospitals NHS Foundation Trust
Cardiff and Vale NHS Trust
City Hospitals Sunderland NHS Foundation Trust
Co. Durham and Darlington NHS Foundation Trust
Countess of Chester NHS Foundation Trust
Derby Hospitals NHS Foundation Trust
Doncaster and Bassetlaw Hospitals NHS Foundation Trust
East and North Hertfordshire NHS Trust
East Kent Hospitals University NHS Foundation Trust154 Appendix 6
Frimley Park Hospital NHS Foundation Trust
George Eliot Hospital NHS Trust
Gloucestershire Hospitals NHS Foundation Trust
Great Western Hospitals NHS Foundation Trust
Gwent Healthcare NHS Trust
Harrogate and District NHS Foundation Trust
Heart of England NHS Foundation Trust
Heatherwood and Wexham Park Hospitals NHS Foundation Trust
Hereford Hospitals NHS Trust
Hinchingbrooke Health Care NHS Trust
Homerton University Hospital NHS Foundation Trust
Hull and East Yorkshire Hospitals NHS Trust
Ipswich Hospital NHS Trust
James Paget University Hospitals NHS Foundation Trust
Kingston Hospital NHS Trust
Leeds Teaching Hospitals NHS Trust
Maidstone and Tunbridge Wells NHS Trust
Mayday Healthcare NHS Trust
Medway NHS Foundation Trust
Mid Cheshire Hospitals NHS Foundation Trust
Mid Yorkshire Hospitals NHS Trust
NHS Ayrshire and Arran
NHS Dumfries and Galloway
NHS Grampian
NHS Greater Glasgow and Clyde
NHS Highland© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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NHS Lanarkshire
NHS Lothian
NHS Tayside
Noble’s Hospital, Isle of Man
Norfolk and Norwich University Hospitals NHS Foundation Trust
North Bristol NHS Trust
North Cumbria University Hospitals NHS Trust
North Wales NHS Trust
North West London Hospitals NHS Trust
North West Wales NHS Trust
Northampton General Hospitals NHS Trust
Northumbria Healthcare NHS Foundation Trust
Nottingham University Hospitals NHS Trust
Oxford Radcliffe Hospitals NHS Trust
Pennine Acute Hospital NHS Trust
Peterborough and Stamford Hospitals Foundation Trust
Plymouth Hospitals NHS Trust
Poole Hospital NHS Trust
Portsmouth Hospitals NHS Trust
Queen Elizabeth Healthcare Trust
Royal Bolton Hospitals NHS Foundation Trust
Royal Cornwall Hospitals NHS Trust
Royal Liverpool and Broadgreen University Hospitals NHS Trust
Royal Surrey County Hospital NHS Trust
Salford Royal NHS Foundation Trust
Sandwell and West Birmingham Hospitals NHS Trust156 Appendix 6
Sheffield Teaching Hospitals NHS Foundation Trust
Shrewsbury and Telford Hospital NHS Trust
South Devon and Exeter NHS Foundation Trust
South Devon Healthcare NHS Foundation Trust
South London Healthcare NHS Trust, London
South Warwickshire NHS Trust
Southampton University Hospitals NHS Trust
Southern Health and Social Care Trust (Northern Ireland)
Southport and Ormskirk NHS Hospital Trust
St Georges Healthcare NHS Trust
St Helens & Knowsley Hospitals NHS Foundation Trust
Taunton and Somerset NHS Foundation Trust
The Dudley Group of Hospitals NHS Foundation Trust
The Hillingdon Hospital NHS Trust
The Newcastle upon Tyne Hospitals NHS Foundation Trust
The Princess Alexandra Hospital NHS Trust
The Royal Marsden NHS Foundation Trust
The Royal Wolverhampton Hospitals NHS Trust
United Lincolnshire Hospitals NHS Trust
University College London Hospitals NHS Foundation Trust
University Hospital Birmingham NHS Foundation Trust
University Hospital of South Manchester NHS Foundation Trust
University Hospitals Coventry and Warwickshire NHS Trust
University Hospitals of Leicester NHS Trust
University Hospitals of Morecambe Bay NHS Foundation Trust
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Warrington and Halton Hospitals NHS Foundation Trust
West Hertfordshire Hospitals NHS Trust
West Middlesex University Hospital NHS Trust
Winchester and Eastleigh Healthcare NHS Trust
Worcestershire Acute Hospitals NHS Trust
Wrightington, Wigan and Leigh NHS Foundation Trust
York Hospitals NHS Foundation Trust© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Appendix 7  
Description of mammography surveillance 
regimens for women following breast-
conserving surgery
Regimen no.
Surveillance regimens for women following BCS
Initiation: 
post surgery 
(months)
Frequency 
(annual, 
18-monthly, 
2-/3- yearly, 
annual for 
5 years then 
biennial, other)
Duration
Discharge from surveillance 
mammography follow-up  Discharge from clinical follow-up
Years post 
surgery
No. of 
respondents: 
n = 165
Years post 
surgery
No. of 
respondents: 
n = 154
1 6 Annual 10 3 3 1
2 6 Annual 10 5 1
3 6 Annual 10 10 1
4 6 Other 5 1 2 1
5 6 Other 10 2 No 1
6 6 Other 10 10 1
7 8 Annual 10 1 5 1
8 9 Annual 5 1 5 1
9 11 Annual No 1 5 1
10 11 Annual 10 2 10 2
11 12 Annual No 32 No 19
12 12 Annual No 3 1
13 12 Annual No 5 7
14 12 Annual No 10 4
15 12 Annual  3 1 3 1
16 12 Annual 5 31 No 4
17 12 Annual 5 2 1
18 12 Annual 5 5 22
19 12 Annual 9 3 5 1
20 12 Annual  10 44 No 2
21 12 Annual 10 3 2
22 12 Annual 10 5 20
23 12 Annual 10 10 18
24 12 Every 18 months 10 6 No 1
25 12 Every 18 months 10 5 4
26 12 Every 18 months 10 10 1
27 12 Every 2 years No 3 5 2
28 12 Every 2 years 5 3 5 3
29 12 Every 2 years 6 1 No 1
30 12 Every 2 years 9 2 1 2
31 12 Every 2 years 10 4 No 1160 Appendix 7
Regimen no.
Surveillance regimens for women following BCS
Initiation: 
post surgery 
(months)
Frequency 
(annual, 
18-monthly, 
2-/3- yearly, 
annual for 
5 years then 
biennial, other)
Duration
Discharge from surveillance 
mammography follow-up  Discharge from clinical follow-up
Years post 
surgery
No. of 
respondents: 
n = 165
Years post 
surgery
No. of 
respondents: 
n = 154
32 12 Every 2 years 10 1 1
33 12 Every 2 years 10 5 2
34 12 Annual to 5 years 
then biennial
No 2 5 2
35 12 Annual to 5 years 
then biennial
5 4 No 1
36 12  Annual to 5 years 
then biennial
5 3 1
37 12 Annual to 5 years 
then biennial
5 5 2
38 12 Annual to 5 years 
then biennial
10 1 5 1
39 12 Annual to 5 years 
then biennial
11 1 5 1
40 12 Other No 2 3 1
41 Other No 5 1
42 12  Other 5 1 5 1
43 12  Other 10 2 3 1
44 12  Other 10 5 1
45 18  Annual 9 1 5 1
46 18  Every 18 months No 2 No 1
47 18  Every 18 months 5 1
48 18 Every 18 months 5 1 5 1
49 18 Every 18 months 6 2 No 1
50 18 Other No 1 5 1
51 24 Every 2 years No 1 6 1
52 24 Every 2 years 5 1 5 1
53 24 Every 2 years 8 1 8 1
54 24 Every 2 years 10 1 10 1© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Appendix 8  
Description of mammography surveillance 
regimens for women following mastectomy
Regimen no.
Surveillance regimens for women following mastectomy
Initiation: post 
surgery (months)
Frequency (annual, 
18-monthly, 2-/ 
3-yearly, annual 
for 5 years then 
biennial, other)
Duration
Discharge from surveillance 
mammography follow-up Discharge from clinical follow-up
Years post 
surgery
No. of 
respondents: 
n = 146
Years post 
surgery
No. of 
respondents: 
n = 136
1 6 Annual 10 2 3 1
2 6 Annual 10 5 1
3 11 Annual 10 1 10 1
4 12 Annual 10 3 1
5 12 Annual No 19 No 10
6 12 Annual No 5 5
7 12 Annual No 10 4
8 12 Annual 3 1 3 1
9 12 Annual 5 20 No 4
10 12 Annual 5 2 1
11 12 Annual 5 5 13
12 12 Annual 9 2
13 12 Annual 10 30 No 2
14 12 Annual 10 3 1
15 12 Annual 10 5 11
16 12 Annual 10 10 15
17 12 Every 18 months No 1 No 1
18 12 Every 18 months 5 1 5 1
19 12 Every 18 months 10 8 No 1
20 12 Every 18 months 10 3 1
21 12 Every 18 months 10 5 5
22 12 Every 18 months 10 10 1
23 12 Every 2 years No 4 3 1
24 12 Every 2 years No 5 3
25 12 Every 2 years 5 8 No 1
26 12 Every 2 years 5 5 7
27 12 Every 2 years 9 2 1 2
28 12 Every 2 years 10 9 No 2
29 12 Every 2 years 10 1 1
30 12 Every 2 years 10 5 4
31 12 Every 2 years 10 10 2162 Appendix 8
Regimen no.
Surveillance regimens for women following mastectomy
Initiation: post 
surgery (months)
Frequency (annual, 
18-monthly, 2-/ 
3-yearly, annual 
for 5 years then 
biennial, other)
Duration
Discharge from surveillance 
mammography follow-up Discharge from clinical follow-up
Years post 
surgery
No. of 
respondents: 
n = 146
Years post 
surgery
No. of 
respondents: 
n = 136
32 12 Every 3 years 5 1 5 1
33 12 Every 3 years 6 1 No 1
34 12 Annual to 5 years 
then biennial
5 2 3 1
35 12 Annual to 5 years 
then biennial
5 5 1
36 12 Annual to 5 years 
then biennial
10 1 5 1
37 12 Annual to 5 years 
then biennial
11 1 5 1
38 12 Other No 2 3 1
39 12 Other No 5 1
40 12 Other 5 1 5 1
41 18 Annual 9 1 5 1
42 18 Every 18 months No 1 No 1
43 18 Every 18 months 6 2 No 1
44 18 Every 18 months 10 2 5 2
45 18 Every 2 years No 1 5 1
46 18 Other No 1 5 1
47 24 Every 2 years No 6 No 4
48 24 Every 2 years No 6 1
49 24 Every 2 years 5 5 2 1
50 24 Every 2 years 5 5 3
51 24 Every 2 years 8 1 8 1
52 24 Every 2 years 10 7 3 1
53 24 Every 2 years 10 5 3
54 24 Every 2 years 10 10 2
55 24 Every 3 years No 1
56 24 Every 3 years 10 1 10 1© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Appendix 9  
List of questions used to help define 
alternative care pathways
For mammographic surveillance:
  ■ For which women is the issue of mammographic surveillance relevant?
  ■ What mammography surveillance should be used?
  ■ Does it vary between women and if so why would it vary?
  ■ How often is it performed?
  ■ Where does it take place?
For clinical follow-up:
  ■ What clinical follow-up is used?
  ■ Does it vary between women and if so why?
  ■ Where does it take place?
  ■ How often?
For unstructured primary care follow-up:
  ■ How might a diagnosis be made?
  ■ At what point would these women enter the care pathway described in Figures 2–4 (see 
Chapter 2)?
More specifically, what factors might influence the choices made about mammographic 
surveillance and clinical follow-up?
Other factors to consider:
  ■ age
  ■ risk factors
  ■ type of primary disease
  ■ type of treatment.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Appendix 10  
Search strategies: systematic review 
of clinical effectiveness of surveillance 
mammography
MEDLINE (1990 – May, week 4, 2009), EMBASE (1990–2009, week 22), 
MEDLINE In-Process (1 June 2009)
Ovid multifile search: http://shibboleth.ovid.com/
1.  exp *breast neoplasms/
2.  breast.ti.
3.  or/1–2
4.  neoplasm recurrence, local/
5.  neoplasms, second primary/
6.  (recur$ or second or secondary or contralateral or ipsilateral or ibtr or mcbc).tw.
7.  or/4–6
8.  exp mammography/
9.  (mammograph$ or mammogram$).tw.
10.  physical examination/
11.  breast self-examination/
12.  ((physical or clinical or self) adj1 (exam? or examin$)).tw.
13.  surveillance.hw,tw. 
14.  follow up.ti.
15.  (routine adj3 (visit or follow up)).tw.
16.  or/8–15
17.  exp clinical trial/
18.  randomized controlled trial.pt.
19.  controlled clinical trial.pt.
20.  randomization/use emez
21.  randomi?ed.ab.
22.  randomly.ab.
23.  trial.ab.
24.  groups.ab.
25.  comparative study/use mesz
26.  follow-up studies/use mesz
27.  time factors/use mesz
28.  Treatment outcome/use emez
29.  major clinical study/use emez
30.  controlled study/use emez
31.  clinical trial/use emez
32.  (chang$ or evaluat$ or reviewed or baseline).tw.
33.  (prospective$ or retrospective$).tw.
34.  (cohort$ or case series).tw.
35.  (compare$ or compara$).tw.
36.  or/17–35
37.  human/
38.  36 and 37166 Appendix 10
39.  3 and 7 and 16 and 38
40.  limit 39 to yr=“1990 – 2009”
41.  remove duplicates from 40
Science Citation Index (1990 – 3 June 2009), BIOSIS (1990 – 4 June 2009)
ISI Web of Knowledge: http://wok.mimas.ac.uk/
# 1 TS=(breast neoplasm* AND (recur* or secondary or contralateral or ipsilateral or ibtr or 
mcbc)) AND Document Type=(Article)
# 2 TS=(breast cancer* AND (recur* or secondary or contralateral or ipsilateral or ibtr or mcbc)) 
AND Document Type=(Article)
# 3 TS=(breast carcin* AND (recur* or secondary or contralateral or ipsilateral or ibtr or mcbc)) 
AND Document Type=(Article)
# 4 TS=(breast tumour* AND (recur* or secondary or contralateral or ipsilateral or ibtr or 
mcbc)) AND Document Type=(Article)
# 5 TS=(breast tumor* AND (recur* or secondary or contralateral or ipsilateral or ibtr or mcbc)) 
AND Document Type=(Article)
# 6 #1 or #2 or #3 or #4 or #5 AND Document Type=(Article)
# 7 #6 and TS=mammogram* AND Document Type=(Article)
# 8 #6 and TS=mammograph* AND Document Type=(Article)
# 9 #6 and TS=surveillance AND Document Type=(Article)
# 10 #6 and TS=routine AND Document Type=(Article)
# 11 TS=“physical exam*” AND Document Type=(Article)
# 12 #6 AND #11 AND Document Type=(Article)
# 13 TS=“self exam*” AND Document Type=(Article)
# 14 #6 and #13 AND Document Type=(Article)
# 15 TS=“clinical exam* “ AND Document Type=(Article)
# 16 #6 and #15 AND Document Type=(Article)
# 17 TI=“follow up” AND Document Type=(Article)
# 18 #6 and #17 AND Document Type=(Article)
# 19 #18 OR #16 OR #14 OR #12 OR #10 OR #9 OR #8 OR #7
# 20 TI=breast AND Document Type=(Article)
# 21 #19 and #20 AND Document Type=(Article)
Cochrane Library Issue 2, 2009 (Cochrane Central Registry of Controlled 
Trials and Cochrane Database of Systematic Reviews)
www3.interscience.wiley.com/
#1 MeSH descriptor Breast Neoplasms explode all trees
#2 (breast):ti
#3 (#1 OR #2)
#4 MeSH descriptor Neoplasm Recurrence, Local explode all trees
#5 MeSH descriptor Neoplasms, Second Primary explode all trees
#6 (recur* or second or secondary):ti,ab,kw or (contralateral or ipsilateral):ti,ab,kw or (ibtr or 
mcbc):ti,ab,kw
#7 (#4 OR #5 OR #6)
#8 MeSH descriptor Mammography explode all trees
#9 (mammograph* or mammogram*):ti,ab,kw
#10 MeSH descriptor Physical Examination, this term only
#11 MeSH descriptor Breast Self-Examination, this term only
#12 (follow up):ti
#13 (routine near/3 visit*):ti,ab,kw or (routine near/3 follow up):ti,ab,kw© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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#14 (physical near/1 exam*):ti,ab,kw or (clinical near/1 exam*):ti,ab,kw or (self near/1 
exam*):ti,ab,kw
#15 (#8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14)
#16 (#3 AND #7 AND #15)
CANCERLIT (3 June 2009)
The US National Library of Medicine: www.ncbi.nlm.nih.gov
#1 Search (breast neoplasms[majr] AND human[mh] AND english[la]) OR dcis[ti] OR lcis[ti] 
OR ((breast[ti] OR breasts[ti] OR mammary[ti] OR nipple[ti] OR nipples[ti]) AND ((cancer*[ti] 
OR carcinoma*[ti] OR adenocarcinoma*[ti] OR malignan*[ti] OR tumor*[ti] OR tumour*[ti] 
OR neoplasm*[ti]) OR in situ[ti]))
#2 Search recur* or secondary or contralateral or ipsilateral or ibtr or mcbc Limits: Cancer
#3 Search #1 and #2 Limits: Cancer
#4 Search ((“mammogram* “[Title]) OR (“examin*”[Title]))
#5 Search ((“surveillance”[Title]) OR (“follow up”[Title]) OR (“routine visit*” [Title]))
#6 #4 OR #5
#7 #3 AND #6
The Health Technology Assessment/Database of Abstracts of Reviews and 
Effects/NHS Economic Evaluation databases, June 2009
Centre for Reviews and Dissemination: http://nhscrd.york.ac.uk/
welcome.htm
# 1 MeSH Breast Neoplasms EXPLODE 1 2
# 2 MeSH Mammography EXPLODE 1
# 3 mammography OR mammogram
# 4 MeSH Population Surveillance EXPLODE 1 2 3 4
# 5 surveillance OR monitor*
# 6 #2 or #3 or #4 or #5
# 7 #1 and #6
# 8 MeSH Postoperative Care EXPLODE 1 2 3
# 9 MeSH Follow-Up Studies EXPLODE 1 2 3
# 10 MeSH Neoplasm Recurrence, Local EXPLODE 1 2
# 11 MeSH Recurrence EXPLODE 1
# 12 recurrence OR secondary OR ipsilateral OR contralateral
# 13 #8 OR #9 OR #10 OR #11 OR #12
# 14 #7 AND #13
# 15 “follow-up strategies”
# 16 follow AND up
# 17 “follow up”
#18 #15 OR #16 OR #17
# 19 #13 or #18
# 20 #7 AND #19
Clinical Trials, June 2009
http://clinicaltrials.gov/ct/gui/c/r
“breast diseases” AND (mammography OR surveillance)
Current Controlled Trials, June 2009
www.controlled-trials.com/
breast AND (mammography OR surveillance)168 Appendix 10
The World Health Organization International Clinical Trials Registry 
Platform, June 2009
World Health Organization: www.who.int/ictrp/en/
breast AND mammography OR breast AND surveillance
National Research Register Archive
National Institute for Health Research portal: https://portal.nihr.
ac.uk/Pages/NRRArchiveSearch.aspx
NIHR portfolio, June 2009
National Institute for Health Research portal: https://portal.nihr.
ac.uk/Search/Advanced.aspx
breast AND mammography OR breast AND surveillance
National Cancer Institute Clinical Trials, June 2009
The US National Institutes of Health: www.cancer.gov
breast cancer (female) AND mammography OR surveillance
Websites consulted
American College of Radiology
www.acr.org/
American Society of Breast Disease
www.asbd.org/
American Society of Clinical Oncology
www.asco.org/
Breast Cancer Surveillance Consortium
http://breastscreening.cancer.gov/
CancerWEB
www.infoventures.com/cancer/
Canadian Task Force on Preventive Health Care
www.ctfphc.org/
Cancer Research UK
www.cancerresearchuk.org/
European Society for Medical Oncology
www.esmo.org/
National Breast and Ovarian Cancer Centre
www.nbocc.org.au
National Cancer Institute
www.cancer.gov/cancertopics/types/breast
National Comprehensive Cancer Network
www.nccn.org/index.asp© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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National Library for Health
www.library.nhs.uk/default.aspx
Royal College of Radiologists
www.rcr.ac.uk/
Surveillance, Epidemiology, and End Results Program
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Appendix 11  
Reports of included studies: systematic 
review of clinical effectiveness of 
surveillance mammography
Churn 2001
Churn M, Kelly V. Outpatient follow-up after treatment for early breast cancer: updated results 
after 5 years. Clin Oncol 2001;13:187–94.
Lash 2005
Lash TL, Clough-Gorr K, Silliman RA. Reduced rates of cancer-related worries and mortality 
associated with guideline surveillance after breast cancer therapy. Breast Cancer Res Treat 
2005;89:61–7.
Lash 2006
Lash TL, Fox MP, Silliman RA. Reduced mortality rate associated with annual mammograms 
after breast cancer therapy. Breast J 2006;12:2–6.
Lash 2007
Lash TL, Fox MP, Buist DS, Wei F, Field TS, Frost FJ, et al. Mammography surveillance and 
mortality in older breast cancer survivors. J Clin Oncol 2007;25:3001–6.
Montgomery 2007
Montgomery DA, Krupa K, Jack WJ, Kerr GR, Kunkler IH, Thomas J, et al. Changing pattern 
of the detection of locoregional relapse in breast cancer: the Edinburgh experience. Br J Cancer 
2007;96:1802–7.
Montgomery 2009
Montgomery DA, Krupa K, Cooke TG. Locoregional relapse after breast cancer: most relapses 
occur late and are not clinically detected. Breast J 2009;15:163–7.
Paszat 2008
Paszat L, Sutradhar R, Grunfeld E, Gainford C, Benk V, Bondy S, et al. Outcomes of surveillance 
mammography after treatment of primary breast cancer: a population-based case series. Breast 
Cancer Res Treat 2008;114:169–78.
Yau 2008
Yau TK, Sze H, Soong IS, Wong W, Chan K, Chang A, et al. Surveillance mammography after 
breast conservation therapy in Hong Kong: effectiveness and feasibility of risk-adapted approach. 
Breast 2008;17:132–7.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
173   Health Technology Assessment 2011; Vol. 15: No. 34 DOI: 10.3310/hta15340
Appendix 12  
Excluded studies: systematic review 
of clinical effectiveness of surveillance 
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Appendix 13  
Data extraction form for the systematic 
review of clinical effectiveness of 
surveillance mammography198 Appendix 13
1 
 
 
HTA Mammography Surveillance – Clinical Effectiveness Review 1 data extraction form 
 
Study id:                                                                     Extractor initials:                                  
 
Date: 
 
Study ids of linked reports: 
 
Aim of study: 
 
 
 
 
Study design: 
             RCT 
  Non-randomised comparison 
  Prospective/Retrospective cohort (please underline) 
 
 
        Multicentre study?             Yes     If Yes number of centres:                         
                                                      No 
        
        Length of follow-up: 
 
        Study start/end dates:                                                  Duration of study: 
 
        Country: 
 
        Source of funding: 
 
        Additional information on study design: 
 
 
 
Types of participants: 
 
  Women without detectable metastatic disease who have received breast conserving 
surgery for primary breast cancer 
 
  Women without detectable metastatic disease who have received mastectomy for 
primary breast cancer 
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2 
 
Type of Intervention /Comparator 
 
RCT/Comparison Studies 
  SM versus No formal direction or contact with a health care professional 
  SM versus Alternative follow up regimen (please state regime) 
  Differences in frequency of SM regimens 
 
Cohorts: 
  Surveillance Mammography 
  Alternative follow up regimen (please state regimen) 
 
Outcomes reported: 
 
     IBTR                                                                      MCBC                     
 
  Overall survival 
  Disease free survival 
  QOL 
  Harms of mammography 
  Uptake of mammography 
 
Participant Characteristics 
Study inclusion criteria: 
 
 
 
 
 
Study exclusion criteria: 
 
 
 
 
 
  Group 1   Group 2  Group 3  All 
No Enrolled 
 
       
[comparison studies] No 
randomised/allocated 
       
No received intervention 
 
       
[RCTs] No of Post randomisation 
exclusions 
       
No Analysed 
 
       
No Lost to follow-up/withdrawn 
 
       
No Age: Mean 
         Median 
         SD 
         Range 
         No <50 
         No 50 and over 
       
Hormone Receptor Status 
 
No ER + 
No ER – 
 
No PR + 
No PR – 
 
       
  Overall survival 
  Disease free survival 
  QOL 
  Harms of mammography 
  Uptake of mammography 
 200 Appendix 13
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No HER2 + 
No HER2 –
NPI Status 
No Low Risk (NPI<3.4) 
No Medium Risk (NPI 3.4–5.4) 
No High Risk (NPI>5.4)  
 
       
Genetic Status  
 
       
No Depcat Score: 
1 
2 
3 
4 
5 
6 
7 
Please record other socio-
economic factors in additional 
patient information 
       
Primary Treatment:         
No received primary breast 
conserving surgery (WLE) 
 
       
No received primary mastectomy 
 
       
No reconstructed breast 
 
       
Primary Tumour Characteristics: 
 
No DCIS 
 
No LCIS 
 
No Invasive 
 
Grade 1 
Grade 2 
Grade 3 
 
Size 
 
 
 
No Lymph Node Status + 
No Lymph Node Status – 
 
       
Nos receiving treatment for 
primary breast cancer 
 
Neoadjuvant radiotherapy 
Neoadjuvant chemotherapy 
 
Adjuvant radiotherapy 
Adjuvant chemotherapy  
Adjuvant tamoxifen /Endocrine 
 
Oopherectomy or ovarian 
ablation 
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4 
 
Primary tumour excision 
margins: 
 
No clear margins 
No  unclear margins 
 
       
Additional patient information: 
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Intervention Group – Group 1  
 
Components of the Intervention 
 
Component 1 
 
  Surveillance Mammography 
  Unstructured Primary Care Follow Up 
  Structured Primary Care Follow Up 
  Specialist led Clinical Exam 
  Healthcare Professional directed self-exam 
  Alternative surveillance regimen (please state) 
 
 
 
 
Intervention Setting 
  Secondary Care 
  Primary Care  
  Other (please state) 
 
Who administered the intervention? (please give experience level if recorded) 
  Radiologist  
  Hospital Clinician 
  Breast Care Nurse 
  Patient 
  Other (please state) 
 
 
 
How long after primary treatment/at what time point was the intervention (or component 1 of the 
intervention) initiated?  
 
 
Frequency of the intervention: 
 
 
Duration of the intervention: 
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6 
 
Components of the Intervention 
 
Component 2 
 
  Surveillance Mammography 
  Unstructured Primary Care Follow Up 
  Structured Primary Care Follow Up 
  Specialist led Clinical Exam 
  Healthcare Professional directed self-exam 
  Alternative surveillance regimen (please state) 
 
 
 
 
Intervention Setting 
  Secondary Care 
  Primary Care  
  Other (please state) 
 
Who administered the intervention? (please give experience level if recorded) 
  Radiologist  
  Hospital Clinician 
  Breast Care Nurse 
  Patient 
  Other (please state) 
 
 
 
How long after primary treatment/at what time point was the intervention (or component 2 of the 
intervention) initiated?  
 
 
Frequency of the intervention: 
 
 
Duration of the intervention: 
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Components of the Intervention 
 
Component 3 
 
  Surveillance Mammography 
  Unstructured Primary Care Follow Up 
  Structured Primary Care Follow Up 
  Specialist led Clinical Exam 
  Healthcare Professional directed self-exam 
  Alternative surveillance regimen (please state) 
 
 
 
 
Intervention Setting 
  Secondary Care 
  Primary Care  
  Other (please state) 
 
Who administered the intervention? (please give experience level if recorded) 
  Radiologist  
  Hospital Clinician 
  Breast Care Nurse 
  Patient 
  Other (please state) 
 
 
 
How long after primary treatment/at what time point was the intervention (or component 3 of the 
intervention) initiated?  
 
 
Frequency of the intervention: 
 
 
Duration of the intervention: 
 
 
 
 
Please use a separate sheet for any additional Group 1 intervention components. 
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Comparison Group – Group 2  
 
Components of the Comparator 
 
Component 1 
 
  Surveillance Mammography 
  Unstructured Primary Care Follow Up 
  Structured Primary Care Follow Up 
  Specialist led Clinical Exam 
  Healthcare Professional directed self-exam 
  Alternative surveillance regimen (please state) 
 
 
 
Comparator Setting 
  Secondary Care 
  Primary Care  
  Other (please state) 
 
 
Who administered the comparator? (please give experience level if recorded) 
  Radiologist  
  Hospital Clinician 
  Breast Care Nurse 
  Patient 
  Other (please state) 
 
 
 
How long after primary treatment/at what time point was the comparator (or component 1 of the 
comparator) initiated?  
 
 
Frequency of the comparator: 
 
 
Duration of the comparator: 
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Components of the Comparator 
 
Component 2 
 
  Surveillance Mammography 
  Unstructured Primary Care Follow Up 
  Structured Primary Care Follow Up 
  Specialist led Clinical Exam 
  Healthcare Professional directed self-exam 
  Alternative surveillance regimen (please state) 
 
 
 
 
Intervention Setting 
  Secondary Care 
  Primary Care  
  Other (please state) 
 
 
Who administered the intervention? (please give experience level if recorded) 
  Radiologist  
  Hospital Clinician 
  Breast Care Nurse 
  Patient 
  Other (please state) 
 
 
 
How long after primary treatment/at what time point was the comparator (or component 2 of the 
comparator) initiated?  
 
 
Frequency of the comparator: 
 
 
Duration of the comparator: 
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10 
 
Components of the Comparator 
 
Component 3 
 
  Surveillance Mammography 
  Unstructured Primary Care Follow Up 
  Structured Primary Care Follow Up 
  Specialist led Clinical Exam 
  Healthcare Professional directed self-exam 
  Alternative surveillance regimen (please state) 
 
 
 
Intervention Setting 
  Secondary Care 
  Primary Care  
  Other (please state) 
 
Who administered the comparator? (please give experience level if recorded) 
  Radiologist  
  Hospital Clinician 
  Breast Care Nurse 
  Patient 
  Other (please state) 
 
 
 
How long after primary treatment/at what time point was the comparator (or component 3 of the 
comparator) initiated?  
 
 
Frequency of the comparator: 
 
 
Duration of the comparator: 
 
 
 
 
Please use a separate sheet for any additional Group2 comparator components. 
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Comparison Group – Group 3 
 
Components of the Comparator 
 
Component 1 
 
  Surveillance Mammography 
  Unstructured Primary Care Follow Up 
  Structured Primary Care Follow Up 
  Specialist led Clinical Exam 
  Healthcare Professional directed self-exam 
  Alternative surveillance regimen (please state) 
 
 
Comparator Setting 
  Secondary Care 
  Primary Care  
  Other (please state) 
 
 
Who administered the comparator? (please give experience level if recorded) 
  Radiologist  
  Hospital Clinician 
  Breast Care Nurse 
  Patient 
  Other (please state) 
 
 
 
How long after primary treatment/at what time point was the comparator (or component 1 of the 
comparator) initiated?  
 
 
Frequency of the comparator: 
 
 
Duration of the comparator: 
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Components of the Comparator 
 
Component 2 
 
  Surveillance Mammography 
  Unstructured Primary Care Follow Up 
  Structured Primary Care Follow Up 
  Specialist led Clinical Exam 
  Healthcare Professional directed self-exam 
  Alternative surveillance regimen (please state) 
 
 
 
Intervention Setting 
  Secondary Care 
  Primary Care  
  Other (please state) 
 
 
Who administered the intervention? (please give experience level if recorded) 
  Radiologist  
  Hospital Clinician 
  Breast Care Nurse 
  Patient 
  Other (please state) 
 
 
 
How long after primary treatment/at what time point was the comparator (or component 2 of the 
comparator) initiated?  
 
 
Frequency of the comparator: 
 
 
Duration of the comparator: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 210 Appendix 13
13 
 
Components of the Comparator 
 
Component 3 
 
  Surveillance Mammography 
  Unstructured Primary Care Follow Up 
  Structured Primary Care Follow Up 
  Specialist led Clinical Exam 
  Healthcare Professional directed self-exam 
  Alternative surveillance regimen (please state) 
 
 
 
Intervention Setting 
  Secondary Care 
  Primary Care  
  Other (please state) 
 
Who administered the comparator? (please give experience level if recorded) 
  Radiologist  
  Hospital Clinician 
  Breast Care Nurse 
  Patient 
  Other (please state) 
 
 
 
How long after primary treatment/at what time point was the comparator (or component 3 of the 
comparator) initiated?  
 
 
Frequency of the comparator: 
 
 
Duration of the comparator: 
 
 
 
Please use a separate sheet for any additional intervention components. 
 
Outcome(s) reported and time point(s) 
 
How were outcome data collected/measured? 
 
 
 
Did the analysis adjust for any confounding factors (if yes please state the confounding 
factor(s)? 
 
 
How was the confounding factor categorised? (e.g. Age, <50 or 50>) 
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Outcome  Time Reported 
Please record for all 
reported time points 
e.g. Year 1, year 2, 
year 3, etc. 
Group 1  Group 2  Group 3  All 
Hazard Ratio (as reported by 
publication) 
 
 
 
 
 
 
 
Median Time to Event 
 
 
 
 
 
 
 
No. Overall Survival  
 
 
Alive 
 
 
 
 
 
 
 
Dead 
 
 
 
 
 
 
 
 
No. Disease free survival 
(without IBTR) 
 
 
Nos with IBTR 
 
 
 
 
 
 
 
 
         212 Appendix 13
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No. Disease free survival 
(without MCBC) 
 
 
 
 
 
 
 
 
 
Nos with MCBC 
 
 
 
 
 
 
 
 
No. Attending/ Uptake of 
mammography 
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Quality of life 
Measure used  Group 1  Group 2  Group 3  Notes 
 
 
 
 
 
 
 
 
 
 
       
Adverse events  
General information on adverse events: 
 
 
 
 
No. Adverse events 
reported & Type of 
Event 
Group 1   Group 2  Group 3  All 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
Additional study information: 
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Study ID        Extractor’s Initials            Date 
 
List of possible subgroups: 
 
 
 
 
 
 
 
 
 
Outcome  Subgroup 
Please write 
below. 
Time Reported 
Please record for 
all reported time 
points e.g. Year 1, 
year 2, year 3, etc. 
Group 1  Group 2  Group 3  All 
Hazard Ratio (as 
reported by 
publication) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Median Time to 
Event 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           
HTA Mammography Surveillance – Clinical Effectiveness Review 1 
Data Extraction Form for Outcomes by Subgroup 
Version 2     09 December 08 
Grade of primary breast cancer tumour, Size of primary breast cancer tumour,  Lymphovascular 
Invasion, NPI status, ER/PR/HER2 status, Genetic status (BRCA genes), Age (Under 50 years, 50 
years and over), Type and extent of surgery for primary breast cancer tumour (Breast conserving, 
Mastectomy,  Excision margins),  Primary neoadjuvant / adjuvant treatment  (Radiotherapy, 
Chemotherapy, Tamoxifen/Endocrine treatment, Oopherectomy or ovarian ablation) Depcat status © Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Outcome  Subgroup 
Please write 
below. 
Time Reported 
Please record for 
all reported time 
points e.g. Year 1, 
year 2, year 3, etc. 
Group 1  Group 2  Group 3  All 
No. Overall 
Survival  
Nos   Alive 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        
 
 
 
 
Nos  Dead 
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Outcome  Subgroup 
Please write 
below. 
Time Reported 
Please record for 
all reported time 
points e.g. Year 1, 
year 2, year 3, etc. 
Group 1  Group 2  Group 3  All 
No. Disease free 
survival  
Nos without 
IBTR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nos with IBTR 
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Outcome  Subgroup 
Please write 
below. 
Time Reported 
Please record for 
all reported time 
points e.g. Year 1, 
year 2, year 3, etc. 
Group 1  Group 2  Group 3  All 
Nos without 
MCBC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nos with MCBC 
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Outcome  Subgroup 
Please write 
below. 
Time Reported 
Please record for 
all reported time 
points e.g. Year 1, 
year 2, year 3, etc. 
Group 1  Group 2  Group 3  All 
No Attending/ 
Uptake of 
mammography 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quality of Life 
(state Measure 
used) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adverse Events 
(give details) 
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Appendix 14  
Quality assessment tool used in the 
systematic review of clinical effectiveness of 
surveillance mammography
HTA mammography surveillance – clinical effectiveness and 
cost-effectiveness review 1
Checklist for quality assessment of non-randomised studies (comparative and cohort studies). 
Items specific to comparative studies are in italic text.
Version 3  May 2010
Study ID:  Reviewer initials:  Date:
Criteria Yes No Unclear Comments
Participants: sample definition and selection
1. Were participants a representative sample selected from a relevant patient 
population?
2. Were the inclusion/exclusion criteria of participants clearly described?
3. Were participants entering the study at a similar point in their disease 
progression? 
4. Was selection of patients consecutive? 
5. Was data collection undertaken prospectively?
6. Were the groups comparable on demographic characteristics and clinical 
features?
Intervention
7. Was the intervention clearly defined?
8. Was the comparison clearly defined?
Outcome measures
9. Were overall survival, disease-free survival and relative survival outcomes 
considered?
10. Were objective (valid and reliable) outcome measure/s used for ascertaining 
disease-free survival?
11. Was the assessment of disease-free outcomes blind?220 Appendix 14
Criteria Yes No Unclear Comments
Follow-up
12. Was follow-up long enough to detect important effects on outcomes of interest? 
Follow-up must be a minimum of 5 years to account for changes in surveillance 
policy after this time due to most recurrences occurring within first 5 years following 
initial breast cancer
13. Was information provided on non-respondents, dropouts?
14. Were participants lost to follow-up likely to introduce bias? (e.g. high dropout 
rate, differential dropout, no description of those lost)
15. Was length of follow-up similar between comparison groups?
Analysis
16. Were important prognostic factors identified? 
17. Were the analyses adjusted for confounding factors? Importance of confounding 
factor as judged by study authors?
18. Did authors attempt to correct for lead time bias?
19. Did authors attempt to correct for length time bias?© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Appendix 15  
Characteristics of the studies included in the 
systematic review of clinical effectiveness of 
surveillance mammography
Study ID Participants
Description of surveillance 
regimen Study comparator Outcomes summarya
Churn 200153
Study design: 
retrospective 
cohort
Follow-up: 5 years
Primary treatment: 
all 1993
Country: UK
Enrolled: n = 612
Excluded: n = 0
Analysed: n = 612
Mastectomy: n = 104 
analysed
BCS: n = 505 analysed
No primary surgery: n = 3 
analysed
Age (years):
Mean NR, SD NR, range 
NR
< 50 years n = 189
50 years and over 
n = 423
Clinical examination 3- to 
4-monthly for first 2–3 
years, 6-monthly for up to 
5 years, annually thereafter. 
System involved alternate 
appointments with the 
surgical and oncological 
teams for 3–5 years, 
followed by discharge to 
continue follow-up in one 
or other of these clinics. 
Surveillance mammography 
according to individual 
clinician preference (usually 
less frequently than annually)
None Type of recurrence: local recurrence 
(IBTR and MCBC?)
Local recurrence at 5 years post 
primary treatment:
BCS (IBTR) n = 25 (four concurrent with 
metastases, two after presentation with 
systemic disease)
Mastectomy (MCBC): n = 9 (three 
concurrent metastases)
Overall survival at 5 years:
Alive all n = 500
Alive breast cancer recurrence NR
Dead all cause n = 112
Dead breast cancer NR
Dead breast cancer recurrence NR
Mode of detection:
IBTR:
SM n = 7
CE n = 8
Symptomatic interim referral n = 9
MCBC:
CE n = 6
Symptomatic interim referral n = 1
Uncertain n = 2
Lash 200559
Study design: 
multicentre 
prospective cohort
Follow-up: median 
7.4 years, range 
10 months to 9.5 
years
Primary treatment: 
October 1992 to 
March 1994
Country: USA
Enrolled: n = 388
Excluded: n = 85
Analysed: n = 303
Mastectomy: n = 71 
analysed
BCS: n = 228 analysed
Primary surgery details 
missing: n = 4 analysed
Age (years):
Mean NR, SD NR, range 
NR
< 50 years n = 0
50 years and over 
n = 388
Guideline surveillance 
– defined as annual CE 
and XRM for patients with 
asymptomatic history
Number of 
consecutive 
years of receipt 
of guideline 
surveillance 
compared with not 
receiving guideline 
surveillance
Recurrence: NR
Overall survival:
Alive all n = 240
Alive breast cancer recurrence NR
Dead (all cause) n = 63
Dead breast cancer n = 27
Dead other n = 36
Dead breast cancer recurrence NR222 Appendix 15
Study ID Participants
Description of surveillance 
regimen Study comparator Outcomes summarya
Lash 200660
Study design: 
multicentre 
prospective cohort
Follow-up: follow-
up time began 
182 days after 
surgery or 90 days 
after completing 
radiation therapy 
or chemotherapy, 
whichever came 
latest; follow-up 
time ended on 
the date of death, 
the date upon 
which the last 
surveillance form 
was returned from 
a physician’s office 
or 30 April 2004, 
whichever came 
first
Primary treatment: 
1 December 1996 
to 30 September 
1999
Country: USA
Enrolled: n = 865
Excluded: n = 531
Analysed: n = 334
Mastectomy: analysed 
n = 161
BCS: analysed n = 168
Primary surgery details 
missing: analysed n = 5
Age (years): 
Mean NR, SD NR, range 
NR
< 50 years n = 0
50 years and over 
n = 865
Presumed guideline 
surveillance – defined as 
annual examination for 
patients with asymptomatic 
history, physical examination 
and XRM
Number of XRMs 
received by women 
who died (all-cause 
mortality) compared 
with the number 
of XRMs received 
by women who did 
not die
Recurrence: NR
Overall survival:
Alive all n = 302
Alive breast cancer recurrence NR
Dead all cause n = 32
Dead breast cancer n = 13
Dead other n = 19
Dead breast cancer recurrence NR
Lash 200758
Study design: 
retrospective 
cohort
Follow-up: 5 years
Primary treatment: 
1990–4
Country: USA
Enrolled: n = 1846
Excluded: NR
Analysed: 812
Mastectomy: enrolled 
n = 973, analysed n = 537
BCS: enrolled n = 851, 
analysed 273
Other surgery: enrolled 
n = 22, analysed n = 2
Age (years):
Mean NR, SD NR, range 
NR
< 50 years n = 0
50 years and over 
n = 1846
Presumed guideline 
surveillance – defined as 
annual examination for 
patients with asymptomatic 
history, physical examination 
and XRM
Number of XRMs 
received by women 
who died (all-cause 
mortality) compared 
with the number 
of XRMs received 
by women who did 
not die
Type of recurrence: local (IBTR) and 
locoregional and distant
Locoregional and distant recurrence at 
5 years n = 231
IBTR recurrence n = 37
Overall survival at 5 years:
Alive NR
Dead all cause n = 391
Dead breast cancer n = 178
Dead breast cancer recurrence n = 130, 
local recurrence n = 37
Dead other causes n = 213© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Study ID Participants
Description of surveillance 
regimen Study comparator Outcomes summarya
Montgomery 
200754
Study design: 
retrospective 
cohort
Follow-up: median 
10 years, range 
1.5–15 years
Primary treatment: 
1991–8
Country: UK
Enrolled: n = 1312
Excluded: n = 42
Analysed: n = 110
Mastectomy: n = 0
BCS: enrolled n = 1312, 
analysed n = 110
Age (years):
Mean 56, SD NR, range 
24–91
< 50 NR
50 and over NR
Outpatient clinical 
examination performed 
3- to 4-monthly for first 2 
years, 6-monthly for 3 years 
then annually until 10 years 
post primary treatment 
from 1991 to 1998. From 
2000, all patients received 
annual clinic visits only. 
Annual bilateral surveillance 
mammography performed. 
All patients received 
instruction in breast self-
examination. Additional 
interval visits arranged as 
required
None Type of recurrence: local recurrence 
(IBTR) and contralateral second primary 
cancer (MCBC)
Recurrence at 5 years:
IBTR n = 48
MCBC n = 35
Bilateral IBTR + MCBC n = 2
Ipsilateral axilla n = 25
Overall survival at 5 years:
Alive all NR
Dead breast cancer recurrence n = 24
Dead IBTR recurrence n = 15
Dead MCBC n = 8
Dead bilateral n = 1
Dead other NR
bMode of detection:6
IBTR:
SM n = 25 (6 died)
CE n = 4 (4 died)
Symptomatic interim referral n = 12 
(4 died)
Symptoms n = 5 (1 died)
MCBC:
SM n = 25 (5 died)
CE n = 2
Symptomatic interim referral n = 5 
(1 died)
Symptoms n = 3 (2 died)
Bilateral IBTR/MCBC:
SM n = 2 (1 died)224 Appendix 15
Study ID Participants
Description of surveillance 
regimen Study comparator Outcomes summarya
Montgomery 
200955
Study design: 
retrospective 
cohort
Follow-up: median 
5.9 years, range 
4 months to 10.5 
years
Primary treatment: 
October 1995 to 
September 2001
Country: UK
Enrolled: n = 198
Excluded: n = 2
Analysed: n = 196
Mastectomy: n = 0
BCS: enrolled n = 198, 
analysed n = 196
Age (years):
Mean 58 years, median 
NR, SD 13.6 years, range 
28–91 years
< 50 NR
50 and over NR
Outpatient clinical 
examination performed 3- to 
4-monthly for first 2 years, 
6-monthly for 3 years, 
annual visits until 10th 
anniversary thereafter. From 
2000 all patients received 
annual clinic visits. Additional 
interval visits arranged as 
required. Annual bilateral 
surveillance mammography 
performed. Patients usually 
discharged to the national 
breast-screening unit at 
10 years
Survival for CE-
detected tumour 
compared with 
survival for XRM-
detected tumour
Type of recurrence: local recurrence 
(IBTR), axilla recurrence and 
contralateral second primary (MCBC)
Local recurrence at 1 year: IBTR n = 0, 
MCBC n = 1
Local recurrence 1–3 years: IBTR n = 1, 
MCBC n = 1, ipsilateral axilla n = 1
Local recurrence > 3 years: IBTR n = 3, 
MCBC n = 4, ipsilateral axilla n = 1
Total recurrence: IBTR n = 4, MCBC 
n = 6, ipsilateral axilla n = 2
Overall survival:
Alive all NR
Dead all cause NR
Alive breast cancer NR
Alive breast cancer recurrence NR
Dead breast cancer NR
Dead breast cancer recurrence NR
Mode of detection:
IBTR:
CE n = 1
MCBC:
SM n = 3
CE n = 2
Locoregional relapse:
Symptomatic interim referral n = 2
Paszat 200856
Study design: 
retrospective 
cohort (random 
sample)
Follow-up:
Recurrence 
1991–2004
Vital status 1991–
2006
≥1 SM episode in 
days:
25th 
percentile:1631
50th percentile: 
4287
75th percentile: 
5011
No episode SM in 
days:
25th percentile:440
50th percentile: 
891
75th percentile: 
1849
Primary treatment:
1991–1993
Country: Canada
Enrolled: n = 1600 (> 1 
episode SBS n = 1200; no 
SBS n = 400)
Excluded: n = 699 (> 1 
episode SBS n = 609; no 
SBS n = 490)
Analysed: n = 901
Mastectomy: n = 317
BCS: n = 584
Age (years):
Mean NR, SD NR, range 
NR
< 50 n = 255
50 and over n = 646
Presumed guideline 
surveillance – defined as 
annual CE and XRM for 
patients with asymptomatic 
history
Number of XRMs 
received compared 
with no receipt of 
XRM
Type of recurrence: local recurrence 
(IBTR) and contralateral second primary 
cancer (MCBC)
Recurrence events:
IBTR n = 84
MCBC n = 49
Overall survival:
Alive n = 389
Dead breast cancer n = 374
Dead other causes n = 138
Mode of detection:
IBTR:
SM n = 33
Other n = 51
MCBC:
SM n = 24
Other n = 25© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Study ID Participants
Description of surveillance 
regimen Study comparator Outcomes summarya
Yau 200857
Study design: 
retrospective 
cohort
Follow-up: median 
5.9 years, range 
0.2–13 years
Primary treatment: 
1994–2003
Country: Hong 
Kong
Enrolled: n = 507
Excluded: n = 0
Analysed: n = 507
Mastectomy: n = 0
BCS: n = 507
Age (years):
Median 46, SD NR, range 
25–90
< 50 NR
50 and over NR
Clinical examination every 
2–3 months in the first 2 
years, every 4–6 months 
in the third to fifth years, 
annually thereafter. Bilateral 
surveillance mammography 
performed annually first 
5 years, once every 1–2 
years for next 5 years. 
Supplementary ultrasound 
performed at clinician’s 
discretion
None Type of recurrence: local recurrence 
(IBTR) and contralateral second primary 
cancer (MCBC)
Recurrence events:
IBTR n = 23
MCBC n = 13
Overall survival:
Alive all NR
Alive breast cancer recurrence NR
Dead all cause NR
Dead breast cancer NR
Dead breast cancer recurrence NR
Mode of detection:
IBTR:
SM n = 10
CE n = 8
Symptomatic interim referral n = 2
Supplementary ultrasound n = 2
MCBC:
SM n = 8
CE n = 3
Symptomatic interim referral n = 1
Supplementary ultrasound n = 1
CE, clinical examination; SBS, subsequent breast surgery; SM, surveillance mammography; XRM, X-ray mammography.
a  The included studies did not include data on the following outcomes considered in our review: quality of life, harms of mammography (adverse 
events), uptake of mammography, economic outcomes.
b  Two patients with IBTR were excluded from mode of detection data by the study authors. Both were diagnosed incidentally during breast 
reshaping procedures. Both patients subsequently died.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
227   Health Technology Assessment 2011; Vol. 15: No. 34 DOI: 10.3310/hta15340
Appendix 16  
Quality assessment of individual studies 
included in the systematic review of clinical 
effectiveness of surveillance mammography228 Appendix 16
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Appendix 17  
Search strategies: systematic review of test 
performance of surveillance mammography 
and comparator tests in detecting 
IBTR/MCBC
MEDLINE (1990 – March, week 1, 2009), EMBASE (1990–2009, week 11) 
MEDLINE In-Process (13 March 2009)
Ovid multifile search: https://shibboleth.ovid.com/
1.  exp *breast neoplasms/use mesz
2.  exp *breast tumor/use emez
3.  breast.ti.
4.  or/1–3
5.  neoplasm recurrence, local/use mesz
6.  tumor recurrence/use emez
7.  cancer recurrence/use emez
8.  neoplasms, second primary/use mesz
9.  second cancer/use emez
10.  (recur$ or second or secondary or contralateral or ipsilateral or ibtr or mcbc).tw.
11.  or/5–10
12.  exp mammography/
13.  (mammograph$ or mammogram$).tw.
14.  physical examination/
15.  breast self-examination/
16.  breast examination/use emez
17.  ((physical or clinical or self) adj1 (exam? or examin$)).tw.
18.  surveillance.hw,tw.
19.  follow up.ti.
20.  (routine adj3 (visit or follow up)).tw.
21.  Magnetic resonance imaging/use mesz
22.  Nuclear Magnetic resonance imaging/use emez
23.  (magnetic resonance imag$ or mri).tw.
24.  ultrasonography, mammary/use mesz
25.  echomammography/use emez
26.  (ultrasound or ultrasonograph$ or echo mammogra$or echomammogra$).tw.
27.  or/12–26
28.  neoplasm recurrence, local/di use mesz
29.  tumor recurrence/di use emez
30.  cancer recurrence/di use emez
31.  neoplasms, second primary/di use mesz
32.  second cancer/di use emez
33.  or/28–32
34.  4 and 33
35.  “sensitivity and specificity”/
36.  roc curve/230 Appendix 17
37.  receiver operating characteristic/use emez
38.  predictive value of tests/
39.  diagnostic errors/use emez
40.  false positive reactions/use mesz
41.  false negative reactions/use mesz
42.  diagnostic accuracy/use emez
43.  diagnostic value/use emez
44.  du.fs. use mesz
45.  sensitivity.tw.
46.  distinguish$.tw.
47.  differentiat$.tw.
48.  identif$.tw.
49.  detect$.tw.
50.  diagnos$.tw.
51.  (predictive adj4 value$).tw.
52.  accura$.tw.
53.  comparison.tw.
54.  or/35–53
55.  27 and 11 and 4 and 54
56.  34 or 55
57.  remove duplicates from 56
58.  limit 57 to yr=“1990 – 2009”
59.  limit 58 to english language
Science Citation Index (1990 –14 March 2009), BIOSIS 
(1990 – 12 March 2009)
ISI Web of Knowledge:http://wok.mimas.ac.uk/
# 1 TS=(breast neoplasm* AND (recur* or secondary or contralateral or ipsilateral or ibtr 
or mcbc))
# 2 TS=(breast cancer* AND (recur* or secondary or contralateral or ipsilateral or ibtr or mcbc))
# 3 TS=(breast carcin* AND (recur* or secondary or contralateral or ipsilateral or ibtr or mcbc))
# 4 TS=(breast tumour* AND (recur* or secondary or contralateral or ipsilateral or ibtr 
or mcbc))
# 5 TS=(breast tumor* AND (recur* or secondary or contralateral or ipsilateral or ibtr or mcbc))
# 6 #1 or #2 or #3 or #4 or #5
# 7 #6 AND TS=mammogram*
# 8 #6 AND TS=mammograph*
# 9 #6 and TS=surveillance
# 10 #6 and TS=routine
# 11 #6 and TS=magnetic resonance imag*
# 12 #6 AND TS=mri
# 13 #6 and TS=ultrasound
# 14 #6 and TS=ultrasonograph*
# 15 #6 and TS=echo mammogra*
# 16 #6 and TS=echomammogra*
# 17 #6 and TS= (cliniCAL EXAM* OR SELF EXAM* OR PHYSICAL EXAM*)
# 18 #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17
# 19 #18 AND TS=(sensitivity or specificity)
# 20 #18 AND TS=(ROC or receiver operat* characteristic)
# 21 #18 AND TS=(diagnos* or detect*)
# 22 #18 AND TS=(differentiat* or distinguish*)
# 23 #18 AND TS=(accura* or identif*)© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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# 24 #23 OR #22 OR #21 OR #20 OR #19 AND Language=(English) AND Document 
Type=(Article)
Databases=SCI-EXPANDED Timespan=1990–2009
Cochrane Library Issue 2, 2009 (Cochrane Central Registry of Controlled 
Trials and Cochrane Database of Systematic Reviews)
www3.interscience.wiley.com/
#1 MeSH descriptor Breast Neoplasms explode all trees
#2 (breast):ti
#3 (#1 OR #2)
#4 MeSH descriptor Neoplasm Recurrence, Local, this term only
#5 MeSH descriptor Neoplasms, Second Primary, this term only
#6 (recur* or second or secondary):ti,ab,kw or (contralateral or ipsilateral):ti,ab,kw or (ibtr or 
mcbc):ti,ab,kw
#7 (#4 OR #5 OR #6)
#8 MeSH descriptor Mammography explode all trees
#9 (mammograph* or mammogram*):ti,ab,kw
#10 MeSH descriptor Physical Examination, this term only
#11 MeSH descriptor Breast Self-Examination, this term only
#12 (physical NEAR/1 exam*):ti,ab,kw or (clinical NEAR/1 exam*):ti,ab,kw or (self NEAR/1 
exam*):ti,ab,kw
#13 (surveillance):ti,ab,kw or (follow up):ti or (routine NEAR/3 visit*):ti,ab,kw or (routine 
NEAR/3 follow up):ab
#14 MeSH descriptor Magnetic Resonance Imaging, this term only
#15 MeSH descriptor Ultrasonography, Mammary, this term only
#16 (magnetic resonance imag* or mri):ti,ab,kw or (ultrasound or ultrasonograph*):ti,ab,kw or 
(echo mammogra* or echomammogra*):ti,ab,kw
#17 (#8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16)
#18 (#3 AND #7 AND #17)
#19 MeSH descriptor Neoplasm Recurrence, Local explode all trees with qualifier: DI
#20 MeSH descriptor Neoplasms, Second Primary explode all trees with qualifier: DI
#21 (#3 AND (#19 OR #20))
#22 #18 OR #21 (1990–2009)
CANCERLIT (20 March 2009)
The US National Library of Medicine: www.ncbi.nlm.nih.gov
#1 Search (breast neoplasms[majr] AND human[mh] AND english[la]) OR dcis[ti] OR lcis[ti] 
OR ((breast[ti] OR breasts[ti] OR mammary[ti] OR nipple[ti] OR nipples[ti]) AND ((cancer*[ti] 
OR carcinoma*[ti] OR adenocarcinoma*[ti] OR malignan*[ti] OR tumor*[ti] OR tumour*[ti] 
OR neoplasm*[ti]) OR in situ[ti])) Limits: Cancer
#2 Search recur* or secondary or contralateral or ipsilateral or ibtr or mcbc Limits: Cancer
#3 Search #1 AND #2 Limits: Cancer
#4 Search ((((Magnetic resonance imaging[MeSH Terms]) OR (ultrasonography, 
mammary[MeSH Terms])) OR (“magnetic resonance imag* or mri”[Text Word])) OR 
(“ultrasound or ultrasonograph* or echo mammogra* or echomammogra*”[Text Word])) AND 
(#1 AND #2) Limits: English
Health Technology Assessment/Database of Abstracts of Reviews and 
Effects/NHS Economic Evaluation databases, March 2009
Centre for Reviews & Dissemination: http://nhscrd.york.ac.uk/
welcome.htm
# 1 MeSH Breast Neoplasms EXPLODE 1 2232 Appendix 17
# 2 (recur* OR ipsilateral OR contralateral OR ibtr OR mcbc OR second OR secondary)
# 3 #1 and #2
MEDION, March 2009
www.mediondatabase.nl/
ICPC CODE=Female genital
AND Signssymp=Medical Imaging
AND Textword=breast
Clinical Trials, March 2009
http://clinicaltrials.gov/ct/gui/c/r
“Breast neoplasms”
AND
Mammography OR ultrasonography OR magnetic resonance imaging
AND
Recurrence or ipsilateral or ccontralateral or ibtr or mcbc
Current Controlled Trials, March 2009
www.controlled-trials.com/
Breast AND (mammography OR magnetic resonance imaging OR ultrasonography)
The World Health Organization International Clinical Trials Registry 
Platform, March 2009
World Health Organization: www.who.int/ictrp/en/
Breast AND (mammography OR magnetic resonance imaging OR ultrasonography)
National Research Register Archive
National Institute for Health Research portal: https://portal.nihr.
ac.uk/Pages/NRRArchiveSearch.aspx
NIHR portfolio, March 2009
National Institute for Health Research portal: https://portal.nihr.
ac.uk/Search/Advanced.aspx
Breast AND (mammography OR magnetic resonance imaging OR ultrasonography)
National Cancer Institute Clinical Trials, March 2009
The US National Institutes of Health: www.cancer.gov
breast cancer (female) AND mammography OR magnetic resonance imaging 
OR ultrasonography
Websites consulted
American College of Radiology
www.acr.org/
American Society of Breast Disease
www.asbd.org/
American Society of Clinical Oncology
www.asco.org/
Breast Cancer Surveillance Consortium
http://breastscreening.cancer.gov/© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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CancerWEB
www.infoventures.com/cancer/
Canadian Task Force on Preventive Health Care
www.ctfphc.org/
Cancer Research UK
www.cancerresearchuk.org/
European Society for Medical Oncology
www.esmo.org/
National Breast and Ovarian Cancer Centre
www.nbocc.org.au/
National Cancer Institute
www.cancer.gov/cancertopics/types/breast
National Comprehensive Cancer Network
www.nccn.org/index.asp
National Library for Health
www.library.nhs.uk/default.aspx
Royal College of Radiologists
www.rcr.ac.uk/
Surveillance, Epidemiology, and End Results (SEER) Program
http://seer.cancer.gov/© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Appendix 18  
Reports of included studies: systematic 
review of test performance of surveillance 
mammography and comparator tests in 
detecting IBTR/MCBC
Belli 2003
Belli P, Pastore G, Romani M, Terribile D, Canade A, Costantini M. Role of magnetic resonance 
imaging in the diagnosis of recurrence after breast conserving therapy. Rays 2002;27:241–57.
Boné 1995
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Shin 2005
Shin JH, Han BK, Choe YH, Nam SJ, Park W, Im YH. Ultrasonographic detection of occult 
cancer in patients after surgical therapy for breast cancer. J Ultrasound Med 2005;24:643–9.
Ternier 2006
Ternier F, Houvenaeghel G, Lecrivain F, Brigand BL, Margain D, Brunelle S, et al. 
Computed tomography in suspected local breast cancer recurrence. Breast Cancer Res Treat 
2006;100:247–54.236 Appendix 18
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Appendix 19  
Reports of excluded studies: systematic 
review of test performance of surveillance 
mammography and comparator tests in 
detecting IBTR/MCBC
Participants ineligible (n = 77)
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Crowe JP. The importance of preoperative breast MRI for patients newly diagnosed with breast 
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Appendix 20  
Data extraction form for the systematic 
review of test performance of surveillance 
mammography and comparator tests in 
detecting IBTR/MCBC252 Appendix 20
HTA Mammography Surveillance  
Diagnostic Accuracy (review 2) data extraction form  
Version 4                    May  2009 
 
Study id:                                                                     Extractor initials:                                 Date: 
 
Study ids of linked reports: 
 
Aim of study: 
 
 
Types of participants: 
 
  Women without detectable metastatic disease who have received breast conserving surgery for 
primary breast cancer 
 
  Women without detectable metastatic disease who have received mastectomy for primary breast 
cancer 
 
Test(s): 
  Mammography 
  GP follow up 
  Self examination 
  Self presentation (of symptoms) 
  MRI 
  Ultrasound 
  Hospital clinician led examination 
  Hospital nurse led examination 
 
Outcomes reported: 
             IBTR                     
             Test performance                 
  Adverse effects 
  Radiological or other operator expertise 
  Interpretability/readability of tests 
  Acceptability of tests 
 
Study design: 
  RCT 
  Non-randomised comparative study with some participants receiving the index test, some receiving 
the comparator test and all receiving the reference standard 
  Direct head-to-head with all participants receiving index test, comparator test and reference 
standard         
  Cohort with all participants receiving either the index test or comparator and reference standard 
             MCBC                     
             Test performance                 
  Adverse effects 
  Radiological or other operator 
expertise 
  Interpretability/readability of tests 
  Acceptability of tests 
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 Multicentre study?         No        Yes     If yes, number of centres:                         
         
        Study start/end dates:                                                  Duration of study: 
 
        Country: 
 
        Source of funding: 
 
        Additional information on study design: 
 
 
 
Inclusion criteria: 
 
 
 
Exclusion criteria: 
 
 
 
Characteristics of the participants 
  Group 1   Group 2   All 
Enrolled 
 
     
[For RCTs – number 
randomised] 
 
     
Received tests 
 
 
     
Received reference 
standard 
 
     
[Post randomisation 
exclusions] 
 
 
     254 Appendix 20
Analysed 
 
 
     
Lost to follow-up 
 
     
No Age: Mean 
              Median 
              SD 
             Range 
             No. <50 
         No. 50 and over 
     
Menopausal status: 
No. premenopausal 
No. postmenopausal 
     
HRT Status: 
No. currently receiving  
HRT  
No. previously received 
HRT  
No. never received 
HRT 
     
Primary Treatment: 
 
     
No. received primary 
breast conserving 
surgery (WLE) 
 
     
No. received primary 
mastectomy 
 
     
No. reconstructed 
breast 
 
     
No. receiving treatment 
for primary breast 
cancer: 
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Neoadjuvant 
radiotherapy 
Neoadjuvant 
chemotherapy 
 
Adjuvant radiotherapy 
Adjuvant chemotherapy  
Adjuvant tamoxifen 
/Endocrine 
 
Oopherectomy or 
ovarian ablation 
 
Additional patient information: 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristics of the tests 
 
Index Test - Mammography 
                                                                
     Film                  
     Digital         
 
      
 
 
 256 Appendix 20
Scoring system and positive test result defined as: 
 
 
 
 
 
 
Details of interpreter/reader experience if reported: 
 
 
 
 
 
 
Additional information on test (e.g. radiation dose, time taken, etc): 
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Comparator test:  
 
  MRI 
  Ultrasound 
 
For the following comparators, a positive test result (e.g. lump identified by palpation) will initiate an imaging 
test prior to biopsy or Fine Needle Aspiration Cytology (FNAC).  Please indicate whether a mammogram or 
other imaging test was conducted prior to biopsy/ FNAC for people with positive test results.  Reported test 
performance (sensitivity/specificity) should reflect the comparator test and not the imaging test alone. 
 
 
                                                                                                       Mammo/Other prior to biopsy/FNAC 
  GP follow up                                                            
  Self Examination 
  Self presentation (of symptoms) 
  Hospital Clinician led examination 
  Hospital Nurse led examination 
 
 
 
 
 
 
Positive test result defined as: 
 
 
 
 
 
 
 
 
 
Details of operator experience if reported: 
 
 
 
 
 
 
                                
   
   
   
   
 
 258 Appendix 20
Additional information on comparator test:   
 
 
 
 
 
 
 
Reference standard: 
 
Positive Index/Comparator test results verified by: 
  Histopathological assessment of biopsied tissue  
  Fine Needle Aspiration Cytology  
 
 
Negative Index/Comparator test results verified by: 
  Subsequent testing within a 3 year follow up period  
 
 
 
Length of follow-up time for verifying negative index/comparator test results: 
 
 
 
 
 
How was tumour size determined? 
 
 
 
 
How was tumour grade determined? 
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Additional information on reference standard: 
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Results 
 
IBTR/MCBC Tumour Type  
Please record the number of women with IBTR and/or MCBC  
 
No of women with:                                                                  No of women with: 
 
 
IBTR                                                                                             MCBC      
                
 
 
Please record the associated the number of women with the following for IBTR and/or MCBC: 
 
 
IBTR – No of women with:                                                     MCBC – No of women with:      
 
 
DCIS                                                                                             DCIS 
 
 
 
 
LCIS                                                                                              LCIS 
 
 
 
 
Invasive                                                                                        Invasive 
 
 
 
 
Grade 1                                                                                         Grade 1 
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Grade 2                                                                                         Grade 2 
 
 
 
 
Grade 3                                                                                         Grade 3 
 
 
 
 
 
 
 
If reported, please record the number of women with the following: 
 
 
IBTR                                                                                         MCBC 
 
 
Size                                                                                           Size  
 
 
Not measurable 
 
  
 
Invasive tumor in mm  
(largest dimension of  
dominant invasive  
tumour focus)  
 
 
 
Whole size of tumor  
(invasive plus  
surrounding DCIS if DCIS  
extends > 1 mm beyond 
invasive)        
 
 
 
Morphologic type  
a. Ductal/no specific (ductal NST)  
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b. Lobular  
 
 
c. Other  
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Test performance (true and false positives and negatives) 
Record data for each level of analysis e.g. patient, all biopsies, e.g. Size, grade, DCIS, Invasive, etc on separate 
sheet(s) containing 2x2 tables 
 
 
General information on IBTR/MCBC: 
 
 
 
 
 
 
 
 
Adverse events associated with tests 
General information on adverse events: 
 
 
 
 
 
 
 
 
 
Adverse events 
reported 
Group 1  
no. of women with event 
and % of total women in 
group 
Group 2  
no. of women with event 
and % of total women in 
group 
All  
no. of women with event 
and % of total women in 
study 
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Inter-observer agreement 
Scale used e.g. 
Kappa 
    Notes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
Additional study information: 
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HTA Mammography Surveillance- Diagnostic Accuracy (review 2) 2x2 form 
Version 2, March 2009 
 
Study id:                                                          Extractor initials:                           Date: 
 
Study ids of linked reports: 
 
Please record the unit of analysis as reported by the study authors – e.g. women level, biopsy 
level.  If given, please record unit of analysis by our considered sub-groups: Age, menopausal 
status, HRT status, primary treatment, second tumour type. 
 
Test:                  IBTR/MCBC 
 
  Unit of analysis:	 ﾠ  
  With disease  Without disease   
Positive	 ﾠtest  TP 
 
FP  Total testing positive 
Negative test  FN 
 
TN  Total testing negative 
  Total with 
disease 
 
Total without 
disease 
 
Sensitivity:          LR+: 
Specificity:          LR-: 
Test:                  IBTR/MCBC © Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
267   Health Technology Assessment 2011; Vol. 15: No. 34 DOI: 10.3310/hta15340
 
  Unit of analysis:	 ﾠ  
  With disease  Without disease   
Positive test 
 
TP 
 
FP  Total testing positive 
Negative test 
 
FN 
 
TN  Total testing negative 
  Total with 
disease 
 
Total without 
disease 
 
Sensitivity:          LR+: 
Specificity:   © Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Appendix 21  
Quality assessment tool used in the 
systematic review of test performance of 
surveillance mammography and comparator 
tests in detecting IBTR/MCBC270 Appendix 21
HTA Mammography Surveillance – Diagnostic Accuracy review 2 
Quality Assessment Form 
Version 4              May 2010 
Study id:                                                                 Extractor initials:           Date:                     
Item    Yes  No  Unclear 
       
1. 
Was the spectrum of patients representative of the 
patients who will receive the test in practice? 
(women previously treated for primary breast 
cancer) 
     
2. 
Is the reference standard likely to correctly classify 
the target condition? 
     
3a 
For positive test results, is the time period 
between reference standard and 
index/comparator test short enough to be 
reasonably sure that the target condition did not 
change between the two tests? (biopsy or FNAC 
within 3 months, histopathology within 6 months) 
     
3b 
For negative test results, is the time period 
between the index/comparator test and the 
reference standard short enough to be reasonably 
sure that the target condition did not change 
between the two tests? (follow-up within 3 years) 
     
4. 
Did the whole sample or a random selection of the 
sample  receive verification using a reference 
standard of diagnosis? 
     
5a 
Did patients testing positively on the 
index/comparator test receive the same reference 
standard (i.e. FNAC or biopsy)? 
     
5b 
Did patients testing negatively on the 
index/comparator test receive the same reference 
standard (i.e. follow up)? 
     
6. 
Was the reference standard independent of the 
index test (i.e. the index test did not form part of 
the reference standard)? 
     
7. 
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
     
8. 
Were the reference standard results interpreted 
without knowledge of the results of the index test? 
     
9. 
Were index and comparator tests interpreted 
independently (if no record the sequence)? 
     
10. 
Were the same clinical data available when test 
results were interpreted as would be available 
when the test is used in practice? 
     
11. 
Were uninterpretable/intermediate test results 
reported? 
     
12.  Were withdrawals from the study explained?       
Adapted from the QUADAS Tool. Whiting et al. BMC Medical Research Methodology 2003 3:25 doi:10.1186/1471-2288-3-25 
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Appendix 22  
Characteristics of the included studies for 
the systematic review of test performance of 
surveillance mammography and comparator 
tests in detecting IBTR/MCBC
Study ID Study design Index tests  Comparator test Test purpose
Belli 200266
Time period: NR
Country: Italy
Study design: direct head-to-
head cohort
Enrolled: 23
Analysed: 23
BCT: 23
Mastectomy: 0
Age (years): mean 52.9 
years; median NR; SD, 
10.8; range 35–75 years
Index test: MRI for local 
recurrence
XRM, CE, US for local 
recurrence
Surveillance for detecting 
IBTR
Boné 199564
Time period: September 
1992 to September 1993
Country: Sweden
Study design: direct head-to-
head cohort
Enrolled: 83
Analysed: 83
BCT: 0
Mastectomy: 83, all with 
breast reconstruction and 
implants
Age (years): mean NR; 
median 50 years; SD, NR; 
range 33–75 years
Index test: XRM for 
local and contralateral 
recurrence
MRI, CE for local 
and contralateral 
recurrence
Surveillance for detecting 
IBTR and MCBC
Drew 199867
Time period: NR
Country: UK
Study design: direct head-to-
head cohort
Enrolled: 105
Analysed: 105
BCT: 105
Mastectomy: 0
Age (years): mean NR; 
median 58 years; SD, NR; 
range 50–65 years
Index test: MRI for local 
recurrence
XRM, CE, XRM + CE for 
local recurrence
Surveillance for detecting 
IBTR
Kim 200965
Time period: January 2003 
to December 2003
Country: South Korea
Study design: direct head-to-
head cohort
Enrolled: 1431
Analysed: 1256
BCT: 292
Mastectomy: 964
Age (years): mean 50 years; 
median 49 years; SD, 10 
years; range 22–82 years
Index test: adjunct 
US (XRM + US) for 
contralateral recurrence
None Surveillance for detecting 
MCBC272 Appendix 22
Study ID Study design Index tests  Comparator test Test purpose
Mumtaz 199768
Time period: NR
Country: UK
Study design: direct head-to-
head cohort
Enrolled: 30
Analysed: 30
BCT: 30
Mastectomy: 0
Age (years): recurrence 
patients mean NR; median 
52 years; SD, NR; range 
34–80 years; recurrence-
free patients mean NR; 
median 62 years; SD, NR; 
range 47–79 years
Index test: XRM for local 
recurrence
MRI for local 
recurrence
Confirmation of suspicious 
result on prior diagnostic 
test (previous clinical 
suspicion)
Rieber 199769
Time period: NR
Country: Germany
Study design: cohort
Enrolled: 140
Analysed: 140
BCT: 140
Mastectomy: 0
Age (years): mean 52.8 
years; median NR; SD, NR; 
range 32–81 years
Index test: MRI for local 
recurrence 
None Confirmation of suspicious 
result on prior diagnostic 
test (suspicious finding 
on at least one of 
the following: clinical 
examination, ultrasound or 
mammography)
Shin 200571
Time period: January 2001 
to February 2004
Country: South Korea
Study design: cohort
Enrolled: 1968
Analysed: 1968
BCT: NR
Mastectomy: NR
Age (years): mean 49 years; 
median NR; SD, NR; range 
32–69 years
Index test: US for 
local and contralateral 
recurrence
None Surveillance for detecting 
IBTR and MCBC
Ternier 200672
Time period: May 1997 to 
May 2002
Country: France
Study design: direct head-to-
head cohort
Enrolled: 103
Analysed: 103
BCT: 103
Mastectomy: 0
Age (years): mean NR; 
median 60 years; SD, NR; 
range 32–82 years 
Index test:a XRM for local 
recurrence
CE, US for local 
recurrence
Confirmation of suspicious 
result on prior diagnostic 
test (suspicious finding 
on at least one of 
the following: clinical 
examination, ultrasound or 
mammography)
Viehweg 200470
Time period: August 1994 to 
April 2001
Country: Germany
Study design: direct head-to-
head cohort
Enrolled:119
Analysed: 119
BCT: 119
Mastectomy: 0
Age (years): mean NR; 
median 55.7 years; SD, 9.8; 
range 25–78 years
Index test: MRI for 
contralateral recurrence
CM (XRM + CE + US); 
MRI + CM for 
contralateral 
recurrence
Surveillance for detecting 
MCBC
CE, clinical examination; CM, conventional methods; US, ultrasound; XRM, X-ray mammography.
a  Study authors considered computerised tomography as the index test in this study but this test was not considered as an included comparator 
in this review.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Appendix 23  
Quality assessment of individual studies 
included in the systematic review of test 
performance of surveillance mammography 
and comparator tests in detecting 
IBTR/MCBC
TABLE 58  Quality assessment for included studies of routine surveillance tests
Study ID Q1 Q2 Q3a Q3b Q4 Q5a Q5b Q6 Q7 Q8 Q9 Q10 Q11 Q12
Boné 199564 - + ? + + + + + + ? ? + + +
Drew 199867 + + ? + - + + + + ? + + + +
Viehweg 200470 + + ? + + + + + ? ? - + - +
Shin 200571 + + + + ? + ? + + ? - + + +
Kim 200965 + + ? + + + + + + ? - + ? +
NA, not applicable; +, yes to the question; – , no to the question; ?, unclear.
TABLE 59  Quality assessment for included studies of non-routine surveillance tests
Study ID Q1 Q2 Q3a Q3b Q4 Q5a Q5b Q6 Q7 Q8 Q9 Q10 Q11 Q12
Mumtaz 199768 + + ? + + + + + + ? + + + +
Rieber 199769 + + ? + + + + + + ? - ? + +
Belli 200266 + + ? + + + + + + ? + + ? ?
Ternier 200672 + + ? + + + + + + ? - + + +
NA, not applicable; +, yes to the question; – , no to the question; ?, unclear.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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Appendix 24  
Histology of cancers detected and not 
detected (true-positives and false-
negatives): systematic review of test 
performance of surveillance mammography 
and comparator tests in detecting 
IBTR/MCBC276 Appendix 24
TABLE 61  Histology of true-positive and false-negative test results for ultrasound
Test Study ID True-positives False-negatives
Ultrasound Kim 200965 IDC n = 12
ILC n = 1
DCIS n = 2
IDC n = 1
DCIS n = 2
Shin 200571 Most frequently lymphadenopathy (non-
palpable?)
Viehweg 
200470
DCIS grade 2 non-comedo n = 1
Ductolobular carcinoma plus DCIS grade 2 non-
comedo n = 1
Minimally invasive carcinoma plus DCIS grade 1 non-
comedo n = 1
Minimally invasive carcinoma plus DCIS grade 3 comedo 
n = 1
DCIS grade 1 non-comedo n = 1
DCIS grade 2 non-comedo n = 2
DCIS grade 1 comedo n = 1
IDC grade 2 n = 3
DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.
TABLE 60  Histology of true-positive and false-negative test results for surveillance mammography
Test Study ID True-positives False-negatives
Surveillance 
mammography
Boné 199564 DCIS n = 7
ILC n = 1
IDC n = 2
IDC n = 4
ILC n = 1
Mumtaz 
199768
Mammographic findings: deformed dense breast n = 4; 
scarring and benign linear microcalcifications n = 3
Viehweg 
200470
Minimally invasive carcinoma plus:
DCIS grade 1 non-comedo n = 1
DCIS grade 1 comedo n = 1
IDC grade 2 n = 2
DCIS grade 2 non-comedo n = 1
Ductolobular carcinoma plus DCIS grade 2 non-
comedo n = 1
Minimally invasive carcinoma plus DCIS grade 3 comedo 
n = 1
DCIS grade 1 non-comedo n = 1
DCIS grade 2 non-comedo n = 3
IDC grade 2 n = 1
Kim 200965 IDC n = 12
ILC n =1
DCIS n = 3
DCIS n = 2
DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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TABLE 63  Histology of true-positive and false-negative test results for clinical examination
Test Study ID True-positives False-negatives
CE Boné 199564 ILC n = 2
IDC n = 4
DCIS n = 1
IDC n = 2
DCIS n = 5
Viehweg 
200470
IDC grade 2 n = 1
Ductolobular carcinoma plus DCIS grade 2 non-
comedo n = 1
Minimally invasive carcinoma plus DCIS grade 1 non-
comedo n = 1
Minimally invasive carcinoma plus DCIS grade 3 comedo 
n = 1
DCIS grade 1 non-comedo n = 1
DCIS grade 2 non-comedo n = 2
Minimally invasive carcinoma plus DCIS grade 1:
comedo n = 1
IDC grade 2 n = 2
Kim 200965  IDC n = 5 IDC n = 8
ILC n = 1
DCIS n = 4
CE, clinical examination; DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.
TABLE 62  Histology of true-positive and false-negative test results for MRI
Test Study ID True-positives False-negatives
MRI Boné 199564 IDC n = 5
DCIS n = 5
ILC n = 2
DCIS, n = 1
IDC, n = 1
Mumtaz 
199768
Diffuse scattered cancer cells within a dense fibrotic 
stroma with no discrete tumour focus n = 1
Viehweg 
200470
Minimally invasive carcinoma plus DCIS grade 1 
non-comedo n = 1
Minimally invasive carcinoma plus DCIS grade 3 
comedo n = 1
DCIS grade 2 non-comedo n = 2
Minimally invasive carcinoma plus DCIS grade 1:
comedo n = 1
IDC grade 2 n = 3
DCIS grade 1 non-comedo n = 1
DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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Appendix 25  
Univariate Cox regression models for the 
WMCIU cohorts
TABLE 64  Cox proportional hazards regression models for time to IBTR in BCS cohort
n N %
Univariate Cox regression Multiple Cox regression
HR 95% CI p-value HR 95% CI p-value
Age (years)
≤ 34 26 350 7.4 3.27 2.17 to 4.92 < 0.001 2.28 1.51 to 3.47 < 0.001
35–49 138 3513 3.9 1.80 1.45 to 2.24 < 0.001 1.44 1.15 to 1.80 0.002
50–64 189 8511 2.2 (1.00) (1.00)
65–74 54 3491 1.5 0.80 0.59 to 1.09 0.154 0.72 0.53 to 0.97 0.033
75–79 25 1034 2.4 1.25 0.83 to 1.89 0.284 0.96 0.63 to 1.47 0.852
80+ 23 807 2.9 1.93 1.27 to 2.93 0.002 1.28 0.81 to 2.03 0.289
Grade
1 60 4193 1.4 (1.00) (1.00)
2 175 7697 2.3 1.75 1.31 to 2.35 < 0.001 1.53 1.14 to 2.07 0.005
3 204 5388 3.8 3.15 2.36 to 4.21 < 0.001 2.32 1.71 to 3.16 < 0.001
Unknown 16 428 3.7 2.75 1.69 to 4.49 < 0.001 1.85 1.06 to 3.26 0.032
Size (mm)
≤ 10 68 3473 2.0 (1.00) (1.00)
> 10 to 
< 20
173 8663 2.0 1.02 0.77 to 1.35 0.892 0.81 0.61 to 1.09 0.161
≥ 20 179 4885 3.7 2.11 1.60 to 2.80 < 0.001 1.31 0.97 to 1.78 0.078
Size cat. 
unknown
35 685 5.1 2.23 1.51 to 3.30 < 0.001 1.28 0.83 to 1.96 0.268
Nodes
0 231 11,630 2.0 (1.00) (1.00)
1–3 103 3367 3.1 1.64 1.30 to 2.07 < 0.001 1.33 1.04 to 1.69 0.021
4+ 59 1232 4.8 2.98 2.23 to 3.96 < 0.001 2.04 1.51 to 2.77 < 0.001
Unknown 62 1477 4.2 2.14 1.63 to 2.80 < 0.001 2.06 1.51 to 2.81 < 0.001
Vascular invasion
No 277 12,887 2.1 (1.00) (1.00)
Yes 140 3559 3.9 1.96 1.60 to 2.40 < 0.001 1.26 1.01 to 1.57 0.043
Unknown 38 1260 3.0 1.40 1.02 to 1.93 0.040 0.98 0.68 to 1.41 0.928
HR, hazard ratio.
N is the size of the subgroup, n is the number of events in that subgroup.280 Appendix 25
TABLE 65  Cox proportional hazards regression models for time to MCBC occurrence in BCS cohort
n N %
Univariate Cox regression Multiple Cox regression
HR 95% CI p-value HR 95% CI p-value
Age (years)
≤ 34 11 350 3.1 1.62 0.88 to 2.98 0.124 1.54 0.82 to 2.86 0.177
35–49 55 3513 1.6 0.87 0.64 to 1.19 0.390 0.85 0.62 to 1.16 0.294
50–64 150 8511 1.8 (1.00)
65–74 33 3491 0.9 0.62 0.43 to 0.90 0.012 0.61 0.42 to 0.89 0.010
75–79 6 1034 0.6 0.36 0.16 to 0.81 0.014 0.34 0.15 to 0.77 0.010
80+ 5 807 0.6 0.49 0.20 to 1.19 0.116 0.46 0.18 to 1.14 0.093
Grade
1 69 4193 1.6 (1.00) (1.00)
2 102 7697 1.3 0.91 0.67 to 1.24 0.558 0.92 0.68 to 1.26 0.623
3 79 5388 1.5 1.11 0.81 to 1.53 0.524 1.06 0.75 to 1.49 0.756
Unknown 10 428 2.3 1.27 0.69 to 2.35 0.439 1.40 0.71 to 2.76 0.329
Size (mm)
≤ 10 45 3473 1.3 (1.00) (1.00)
> 10 to 
< 20
125 8663 1.4 1.13 0.80 to 1.59 0.485 1.25 0.88 to 1.76 0.217
≥ 20 74 4885 1.5 1.35 0.93 to 1.96 0.109 1.60 1.08 to 2.38 0.019
Size cat. 
unknown
16 685 2.3 1.54 0.90 to 2.63 0.115 1.81 1.01 to 3.22 0.044
Nodes
0 183 11,630 1.6 (1.00) (1.00)
1–3 38 3367 1.1 0.75 0.53 to 1.06 0.100 0.72 0.50 to 1.03 0.075
4+ 19 1232 1.5 1.19 0.74 to 1.91 0.473 1.20 0.73 to 1.96 0.479
Unknown 20 1477 1.4 0.89 0.58 to 1.38 0.608 1.07 0.67 to 1.73 0.771
Vascular invasion
No 204 12,887 1.6 (1.00) (1.00)
Yes 43 3559 1.2 0.80 0.57 to 1.11 0.175 0.74 0.52 to 1.05 0.096
Unknown 13 1260 1.0 0.68 0.41 to 1.13 0.139 0.58 0.33 to 1.01 0.053
HR, hazard ratio.
N is the size of the subgroup, n is the number of events in that subgroup.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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TABLE 66  Cox proportional hazards regression models for time to all-cause death in BCS cohort
n N %
Univariate Cox regression Multiple Cox regression
HR 95% CI p-value HR 95% CI p-value
Age (years)
≤ 34 60 350 17.1 1.57 1.21 to 2.04 0.001 1.00 0.77 to 1.30 0.987
35–49 371 3513 10.6 1.05 0.93 to 1.18 0.463 0.78 0.69 to 0.89 < 0.001
50–64 848 8511 10.0 (1.00) (1.00)
65–74 594 3491 17.0 1.96 1.76 to 2.17 < 0.001 1.80 1.62 to 2.01 < 0.001
75–79 293 1034 28.3 3.16 2.77 to 3.61 < 0.001 2.55 2.23 to 2.93 < 0.001
80+ 362 807 44.9 6.49 5.74 to 7.33 < 0.001 4.83 4.22 to 5.52 < 0.001
Grade
1 344 4193 8.2 (1.00) (1.00)
2 1002 7697 13.0 1.77 1.57 to 2.00 < 0.001 1.33 1.17 to 1.50 < 0.001
3 1114 5388 20.7 3.04 2.69 to 3.43 < 0.001 2.20 1.93 to 2.50 < 0.001
Unknown 68 428 15.9 2.05 1.64 to 2.57 < 0.001 1.15 0.88 to 1.50 0.207
Size (mm)
≤ 10 230 3473 6.6 (1.00) (1.00)
> 10 to < 20 1030 8663 11.9 1.81 1.57 to 2.09 < 0.001 1.32 1.14 to 1.53 < 0.001
≥ 20 1117 4885 22.9 3.92 3.40 to 4.52 < 0.001 2.04 1.76 to 2.37 < 0.001
Size cat. 
unknown
151 685 22.0 2.83 2.33 to 3.45 < 0.001 1.54 1.25 to 1.91 < 0.001
Nodes
0 1073 11,630 9.2 (1.00) (1.00)
1–3 573 3367 17.0 1.94 1.75 to 2.15 < 0.001 1.57 1.41 to 1.74 < 0.001
4+ 416 1232 33.8 4.44 3.96 to 4.97 < 0.001 2.96 2.62 to 3.34 < 0.001
Unknown 466 1477 31.6 3.27 2.94 to 3.63 < 0.001 1.92 1.70 to 2.17 < 0.001
Vascular invasion
No 1460 12,887 11.3 (1.00) (1.00)
Yes 847 3559 23.8 2.22 2.04 to 2.41 < 0.001 1.36 1.24 to 1.49 < 0.001
Unknown 221 1260 17.5 1.50 1.31 to 1.71 < 0.001 1.15 0.99 to 1.33 0.066
Ipsilateral recurrence
No 2350 17,251 13.6 (1.00)
Yes 178 455 39.1 2.29 1.97 to 2.67 < 0.001 1.76 1.51 to 2.05 < 0.001
Contralateral occurrence
No 2475 17,446 14.2 (1.00) (1.00)
Yes 53 260 20.4 0.99 0.76 to 1.30 0.97 1.05 0.80 to 1.39 0.715
HR, hazard ratio.
N is the size of the subgroup, n is the number of events in that subgroup.282 Appendix 25
TABLE 67  Cox proportional hazards regression models for time to death from breast cancer in BCS cohort
n N %
Univariate Cox regression Multiple Cox regression
HR 95% CI p-value HR 95% CI p-value
Age (years)
≤ 34 55 350 15.7 2.33 1.77 to 3.08 < 0.001 1.21 0.91 to 1.60 0.182
35–49 310 3513 8.8 1.39 1.21 to 1.60 < 0.001 0.90 0.78 to 1.04 0.157
50–64 535 8511 6.3 (1.00) (1.00)
65–74 278 3491 8.0 1.43 1.24 to 1.65 < 0.001 1.28 1.10 to 1.48 0.001
75–79 96 1034 9.3 1.63 1.32 to 2.03 < 0.001 1.27 1.02 to 1.58 0.034
80+ 104 807 12.9 2.85 2.32 to 3.51 < 0.001 2.06 1.65 to 2.57 < 0.001
Grade
1 76 4193 1.8 (1.00) (1.00)
2 489 7697 6.4 3.87 3.04 to 4.92 < 0.001 2.60 2.03 to 3.32 < 0.001
3 786 5388 14.6 9.56 7.55 to 12.10 < 0.001 5.31 4.17 to 6.77 < 0.001
Unknown 27 428 6.3 4.21 2.90 to 6.12 < 0.001 2.39 1.62 to 3.54 0.207
Size (mm)
≤ 10 75 3473 2.2 (1.00) (1.00)
> 10 to 
< 20
510 8663 5.9 2.75 2.16 to 3.50 < 0.001 1.73 1.35 to 2.21 < 0.001
≥ 20 717 4885 14.7 7.66 6.04 to 9.71 < 0.001 3.04 2.37 to 3.89 < 0.001
Size cat. 
unknown
76 685 11.1 4.61 3.39 to 6.25 < 0.001 2.09 1.52 to 2.88 < 0.001
Nodes
0 505 11,630 4.3 (1.00) (1.00)
1–3 366 3367 10.9 2.63 2.30 to 3.01 < 0.001 1.82 1.59 to 2.10 < 0.001
4+ 332 1232 26.9 7.42 6.46 to 8.53 < 0.001 3.88 3.34 to 4.51 < 0.001
Unknown 175 1477 11.8 2.72 2.30 to 3.22 < 0.001 2.23 1.85 to 2.69 < 0.001
Vascular invasion
No 679 12,887 5.3 (1.00) (1.00)
Yes 606 3559 17.0 3.40 3.04 to 3.79 < 0.001 1.59 1.41 to 1.79 < 0.001
Unknown 93 1260 7.4 1.44 1.17 to 1.76 < 0.001 1.09 0.88 to 1.36 0.430
Ipsilateral recurrence
No 1247 17,251 7.2
Yes 131 455 28.8 3.30 2.76 to 3.94 < 0.001 2.13 1.78 to 2.56 < 0.001
Contralateral occurrence
No 1375 17,446 7.9 (1.00)
Yes 3 260 1.2 1.13 0.86 to 1.49 0.378
HR, hazard ratio.
N is the size of the subgroup, n is the number of events in that subgroup.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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TABLE 68  Multiple Cox proportional hazards regression models for time to IBTR in mastectomy cohort
n N %
Univariate Cox regression Multiple Cox regression
HR 95% CI p-value HR 95% CI p-value
Age (years)
≤ 34 10 360 2.8 1.36 0.71 to 2.60 0.352 0.97 0.51 to 1.87 0.937
35–49 65 3188 2.0 0.97 0.72 to 1.32 0.854 0.85 0.62 to 1.16 0.298
50–64 110 5229 2.1 (1.00) (1.00)
65–74 77 3422 2.3 1.11 0.83 to 1.48 0.498 1.14 0.85 to 1.54 0.368
75–79 26 1547 1.7 0.90 0.59 to 1.38 0.629 0.97 0.63 to 1.49 0.882
80+ 22 1425 1.5 1.05 0.67 to 1.63 0.834 0.98 0.62 to 1.57 0.945
Grade
1 23 1827 1.3 (1.00) (1.00)
2 116 6918 1.7 1.48 0.95 to 2.32 0.085 1.23 0.78 to 1.94 0.363
3 157 5852 2.7 2.78 1.79 to 4.31 < 0.001 2.06 1.31 to 3.24 0.002
Unknown 14 574 2.4 2.34 1.28 to 4.30 0.006 1.44 0.73 to 2.82 0.293
Size (mm)
≤ 10 13 1103 1.2 (1.00) (1.00)
> 10 to 
< 20
68 4224 1.6 1.38 0.76 to 2.51 0.283 1.24 0.68 to 2.25 0.485
≥ 20 175 8627 2.0 2.04 1.16 to 3.59 0.013 1.43 0.80 to 2.56 0.224
Size cat. 
unknown
54 1217 4.4 3.82 2.09 to 6.97 < 0.001 2.61 1.40 to 4.84 0.002
Nodes
0 114 6938 1.6 (1.00) (1.00)
1–3 68 4147 1.6 1.10 0.82 to 1.49 0.518 0.95 0.69 to 1.29 0.723
4+ 97 3402 2.9 2.33 1.78 to 3.06 < 0.001 1.62 1.20 to 2.19 0.002
Unknown 31 684 4.5 3.42 2.35 to 4.98 < 0.001 2.55 1.65 to 3.95 < 0.001
Vascular invasion
No 126 8608 1.5 (1.00) (1.00)
Yes 150 5341 2.8 2.24 1.76 to 2.84 < 0.001 1.68 1.29 to 2.19 < 0.001
Unknown 34 1222 2.8 2.14 1.49 to 3.06 < 0.001 1.25 0.82 to 1.90 0.307
HR, hazard ratio.
N is the size of the subgroup, n is the number of events in that subgroup.284 Appendix 25
TABLE 69  Multiple Cox proportional hazards regression models for time to MCBC occurrence in mastectomy cohort
n N %
Univariate Cox regression Multiple Cox regression
HR 95% CI p-value HR 95% CI p-value
Age (years)
≤ 34 13 360 3.6 1.79 1.01 to 3.17 0.048 1.55 0.87 to 2.77 0.138
35–49 64 3188 2.0 0.96 0.71 to 1.31 0.817 0.89 0.65 to 1.21 0.459
50–64 114 5229 2.2 (1.00) (1.00)
65–74 52 3422 1.5 0.79 0.57 to 1.09 0.156 0.77 0.55 to 1.07 0.118
75–79 13 1547 0.8 0.45 0.25 to 0.80 0.007 0.45 0.25 to 0.81 0.007
80+ 6 1425 0.4 0.31 0.15 to 0.68 0.003 0.27 0.12 to 0.61 0.002
Grade
1 31 1827 1.7 (1.00) (1.00)
2 110 6918 1.6 1.03 0.69 to 1.54 0.870 0.91 0.61 to 1.37 0.660
3 111 5852 1.9 1.52 1.02 to 2.26 0.040 1.18 0.78 to 1.79 0.436
Unknown 10 574 1.7 1.12 0.57 to 2.18 0.742 0.87 0.41 to 1.86 0.726
Size (mm)
≤ 10 14 1103 1.3 (1.00) (1.00)
> 10 to 
< 20
67 4224 1.6 1.42 0.77 to 2.63 0.263 1.45 0.78 to 2.69 0.244
≥ 20 156 8627 1.8 1.96 1.09 to 3.53 0.025 1.81 0.99 to 3.31 0.054
Size cat. 
unknown
25 1217 2.1 2.01 1.03 to 3.94 0.042 1.74 0.87 to 3.50 0.117
Nodes
0 110 6938 1.6 (1.00) (1.00)
1–3 64 4147 1.5 1.08 0.79 to 1.47 0.634 0.95 0.69 to 1.31 0.774
4+ 75 3402 2.2 1.90 1.42 to 2.55 < 0.001 1.53 1.10 to 2.12 0.012
Unknown 13 684 1.9 1.40 0.81 to 2.45 0.231 1.44 0.76 to 2.75 0.264
Vascular invasion
No 137 8608 1.6 (1.00) (1.00)
Yes 105 5341 2.0 1.44 1.12 to 1.86 0.005 1.09 0.82 to 1.45 0.543
Unknown 20 1222 1.6 1.07 0.67 to 1.69 0.784 0.89 0.53 to 1.50 0.669
HR, hazard ratio.
N is the size of the subgroup, n is the number of events in that subgroup.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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TABLE 70  Multiple Cox proportional hazards regression models for time to death from all causes in mastectomy cohort
n N %
Univariate Cox regression Multiple Cox regression
HR 95% CI p-value HR 95% CI p-value
Age (years)
≤ 34 108 360 30.0 1.37 1.13 to 1.67 0.002 0.99 0.81 to 1.20 0.895
35–49 647 3188 20.3 0.91 0.82 to 1.00 0.042 0.78 0.71 to 0.86 < 0.001
50–64 1179 5229 22.5 (1.00) (1.00)
65–74 1088 3422 31.8 1.51 1.39 to 1.64 < 0.001 1.54 1.42 to 1.68 < 0.001
75–79 608 1547 39.3 2.06 1.86 to 2.27 < 0.001 2.18 1.98 to 2.41 < 0.001
80+ 715 1425 50.2 3.14 2.87 to 3.45 < 0.001 3.29 2.99 to 3.61 < 0.001
Grade
1 336 1827 18.4 (1.00) (1.00)
2 1697 6918 24.5 1.50 1.34 to 1.69 < 0.001 1.21 1.08 to 1.36 0.001
3 2148 5852 36.7 2.68 2.39 to 3.01 < 0.001 2.02 1.79 to 2.27 < 0.001
Unknown 164 574 28.6 1.85 1.56 to 2.19 < 0.001 1.35 1.13 to 1.61 0.001
Size (mm)
≤ 10 125 1103 11.3 (1.00) (1.00)
> 10 to 
< 20
846 4224 20.0 1.79 1.48 to 2.15 < 0.001 1.38 1.14 to 1.66 0.001
≥ 20 2926 8627 33.9 3.60 3.01 to 4.31 < 0.001 2.02 1.68 to 2.42 < 0.001
Size cat. 
unknown
448 1217 36.8 3.39 2.78 to 4.12 < 0.001 2.10 1.72 to 2.56 < 0.001
Nodes
0 1286 6938 18.5 (1.00) (1.00)
1–3 1115 4147 26.9 1.61 1.49 to 1.75 < 0.001 1.50 1.38 to 1.63 < 0.001
4+ 1589 3402 46.7 3.45 3.20 to 3.71 < 0.001 2.70 2.49 to 2.92 < 0.001
Unknown 355 684 51.9 3.42 3.06 to 3.82 < 0.001 2.45 2.16 to 2.77 < 0.001
Vascular invasion
No 1866 8608 21.7 (1.00) (1.00)
Yes 2079 5341 38.9 2.09 1.96 to 2.23 < 0.001 1.37 1.28 to 1.47 < 0.001
Unknown 400 1222 32.7 1.67 1.51 to 1.85 < 0.001 1.14 1.01 to 1.28 0.030
Ipsilateral recurrence
No 4150 14,861 27.9
Yes 195 310 62.9 2.14 1.86 to 2.47 < 0.001 1.64 1.42 to 1.89 < 0.001
Contralateral occurrence
No 4245 14,909 28.5
Yes 100 262 38.2 1.01 0.83 to 1.24 0.901 0.99 0.81 to 1.21 0.906
HR, hazard ratio.
N is the size of the subgroup, n is the number of events in that subgroup.286 Appendix 25
TABLE 71  Multiple Cox proportional hazards regression models for time to death from breast cancer in 
mastectomy cohort
n N %
Univariate Cox regression Multiple Cox regression
HR 95% CI p-value HR 95% CI p-value
Age (years)
≤ 34 96 360 26.7 1.61 1.30 to 1.98 < 0.001 1.08 0.87 to 1.33 0.477
35–49 562 3188 17.6 1.03 0.93 to 1.15 0.561 0.85 0.76 to 0.94 0.002
50–64 901 5229 17.2 (1.00) (1.00)
65–74 632 3422 18.5 1.14 1.03 to 1.27 0.009 1.17 1.06 to 1.30 0.002
75–79 269 1547 17.4 1.17 1.03 to 1.34 0.020 1.26 1.10 to 1.44 0.002
80+ 253 1425 17.8 1.39 1.21 to 1.60 < 0.001 1.51 1.31 to 1.74 0.001
Grade
1 117 1827 6.4 (1.00) (1.00)
2 924 6918 13.4 2.32 1.91 to 2.81 < 0.001 1.68 1.38 to 2.04 < 0.001
3 1585 5852 27.1 5.55 4.60 to 6.70 < 0.001 3.38 2.79 to 4.10 < 0.001
Unknown 87 574 15.2 2.98 2.32 to 3.84 < 0.001 1.90 1.43 to 2.51 < 0.001
Size (mm)
≤ 10 49 1103 4.4 (1.00) (1.00)
> 10 to 
< 20
438 4224 10.4 2.36 1.75 to 3.17 < 0.001 1.74 1.29 to 2.34 < 0.001
≥ 20 1916 8627 22.2 5.93 4.46 to 7.87 < 0.001 2.83 2.12 to 3.77 < 0.001
Size cat. 
unknown
310 1217 25.5 6.00 4.45 to 8.09 < 0.001 3.08 2.27 to 4.18 < 0.001
Nodes
0 568 6938 8.2 (1.00) (1.00)
1–3 714 4147 17.2 2.32 2.07 to 2.59 < 0.001 1.92 1.71 to 2.15 < 0.001
4+ 1250 3402 36.7 5.99 5.42 to 6.62 < 0.001 3.89 3.49 to 4.34 < 0.001
Unknown 181 684 26.5 4.07 3.48 to 4.76 < 0.001 2.96 2.47 to 3.54 < 0.001
Vascular invasion
No 942 8608 10.9 (1.00) (1.00)
Yes 1533 5341 28.7 3.02 2.79 to 3.28 < 0.001 1.51 1.38 to 1.65 < 0.001
Unknown 238 1222 19.5 2.00 1.75 to 2.29 < 0.001 1.28 1.10 to 1.49 0.002
Ipsilateral recurrence
No 2558 14,861 17.2
Yes 155 310 50.0 2.78 2.37 to 3.27 < 0.001 2.12 1.80 to 2.50 < 0.001
Contralateral occurrence
No 2707 14,909 18.2
Yes 6 262 2.3 0.09 0.04 to 0.19 < 0.001
HR, hazard ratio.
N is the size of the subgroup, n is the number of events in that subgroup.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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Appendix 26  
Univariate Cox regression models for the 
Edinburgh cohort
TABLE 72  Description of the Edinburgh breast cancer cohort
n = 1439
Age at diagnosis (years)
Mean (SD) 56 (11)
Median (25th, 75th centile) 56 (50, 63)
Minimum, maximum 24, 91
n %
Age categories (years)
≤ 34 40 2.8
35–49 308 21.4
50–64 826 57.4
65–74 201 14.0
75+ 64 4.4
Grade
1 363 25.2
2 642 44.6
3 402 27.9
Unknown 32 2.2
Size (mm)
≤ 10 339 23.6
> 10 to < 20 632 43.9
≥ 20 414 28.8
Size cat. unknown 54 3.8
Nodes
0 1052 73.1
1–3 312 21.7
4+ 75 5.2
Outcomes
Death all cause 124 8.6
Death breast cancer 67 4.7
Ipsilateral event 434 30.2
Contralateral event 234 16.3
Note that all of the women in the Edinburgh breast cancer cohort were treated surgically with BCS.288 Appendix 26
FIGURE 34  Incidence per 1000 per year of ipsilateral recurrence and contralateral occurrence for Edinburgh breast 
cancer cohort.
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TABLE 73  Multiple Cox regression models for IBTR in Edinburgh breast cancer cohort
n N %
Univariate Cox regression Multiple Cox regression
HR 95% CI p-value HR 95% CI p-value
Age (years)
≤ 34 15 40 37.5 6.60 3.75 to 11.62 < 0.001 4.65 2.58 to 8.37 < 0.001
35–49 35 308 11.4 1.55 1.02 to 2.35 0.039 1.18 0.77 to 1.80 0.452
50–64 61 826 7.4 (1.00) (1.00)
65–74 11 201 5.5 0.81 0.43 to 1.54 0.516 0.77 0.41 to 1.48 0.439
75+ 2 64 3.1 0.60 0.15 to 2.47 0.482 0.51 0.12 to 2.09 0.349
Grade
1 16 363 4.4 (1.00) (1.00)
2 55 642 8.6 2.19 1.25 to 3.82 0.006 1.86 1.06 to 3.27 0.030
3 50 402 12.4 3.56 2.03 to 6.26 < 0.001 2.36 1.31 to 4.27 0.004
Unknown 3 32 9.4 2.09 0.61 to 7.16 0.243 1.72 0.49 to 6.07 0.402
Size (mm)
≤ 10 20 339 5.9 (1.00) (1.00)
> 10 to 
< 20
24 632 3.8 1.23 0.72 to 2.09 0.450 0.90 0.52 to 1.57 0.720
≥ 20 56 414 13.5 2.80 1.68 to 4.67 < 0.001 1.55 0.89 to 2.73 0.124
Size cat. 
unknown
6 54 11.1 2.14 0.86 to 5.32 0.103 1.53 0.61 to 3.89 0.367
Nodes
0 69 1052 6.6 (1.00) (1.00)
1–3 36 312 11.5 2.02 1.35 to 3.02 0.001 1.75 1.15 to 2.67 0.009
4+ 19 75 25.3 5.68 3.41 to 9.45 < 0.001 4.18 2.45 to 7.12 < 0.001
HR, hazard ratio.
N is the size of the subgroup, n is the number of events in that subgroup.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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TABLE 74  Multiple Cox regression models for MCBC occurrence in Edinburgh breast cancer cohort
n N %
Univariate Cox regression Multiple Cox regression
HR 95% CI p-value HR 95% CI p-value
Age (years)
≤ 34 6 40 6 4.79 2.01 to 11.43 < 0.001 3.94 1.60 to 9.74 0.003
35–49 19 308 19 1.55 0.88 to 2.73 0.128 1.51 0.84 to 2.71 0.165
50–64 33 826 33 (1.00)
65–74 7 201 7 0.99 0.44 to 2.25 0.990 1.03 0.45 to 2.36 0.936
75–79 2 64 2 1.28 0.30 to 5.34 0.738 1.29 0.31 to 5.49 0.726
Grade
1 14 363 3.9 (1.00) (1.00)
2 25 642 3.9 0.38 0.59 to 2.19 0.695 1.10 0.57 to 2.14 0.769
3 24 402 6.0 0.67 1.03 to 3.86 0.041 1.81 0.90 to 3.64 0.098
Unknown 4 32 12.5 1.95 1.13 to 10.47 0.030 2.61 0.82 to 8.30 0.104
Size (mm)
≤ 10 17 339 5.0 (1.00) (1.00)
> 10 to 
< 20
27 632 4.3 0.93 0.51 to 1.71 0.817 0.81 0.43 to 1.52 0.508
≥ 20 19 414 4.6 1.13 0.59 to 2.17 0.720 0.83 0.40 to 1.69 0.601
Size cat. 
unknown
4 54 7.4 1.73 0.58 to 5.15 0.323 1.37 0.45 to 4.16 0.580
Nodes
0 55 1052 5.2 (1.00) (1.00)
1–3 15 312 4.8 1.16 0.65 to 2.06 0.617 1.18 0.65 to 2.15 0.580
4+ 1 75 1.3 0.40 0.05 to 2.88 0.362 0.39 0.05 to 2.88 0.357
HR, hazard ratio.
N is the size of the subgroup, n is the number of events in that subgroup.290 Appendix 26
TABLE 75  Multiple Cox regression models for all-cause death in Edinburgh breast cancer cohort
n N %
Univariate Cox regression Multiple Cox regression
HR 95% CI p-value HR 95% CI p-value
Age (years)
≤ 34 14 40 35.0 1.58 0.92 to 2.71 0.099 0.97 0.55 to 1.70 0.917
35–49 78 308 25.3 0.98 0.76 to 1.27 0.871 0.77 0.59 to 1.00 0.050
50–64 215 826 26.0 (1.00) (1.00)
65–74 87 201 43.3 1.90 1.48 to 2.44 < 0.001 1.89 1.47 to 2.44 < 0.001
75–79 40 64 62.5 3.78 2.69 to 5.32 < 0.001 3.33 2.35 to 4.72 < 0.001
Grade
1 80 363 22.0 (1.00) (1.00)
2 193 642 30.1 1.53 1.18 to 1.99 0.001 1.25 0.96 to 1.62 0.105
3 150 402 37.3 2.11 1.61 to 2.77 < 0.001 1.72 1.29 to 2.28 < 0.001
Unknown 11 32 34.4 1.50 0.80 to 2.81 0.210 1.86 0.97 to 3.56 0.061
Size (mm)
≤ 10 60 339 17.7 (1.00) (1.00)
> 10 to 
< 20
184 632 29.1 1.80 1.35 to 2.41 < 0.001 1.44 1.06 to 1.94 0.018
≥ 20 168 414 40.6 2.76 2.06 to 3.71 < 0.001 1.79 1.30 to 2.47 < 0.001
Size cat. 
unknown
22 54 40.7 2.58 1.58 to 4.21 < 0.001 1.93 1.16 to 3.20 0.011
Nodes
0 266 1052 25.3 (1.00) (1.00)
1–3 124 312 39.7 1.79 1.44 to 2.21 < 0.001 1.59 1.28 to 1.98 < 0.001
4+ 44 75 58.7 3.22 2.33 to 4.45 < 0.001 2.72 1.94 to 3.81 < 0.001
Ipsilateral recurrence
No 372 1315 28.3 (1.00)
Yes 62 124 50.0 1.94 1.48 to 2.54 < 0.001 1.87 1.41 to 2.49 < 0.001
Contralateral occurrence
No 416 1372 30.3 (1.00) (1.00)
Yes 18 67 26.9 0.77 0.48 to 1.23 0.277 0.70 0.43 to 1.13 0.140
HR, hazard ratio.
N is the size of the subgroup, n is the number of events in that subgroup.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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TABLE 76  Multiple Cox regression models for death from breast cancer in Edinburgh breast cancer cohort
n N %
Univariate Cox regression Multiple Cox regression
HR 95% CI p-value HR 95% CI p-value
Age (years)
≤ 34 14 40 35.0 2.70 1.55 to 4.69 < 0.001 1.17 0.65 to 2.10 0.599
35–49 57 308 18.5 1.25 0.91 to 1.71 0.163 0.89 0.65 to 1.23 0.487
50–64 123 826 14.9 (1.00) (1.00)
65–74 27 201 13.4 0.98 0.65 to 1.49 0.935 1.00 0.65 to 1.52 0.987
75–79 13 64 20.3 1.84 1.04 to 3.27 0.037 1.52 0.85 to 2.72 0.160
Grade
1 26 363 7.2 (1.00) (1.00)
2 101 642 15.7 2.38 1.55 to 3.67 < 0.001 1.79 1.16 to 2.77 0.009
3 101 402 25.1 4.18 2.71 to 6.43 < 0.001 2.86 1.83 to 4.47 < 0.001
Unknown 6 32 18.8 2.64 1.08 to 6.41 0.032 3.30 1.32 to 8.21 0.010
Size (mm)
≤ 10 21 339 6.2 (1.00) (1.00)
> 10 to 
< 20
91 632 14.4 2.48 1.55 to 3.99 < 0.001 1.86 1.14 to 3.02 0.013
≥ 20 111 414 26.8 5.07 3.18 to 8.09 < 0.001 2.61 1.58 to 4.29 < 0.001
Size cat. 
unknown
11 54 20.4 3.70 1.78 to 7.68 < 0.001 2.08 0.96 to 4.48 0.062
Nodes
0 120 1052 11.4 (1.00) (1.00)
1–3 78 312 25.0 2.45 1.84 to 3.26 < 0.001 2.05 1.53 to 2.76 < 0.001
4+ 36 75 48.0 5.50 3.77 to 8.02 < 0.001 3.42 2.29 to 5.11 < 0.001
Ipsilateral recurrence
No 179 1315 13.6
Yes 55 124 44.4 3.59 2.65 to 4.86 < 0.001 2.69 1.94 to 3.72 < 0.001
Contralateral occurrence 
No 223 1372 16.3 (1.00)
Yes 11 67 16.4 0.91 0.49 to 1.66 0.747 0.66 0.35 to 1.24 0.199
HR, hazard ratio.
N is the size of the subgroup, n is the number of events in that subgroup.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Appendix 27  
Example of detailed outline of economic 
model structure294 Appendix 27
Severity 1 managed
Severity 1
Severity 1
True-positives
True-positive
mammography
False-negative
mammography
#
#
#
#
#
#
#
#
#
Disease
No disease No cancer
No cancer
P_Sens_Mammog_clinical
P_Sens_Mammog_clinical
P_sens_GP
P_present_GP
P_cancer_BC
P_present_GP
P_Spec_GP
P_spec_mammog_clinical
1-P_Spec_GP
1-P_spec_mammog_clinical
GP true-negative
True-negative mammography 
GP false-positive
False-positive mammography
Present at GP
Live
Disease
P_spec_mammog_clinical
False-negatives
False-positives
GP true-
positives
GP false-negatives
No presentation No
surveillance
No
cancer
Die
Dead
Life_Table [Starting_age+(_stage/2);1]
1
No disease
Present at GP
No presentation
No cancer
No cancer
No cancer
No cancer
True-negatives
P_cancer_3C
Survellance
(e.g. mammography)
Survellance_interval
[ _stage;Surv_interval]
Severity 2 managed
Severity 3 managed
Severity 4 managed
Severity 5 managed
1
Severity 2
#
Severity 3
0
Severity 4
0
Severity 5
1
Severity 2
0
Severity 3
0
Severity 4
0
Severity 5
Severity 1
Severity 1
1
Severity 2
#
Severity 3
0
Severity 4
0
Severity 5
1
Severity 2
0
Severity 3
0
Severity 4
0
Severity 5
0
0
0
0
Severity 1 unmanaged
Severity 2 unmanaged
Severity 3 unmanaged
Severity 4 unmanaged
Severity 5 unmanaged
Severity 1 managed
Severity 2 managed
Severity 3 managed
Severity 4 managed
Severity 5 managed
Severity 1 unmanaged
Severity 2 unmanaged
Severity 3 unmanaged
Severity 4 unmanaged
Severity 5 unmanaged
Severity 1
1
Severity 2
#
Severity 3
0
Severity 4
0
Severity 5
Severity 1 unmanaged
Severity 2 unmanaged
Severity 3 unmanaged
Severity 4 unmanaged
Severity 5 unmanaged
0
Severity 1
1
Severity 2
#
Severity 3
0
Severity 4
0
Severity 5
Severity 1 unmanaged
Severity 2 unmanaged
Severity 3 unmanaged
Severity 4 unmanaged
Severity 5 unmanaged© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
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Appendix 28  
Review of management guidelines for breast 
cancer
Overview
In order to assess the cost-effectiveness of different surveillance mammography regimens after 
the treatment for primary breast cancer, the clinical effectiveness of standard treatment options of 
any subsequent cancers were required for the economic model.
The objective of this review is to determine the effect of treatment options on survival in 
patients who are identified as having breast cancer during surveillance. After searching relevant 
guidelines, the recent updated NICE guideline Early and Locally Advanced Breast Cancer, 
published in February 2009, was identified as providing the best available evidence of treatments 
for early breast cancer relevant to the UK.24 This review, therefore, is mainly based on this 
guideline and the source data used to inform the guideline: the EBCTCG83 and Adjuvant! Online 
computer program.84 Using these sources, estimates of survival following various treatment 
options were prepared using the Adjuvant! Online computer program due to its flexibility.
Methods
At the beginning of this review, initial scoping searches were carried out into identify relevant 
local, national or international guidelines. Eleven guidelines were identified describing various 
treatments or managements of primary breast cancer.21–25,28,111–115 The most recent of these, and 
most applicable to the UK, were the NICE guidelines published in February 2009.24 Few data 
were available on the effectiveness of treatments for cancers identified following treatment for 
a primary cancer. As a consequence, it was judged that, in the absence of data in the literature 
directly relevant to our study question, the best source of information would relate to treatment 
of primary cancer. It was judged that, of the guidelines available, the best available summary 
of existing evidence on the clinical effectiveness of treatments of breast cancer, including early, 
locally advanced and advanced disease, was provided by the NICE guidelines. The literature 
searches used to inform these guidelines considered papers published up to July 2008.
NICE guideline: Early and Locally Advanced Breast Cancer
The NICE guideline Early and Locally Advanced Breast Cancer,24 published in February 2009, 
updated and developed guidance from three NICE technology appraisals: 109 (docetaxel), 108 
(paclitaxel) and 107 (trastuzumab).99,116,117 The evidence on clinical effectiveness of diagnoses 
and treatments for early and locally advanced breast cancer is based on the systematic review of 
relevant clinical literatures and critical appraisal.
Search strategy
Papers that were published or accepted for publication in peer-reviewed journals were considered 
as relevant. Search filters, such as those to identify systematic reviews and RCTs, were applied to 
the search strategies when there was a wealth of these types of studies. No language restrictions 
were applied to the search; however, foreign language papers were not requested or reviewed 296 Appendix 28
(unless of particular importance to the question). Any evidence published before July 2008 was 
included. The following databases were included in the literature search:
  ■ The Cochrane Library
  ■ MEDLINE and PREMEDLINE 1950 onwards
  ■ Excerpta Medica (EMBASE) 1980 onwards
  ■ Cumulative Index to Nursing and Allied Health Literature (CINAHL) 1982 onwards
  ■ Allied & Complementary Medicine (AMED) 1985 onwards
  ■ British Nursing Index (BNI) 1994 onwards
  ■ PsycINFO 1806 onwards
  ■ Web of Science 1970 onwards [specifically SCI Expanded and Social Sciences Citation 
Index (SSCI)]
  ■ System for Information on Grey Literature In Europe (SIGLE) 1980–2005
  ■ BioMed Central 1997 onwards
  ■ NRR
  ■ CCT.
Types of studies included in the guideline
Relevant guidelines, systematic reviews and RCTs of different treatments for early or locally 
advanced breast cancer. In the absence of RCT evidence, the observational studies were 
considered in the review such as cohort, case–controls, etc.
Types of interventions considered in the guideline
Table 77 summarises the treatment interventions included in the NICE guideline. Surgery is 
considered as the first line of treatment in primary breast cancer, such as mastectomy, BCT and 
surgery to the axilla. Adjuvant therapies were used in management of breast cancer after the 
surgery, including hormonal therapy, chemotherapy, biological therapy and radiotherapy.
Critical appraisal of studies included in the NICE guideline
One researcher independently scanned the titles and abstracts of every article. Full texts were 
obtained for any papers that were considered potentially relevant or where there was insufficient 
information. The researcher then applied the inclusion/exclusion criteria to determine which 
studies were relevant. Included papers were critically appraised and data extracted. Quality 
assessment was based on the SIGN criteria.
Summary
The NICE guideline overviewed the best clinical evidence of treatment options derived from the 
studies that it reviewed and appraised.24 In addition to BCS or mastectomy, adjuvant treatments 
are used and the selection of adjuvant therapies depends on tumour factors (ER and HER2 
status) and patient characteristics (age and menopausal status). However, the NICE guideline 
did not report the detailed data but rather made a recommendation on the use of adjuvant 
treatments. The guideline suggested that two sources were more likely to provide reliable data on 
the effectiveness of adjuvant treatments: (1) a series of overviews and meta-analyses of different 
treatments in the EBCTCG that provides the effectiveness of adjuvant treatment after surgical 
therapy for early breast cancer, and (2) Adjuvant! Online, based on a US population, to estimate 
the efficacy of adjuvant therapies (hormonal or chemotherapy) after initial surgical treatment.
Effect of adjuvant treatments on survival based on overview in 
EBCTCG
The NICE guideline suggested that overviews of meta-analyses in EBCTCG appear to provide 
the best evidence for estimating risk for treating breast cancer in the UK. The EBCTCG was 
established in 1984. The most recent publications from the EBCTCG relate to:© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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  ■ adjuvant polychemotherapy in ER-poor breast cancer: meta-analysis of individual patient 
data from the randomised trials118
  ■ chemotherapy and hormonal therapy for early breast cancer: effects on recurrence and 
15-year survival in an overview of the randomised trials3
  ■ effects of radiotherapy and of differences in the extent of surgery for early breast cancer on 
local recurrence and 15-year survival: an overview of the randomised trials.2
Some adjuvant treatments tested in the 1980s have clear evidence that they substantially reduce 
5-year recurrence rates and also substantially reduce 15-year overall mortality rates (e.g. 
tamoxifen, polychemotherapy regimens and radiotherapy). Further improvements in long-term 
TABLE 77  Treatments considered in the NICE guideline
Interventions
Population setting: early and locally 
advanced breast cancer  Studies
Surgery to breast
Mastectomy
Breast-conserving therapy
DCIS 33 observation studies
Surgery to the axilla
Sentinel lymph node biopsy (SNLB)
Invasive breast cancer SLNB vs clearance or 
axillary sampling: 33 RCTs and case series, a 
systematic review (69 studies)
Axillary sampling as staging surgery: 15 studies 
(two RCTs, 13 case series)
Adjuvant endocrine therapy (hormonal) Invasive disease with hormone receptor 
positive
Tamoxifen ER alpha positive
Aromatase inhibitors:
 Anastrozole  ER or PR positive Nine RCTs
 Letrozole ER or PR positive Five RCTs
 Exemestane ER or PR positive Four RCTs
Adjuvant chemotherapy A meta-analysis from EBCTCG
Docetaxel Early lymph node positive  Four RCTs, one Cochrane, a HTA report, a meta-
analysis, a pooled analysis
Paclitaxel  Early lymph node positive  Four RCTs, one Cochrane, a HTA report, a meta-
analysis, a pooled analysis
Taxanes Two RCTs, a meta-analysis and a pooled analysis, 
a TACT study
Adjuvant biological therapy HER2 receptor positive 
Humanised monoclonal antibody (trastuzumab) Four RCTs (HERA, NSABP B-31, NCCTG N9831 
and E2198)
Adjuvant radiotherapy Invasive breast, DCIS
BCS and radiotherapy Invasive breast, DCIS One RCT, two non-RCTs, three reviews and four 
guidelines for invasive, three studies (two RCTs, 
one retrospective) for DCIS
Postmastectomy radiotherapy  EBCTCG and five additional RCTs
Primary systematic therapy Three systematic reviews of RCTs and a published 
review
Neoadjuvant endocrine therapy One systematic review of RCTs
Neoadjuvant chemotherapy  One systematic review of RCTs and a published 
review 
Neoadjuvant radiotherapy
PR, progesterone receptor; SNLB, sentinel lymph node biopsy.298 Appendix 28
survival could be available from newer drugs, or better use of older drugs. The reviews, however, 
although excellent, do not provide data readily useable in an economic model, as it is not possible 
to estimate survivals for specific types of cancer. However, for completeness a summary of key 
findings is presented below.
Adjuvant chemotherapy
The number of randomised trials of chemotherapy increased substantially over the first two 
decades of the EBCTCG overview, with a shift from trials comparing chemotherapy with no 
chemotherapy, to trials of different types of chemotherapy. In the first cycle of the overview, 
31 randomised trials of no chemotherapy versus chemotherapy using one or more drugs were 
included. This involved a total of 9000 women, of whom 2900 had died. Subsequent cycles 
refined this to focus on trials of prolonged multiagent chemotherapy. By the third cycle of the 
EBCTCG overview, this analysis was based on 18,000 women from 47 trials, and it had risen 
further to 60 trials (29,000 women and 10,000 deaths) by the fourth cycle. The recent meta-
analysis from randomised trials is to assess the long-term effects of adjuvant polychemotherapy 
regimens in ER-poor breast cancer, and the extent to which these effects are modified by age or 
tamoxifen use.118 This study analysed 6000 patients with ER-poor breast cancer in 46 trials of 
polychemotherapy against not, and about 14,000 women with ER-poor breast cancer in 50 trials 
of tamoxifen versus not.
Adjuvant hormonal therapy
The first EBCTCG review of tamoxifen, in the mid-1980s, included data from a total of 16,500 
women in 28 randomised trials, of whom nearly 3800 were known to have died. This grew to 
40 trials (30,000 women and 8200 deaths) in the second cycle; and then to 55 trials, involving 
> 12,000 deaths among 37,000 women. By the 2000–5 cycle of the EBCTCG overview, the growth 
in the number of trials included had levelled off at 56, but further accrual to some of these trials 
and five more years of follow-up for many of them meant that the number of women in the 
analysis had increased to 48,000, with a total of 18,000 deaths.3 This represented 88% of the total 
number of women randomised into eligible trials of adjuvant tamoxifen versus no immediate 
tamoxifen worldwide.
Adjuvant radiotherapy
The most recent overview of radiotherapy and differences of surgery published in 20052 was 
based on the analysis of 42,000 women in 78 randomised treatment comparisons (radiotherapy 
vs no radiotherapy, 23,500; more surgery vs less surgery, 9300; more surgery vs radiotherapy, 
9300). A total of 24 types of local treatment comparison were identified to help relate the effect 
on local (i.e. locoregional) recurrence to that on breast cancer mortality.
Effect of treatments on survival for breast cancer using the Adjuvant! 
Online computer program
Adjuvant! Online is a tool of assessment of risk of an individual patient developing recurrent 
disease and/or dying within 10 years. Adjuvant! Online draws information from mortality 
statistics in the USA, the SEER database, and meta-analyses and individual clinical trials. Based 
on well-validated factors, such as age, menopausal status, ER status, tumour size and grade, 
nodes status, etc., predictions can be made about survival for alternative adjuvant treatment 
regimens, such as chemotherapy, endocrine, etc. However, survival estimates are derived from 
the US population. Version 8 of this tool may underestimate the risk of mortality and the benefit 
of trastuzumab in HER-2-positive patients. Table 78 describes the information used to predict 
recurrence and mortality.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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The NICE guideline summarised the following issues in its critical appraisal of this tool:
  ■ The predictions made by Adjuvant! Online are based on the published methodology, which 
has been updated periodically as evidence of treatment effectiveness and data on risk factors 
become available.
  ■ Help files and published descriptions of the tool make clear some of the assumptions and 
limitations that underpin the methodology. The impact of these individual assumptions is 
difficult to assess. Adjuvant! Online deals with key uncertainties by alerting the user to them 
at relevant points.
  ■ Survival estimates are derived from the US population. Quantifying the impact on survival 
of socioeconomic background and of ethnic differences between US and UK populations 
is difficult.
  ■ Adjuvant! Online is already used in the UK and is designed to incorporate the Oxford 
overview meta-analyses.
  ■ The strongest evidence of Adjuvant! Online validity for the UK is derived from comparisons 
between predictions and observed outcomes using a Canadian population. This study found 
its predications to be reliable for most groups. Further validation is under way using a 
European population.
Survival estimates for treatment options using the Adjuvant! Online 
computer program
Adjuvant! Online integrates patient-related information (age and comorbidity) and tumour-
related information (nodal status, tumour size, histological grade, ER status and histological 
subtype) to make estimates of mortality caused by cancer or from other causes. Table 79 
reports an example of mortality estimates for a woman with breast cancer depending upon her 
characteristics and tumour factors when the woman is 40 years old, has perfect health, tumour 
grade is undefined and oestrogen status is positive.
Summary
Decisions on the treatment for every woman with breast cancer should be based on the best 
evidence. This requires a combination of information about the patient and tumour along with 
evidence on the effectiveness of the treatments being considered. This evidence needs to be as 
reliable as possible. It was judged by the research team that the NICE guideline Early and Locally 
Advanced Breast Cancer provided the best available summary of evidence of breast cancer 
treatments. However, the NICE guideline did not report estimates of clinical effectiveness of 
treatment options. Based on the NICE guideline, there are two reliable sources that produce the 
TABLE 78  Prognostic factors in Adjuvant! Online
Comorbidity Perfect
Minor 
problems Average for age Major 10 Major 20 Major 30
ER status Undefined Positive Negative
Tumour size (cm) 0.1–1 1.1–2 2.1–3 3.1–5 > 5
Positive nodes 0 1–3 4–9 > 9
Tumour grade Undefined 1 2 3
Age (years) 1–99300 Appendix 28
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estimates of effectiveness of adjuvant treatments: EBCTCG overviews and Adjuvant! Online. 
Of these Adjuvant! Online was sufficiently flexible to allow relevant data to be estimated for 
the economic model. Estimates from Adjuvant! Online provide similar/dissimilar estimates to 
the EBCTCG overviews, which, arguably, are more applicable to a UK population. However, as 
EBCTCG overview subset analyses are carried out largely as a set of univariate subset analyses it 
is impossible to tell if two univariate effects are independent.
Adjuvant! Online integrates patient-related information (age and comorbidity) and tumour-
related information (nodal status, tumour size, histological grade, ER status and histological 
subtype) to make estimates of mortality and recurrence. However, survival estimates are derived 
from the US population.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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Appendix 29  
Estimates of the different types of cancer 
that exist
Categories
Count Total Percentage Size (mm) Grade Nodes
Vascular 
invasion
0–20 1 0 No 3207 3326 12.28
Yes 119
1–3 No 503 589 2.18
Yes 86
4+ No 54 88 0.32
Yes 34
2 0 No 4522 5178 19.12
Yes 656
1–3 No 1031 1471 5.43
Yes 440
4+ No 253 450 1.66
Yes
No
197
3 0 2105 2695 9.95
Yes 590
1–3 No 491 916 3.38
Yes 425
4+ No 161 462 1.71
Yes 301
20.001–49.999 1 0 No 477 528 1.95
Yes 51
1–3 No 209 283 1.05
Yes 74
4+ No 59 109 0.40
Yes 50
2 0 No 1781 2233 8.25
Yes 452
1–3 No 912 1541 5.69
Yes 629
4+ No 392 1018 3.76
Yes 626
3 0 No 1526 2209 8.16
Yes 683
1–3 No 628 1467 5.42
Yes 839
4+ No 292 1256 4.64
Yes 964304 Appendix 29
Categories
Count Total Percentage Size (mm) Grade Nodes
Vascular 
invasion
50+ 1 0 No 22 24 0.09
Yes 2
1–3 No 11 15 0.06
Yes 4
4+ No 9 26 0.10
Yes 17
2 0 No 92 110 0.41
Yes 18
1–3 No 105 172 0.64
Yes 67
4+ No 95 280 1.03
Yes 185
3 0 No 76 118 0.44
Yes 42
1 –3 No 44 161 0.59
Yes 117
4+ No 45 355 1.31
Yes 310
Total 27,080 100© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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Appendix 30  
Summary of data from Adjuvant! Online 
used – estimated 10-year survival306 Appendix 30
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Assumptions
Decision rules for treatment
1. ER+ = hormone therapy
2. Grade 3 = chemotherapy
3. ER+ and positive nodes = hormone + chemotherapy
4. ER–, 0 nodes = nothing
5. ER– = chemotherapy (15% might get hormone therapy in addition)© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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Index (cycle) Value
0 0.002185889
1 0.000176516
2 9.65047E-05
3 8.05032E-05
4 5.85017E-05
5 4.80012E-05
6 4.90012E-05
7 4.10008E-05
8 4.5001E-05
9 3.90008E-05
10 4.65011E-05
11 4.85012E-05
12 5.00013E-05
13 5.90017E-05
14 5.95018E-05
15 7.90031E-05
16 8.65037E-05
17 0.000122508
18 0.000135509
19 0.000128508
20 0.000120507
21 0.000132009
22 0.000131509
23 0.000123508
24 0.000147011
25 0.00014351
26 0.000168514
27 0.000155512
28 0.000179016
29 0.000190518
30 0.000208022
31 0.000203021
32 0.00024353
33 0.000269536
34 0.000287541
35 0.000299045
36 0.000322052
37 0.000363566
38 0.000397579
39 0.000448601
40 0.00049012
41 0.000528139
42 0.000575666
Appendix 31  
All-cause mortality rates
Index (cycle) Value
43 0.000633701
44 0.000670725
45 0.000765293
46 0.00082434
47 0.000914418
48 0.001034035
49 0.001076079
50 0.00128032
51 0.001346907
52 0.001431525
53 0.001580249
54 0.001770067
55 0.001879266
56 0.002072648
57 0.002197414
58 0.002361288
59 0.002655025
60 0.002852067
61 0.00323122
62 0.003459484
63 0.003906631
64 0.004267104
65 0.004599578
66 0.005054775
67 0.005641413
68 0.006184122
69 0.006790556
70 0.007564612
71 0.00831507
72 0.009229593
73 0.010470819
74 0.011811253
75 0.013020264
76 0.01471527
77 0.016491993
78 0.018562279
79 0.021135862
80 0.023809957
81 0.026686587
82 0.029678404
83 0.033678625
84 0.037974533
85 0.04250483312 Appendix 31
Index (cycle) Value
86 0.047340565
87 0.05188872
88 0.058742862
89 0.06434889
90 0.072877031
91 0.083887561
92 0.093932122
93 0.104376753
94 0.114247213
95 0.125022286
96 0.13718484
97 0.146604429
98 0.163656171
99 0.172317694
100 0.188410202© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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Appendix 32  
Summary of findings of the structured review 
of doubling times
T
he identified papers are summarised in Table 80 and described below. Peer and colleagues89 
conducted a study in the Netherlands using data from the Breast Screening Programme 
from the period 1980–91 to determine the growth rate of primary breast cancer stratified by age. 
The authors report the mean breast cancer doubling times by age, based on information from 
236 cancers with a measurable tumour nucleus (Table 81). The authors reported that tumour 
doubling time was age dependent, with those of a younger age having a shorter tumour doubling 
time. In addition to the data reported in Table 81 the authors also present doubling times for 
other studies. Doubling times from these studies range from a low of 60 days119 to 268 days.120
Spratt121 undertook a study to determine the association of doubling times of primary breast 
cancer and other histopathological and mammography characteristics. The study was undertaken 
at the University of Louisville Breast Cancer Detection and Demonstration Project (BCDDP). 
The data used consisted of 23 tumours with doubling times ranging from 109 days to 944 days 
(median 324 days). The authors found an association between faster growth rate and three 
factors, one of which was the nuclear grade of tumour; however, no information was presented 
on the actual increased doubling time by grade. A further study88 used data from both the 
University of Louisville and University of Heidelberg of women who had undergone routine 
mammography as part of a breast-screening programme. In total, 448 observations were obtained 
and used to measure the growth rate of tumours. The authors found that the median doubling 
time was 260 days (mean age 53 years). A large variation in doubling time was observed, 
however, ranging from 10 days to 7051 days.
Arnerlöv and colleagues122 analysed the doubling time of tumours based on information from 158 
patients with breast cancer who were diagnosed between 1974 and 1987 in Sweden. The authors 
found large variations in tumour doubling rates. The median doubling time was 11 months. In 
contrast with Spratt’s study, the authors found no association between doubling time and grade, 
although they did find that short doubling times were significantly correlated with tumour size.
In a recent study, Weedon-Fekjaer and colleagues123 used a likelihood-based estimating procedure 
to estimate tumour growth, using data from the Norwegian Breast Cancer Screening Programme. 
The data relate to 503 women aged between 50 and 69 years, over the period 1985–94. The 
authors found a large variation in tumour growth rates, with 5% of tumours taking < 1.2 months 
to double in size from 10 to 20 mm. At the other extreme, the authors found that 5% of tumours 
had a doubling time of 6.3 years. Mean tumour doubling time was found to be 1.7 years, with 
doubling time increasing with age. Overall, evidence from these studies shows a large variation in 
doubling times.
Brekelmans and colleagues124 conducted a study based on data from a breast-screening 
programme in the Netherlands. The results were based on 104 invasive tumours detected 
between 1975 and 1986. The mean doubling time was reported to be 99 days (range 6–309 days).314 Appendix 32
TABLE 80  Summary of studies reporting data on doubling times of breast cancer
Author (date)
Location Methods Results
Peer et al. (1993)89
Nijmegen, Netherlands
Study based on data from the Breast Cancer Screening 
Programme conducted in the Netherlands since 1975. The 
study data are from the period 1980–91 and are based on 
236 cancers with measurable tumour nucleus
The authors calculated the doubling time of tumours by age 
group: < 50 years (n = 32 cancers); 50–70 years (n = 154 
cancers); > 70 years (n = 50 cancers)
The tumour doubling time was found to be age 
dependent:
< 50 years’ doubling time was 80 days (95% CI 44 to 
147 days)
50–70 years’ doubling time was 157 days (95% CI 
121 to 204 days)
> 70 years’ doubling time 188 days (95% CI 120 to 
295)
Brekelmans et al. 
(1996)124
Netherlands
Study based on data from a breast-screening programme 
(DOM project) in the Netherlands
Based on 139 cancers detected between 1975 and 1986. 
After exclusions the analysis was based on 104 invasive 
tumours
The analysis was subdivided into four groups: missed 
cancers; masked cancers; intermediate growth rate; and fast 
growth rate
The mean doubling time of the whole group was 99 
days (range 6–309 days)
By subgroup analysis this was:
51 days in the masked group
128 days in the intermediate group
79 days in the fast-growing group
Arnerlöv et al. (1992)122
Sweden
Study analyses the doubling time of tumours based on 
information form 158 patients with breast cancer who were 
diagnosed between 1974 and 1987
The mean age of patients was 65 years. The authors 
found variations in the tumour doubling rate (0.6 
months to indefinite time). Median doubling time 
was 11 months (approximately 330 days) and mean 
doubling time was 10.9 months
Spratt et al. (1993)88
Heidelberg and 
Louisville
Used data (from both Heidelberg and Louisville) of women 
who had undergone routine mammography as part of a 
breast-screening programme. In total, 448 observations were 
obtained and used to measure the growth rate of breast 
cancers
The mean age of patients was 53 years. The authors 
found the median doubling time to be 260 days, 
ranging from the shortest doubling time of 10 days to 
7051 days
Spratt (1981)121
University of Louisville
Spratt undertook a study to determine the association 
of doubling times of primary breast cancer and other 
histopathologic and mammography characteristics. The study 
was undertaken at the University of Louisville Breast Cancer 
Detection and Demonstration Project (BCDDP)
The data used consisted of 23 tumours with doubling 
times ranging from 109 to 944 days (median 324 
days). The authors found an association between faster 
growth rate and three factors, one of which was the 
nuclear grade of tumour; however, no information was 
presented on the actual increased doubling time by 
grade
Tilanus-Linthorst et al. 
(2007)125
UK, the Netherlands and 
Canada
Analysed breast cancer growth rates found during screening 
for patients in the UK, Holland and Canada. The authors were 
able to assess doubling time of tumours in 100 cases. These 
cases were subdivided into BRCA1 mutation (43 women); 
BRCA2 mutation (16 women) and high risk (41 women)
The authors found an inverse relationship between 
growth rate and age. The authors grouped their 
analysis into three age groups: ≤ 40, 41–50 and 
> 50 years There were differences in doubling times 
between the subgroups by severity and age: doubling 
time in BRCA1/2 mutations in the three age categories 
was 28, 68 and 81 days, respectively
In the high-risk group, without mutations, the doubling 
time in the three age groups was 83, 121 and 173 
days, respectively
Weedon-Fekjaer et al. 
(2008)123
Norway
The authors used a likelihood-based modelling method to 
estimate the growth rate of cancers using mammography 
screening data. The data pertains to 503 women aged 
between 50 and 69 years over the period 1985–94
The authors found large variation in the growth rates 
of tumours
In women aged 50–59 years the mean doubling time 
(from 10 to 20 mm) was 1.4 years. This increased to 
2.1 years in women aged 60–69 years
Over both age groups this was estimated to be 1.7 
years (SD 2.2 years)© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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Tilanus-Linthorst and colleagues125 analysed breast cancer growth rates found during screening 
patients in the UK, Holland and Canada. The authors assessed doubling time of tumours in 100 
cases. These cases were subdivided into BRCA1 mutation (43 women), BRCA2 mutation (16 
women) and high risk (41 women). The mean age of patients was 65 years. The authors found 
variations in the tumour doubling rate (0.6 months to indefinite time). Median doubling time 
was 11 months (approximately 330 days) and mean doubling time was 10.9 months.
TABLE 81  Mean breast cancer doubling times by age
Age at diagnosis (years) Mean (95% CI)
< 50 80 (44 to 147) days
50–70 157 (121 to 204) days
> 70 188 (120 to 295) days
Source: Peer and colleagues.89© Queen’s Printer and Controller of HMSO 2011. This work was produced by Robertson et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
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